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Pregnancy and parturition necessitate profound alterations in the maternal immune
response likely effected by paracrine interactions between inflammatory mediators,
hormones and various local factors. However, the nature of these interactions and how
they effect the recognition and maintenance of pregnancy and initiation of parturition are
not well understood. The aim of this thesis was to investigate the role of inflammatory
mediators, specifically cytokines, prostaglandin E2 (PGE2), nitric oxide (NO),
metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) during pregnancy
and parturition.
Part 1.
This investigated the roles of inflammatory mediators in the initiation and maintenance of
pregnancy. The role of seminal plasma, specifically its component PGs (PGE2 and 19-
hydroxy PG), in the initial adaptation of the maternal immune response to pregnancy was
studied in the non-pregnant cervix, peripheral blood and a monocyte cell line. PGs
stimulated release of IL-10, thus favouring development of a T-helper (Th)-2 type,
pregnancy favourable immune response. They also stimulated release of the neutrophil
chemotactic factor IL-8, which may be involved in mediating post-coital cervical
leukocytosis. Furthermore, peripheral blood from pregnant women, specifically the
mononuclear cell (CD14+) fraction, released significantly more monocyte chemotactic
peptide-1 (MCP-1), which also favours a Th-2 type immune response, than that from
non-pregnant women. Release of IL-8 and regulated on activation and normally T-cell
expressed and secreted (RANTES) was comparable between groups. The concentrations
of MCP-1, IL-8 and RANTES in the fluid compartments within the first trimester uterus
were also examined. The chemokines were differentially distributed with MCP-1 and IL-
8 being present in amniotic fluid, maternal serum and extra-embryonic coelom with
highest levels of both in the latter compartment. RANTES was only detectable in
peripheral serum. These findings support the hypothesis that inflammatory mediators are
important in the initiation and maintenance of pregnancy and may play a role in early
placental and fetal development.
Part 2.
This examined the involvement and regulation of inflammatory mediators in cervical
ripening and parturition. Cervical ripening involves tissue remodelling mediated by
inflammatory mediators, infiltrating cells, MMPs and TIMPs. However their regulation in
the cervix are not well understood. In the non-pregnant cervix, IL-8 release was
stimulated by PGE2 and NO and inhibited by dexamethasone and progesterone. In
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addition, the anti-inflammatory factor secretory leukocyte protease inhibitor was
stimulated by progesterone and inhibited by PGE2 and PGE2 release was stimulated by
NO. In addition, MMP-2 and -9 and TIMPs-1 and -4 were released by the non-pregnant
cervix but this secretion was not affected by in vitro administration of PGE2 or NO.
Withdrawal of progesterone, which is essential for pregnancy maintenance, also initiates
cervical ripening by unknown mechanisms. In vivo administration of the anti-gestogen
mifepristone increased protein expression of MMP-1, -8 and -9, CD45 (leukocyte
common antigen), neutrophil elastase and CD68 (monocyte marker) but not MMP-2,
TIMP-1, -2 and -4 in the first trimester cervix as detected by immunohistochemistry. To
summarise the cervical studies, the non-pregnant and pregnant cervix are capable of
releasing a wide range of inflammatory mediators, MMPs and TIMPs, co-ordination of
which may mediate cervical ripening. Next, the release and regulation of inflammatory
mediators at the materno-fetal interface were investigated. MCP-1, IL-8, RANTES and
IL-10 were released by third trimester amnion, chorion, decidua and placenta with
secretion of MCP-1, IL-8 and IL-10 but not RANTES being stimulated by PGE2 in a
perfused placental cotyledon system. Secretory leukocyte protease inhibitor was released
predominantly by decidua and was present in increasing concentrations within amniotic
fluid during pregnancy and labour. Cytokines may play a role in the inflammatory
process of parturition, PGE2 may play an important immunomodulatory role within the
placenta at term and secretory leukocyte protease inhibitor might act both to limit the pro¬
inflammatory cascades ongoing during parturition and to protect against microbial
invasion. To summarise this section, inflammatory mediators are important in the
initiation and regulation of cervical ripening and parturition with complex interactions
occurring within the cervix and at the feto-maternal interface.
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1.1 PREGNANCY, PARTURITION AND INFLAMMATION
Many reproductive processes depend on the timely activation and regulation of
inflammatory processes. Inflammation is the physiological response to most types of
tissue injury, infection, immunological stimulation and foreign or altered host antigen.
Systemically, it is manifested by release of acute phase proteins by the liver and elevation
of the body temperature. At the local level, it is characterised by an initial vasodilation and
increased vascular permeability, followed by directional accumulation and extravasation of
effector cell into the surrounding tissue (neutrophils and monocytes then B- and T-cells).
A wide range of inflammatory mediators are involved in co-ordinating these events
including cytokines, chemokines, anaphylotoxins of the complement cascade, kinins of
the coagulation cascade, prostaglandins, leukotrienes and other fatty acid or lipid
mediators.
The initiation, recognition and maintenance of pregnancy, control of cervical ripening and
stimulation and regulation of parturition are processes in which inflammatory mediators,
by interacting with hormones and various local factors, are thought to have a pivotal role.
The nature and regulation of these interactions are not well understood. However, it is
vitally important that these mechanisms, which operate in normal pregnancy, are better
understood. Until this is achieved, therapeutic options available to treat
pathophysiological situations such as implantation failure, recurrent miscarriage and
preterm labour will remain sub-optimal.
The ensuing literature review will initially cover some of the cytokines, chemokines and
other inflammatory mediators, which are likely involved in generating and regulating
inflammatory and immunological responses during pregnancy. The current knowledge as
to the roles of inflammatory mediators in the specific processes of the initiation and
maintenance of pregnancy, control of cervical ripening and parturition will then be
considered.
1.2 CYTOKINES
Cytokines are soluble proteins or glycoproteins that act as humoral regulators at nano- to
pico-molar concentrations under normal or pathological conditions to modulate functional
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activities of individual cells or tissues. In addition, they mediate interactions between cells
directly and regulate process occurring in the extracellular environment by autocrine,
paracrine and juxtacrine means. Cytokines differ from classical hormones in they have
many sites of production, a high degree of biological redundancy and pleiotropy, act on
relatively selective cellular targets and are rarely found in the circulation. They bind to
specific receptors on the surface of the target cell, which are coupled to intra-cellular
signalling systems and second messenger pathways, thus effecting their action.
The rapidly expanding cytokine family is diverse and can be subdivided into many
divisions including the interleukins (IL-1 to IL-18, to date), colony stimulating factors
(GM-CSF, C-CSF, M-CSF), interferons (IFN-a, -(3 and -y) and growth factors (platelet
derived growth factors, PDGF; epidermal derived growth factors, EDGF; transforming
growth factors, TGF). Alternatively, cytokines can be classified according to their
principal function into pro-inflammatory, anti-inflammatory and immunomodulatory
mediators. Due to huge number of different cytokines, only those that are studied in this
thesis or which have relevance to reproduction will be discussed.
The pleiotrophic functions of cytokines necessitate that their release is tightly regulated.
This occurs at many levels.
Gene expression
Although a few cytokines (IL-6) are constitutively expressed, the majority are expressed
and synthesised only after stimulation by agents such as infection and inflammation. The
synthesised cytokines may then be stored in granules (PDGF), bound to membrane
proteins (tumour necrosis factor a, TNF-a; IL-1) or complexed to extra-cellular matrix
(ECM) or membrane receptors (IL-8).
Processing
Many cytokines require enzymatic cleavage (IL-1, TNF-a) to be activated although the in
vivo mechanism remains to be established for some (transforming growth factor-(3, TGF-
P).
Sequestration
Certain cytokines are sequestered, binding to molecules like heparin sulphate, decorin and
cellular differentiation (CD) 44 in ECM (IL-la), stromal cells or endothelial cells (IL-8).
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Other cytokines are bound to soluble binding molecules that may sequester, transport or
activate them.
Receptor modulation
The effect of cytokines can be antagonised at the level of the receptor by natural receptor





Cytokine natural killer cell stimulatory cell factor or cytotoxic lymphocyte maturation
factor was initially discovered in 1989 as a stimulator of natural killer cell proliferation and
augmentor of cytotoxic lymphocyte responses. It was subsequently renamed interleukin-
12 (IL-12; Gubler, et al., 1991).
Gene and protein structure
IL-12 is unusual in that it is a 70 kDa heterodimer composed of a p35 and a p40 subunit
encoded by 3pl2-ql3.2 and 5q31-q33, respectively (Snijders, et al., 1996). The
production of each subunit is regulated independently, mainly at the mRNA level, by
transcription factors such as nuclear factor kappa-beta (NFkB; Murphy, et al., 1995) with
the amount of bioactive IL-12 being determined by the level of p35 expression.
Receptors
The IL-12 receptor is a 110 kDa protein which is expressed on natural killer (NK) cells
and activated peripheral blood mononuclear cells (1000 - 9000 per cell) and CD4+ and
CD8+ T lymphocytes (Desai, et al., 1992).
Sources
IL-12 is released by a wide range of cells including monocytes and macrophages (Blotta,
et al., 1997), B-cells, polymorphonuclear cells (Cassatella, et al., 1995) and Langerhan
cells (Kang, et al., 1996). Release of IL-12 is stimulated by GM-CSF, IFN-y (Trinchieri
and Gerosa, 1996), HIV surface glycoprotein 120 (Fantuzzi, et al., 1996), class II MHC
19
(Koch, et al., 1996), interaction with CD40 - CD40 ligand (Kato, et al., 1966) and
lipopolysaccharide (LPS) (Hilkens, et al., 1996) and inhibited by corticosteroids (Blotta,
et al., 1997), monocyte chemotactic peptide-1 (MCP-1; Chensue, et al., 1996), IL-10
(D'Andrea, et al., 1993), TGF-(3 (Hunter, et al., 1995), IL-4 (Koch, et al., 1996) and
prostaglandin E2 (PGE2; Kelly, et al., 1997; Kraan, et al., 1995).
Biological Function
IL-12 favours a T helper-1 (Th-1) type of immune response (Gazzinelli, et al., 1994),
described in detail later, by stimulating IFN-y synthesis (Gerosa, et al., 1996) and
inducing cytotoxic T-cell differentiation (Kang, et al., 1996). It also effects differentiation
and activation of NK cells and cytotoxic T-cells via stat 4 (Thierfelder, et al., 1996),
inhibits IL-13 release, immunoglobulin E (IgE) class switching (Morris, et al., 1994) and
apoptosis (Clerici, et al., 1994).
Other pro-inflammatory cytokines
IL-1 and TNF-a are important cytokines involved in initiating many inflammatory
reactions (Brannstrom, et al., 1993).
The IL-1 system comprises the two ligands, IL-la and IL-ip, which share 26 %
homology, receptors (type 1 and type 2) and the IL-1 receptor antagonist. Secreted by
most cells, IL-1 release is stimulated many factors including TNF-a, IFN-y, bacteria and
LPS. In addition to its potent pro-inflammatory effects, it stimulates T-helper cells,
immunoglobulin production, pituitary adrenocorticotrophic releasing hormone (ACTH)
release, astro- and microglial cell proliferation, is prothrombotic and activates neutrophils.
TNF-a is secreted by many different cell types including monocytes, macrophages, T-
cells, neutrophils and NK cells with its release being stimulated by many factors including
IL-6, TGF-p, bacteria and LPS. Via binding to its cognate receptors (type 1 and type 2),
TNF-a induces cytolysis, cytostasis, coagulation, neutrophil chemotaxis, angiogenesis





The cDNA encoding a cytokine synthesis inhibitory factor was first identified from a
library of activated murine T cell clones in 1989. The human homologue was
subsequently cloned, expressed and renamed interleukin-10 (For reviews see: Trotta and
Windsor, 1995; Yssel and de Waal Malefyt, 1995).
Gene and protein structure
The human IL-10 gene (4.7 kBa), contains five exons, four introns and binding sites for a
wide number of transcription factors including glucocorticoids and cyclic adenine
monophosphate (cAMP). The mature encoded IL-10 protein contains 160 amino acids
and exists as a dimer in solution (Trotta and Windsor, 1995).
Receptors
The human IL-10 receptor, which is structurally related to the IFN-y receptor, is a 61 kDa
protein encoded by chromosome 11 (Tan, et al., 1993). It is expressed by cells of
haemopoietic origin including monocytes, B-cells, NK cells and T-cells.
Sources
IL-10 is released by a wide range of different cell types including T lymphocytes (Yssel
and de Waal Malefyt, 1995), eosinophils (Nakajima, et al., 1996), Langerhan (Chang, et
al., 1995), dendritic (deSaintVis, et al., 1998) and microglial cells (Ehrlich, et al., 1998).
Its release is regulated locally at the paracrine and autocrine level (Cohen, et al., 1997) by
many factors including IL-12 (Peritt, et al., 1995), IL-8 (Lu, et al., 1995), PGE2 (Kraan,
et al., 1995) and glucocorticoids.
Biological Functions
IL-10, as its initial name cytokine synthesis inhibitory factor suggests, is a potent
immunosuppressive and immunomodulatory cytokine. It has profound effects on T cell
function favouring development of a T helper-2 (Th-2) type of immune response
(Mosmann and Moore, 1991), suppressing T-cell proliferation (Ayala, et al., 1994),
downregulating expression of the T-cell co-stimulatory ligand B7-1 (Iglesias, et al., 1997)
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and inducing anergy in T-cell clones (Groux, et al., 1996; Groux, et al., 1997). In
addition, IL-10 induces apoptosis (Estaquier, et al., 1997) and is important in post¬




Interleukin-6 (IL-6) is a pleiotrophic, immunomodulatory cytokine released by many cells.
Its receptors are expressed predominately on peripheral monocytes, macrophages, T- and
B-lymphocytes. IL-6 has been described as a "physiological regulator of the acute phase
reaction" and in addition, is a potent haemopoietic agent, B- and T cell differentiation
factor, neurotroph and stimulator of pituitary ACTH.
1.3 CHEMOKINES
Chemokines, previously referred to as members of the intercrines or small cytokine family
(scy family), are a subset of cytokines that are specific in their ability to induce chemotaxis
and activation of different cell types (Baggiolini, 1998; Baggiolini, et al., 1997;
Mantovani, et al., 1996). The chemokine family comprises small heparin binding
glycoproteins (8-10 kDa), which demonstrate 20 - 50 % sequence homologies at the
amino acid sequence and have common gene structures. In addition, they are identified by
the presence of four conserved cysteine residues that are involved in intramolecular
disulphide bonds giving them comparable secondary structures. Chemokines can be
divided structurally, by the positioning of the first two amino-terminal cysteine residues,
into one of four subfamilies (Figure 1). The C-X-C (cysteine - X amino acid - cysteine)
or a-chemokines are characterised by separation of the cysteine pair by a non-conserved
amino acid. In contrast, the two cysteine amino acids are adjacent in C-C (cysteine -
cysteine) or (3-chemokines. Recently two further classes of chemokines have been
identified. The C or y subclass (Kelner, et al., 1994) have a single cysteine at the N-
terminal. To date, the sole member of this class is lymphotactin, which is chemotactic for
T and B lymphocytes but not neutrophils and monocytes. The final subfamily is the
fractalkines, characterised by the C-X-X-X-C (Bazan, et al., 1997) motif.
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Figure 1
Amino acid sequences and two-loop structure of representative C-X-C and C-C
chemokines. Sequences are aligned according to the four highly conserved cysteine
residues, shown in boxes. The secondary structures for EL-8 and MCP-1 are also
illustrated with their disulphide bonds. A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G,
Gly; H, His; I, lie; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gin; R, Arg; S, Ser;
T, Thr; V, Val; W, Trp and Y, Tyr (Modifiedfrom Baggiolini et al, 1994)
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1.31 LEUKOCYTE CHEMOTAXIS
The key property of chemokines is their ability to induce leukocyte chemotaxis.
Leukocyte migration is a complex multistep process (Dunon, et al., 1996; Fowman, et ah,
1997) and is thought to occur in a number of sequential steps.
1. Leukocytes constitutively express the cell adhesion molecule, L-Selectin, which
contains the carbohydrate sialyl ligand, Lewis X. At inflammatory sites, pro¬
inflammatory cytokines such as TNF-a upregulate expression of E- and P-Selectin on
vascular endothelium. Leukocytes then bind transiently to E- and P-Selectin on the
activated endothelium via L-Selectin. The binding is weak permitting rolling of leukocytes
along the endothelial wall.
2. High local concentrations of cytokines and chemokines induce shedding of L-Selectin
from the leukocyte surface and upregulation and activation of (11 and (52 integrin
expression. The integrins bind strongly to their counterligands, vascular cell adhesion
molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1), expressed on
vascular endothelium, thus arresting leukocyte rolling. Leukocytes subsequently flatten
and adhere tightly to the endothelial surface.
3. Within tissue stroma, chemokines adhere to glycosaminoglycans (GAGs), such as
heparin and chondroitin sulphate (Koopman and Krangel, 1997; Middleton, et al., 1997;
Witt and Lander, 1994). This creates a transendothelial chemotactic gradient facilitating
leukocyte extravasation from the vasculature and subsequent migration to the site of high
chemokine concentration within the stroma.
1.32 CHEMOKINE RECEPTORS
Chemokines act via seven-transmembrane binding (7-TMB) receptors, which are linked,
to guanine nucleotide binding (G) proteins. The 7-TMB receptors form part of the
rhodopsin or serpentine superfamily of receptors which mediate many biological functions
including neurotransmission, hormone action and light perception (Strader, et al., 1994).
The receptors (339 - 373 amino acids) comprise an extra-cellular N-terminal domain
connected to the intra-cellular C-terminal domain by seven hydrophobic a-helical
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transmembrane spanning regions, which form three intracellular and three extracellular
transmembrane loops. The N-terminus contains many aspartate and glutamate residues
whereas the C-tail is rich in serines and threonines. Afterreceptor activation, the latter
become phosphorylated and bind arrestin thus desensitising the receptor (Lefkowitz,
1994). The receptors are coupled to G-proteins via their 2nd and 3rd intra-cellular loops.
G-proteins exist in an inactive form bound to guanine diphosphate (GDP) and are
activated after binding guanine triphosphate (GTP). Both monomeric and heterotrimeric
(a, p and y) forms exist but it is the latter that is involved in chemokine signal
transduction.
The interaction and subsequent receptor activation is best described for interleukin-8 (IL-
8), although it is likely that other chemokines will operate in a similar manner. Receptor
activation can be considered in a series of sequential steps. The ordered domain of
monomeric IL-8 binds to the extracellular domains of the 7-TMB (Ratharathanam, et al.,
1994). This induces a conformational change in the receptor partly exposing the
transmembrane domains which bind to the N-terminal domain of IL-8, inducing receptor
and then G-protein activation (Murphy, 1996). A variety of downstream effectors can
then be activated including adenylcyclase, phospholipase A2 (PLA2), C and D and tyrosine
kinase. There is no evidence that an individual chemokine receptors can discriminate
between two separate chemokines to generate distinct signal transduction pathways.
Chemokine signals can however be sorted functionally by cell type-dependant (Baggiolini
and Dahinden, 1994) and concentration dependant signal-sorting (Laudanna, et al., 1996).
Chemokine receptors can be subdivided into four main classes:
1. C-X-C chemokine receptors
C-X-C receptors demonstrate 36 - 77 % homology (Baggiolini, et al., 1997) and usually
bind a specific C-X-C chemokine with high affinity thereby affording them a relatively
selective function. Four different C-X-C receptors have been identified, C-X-C receptor
1-4 (R1-R4).
2. C-C chemokine receptors
C-C receptors demonstrate 46 - 89 % homology (Baggiolini, et al., 1997) but unlike C-X-
C chemokines are relatively non-specific, with each receptor binding a wide range of
different C-C chemokines. To date, five C-C chemokine receptors have been identified
(C-C 1-5) with each capable of binding at least three different C-C chemokines.
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3. Duffy antigen/receptor for chemokines (DARC)
DARC (338 amino acids) has <20 % homology with C-X-C and C-C receptors and,
although it binds both C-X-C and C-C chemokines, is not capable of signal transduction.
It was initially identified as the invasin for the malaria parasite Plasmodium vivax (Miller,
et al., 1976). DARC present on all erythrocytes and some non-erythroid cells including
endothelium of post-capillary venules, Purkinje cells of the brain (Horuk, et al., 1996)
and some B and T cells. The function of DARC is not certain but it has been proposed as a
sink for chemokines within the blood (Darbonne, et al., 1991) and more recently as a
vehicle for chemokine presentation (Murphy, 1996).
4. Viral chemokine receptors
Many viral receptors are homologous to chemokine receptors; for example the
cytomegalovirus receptor (CMV) US28 recognises MCP-1, regulated on activation and
normally T-cell expressed and presumably secreted (RANTES), monocyte inhibitory
peptide-la (MlP-la) and MIP-lp (Gao and Murphy, 1994) and C-C R3 and R5 and C-C
R4 (fusin) act as HIV receptor cofactors with CD4 for HIV infection into macrophages
(Deng, et al., 1996) and T cells (Feng, et al., 1996), respectively. In addition, certain
viral infections induce expression of chemokine receptors, such as the induction of IL-8
receptors by CMV infection (Marayama, et al., 1994) and C-C receptors by HIV
(Schmidtmayerova, et al., 1996). Further evidence supporting the link between
chemokines and viral infectivity comes from humans, homozygous for an inactivating
mutation of the C-C R5 gene who are resistant to HIV infection (Samson, et al., 1996).
x 33 a- OR C-X-C CHEMOKINES
a-Chemokines can be subdivided into those containing the ELR (glutamic acid - leucine -
arginine) motif between the NH2 terminus and the first cysteine which are chemotactic for
neutrophils, such as interleukin-8 (IL-8; Clark-Lewis, et al., 1991) and those without this





The cDNA for IL-8 was initially cloned in 1987 from a differential screen of stimulated
peripheral blood mononuclear cells and named 3-10C (Schmid and Weissman, 1987). It
was subsequently identified as a soluble factor in culture supernatants of peripheral blood
monocytes after LPS stimulation and classified as a chemokine (Lindley, et al., 1993).
IL-8 has many synonyms including neutrophil activating factor (NAT; Waltz, et al.,
1987), monocyte derived neutrophil chemotactic factor (MDNCF; Yoshimura, et al.,
1987), monocyte derived chemotaxin (MDC; Kownatzki, et al., 1991) and neutrophil
chemotactic factor (NCF).
Gene and protein structure
The IL-8 gene is 5.25 kBa in length, contains four exons (Mukaida, et al., 1989) and
encodes a mRNA transcript of approximately 1.8 kBa (Schmid and Weissman, 1987).
Many regulatory nuclear transcription factors such as NFkB, activator protein-1 (AP-1),
AP-2 and the glucocorticoid response element, can potentially bind to the 5' flanking
region of the IL-8 gene (Mukaida, et al., 1989). The IL-8 protein is a 99 amino acid non-
glycosylated peptide which is cleaved enzymatically on release from the cells generating
the mature 8 kDa (72 amino acid) protein (Lindley and Aschauer, 1988). N-terminal
proteolytic cleavage generates both shorter (69 amino acids) and longer (79 amino acid)
variants including the 77 amino acid endothelial form with the shorter variants being more
biologically active (Gimbrone, et al., 1989). The principal structural features of IL-8 are
the Cys - Cys bridges and the ELR motif. The latter is essential for functional activation
of the neutrophil receptor (Clark-Lewis, et al., 1991) and its angiogenic properties
(Strieter, et al., 1992; Strieter, et al., 1995). On crystallisation or in concentrated
solution, IL-8 exists as a non-covalent homodimer which is stabilised by side chain
interactions and hydrogen bonds to form two parallel a-helixes lying on an anti-parallel (1-
pleated sheet (Baldwin, et al., 1990). However, it likely that in vivo IL-8 acts as a
monomer (Clore, et al., 1992; Rajarathnam, et al., 1994).
Receptors
There are two forms of IL-8 receptor (Cerretti, et al., 1993), type I (interleukin receptor A;
C-X-C Rl) and type II (interleukin receptor B; C-X-C R2). Both receptors are dimeric G-
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protein coupled glycoproteins (59 kDa and 67 kDa subunits) encoded by the gene 2q35
(Morris, et al., 1992). They are present on the surface of neutrophils (20,000 - 75,000
receptor sites per cell; Besmer, et al., 1989) and T-lymphocytes (300 receptor sites per
cell). Binding of IL-8 to the specific type 1 receptor (Kd for IL-8 = 0.80 - 0.40 nM) is
thought to mediate neutrophil chemotaxis, degranulation and generation of superoxide
radicles. Type II receptor (Kd for IL-8 = 0.3-5 nM) is non-specific and recognises
chemokines related to IL-8 such as neutrophil activating peptide - 2 (NAP-2) and MIP-2.
IL-8 also binds to the DARC receptor (Besmer, et al., 1989).
Sources
IL-8 is released by a wide range of different cell types including monocytes (Yoshimura,
et al., 1987), macrophages, endothelial cells (Gimbrone, et al., 1989), lymphocytes,
fibroblasts (Larsen, et al., 1989), epithelial cells, neutrophils (Fujishima, et al., 1993),
mesangial and microglial cells (Ehrlich, et al., 1998). Its synthesis is induced by many
factors including inflammatory cytokines such as IL-1 (DeMarco, et al., 1991; Kaplanski,
et al., 1994) and TNF-a (Goldstein, et al., 1996), LPS, hypoxia (Karakurum, et al.,
1994), sheer stress, neutrophil adherence to endothelium, dsDNA and viral and bacterial
infection. Its synthesis is inhibited by dexamethasone, progesterone (Kelly, et al., 1992),
IL-10 (Wang, et al., 1994), TGF-(3 (Smith, et al., 1996) and IL-4.
Biological Functions
The principal function of IL-8 is in inducing the adhesion, chemotaxis, activation and
degranulation of neutrophils (Baggiolini, et al., 1989; Colditz, et al., 1989) with the
chemokine having a role in all stages. IL-8 facilitates neutrophil adhesion by inducing
shedding of L-selectin from the neutrophil surface and inducing translocation of the
CD 11-CD 18 integrin heterodimer to the neutrophil surface, which then binds to
endothelial ICAM-1. The chemokine induces neutrophil chemotaxis directly by binding to
vascular endothelium (Roit, 1992), thus promoting neutrophil adherence to vascular
endothelium and subsequent emigration, and indirectly by binding to the ECM creating a
diffusion gradient. In addition, IL-8 induced neutrophil extravasation is facilitated by the
presence of the vasodilator PGE2 which, by raising the threshold for infiltration from 10 "
mol to 10"14 mol IL-8 (Colditz, 1990), increases the number of accumulating neutrophils
and the associated volume of plasma exudation (Rampart, et al., 1989). Finally, IL-8
causes activation of extravasated neutrophils within tissue. Structural changes in the
neutrophil membrane (Wymann, et al., 1987) precede exocytosis of intra-cellular granules
and stimulation of the respiratory burst (Baggiolini and Wymann, 1990). Two types of
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intra-cellular granules are released, the specific granules containing matrix
metalloproteinase-8 (MMP-8; neutrophil collagenase), lysozyme, B12-binding proteins and
lactoferrin and the azurophilic granules containing elastase, myeloperoxidase and
lysozyme. The respiratory burst, generated by the trans-membrane NADPH-oxidase
electron transport system, results in formation of cytotoxic hydrogen peroxide and
superoxide radicals (Baggiolini, et al., 1992).
IL-8 is also chemotactic for T-cells (Larsen, et al., 1989), smooth muscle cells
(Baggiolini, et al., 1992), eosinophils and basophils, inducing histamine release from the
latter cell type. The chemokine also acts as a mitogenic and chemotactic agent in
keratinocytes (Larsen, et al., 1989), an angiogenic factor (Koch, et al., 1992) and has
been implicated in tumour growth and metastasis (Luca, et al., 1997).
1 34 |3- OR C-C CHEMOKINES
p-chemokines map to human chromosome 17qll-32.
Specific C-C chemokines
Monocyte Chemotactic Peptide - 1 (MCP-1)
Background
In the early 1980's, it was reported that human tumour culture supernatants contained
chemotactic activity for mononuclear cells (Bottazzi, et al., 1983). This activity was
subsequently identified as monocyte chemotactic factor, monocyte chemotactic and
activating factor, chemotactic factor or monocyte chemotactic peptide-1 (Rollins, et al.,
1988).
Gene and protein structure
The MCP-1 gene (Mehrabian, et al., 1991) is analogous to the mouse competence gene JE
(Yoshimura, et al., 1989) containing three exons, two introns (Chang, et al., 1989) and
binding sites for a variety of transcription factors including NFkB and AP-1. The protein
is a 76 amino acid basic heparin binding glycoprotein (12 kDa) which displays varying
degrees of glycosylation (Jiang, et al., 1990). The tertiary structure of MCP-1 is similar
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to that of IL-8 with both capable of existing as monomers and dimers (Gronenborn and
Clore, 1991).
Receptors
MCP-1 binds to C-C R-2 and C-C R-4 receptors with the carboxy terminal of the
receptors thought to be critical for chemotaxis, signalling and receptor internalisation
(Aral, et al., 1997).
Sources
MCP-1 is released by a wide range of different cell types including monocytes, pericytes
(Chensue, et al., 1995), fibroblasts (Rolfe, et al., 1992), vascular smooth muscle (Wang,
et al., 1991), endothelial (Hub and Rot, 1998), retinal pigment (Elner, et al., 1997) and
synovial cells (DeMarco, et al., 1991) cells. MCP-1 is induced by a wide range of factors
including LPS, IL-1, TNF-a (Goldstein, et al., 1996) and the membrane attack
component of complement (Kilgore, et al., 1996) and inhibited by progesterone (Kelly, et
al., 1997).
Biological Function
MCP-1, in addition to being a monocyte chemotaxin, is also chemotactic for T-cells (Cai,
et al., 1995), basophils, mast cells (Feliciani, et al., 1995), NK cells and IL-2 activated
NK cells (Allavena, et al., 1994). A number of other functions have also been ascribed to
MCP-1 including that of an angiogenic agent, tumour suppressive agent (Rollins and
Sunday, 1991), mitogen for vascular smooth muscle (Porreca, et al., 1997), regulator of
cytokine expression (Jiang, et al., 1992) and immunomodulator, favouring development
of a Th-2 type of immune response (Chensue, et al., 1996).
Regulated on Activation and Normally T-cell Expressed and Secreted
(RANTES)
Background
The cDNA was first identified during a general genetic screen of T-cells (Schall, et al.,
1988) with the protein subsequently given the acronym RANTES, based on functional
predictions from the gene and protein.
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Gene and protein structure
The RANTES gene has three exons and two introns and encodes a mRNA transcript of
approximately 1.2 kBa in length. Unlike MCP-1 and IL-8, the transcriptional regulation
of RANTES depends on the cell in which it is being expressed with transcription in T-
cells, fibroblasts and endothelial and epithelial cells being developmentally regulated
(Ortiz, et ah, 1996), an immediate early gene response (Rathanaswami, et al., 1993) and
the result of cytokine stimulation (Crane, et al., 1998), respectively. RANTES protein
comprises a highly basic 91 amino acid glycosylated polypeptide which likely exists as a
dimer at physiological pH (Fairbrother and Skelton, 1996).
Receptors
RANTES binds to C-C Rl, R3, R4 and R5 receptors, which are expressed on
monocytes, eosinophils, basophils and T-cells. It also binds to the DARC antigen and the
CMV US28 receptor.
Sources
RANTES is released by many cell types including T-cells (Wingett, et al., 1996),
monocytes, basophils, mesangial cells, fibroblasts, endothelium (Hub and Rot, 1998),
epithelium (Stellato, et al., 1995), airway smooth muscle cells (John, et al., 1997) and
eosinophils.
Biological Function
RANTES is a potent chemotactic and activating agent for CD4+ and CD45RO+ (memory)
T-cells, eosinophils (Alam, et al., 1993) and basophils, is chemo- and haptotactic for
monocytes and chemotactic for NK cells, inducing histamine release from the latter cell
type (Kuna, et al., 1992). It also mediates adhesion of CD4+ T cells to ICAM-1 and
VCAM-1 via upregulation of (31 and (32 integrin expression. Recently, RANTES has been
demonstrated to inhibit HIV replication by competing for binding to C-C R5 receptor.
RANTES expression is induced by many factors including TNF-a and IL-la and
inhibited by TGF-p, IL-6 and IFN-y.
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1.4 OTHER INFLAMMATORY MEDIATORS
1.41 PROSTAGLANDINS
Nomenclature
Prostaglandins were first identified in 1936 by Von Euler in prostatic extracts (Von Euler,
1936). Structurally, they comprise a family of C20 carboxylic acids with a cyclopentane
ring from which two aliphatic side chains linked to a carboxyl and methyl group protrude
(Mitchell, 1992). Prostaglandins are divided into the A, B, C, D, E, F, J, G and H series
with the latter two being unstable endoperoxide intermediates involved in prostaglandin
synthesis. The PGE and PGF series can be further classified into three subgroups, E,, E2
and E3 and Fla, F2a and F3 a, respectively with the subscript denoting the number of side
chain double bonds. The two series differ in that the PGEs have a C-9 keto-oxygen and a
C-ll hydroxyl group in the cyclopentane ring whereas the PGFs have hydroxyl groups at
both positions (Willis and Smith, 1994).
Synthesis
Prostaglandins are produced by de novo synthesis from the fatty acid precursor
arachidonic acid (5, 8, 11, 14-eicosatetraenoic acid, AA) which is released from
membrane bound phospholipids (phosphatidylcholine and phosphatidylethanolamine),
after cell signalling, principally by PLA2. Phospholipase C, in conjunction with
diacylglycerol lipase, also releases a small amount of arachidonic acid. Subsequent
synthesis is by the multi-enzyme prostaglandin H endoperoxide synthase/cyclooxygenase
(PGHS/COX) complex. Arachidonic acid initially undergoes double oxidation
(cyclooxygenation) to produce PGG2, which then rapidly undergoes peroxidase
conversion to PGH2. The endoperoxides are subsequently modified by synthases or
isomerases to generate specific prostanoids, the most common being PGE2, PGF2„,
PGD2, prostacyclin (PGI2) and thromboxane A2 (TXA2).
Cyclooxygenase enzymes
Two isoforms of the cyclooxygenase enzyme have been identified, COX-1 and more
recently COX-2 (Goppelt-Streube, 1995; Kujubu, et al., 1991). Although the isoforms
share 60 % homology at the amino acid level, they are products of different genes and
have marked differences in their regulation and subcellular expression. The constitutively
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expressed COX-1 is thought to play a housekeeping role in prostaglandin production
(O'Banion, et al., 1992; Simmons, et al., 1991) and is associated with the endoplasmic
reticulum (Morita, et al., 1995). In contrast, COX-2 is dynamically regulated, in part via
NFkB and localised to the nuclear envelope (Morita, et al., 1995). COX-2 is a typical
inducible gene with many binding sites in the 5' untranslated TATA box and the presence
of binding sequences (AUUUA) for ribonucleases in the 3' untranslated end (Malter,
1989). The expression of its 4.1 kBa mRNA is tightly regulated at the level of
transcription, being stimulated by inflammatory mediators (LPS, Phorbol 12 - Myristate
13 - Acetate, PMA), growth factors (PDGF), cytokines (IL-1, TNF-a) and hormones
(human chorionic gonadotrophin; (hCG; Han, et al., 1996) and inhibited by
glucocorticoids (Masferrer and Seibert, 1994) and IL-1 receptor antagonist (Porreca, et
al., 1996). Further regulation occurs pre-translation by modulation of mRNA stability
and post-translation by rapid degradation of the mRNA by ribonucleases.
Metabolism
The principle site of prostaglandin metabolism is the lung with prostaglandins being
metabolised by the progesterone stimulated prostaglandin dehydrogenases (PGDH-1 and
PGDH-2) and Al3-reductase to the inactive 13-14-dihydro-15-keto metabolites. The
majority of circulating prostaglandins are metabolised with one passage through the lung
with only a small amount of catabolism occurring locally within tissues. However during
pregnancy, uterine PGDH localised predominately in fetal membrane trophoblast, also
contributes significantly to prostaglandin metabolism (Cheung, et al., 1990).
Receptors
Prostaglandin receptors are members of the 7-TMB class of receptors. The physiological
response elicited by a specific receptor is unique and due in part to utilisation of different
intracellular 2nd messenger systems such as phosphatidylinositol and adenylate cyclase
(Pierce, et al., 1995). Five classes of receptor have been identified, DP, EP, FP, IP and
TP with the receptors preferentially binding PGD, PGE, PGF, PGI and TXA,
respectively (Coleman, et al., 1990). The EP and TP families are further divided into
subfamilies with four EP receptor isoforms, EP-1, -2, -3 and -4 being identified so far. In
general, EP-1 and EP-3 elicit stimulatory responses whereas EP-2 and EP-4 evoke
inhibitory effects (Coleman, et al., 1994).
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Biological Effects
Prostaglandins are powerful mediators, which exert diverse effects in many biological
systems. Their general effects which include pro- (TXA2) and anti- (PGEs, PGI2)
coagulant properties, inducing vasodilation (PGEs and PGI2) and vasoconstriction (PGFs
and TXA2), bronchodilation (PGEs) and bronchoconstriction (PGFs) and regulation of
transmembrane ion flow are well established. More recently, it has been established that
prostaglandins possess powerful immunomodulatory properties and are capable of both
promoting and inhibiting immune responses via their interactions with and regulation of
local cytokine release. Many of these have already been discussed and those of direct
relevance to pregnancy and parturition will be covered later.
1.42 NITRIC OXIDE
Nitric oxide is a potent locally acting mediator which is synthesised from arginine by nitric
oxide synthase (NOS) which generates nitric oxide and citrulline. Alternatively, arginine
can be metabolised by arginase to give urea and ornithine. Three different isoforms of
NOS have been identified, endothelial NOS (eNOS), neuronal NOS (nNOS) and
inducible NOS (iNOS). Endothelial NOS and nNOS, encoded by chromosomes 12 (150
kBa, 29 exons) and 7 (21 - 22 kBa, 26 exons) respectively, are constitutively expressed
and calcium/calmodulin dependant (Mayer and Hemmens, 1997). In contrast, iNOS,
encoded by chromosome 17 (37 kBa, 26 exons), is rapidly induced and
calcium/calmodulin independent (Mayer and Hemmens, 1997). All three isoforms are
composed of a C-terminal reductase, which has binding sites for FAD, FMN and NADPH
and an N-terminal oxygenase that binds haem and tetrahydrobiopterin, the latter being a
cofactor for the NAPDH dependant oxygenation of nitric oxide.
Nitric oxide is synthesised by a wide range of different cell types including macrophages
(Imai, et al., 1993), cardiac muscle, astroglia, hepatocytes, osteoclasts (Sunyer, et al.,
1996), endothelium (Berman, et al., 1998), myometrium (Thomson, et al., 1997), fetal
membranes (Ticconi, et al., 1996) and cervix. Release of nitric oxide is regulated by
many hormones and inflammatory mediators, with the latter thought to act via NFkB
(DeVera, et al., 1997). Nitric oxide is stimulated by LPS, IFN-y (Corraliza, et al., 1995;
Haddad, et al., 1997), TNF-a, IL-la (Nusing, et al., 1996; Sunyer, et al., 1996),
hypoxia (Palmer, et al., 1998) and oestrogen (Hunt, et al., 1997; Kleinert, et al., 1998)
and inhibited by TGF-|3 (Alleva, et al., 1994) and dexamethasone (O'Connor and
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Moncada, 1991). Modolell (Modolell, et al., 1995) proposed that the NOS and arginase
were reciprocally regulated with Th-1 cytokines favouring NOS and Th-2 cytokines
arginase. The effects of many factors on nitric oxide production however frequently
conflict, with PGE9, IL-8, IL-10 and progesterone being capable of stimulating
(Benbernou, et al., 1997; Sunyer, et al., 1996) and inhibiting nitric oxide release (Alleva,
et al., 1994; Modolell, et al., 1995). Therefore, the proposed regulatory control exerted
by Th-l/-2 cytokines on the NOS/arginase balance is controversial. Control of nitric
oxide synthesis is thus highly complicated and may be influenced by many factors
including intra-tissue differences, experimental procedures and the concentration of nitric
oxide within the system being studied (Swierkosz, et al., 1995).
Unlike cytokines and prostaglandins, nitric oxide does not act as a classical intracellular
messenger by binding to soluble or membrane bound receptors. Instead, it is freely
diffusible and its biological effects are determined by its chemical reactivity and site of
synthesis. Many, but not all of the physiological effects of nitric oxide are mediated by its
binding to the haem group of soluble guanylate cyclase, thereby stimulating cyclic
monophosphate (cGMP) formation by several hundred fold. Nitric oxide is a potent
mediator of platelet aggregation, vascular permeability and smooth muscle relaxation
(Buhimschi, et al., 1997) and proliferation. It is an important mediator of the immune
system stimulating IL-8 (Corriveau, et al., 1998; Cuthbertson, et al., 1998) and MMP
(Maeda, et al., 1998) release via activating the cysteine shift and inhibiting IL-1(3 and
TNF-a secretion. In addition, nitric oxide regulates the release of pituitary luteinising
hormone releasing hormone (LHRH; Moretto, et al., 1993) and placental corticotrophin
releasing hormone (CRH) release (Clifton and Challis, 1997) and can paradoxically both
stimulate (Brockhaus and Brune, 1998) and inhibit apoptosis (Kim, et al., 1997)
depending on other environmental factors. Nitric oxide also exerts opposing effects on
COX-2, stimulating and inhibiting the enzyme in vitro and in vivo (Salvemini, et al.,
1994; Vane, et al., 1994). Whether a positive or negative feedback exists between nitric
oxide and COX-2 is not certain (Tetsuka, et al., 1994).
35
1.43 MATRIX METALLOPROTEINASES AND TISSUE
INHIBITORS OF METALLOPROTEINASES
Matrix metalloproteinases (MMPs) are a family of zinc and calcium dependent enzymes
that are responsible for degradation of the ECM. They can be subdivided, by nature of
their specificity for the ECM and location into the collagenases, gelatinases, stromelysins,
membrane-type MMPs and a miscellaneous group. Seventeen MMPs have so far been
characterised (Table 1).
MMPs are secreted as inactive proMMPs or zymogens, which are activated by proteolytic
cleavage to give the active enzyme (Hulboy, et al., 1997). At the amino terminus is the
'pre' domain, which signals for cellular export. Cleavage and removal of the 'pro'
domain, which is adjacent to the 'pre' domain, by other MMPs including membrane
bound MMPs (Sato, et al., 1994), serine proteases (plasminogen activator and kallikreins;
Espey, 1992) and mast cell proteases (Suzuki, et al., 1995) converts proMMPs to the
active enzyme. 'Pro' domain cleavage, otherwise known as the cysteine switch
mechanism, involves disengagement of a cysteine in the conserved 'pro' domain sequence
PRCGVPDV. This uncovers a zinc ion, which is held by co-ordinate bonding to three
histidines in the active site (amino acid consensus sequence HEXGHXXGXXHS) in the
adjacent catalytic domain. Finally, binding of water to the uncovered zinc in the active site
completes MMP activation.
In addition to the three fundamental domains, all MMPs apart from MMP-7 possess other
regions that confer diversity in their association with ECM and substrate. For example;
haemopexin-like domains (all MMPs) mediate association to the ECM and MMP inhibitors
(Baragi, et al., 1994), fibronectin domains (MMP-2 and MMP-9) facilitate gelatin
binding, Mt-MMPs contain a transmembrane domain that localises the enzyme to the
plasma membrane and Mt-MMPs and MMP-11 possess a region which binds furins,
which are protein-processing enzymes.
Expression of proMMP genes is subject to control during transcription, translation, by
changes in mRNA stability, at the activation of the pro-enzymes by proteolytic cleavage
and by the association and dissociation of MMPs with their specific inhibitors. MMP
release can be stimulated by cytokines (IL-1, TNF-a and IL-6), ECM components,
MMPs, LPS, nitric oxide and PGE2 and inhibited by SLPI, cytokines (IL-4, IL-10, TGF-







Collagenases Interstitial MMP-1 (52000) Collagens I, II, III, VII,
collagenase 42000 gelatins, TNF-a
(56000)
46,000
Neutrophil MMP-8 (75000) Collagens I, II, III
collagenase 65000
Collagenase 3 MMP-13 (53700) Collagen I
Gelatinases 72 kDa MMP-2 (72000) Gelatins, collagens I, IV,
Gelatinase 62000 V, VII, elastin,
fibronectin, TNF-a
92 kDa MMP-9 (92000) Gelatins, collagens IV,
Gelatinase 84000 V, elastin, TNF-a
Stromelysins Stromelysin MMP-3 (56000) Proteoglycans, laminin,
45000 fibronectin, collagen III,
(59000) IV, V, gelatins, TNF-a,
28000 MMP-1, -8, and -9
Matrilysin MMP-7 (28000) Proteoglycans, laminin,
19000 fibronectin, gelatin,
collagen IV, elastin,
TNF-a, MMP-1 and -9
Stromelysin 2 MMP-10 (60000) Proteoglycans,
55000 fibronectin, collagen III,
IV, V, gelatins, MMP-8
Stromelysin 3 MMP-11 Laminin, fibronectin
Membrane Mt-MMP-1 MMP-14 (63000) MMP-2
type MMPs
Mt-MMP-2 MMP-15 ? ?
Mt-MMP-3 MMP-16 ? MMP-2
Mt-MMP-4 MMP-17 ? ?
Other Metalloelastase MMP-12 ? Elastin, fibronectin,
collagen IV
Table 1
Matrix metalloproteinases - nomenclature and substrate specificity
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The principal inhibitors of MMP function are the liver derived, serum borne a2-
macroglobulin and the natural inhibitors, the tissue inhibitors of metalloproteinase release
(TIMPs). TIMPs are arranged in two domains by disulphide bonds with each TIMP
inhibiting the activity of most MMPs by non-covalent 1 : 1 stoichiometric binding to the
active site of the MMP. There is no apparent selectivity of TIMPs for particular MMPs
with this residing in their specific distribution within tissues. Four TIMPs have so far





TIMP-1 28 000 Glycosylated Soluble in ECM and
body fluids
TIMP-2 21 000 Not glycosylated Soluble in ECM and
body fluids
TIMP-3 24 000 Not glycosylated Bound to ECM
TIMP-4 22 000 ? ?
Table 2
Tissue inhibitors of matrix metalloproteinases - nomenclature and substrate specificity
The ratio of MMPs to TIMPs determines whether tissue remodelling or deposition occurs.
In addition to inhibiting MMP activity, TIMPs stimulate progesterone production by
various cells (Boujrad, et al., 1995) and stimulate proliferation of various cell types
(Edwards, et al., 1996).
1.44 SECRETORY LEUKOCYTE PROTEASE INHIBITOR
Gene and protein structure
Secretory leukocyte protease inhibitor is a member of the chelonianin family of proteinase
inhibitors which also includes elafin (Francart, et al., 1997). The majority of its protease
inhibitor action activity resides in the carboxy domain (Meckelein, et al., 1991). The
function of the amino domain is less well defined but it may have a role in stabilising
binding of secretory leukocyte protease inhibitor to elastase (Ying, et al., 1994) and in




Secretory leukocyte protease inhibitor binds to a high affinity, surface receptor on
monocytes (equivalent to 7,000 receptors per monocyte; Kd = 55 ± 5 kDa) of molecular
weight 55 ± 5 kDa. In other sites, such as epithelial surfaces, secretory leukocyte
protease inhibitor receptor has not been characterised.
Sources
Secretory leukocyte protease inhibitor is released by a wide range of cells and tissues
including neutrophils, intact (Asano, et al., 1995) and remodelled epithelial (Marchand, et
al., 1995) surfaces and endometrium (Badinga, et al., 1994). In addition, secretory
leukocyte protease inhibitor is present in serum (Reed, et al., 1998), seminal plasma
(Ohlsson, et al., 1995), peritoneal fluid (Bergenfeldt and Ohlsson, 1993) and in ECM
associated with elastin fibres (Kramps, et al., 1989; Rudolphus, et al., 1994). Release of
secretory leukocyte protease inhibitor is stimulated by corticosteroids (Abbinantenissen, et
al., 1995; Abe, et al., 1997), trypsin (Abbinantenissen, et al., 1993), cytokines (Jin, et
al., 1998; Sallenave, et al., 1994) and PMA (Maruyama, et al., 1994). Secretory
leukocyte protease inhibitor is inhibited by elastase (Marchand, et al., 1997) and IFN-y
(Jin, et al., 1997).
Biological Function
Although initially described as a potent inhibitor of neutrophil elastase and cathepsin-G
(Thompson and Ohlsson, 1986), secretory leukocyte protease inhibitor also inhibits the
activity of mast cell kinases (Pemberton, et al., 1998; Walter, et al., 1996) and
chymotrypsin (Franzke, et al., 1996), prolongs clotting (Masuda, et al., 1995) and has
anti-bacterial (Hiemstra, et al., 1996), anti-fungal (Tomee, et al., 1997) and anti-viral
(Shine, et al., 1997) activity including against HIV (Shugars, et al., 1996) and anti¬
coagulant properties (Masuda, et al., 1995). Recently secretory leukocyte protease
inhibitor has also been shown to suppress the LPS-induced activation of NFkB,
production of nitric oxide and TNF-a (Jin, et al., 1997) and inhibit release of MMPs via
inhibition of COX-2 (Zhang, et al., 1996).
1.45 Th-1 AND Th-2 IMMUNE MODULATION
In 1988, Mosmann and colleagues (Mosmann and Coffman, 1989) proposed the
hypothesis that T-helper cells (CD4+) could be divided into Th-1 and Th-2 subtypes
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according to their profile of cytokine release and immunological functions. Th-1 type
cytokines (IL-2, IL-12, IFN-y) are pro-inflammatory and stimulate a cell mediated type of
immune response whereas Th-2 type cytokines (IL-10, IL-4, IL-5 and IL-6) tend to be
immunosuppressive and favour humoral immune responses. The original concept has
now been expanded since cells other than T cells have been found to secrete Th-1 and Th-
2 type cytokines (Mosmann and Sad, 1996). It is now appreciated that cellular cytokine
secretion is likely a continuum, with "pure" Th-1 and Th-2 type release representing the
two extremes. In addition, other regulatory T-cell subsets have recently been described
with Th-0 cells secreting both patterns of cytokines (Mosmann and Coffman, 1989), Th-3
releasing high amounts of TGF-(3 (Chen, et al., 1994) and Tr-1 or regulatory T-cells
(Groux, et al., 1997).
The generation of a Th-1 or Th-2 immune response is tightly controlled with a variety of
factors being implicated. There is mutual repression between Th-1 and Th-2 responses
with IL-12 stimulating Th-1 cytokines and inhibiting Th-2 (Trinchieri, 1993) and T cell
derived IL-10 effecting the opposite (Mosmann and Moore, 1991). Chemokines, by
virtue of their specific chemotactic properties, preferentially attract Th-1 (monocyte
inhibitory peptide-1, MlP-la; MIP-l|f and RANTES) or Th-2 (MCP-1; (Chensue, et al.,
1996) or both T cell subsets (stromal cell-derived factor-a; Siveke and Hamann, 1998).
In addition, MlP-la and MCP-1 drive uncommitted Th-0 cells to differentiate into Th-1
and Th-2 secreting T helper cell populations, respectively (Karpus and Kennedy, 1997).
Prostaglandins are also important modulators of humoral and cell mediated immune
responses with PGE2 being recently shown to favour a Th-2 tilt (downregulation of IFN-
y, IL-12 and IL-2 and upregulation of IL-10) to the immune response (Fedyk, et al.,
1997; Hilkens, et al., 1995; Kelly, et al., 1997; Kraan, et al., 1995; Snijdewint, et al.,
1993). Other inflammatory mediators have contradictory effects on the Th-l/Th-2
balance. In mice, nitric oxide favours a Th-2 response (Bauer, et al., 1997) but in
humans, it has been shown to prevent over-expansion of Th-1 cells (TaylorRobinson,
1997), induce a Th-2 response (Benbernou, et al., 1997) and have an equal effect on both
T cell subtypes depending on the system studied (Bauer, et al., 1997).
Th-l/Th-2 shift during pregnancy
Wegmann proposed the hypothesis that a Th-l/Th-2 paradigm exists during pregnancy
(Wegmann, et al., 1993). He postulated that a Th-2 cytokine profile would confer local
immunosuppression at the materno-fetal interface thus favouring successful pregnancy.
In contrast, a Th-1 response would be detrimental to pregnancy and be associated with a
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poor reproductive outcome. Considerable experimental and clinical evidence now
supports these postulates. Both the peri-implantation endometrium (Lim, et al., 1998) and
fertilised ovum (Kelemen, et al., 1998) induce and secrete a predominant Th-2 type
cytokine profile. This is supported by high levels of circulating progesterone, which
favours a Th-2 type cytokine response (Piccinni, et al., 1995) and CD4+ and CD8+ T-cells
which, during successful pregnancy, preferentially secrete Th-2 cytokines (Reinhard, et
al., 1998). In contrast, the Th-1 cytokines TNF-a, IFN-y and IL-2 have adverse effects
on trophoblast proliferation and trophoblast development (Raghupathy, 1997). This is
manifested clinically in women with a history of recurrent spontaneous miscarriage who
demonstrate a Th-1 bias in their immune response locally within the uterus (Haynes and
Smith, 1997; Hill, et al., 1995) and peripherally in circulating T-cell clones (Piccinni and
Romagnani, 1996; Raghupathy, 1997). Furthermore, there is evidence that conditions
such as rheumatoid arthritis, associated with a Th-1 response remit during pregnancy and
those such as systemic lupus erythematosis, mediated by a Th-2 response, are exacerbated
(Wilder, 1998). Within the uterus, many cells are capable of secreting Th-2 type
cytokines including NK cells (Chaouat, et al., 1997), T helper cells, macrophages,
trophoblast and endometrial cells (Kelly and Critchley, 1997).
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1.5 PARTURITION
In many animal species, such as sheep, the mechanisms and mediators involved in the
initiation and maintenance of parturition are well characterised. However, in humans the
precise factors involved are not well understood and knowledge of the initiating agents has
progressed little since Hippocrates proposed in about 430 BC that:
"When the child is grown big and the mother can no longer provide him with enough
nourishment he becomes agitated, breaks through the membranes and incontinently
passes out into the external world free from any bonds."
James Young Simpson subsequently refuted the various theories of parturition which
existed at that time such as:
"the supposed origin of the act of labour in certain states of vital development or
physical expansion of the fundus, body or cervix uteri, in some supposed conditions
of the foetus, liquor amnii, or placenta etc., " and suggested that "the loosening or
decadence of the membranes, or membranes and placenta from the interior of the
uterus, constituted the determining cause of parturition; and that this loosening or
decadence was itself the result of the effete degeneration of the structure of the decidua
towards the full term pregnancy."
Although many theories, some of which are described below, have been proposed for
parturition, none fully accounts for the unique and highly complex process that cumulates
in emptying of the uterus and delivery of the neonate.
1.51 THEORIES OF PARTURITION
Progesterone withdrawal
High levels of progesterone within the utero-placental unit are essential for initiation and
maintenance of a successful pregnancy. Progesterone acts locally within the uterus during
pregnancy to suppress uterine contractions (Beck, et al., 1978) and decrease gap junction
formation (Ambrus and Rao, 1994). In many species such as sheep, a relative fall in
progesterone and rise in oestrogen levels, peripherally and locally within the uterus,
heralds the onset of parturition. In term rat myometrium, a significant decrease in nuclear
42
progesterone receptors and increase in oestrogen receptors correlates with an increase in
gap junction formation and initiation of parturition (Nathanielsz, 1991). Similarly, a pre-
partum rise in oestrogen in monkeys at term induces gap junction formation, synthesis of
oxytocin and prostaglandins and alteration of myometrial activity from contractures to
parturient contractions (Saito, et ah, 1985).
Csapo, therefore postulated that a similar "progesterone block" might operate at term in
humans (Csapo, 1956) and, in 1975 hypothesised the "see-saw" theory of pregnancy
(Csapo, 1975). He proposed that pregnancy maintenance was dependent on the balance
between factors favouring pregnancy, such as progesterone and those promoting its
termination, such as PGF2a. To date, however, there is no good experimental evidence to
support progesterone withdrawal as the initiating factor for human parturition. A study
which examined peripheral levels of progesterone, dehydroepiandrosterone, (DHEAS; an
oestrogen precursor), oestrogen and oestradiol in women with favourable (Modified
Bishops Score >4) and unfavourable cervices (Modified Bishops Score <4) prior to the
induction of term labour found that concentrations of DHEAS were significantly elevated
only in those with ripe cervices (Zuidema, et al., 1986). This study and others
(Anderson, et al., 1985) did not demonstrate a pre-parturient fall in peripheral
progesterone concentrations. Furthermore, it has been demonstrated that peripheral
progesterone levels are lower in women with dysfunctional compared with normal
spontaneous labour at term, the conclusion being that "high" circulating progesterone was
necessary for normal parturition. In contrast, an increased salivary oestriol/progesterone
ratio has been demonstrated in the three weeks prior to the onset of spontaneous labour
but not in women who ultimately delivered post-dates.
The situation is no less confusing within the term uterus with evidence for local changes in
the progesterone : oestrogen ratio (Romero, et al., 1988), and their metabolism (Milewich,
et al., 1977) being conflicting. In addition, although the number of nuclear progesterone
and oestrogen receptors within the uterus decreases during pregnancy to low (Khan-
Dawood and Dawood, 1984; Padayachi, et al., 1987; Perrot-Applanat, et al., 1994) or
undetectable levels at term (Padayachi, et al., 1987), there is no evidence that any further
alteration in receptor number (Khan-Dawood and Dawood, 1984) or isotype occurs at
parturition. It may be however, that formation of a local anti-gestogen (e.g. TGF-|3),
reduction in affinity of progesterone binding for its receptors or sequestration by a binding
protein may effect a local fall in progesterone concentration within the feto-placental unit
thus permitting parturition. Indirect evidence supporting a local fall in progesterone at
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term comes from studies demonstrating a rise in concentrations of IL-8 (Sennstrom, et al.,
1997) and gap junctions (Chow and Lye, 1994) within the uterus at parturition. These
factors are normally inhibited by progesterone (Ambrus and Rao, 1994; Kelly, et al.,
1994).
Inflammatory reaction
More recently, parturition has been likened to an inflammatory reaction (Liggins, 1981)
with pro-inflammatory cytokines such as IL-1, IL-6 and IL-8 acting as initiators and
propagators at the local level (Steinborn, et al., 1998). Concentrations of IL-1 and IL-6
rise in peripheral serum (Arntzen, et al., 1997), in the uterus (Ammala, et al., 1997) and
amniotic fluid at the onset of labour with levels increasing with the strength of uterine
contractions (Arntzen, et al., 1997), the degree of leukocyte invasion (Halgunset, et al.,
1994) and cervical dilatation (Steinborn, et al., 1996). In addition, IL-1 and IL-6 can
potentially further propagate the inflammatory reaction by stimulating release of IL-8 and
uterine prostaglandins (Kelly, 1994). However, the criticism that has been raised about
all studies conducted on cytokines and parturition, is whether changes in cytokine levels
are the cause or effect of the parturient process.
Prostaglandins, particularly the PGE and PGF series, are thought to have an important
role in parturition. They are synthesised by amnion, chorion and decidua and act within
the uterus to change membrane structure (Gibb, 1998) and contract the myometrium. It is
generally accepted (MacDonald and Casey, 1993) that concentrations of PGE, and PGF2„
rise in amniotic fluid prior to the onset of uterine contractions (Romero, et al., 1996) and
increase further with the onset of labour (Gibb, 1998). The expression of the inducible
PGHS-2 isoenzyme (Mijovic, et al., 1998) increases within chorion and amnion and
expression of PGDH decreases in chorion at term. Alteration in the ratio of these
enzymes, which may in part be due to the regulatory effect of glucocorticoids, may permit
prostaglandins synthesised by the fetal membranes to gain access to the myometrium and
cervix. In addition, a factor present in amniotic fluid at term is thought to have a
permissive effect on the release of prostanoids from the fetal membranes (Brennand, et
al., 1998).
Recently, nitric oxide has also been implicated in parturition although whether it acts to
promote (Chwalisz and Garfield, 1998) or inhibit the process is controversial (Nanno, et
al., 1998). Experimental and clinical evidence suggests that nitric oxide plays an
important role in animals during pregnancy by maintaining uterine quiescence and
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placental perfusion. In rats at term, uterine nitric oxide expression is significantly down
regulated prior to parturition, thus permitting uterine contractions. However, in humans
although there is a significant fall in peripheral levels of nitric oxide (Nanno, et ah, 1998),
studies in the uterus have failed to demonstrate changes in levels of nitric oxide or nitric
oxide synthase (Thomson, et ah, 1997) during human parturition.
Many other factors have been implicated in initiating and maintaining parturition.
Concentrations of gravidin, a phospholipase A2 inhibitor (Baumann, et al., 1998) and
activin A, an immunomodulatory agent which stimulates PGE2 release (Petraglia, et al.,
1993) also increase (Petraglia, et al., 1997) prior to parturition. In addition, the
expression of certain endothelial cell adhesion molecules (endothelial leukocyte adhesion
molecule-1 and VCAM-1) increase within the lower uterine segment (Winkler, et al.,
1998). These factors could further promote a pro-inflammatory parturient response.
Placental clock
Concentrations of maternal plasma corticotrophin releasing hormone (CRH), which is
secreted mainly by the placenta, rise during pregnancy and are elevated at the time of
preterm labour (Campbell, et al., 1987). McLean and colleagues demonstrated that
maternal plasma levels of CRH were elevated in the first trimester in those women
destined to deliver prematurely and were lower in those who delivered post-dates. In
addition, high circulating concentrations of corticotrophin releasing hormone binding
protein (CRH-BP) effectively blocked the bioactivity of CRH until the final three weeks
before parturition when the rise in plasma CRH was accompanied by a fall in CRH-BP.
They suggest the existence of "a placental clock which triggers the onset of parturition
after a predetermined length of gestation and that the maternal plasma CRH is an indicator
of the rate of progress towards this event".
Supportive of this hypothesis is the observation that levels of CRH-type 1 receptor (CRH-
Rl) mRNA and protein increase within the lower uterine segment with the onset of
labour. Challis and colleagues (Challis, 1998) have suggested that the rise in placental
CRH may contribute to relaxation of the lower uterine segment via CRH-R1 and to
stimulation of fundal myometrial activity either directly via binding to CRH-R2 and
inducing calcium mobilisation or indirectly by stimulating fundal prostaglandin
production.
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Maturation of the fetal hypothalamo-pituitary-adrenal axis
A number of theories have been proposed in which the fetal adrenal interacts with steroid
hormone production by the placenta to trigger parturition.
One hypothesis propounded by Wilson et al (1996) (Wilson and Parsons, 1996) is that
increased levels of oestriol at term stimulate placental ll(3-hydroxysteroid dehydrogenase,
which converts Cortisol to inactive cortisone thus lowering exposure of the fetus to
maternal Cortisol. Negative feedback to the fetal pituitary releases corticotrophin, which
stimulates fetal adrenal DHEAS synthesis. DHEAS is then converted to oestriol in the
placenta after being 16 a-hydroxylated in the fetal liver. The rise in placental oestriol
release could then stimulate release of oxytocin, prostaglandins and gap junctions, leading
to uterine contractions and cervical dilatation.
An alternative model suggests that Cortisol blockade of progesterone acts to initiates
parturition (Karalis, et al., 1996). Karalis et al., (1996) suggest that the huge rise in fetal
Cortisol at term competes with progesterone for glucocorticoid-receptor binding thus
blocking progesterone inhibition of the placental CRH gene. The rise in placental CRH
augments fetal corticotrophin, which then stimulates fetal adrenal Cortisol and DHEAS
production. Parturition would then be initiated by an increase in placental oestriol as
described above.
Tensegrity and parturition
Tensegrity theory and frameworks (structures with cables, bars and struts) have been
employed in the field of continuum mechanics for over 50 years (Djouadi, et al., 1998). It
is only recently, however that such models have been applied to biological systems such
as angiogenesis (Vailhe, et al., 1997). Tensegrity theory proposes that living cells and
nuclei are hard-wired to respond immediately to mechanical stresses transmitted over cell
surface receptors that physically couple the cytoskeleton to the extracellular environmental
matrix (for example integrins; Maniotis, et al., 1997) or to other cells (for example
cadherins, selectins and cell adhesion molecules (Potard, et al., 1997). Many cell
adhesion molecules, that are activated by cell binding to growth factors and ECM,
associate with cytoskeletal scaffolds within focal adhesion complexes. Mechanical signals
may therefore be integrated with other environmental signals and transduced into a
biochemical response through force-dependant changes in scaffold geometry or molecular
mechanics.
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It has been proposed that during pregnancy, the increase in fetal size leads to stretch
induced uterine growth via progesterone mediated myometrial hypertrophy. At term, a
local reduction in progesterone would result in fetal growth not being translated into
myometrial growth thus leading to an increase in myometrial wall tension (Lye, 1998).
By applying the theory of tensegrity, this increased tension on the ECM could be
transmitted to the nucleus via the surface focal adhesion complexes, leading to alterations
in gene expression and transcription of pro-parturient factors such as IL-8 and contraction
associated proteins including connexin-43 and the oxytocin receptor (Lye, 1998).
1.52 CERVIX
Background
Prior to the 1940s, clinicians and scientists assumed that the cervix was synonymous with
the muscular uterus. However, in 1947, Danforth (Danforth, 1947) described the cervix
as a fibrous organ consisting mainly of collagen and elastin, embedded in a proteoglycan
ECM. This was poorly received by the scientific community and "provoked little
response except for sporadic criticism and implication that (the) findings were due either to
artefact or faulty technique" (Danforth, 1980). However, this initial description was
subsequently confirmed in 1954 (Danforth, 1954) when it was established that the cervix
was a fibrous organ which contained less that 15 % poorly organised peripherally located
smooth muscle. The cervix is delineated from the uterine corpus by an ill-defined
fibromuscular junction, which lies near the internal os.
Structural components
Collagen
The basic tropocollagen molecule (MW 300,000) is composed of three parallel
polypeptide chains, which are tightly coiled into a superhelix (Uldbjerg, et al., 1983).
These spontaneously form fibrils through alignment of charged and hydrophobic amino
acids. Every third residue in tropocollagen is glycine with proline and 3- and 4-
hydroxyproline constituting a further 20 - 23 % (Kokenyesi, 1991). The cervix is
composed of collagen types I (70 %) and III (30 %), in which the superhelixes form
parallel striated fibrils (Minamoto, et al., 1987), and a small amount of collagen type IV
(Leppert and Yu, 1991). The majority of cervical collagen is likely produced by the
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fibroblasts although the smooth muscle cells may contribute a small component. It is
arranged in an inner and outer longitudinal layer separated by circularly arranged fibres.
Collagen types II, IV and V are mainly found in cartilage and basement membrane,
respectively.
Collagen mRNA is translated on ribosomes as prepro a chains, which contain a signal
peptide required for the passage of chains through the endoplasmic reticulum. The signal
peptide is cleaved and the prepro a chains assemble into procollagen. Procollagen
undergoes further post-translational modification within the cell and in the extracellular
space, after secretion via Golgi-derived vesicle molecules, to produce mature
tropocollagen. Mature collagen fibrils are then formed by aggregation of tropocollagen
molecules which form intermolecular cross bridges between their lysine and
hydroxylysine residues (Fietzek and Kihn, 1976).
Elastin
Elastin comprises about 1.5 % of the connective tissue fraction of the cervix (Leppert, et
al., 1983). It comprises one-third glycine residues with a higher proportion of valine and
alanine and a lower proportion of hydroxyproline and proline than collagen. Elastin is the
main component of elastin fibrils which extend from the external os to the periphery and
the upwards to the internal os underlying smooth muscle cells (Leppert, et al., 1986). The
fibrils are cross-linked by desmosine bonds between lysine and allysine. Elastin contains
regions known as "oiled coils", which are capable of stretching to 2.5 times their original
length (Smith, et al., 1983), and these are thought to be responsible for the elastic recoil of
the cervix during ripening and parturition (Christiansen, et al., 1991).
Proteoglycan Matrix
The proteoglycan matrix consists of glycoproteins comprising heteropolysaccharide
glycosaminoglycan (GAG) chains attached to a protein core backbone (Kokenyesi, 1991).
Glycosaminoglycans are highly hydrophilic sulphated polysaccharides composed of
repeating polysaccharide subunits. The principal GAGs within the cervix are heparin,
heparan sulphate, keratan sulphate, chondroitin - 4 and - 6 sulphate, dermatan sulphate
and decorin, the most abundant GAG (Uldbjerg, et al., 1983) formed by attachment of
any GAG to a small core protein. Hyaluronic acid is the exception to the general
description of GAGs being a much larger molecule (80 x 106) which is neither sulphated
nor attached to a core protein. The proteoglycan matrix forms a scaffold to which collagen
and elastin are attached, thus conferring structure and rigidity to the cervical stroma. The
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strength of the collagen attachment is dependant on the nature of the GAG side chains with
those containing iduronic acid, such as dermatan sulphate and heparan sulphate, having
increased conformational flexibility and collagen binding compared with those without
such as chondroitin sulphate. Finally, the uterine cervix contains a high percentage of
water (80 % in non-pregnant) with hyaluronic acid possessing a particularly high affinity
for it.
Smooth muscle
Cervical tissue comprises 10 - 15 % smooth muscle fibres, which are peripherally located.
There is a wide variation in amount and distribution of these fibres between different
individuals and they are not thought to contribute significantly to either the structure or
function of the cervix.
Structure of cervix during pregnancy and parturition
The structure of the cervix alters throughout pregnancy. However, the most profound
changes occur at parturition during cervical ripening when a marked loosening of the
tightly ordered collagen bundles and stromal remodelling occurs. Unfortunately, studies
which have aimed to quantify this structural remodelling, have often yielded conflicting
results. There are many reasons for this. The techniques utilised between studies are
different thus making interstudy comparisons difficult. For example, the amount of
hydroxyproline is frequently used to estimate the amount of collagen within the cervix.
This biochemical method detects both polymerised and depolymerised collagen fibrils
despite the latter likely contributing little to the structural rigidity of the tissue (Uldbjerg, et
al., 1983). In contrast, the alternative Picrosirius red staining technique stains only
orientated polymerised fibrils with dissociated collagen being unstained (Junqueira, et al.,
1979). In addition, the methods use to calculate concentrations of collagen or GAGs are
not standardised with dry weight (Cabrol, et al., 1980), dry defatted weight (Kitamura, et
al., 1980) and wet tissue weight (Uldbjerg, et al., 1983) all being used as the
denominator. More importantly, due to the heterogeneous nature of the cervix and the
rapid remodelling that occurs during labour, the precise site and timing of the sample can
affect the tissues obtained and therefore the subsequent analysis. With these provisos, the
following structural changes occur in the cervix during pregnancy and at term.
The absolute concentration (as measured by extractable hydroxyproline) of collagen
decreases by about 70 % during pregnancy but its solubility (by pepsin digestion) doubles
indicating increased turnover (Ekman-Ordeberg, 1998). As labour approaches, the
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collagen fibrils become looser, more widely scattered and exhibit less crosslinking.
During cervical ripening, active degradation of collagen by collagenases generates
irregular fibres surrounded by amorphous conglomerations of partially depolymerised
collagen with the amount of intact collagen being inversely proportional to the degree of
cervical ripeness (Ekman-Ordeberg, et al., 1986). In contrast, the concentration of elastin
within the uterus increases eight-fold during pregnancy with levels rapidly returning to the
non-pregnant state post partum (Gunja Smith and Woessner, 1985).
Measurement of cervical GAGs is controversial with some studies demonstrating an
increase (up to two and a half fold (Danforth, et al., 1974; Owiny, et al., 1987; Rath, et
al., 1994), and others a decrease (Ekman-Ordeberg, 1998) in total concentration
throughout pregnancy and parturition. Other studies have however reported an increase in
GAG concentration up to the onset of parturition followed by a precipitous fall during
labour (Rath, et al., 1991; Von Maillot, et al., 1979) or almost no difference between the
composition of non-pregnant and intra-partum cervices (Junqueira, et al., 1979). The
relative proportions of different proteoglycans alters at parturition with an increase in high
molecular weight proteoglycans such as versican (10 - 15 %; Ekman-Ordeberg, 1998)
and chondroitin sulphate and a decrease in lower molecular weight proteoglycans such as
decorin. This is thought to contribute to collagen fibril disintegration. Whether other
proteoglycans such as hyaluronic acid increase or decrease at parturition remain however a
matter of debate.
The pregnant and parturient cervix contains a higher proportion of water than the non¬
pregnant cervix with reported values being 78 - 86 % compared with 74 %, respectively.
Other changes during cervical ripening
The neuronal innervation of the cervix alters during cervical ripening with an increase in
neurones releasing vasoactive intestinal peptide (VIP) and PHM-27, thus favouring
vasodilation and a decrease those receptive to cGRP thereby reducing pain nocioception.
Expression of HLA-DR and S-100 also fall suggesting that the immune status of the
cervix might alter during parturition. The concentrations of oestrogen and progesterone
receptors decrease at term. The level of their mRNA however, remains constant
suggesting that there is increased turnover of the respective receptor. Finally, the
concentrations of mRNA and receptor for both insulin growth factor-1 (IGF-1) and
endocervical oxytocin increase prior to parturition (Ekman-Ordeberg, 1998).
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Mechanism of cervical ripening
Liggins proposed in 1981 that cervical ripening resembled an inflammatory reaction
(Liggins, 1981). This hypothesis was in part based on histological studies, which had
demonstrated that cervical ripening was accompanied by marked infiltration of the cervical
stroma by neutrophils, macrophages and mast cells emigrating from cervical venules
(Junqueira, et al., 1980). It is only recently, however that the local mediators involved in
this process have begun to be unravelled.
The profound collagen degradation occurring during cervical ripening is thought to be
mediated by collagenases. Studies have demonstrated that they increase significantly
within the cervix and lower uterine segment (frequently assumed to reflect cervical events)
during the latter stages of cervical ripening (Osmers, et al., 1992; Rajabi, et al., 1988;
Rechberger and Woessner, 1993) and labour (13 - 23 fold). The two principal
collagenases, MMP-8 and MMP-1 are secreted by different cell types and have distinct
collagen specificity's. MMP-8 is released in granules from neutrophils and cleaves
collagen type I twenty times faster than type III whereas MMP-1 is a fibroblast product
and degrades collagen type III fifteen times more effectively than type I (Hasty, et al.,
1987). Due to its enzymatic specificity and cellular origin it likely that MMP-8 is the
predominant collagenolytic enzyme involved in cervical remodelling. This hypothesis is
supported by studies demonstrating release of neutrophil derived MMP-8 (Hasty, et al.,
1990) and an increase in leukocyte elastase (Uldbjerg, et al., 1983) activity during cervical
ripening. In contrast, in-situ hybridisation studies have failed to demonstrate an increase
in MMP-1 release by cervical fibroblasts during cervical ripening (Osmers, et al., 1992;
Rath, et al., 1991).
Inflammatory mediators and cervical ripening
A variety of inflammatory mediators have been implicated in cervical ripening.
Prostaglandins, particularly the PGE2 series have been used for over 30 years to ripen the
cervix (Calder and Embrey, 1973) and they are still the most widely used and effective
cervical ripening agents in current clinical practice. However, the mechanism by which
prostaglandins effect cervical remodelling is not well understood. Prostaglandin E2, PGI2
and PGF2a are released by the cervix with concentrations increasing within the cervix
(Ellwood, et al., 1980) and cervical mucus at term. In addition, cervical tissue expresses
PGE2 and PGF2a receptors (Greer, 1992), with the former being predominately of the
EP2 subtype in baboons (Smith, et al., 1998). Administration of PGE2 reduces cervical
collagen concentration but it is not clear whether this is a direct consequence of collagen
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breakdown with some studies demonstrating an increase in collagenase activity (Szalay, et
al., 1989) and others no difference (Rath, et ah, 1987). Alternatively, prostaglandins
might act by modifying the composition of GAGs such as chondroitin sulphate thus
altering the interaction of collagen with ECM and its hydration (Calder and Greer, 1991).
Finally, it has been suggested that PGE2 might act primarily as a vasodilator and synergise
with chemotactic agents to facilitate leukocyte infiltration into the cervix thereby effecting
cervical ripening (Kelly, 1994).
The potent neutrophil chemoattractant IL-8 is released by cervix and cervical fibroblasts in
vitro and in vivo in both humans (Barclay, et al., 1993) and animals. In rabbits (El
Maradny, et al., 1994) and guinea pigs (Chwalisz, et al., 1994), its intra-cervical
application induces cervical ripening, which is characterised by neutrophil infiltration and
stromal oedema that is morphologically indistinguishable from the physiological process.
Studies in humans have demonstrated a significant increase in IL-8 concentration within
the cervix (Sennstrom, et al., 1997) and lower uterine segment at term (Winkler, et al.,
1998) with levels correlating with MMP-8 and MMP-9 concentrations (Osmers, et al.,
1995). In addition, the synergism between the progesterone regulated (Ito, et al., 1994)
IL-8 and mediators such as DHEAS (Kanayama, et al., 1998; Ogawa, et al., 1998), IL-1
and hyaluronic acid (Kobayashi and Terao, 1997), which are also implicated in cervical
remodelling, further supports a role of IL-8 in cervical ripening. Other cytokines such as
IL-ip and TNF-a have also been shown to induce cervical ripening in rabbits (El
Maradny, et al., 1996) and guinea pigs (Chwalisz, et al., 1994) however the remodelling
which they effect less closely resembles the physiological process.
Finally, nitric oxide has recently been proposed as a mediator of cervical ripening
(Chwalisz and Garfield, 1998). In the rat there is down regulation of cervical iNOS
expression during pregnancy and upregulation at the time of parturition (Ali, et al., 1997)
and in guinea pigs, intra-cervical application of sodium nitroprusside (SNP), a nitric oxide
donor, induces cervical ripening which is morphologically identical to the physiological
process (Chwalisz, et al., 1997). The role of nitric oxide in inducing cervical ripening in
humans is less clear. Nitric oxide has been demonstrated to induce clinically effective
cervical softening in primiparous women, comparable to the cervical state of parous
women, prior to termination of pregnancy (Thomson, et al., 1997). Conversely, there are
studies documenting its successful use in arresting preterm labour with premature cervical
dilatation (Lees, et al., 1994; Rowlands, et al., 1996). However, this effect may be due
to the tocolytic properties of nitric oxide and not the consequence of a direct cervical
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effect. The mechanism by which nitric oxide may effect cervical ripening is not known
but given that it interacts with prostaglandins, MMPs and cytokines it is likely that, in
addition to acting as a vasodilator, it will participate in pro-inflammatory remodelling
cascades.
1.52 MYOMETRIAL CONTRACTIONS
The onset of regular uterine contractions is an essential component of parturition since, in
conjunction with progressive cervical dilatation, this leads to delivery of the fetus. Any
discussion of parturition is therefore incomplete unless the structure and physiology of the
myometrial "powerhouse" is considered.
Structure
Myometrium is composed of smooth muscle fibres, comprising actin, myosin and
intermediate filaments, which are embedded in a collagenous ECM. Myosin consists of
two heavy (20 kDa) and two light chains (15 kDa). These are arranged functionally into
the head, which contains the actin binding complex and the ATPase enzyme involved in
contraction and relaxation, and the tail which participates in formation of the myosin
filaments and transmission of muscle tension. Actin monomers (45 kDa) are polymerised
into long thin filaments that form cross-bridges with the myosin heads to generate the
contractile forces during uterine contractions. Finally, intermediate filaments, by acting as
a scaffold to link proteinaceous dense bodies with individual muscle fibres, help to co¬
ordinate uterine contractions. Transmission and integration of myometrial contractions is
further facilitated by the connective tissue and arrangement of the fibres into random
bundles (Huszar and Roberts, 1982).
Physiology of Myometrial contractions
In myometrium, the actin-myosin interaction is regulated by enzymatic phosphorylation
(contraction) or dephosphorylation (relaxation) of myosin light chains (Adelstein and
Eisenberg, 1980). Myosin light chain phosphorylation depends on the activity of myosin
light chain kinase (MLCK) whose activity is tightly regulated.
MLCK is activated by binding to a hydrophilic domain of calmodulin and calcium. The
calcium originates either by release from intra-cellular calcium stores within the
sarcoplasmic reticulum or from entry into the cell via calcium channels. Release of
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calcium by the sarcoplasmic reticulum is promoted by inositol 1,4,5-triphosphate (IP3),
generated by phospholipase C mediated hydrolysis of phosphatidyl inositol, which opens
sarcoplasmic calcium channels. Extra-cellular calcium enters the cell through voltage
gated membrane channels which open with cellular depolarisation. The depolarisation is
facilitated by gap junctions, composed of connexins, which have low electrical resistance
(Lowenstein, 1981) and enhance metabolic coupling between cells (Larsen, 1983). In
addition, oxytocin can further increase intra-cellular calcium by stimulating its release from
the sarcoplasmic reticulum (Egarter and Husselein, 1992), favouring ingress through the
voltage gated channels (Ciray, et al., 1998) and inhibiting the ATPase pump which
normally pumps calcium out of the cell. Myometrial contractions and phosphorylation of
MLCK correlate closely with intra-cellular calcium concentrations with levels of at least
1(F6M required to generate a contraction (Huszar and Naftolin, 1984).
MLCK is inhibited by protein kinase A which both phosphorylates MLCK, decreasing its
affinity for the myosin light chains and generates cAMP, which facilitates calcium uptake
into the sarcoplasmic reticulum, thus reducing free calcium. Intracellular calcium is
further reduced by cellular repolarisation which closes the voltage gated calcium channels
and activation of membrane bound calcium/sodium ion 'pumps' which pump calcium out
of the cell. Finally, actin-myosin relaxation can also occur by the action of myosin light
chain phosphatase, which cleaves phosphate from the myosin light chain resulting in
dissociation of the actin-myosin complex.
Uterine contractions and parturition
In many pregnant animals such as sheep and non-human primates (Nathanielsz, 1991), a
pattern of myometrial activity termed contractures have been described. These are an
intrinsic property of uterine muscle (Lye and Freiag, 1988) and consist of prolonged, low
amplitude increases in intrauterine pressure. Prior to parturition, contractures switch to
uterine contractions, which are shorter, more regular and generate greater intrauterine
pressures. The precise timing of this switch differs between species and is dependant on a
circadian rhythm (Honnebier, et al., 1991) and photoperiodicity (Nathanielsz and
Honnebier, 1992), generally occurring at night.
Human myometrium is also capable of exhibiting uncoordinated activity, termed Braxton-
Hicks contractions (Braxton-Hicks, 1872), from early pregnancy. Whether contractures
precede contractions is however less certain due to difficulty in achieving accurate intra¬
uterine pressure recordings. The majority of studies that have been performed utilise
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external tocography, which although being a reasonable reflection of the intra-uterine
environment (Buhimschi, et al., 1998), is inherently inaccurate. Longitudinal studies
have demonstrated that uterine activity increases in frequency, amplitude and duration
from 20 - 24 weeks (0 - 1 contraction/hour) to 37 - 40 weeks (5 - 10 contractions/hour)
when it is maximal nocturnally (Moore, et al., 1994) originating from the right upper
quadrant of the uterus (Fallenstein, et al., 1997). Contraction pattern is influenced by
rest, coitus (Moore, et al., 1994) and medical contact (Bennett, et al., 1995) but whether
parity has an independent effect is more controversial (Dickinson, et al., 1997;
Fallenstein, et al., 1997).
At parturition, the myometrium functions as a syncytium. This is facilitated by the
expression of low resistance gap junctions within the myometrium which increase in
number (Geimonen, et al., 1998) and size (Ciray, et al., 1995) at the onset of labour. The
concentration of gap junctions (250 per cell) correlates with the frequency of uterine
contractions and the stage of cervical dilatation (Garfield, 1981). Gap junctions are
composed of six identical connexin proteins which are arranged in a hexameric array
(Revel and Karnovsky, 1967). The predominant connexin present in myometrium is
connexin-43 but recently the presence of connexin-40 and -45 have also been identified
(Kilarski, et al., 1998).
The role of oxytocin in augmenting parturition and uterine contractions has been more
controversial with early studies failing to demonstrate a change in levels at parturition
(Dawood, et al., 1978). More recent studies, employing frequent sampling, however
demonstrated that oxytocin was released in a pulsatile manner with the frequency and
amplitude of pulses increasing significantly throughout labour (Fuchs, et al., 1991). In
addition, the concentration, but not the affinity (Fuchs, et al., 1984), of the G-protein
coupled oxytocin receptor and its mRNA increases throughout pregnancy with levels of
the latter reaching 300 times that of the non-pregnant state during the first stage of labour
(Kimura, et al., 1996). In addition to increasing intracellular calcium, thus favouring
uterine contractions as previously described, oxytocin depolarises myometrial membranes
(Ciray, et al., 1998) and may increase the number of gap junctions (Ambrus and Rao,
1994), although this is controversial (Ciray, et al., 1995).
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1.54 OTHER INTRA UTERINE COMPONENTS
Placenta
The placenta is composed of cytotrophoblast and syncytiotrophoblast. Placenta has many
functions including mediating fetal gaseous exchange, excreting waste products,
elaborating many hormones and cytokines and contributing to the matemo-fetal
immunological interface. At parturition, the placenta secretes hormones such as oestriol,
and there is increased release of pro-inflammatory mediators (IL-1, IL-6; Mitchell, et al.,
1993).
Fetal membranes
Fetal membranes consist of amnion and chorion. The avascular amnion comprises an
inner epithelial layer, basement membrane, compact, fibroblast and an outer reticular
layer, which underlies the chorion. Chorion is composed of a fibroblast and reticular
layer, basement membrane and its principal constituent, the trophoblast, which is adjacent
and adherent to decidua (Chard and Lilford, 1997). Fetal membranes release many
inflammatory mediators including cytokines, prostaglandins, MMPs and TIMPs.
Although amnion derived prostaglandins increase at labour (Bennett, et al., 1992)
(Skinner and Challis, 1985) whether significant quantities gain access to the myometrium
is not certain due to the high concentrations of PGDH in the chorion (Cheung and Challis,
1989).
Decidua
Under the influence of progesterone, endometrial stromal cells enlarge, proliferate and
store glycogen converting the endometrial lining of the non-pregnant uterus into the
decidua of pregnancy. During the first half of pregnancy, decidual stroma comprises
mainly large granular lymphocytes and trophoblast associated macrophages with some B-
and T-lymphocytes (Chard and Lilford, 1997). As pregnancy progresses, these cells
decline in number resulting in term decidua being much less distinct and lined with
flattened epithelium. Decidua is divided into three regions in relation to the developing
fetus. Decidua basalis underlies the conceptus, is adjacent to the chorion and is involved
in formation of the maternal side of the placenta. The decidua capsularis lies over the
surface of the conceptus and the decidua parietalis lines the remainder of the uterus
(Ritchie, 1995). Decidua synthesises many cytokines (IL-1, IL-6), hormones (prolactin,
relaxin) and prostaglandins which, at parturition, likely interact in a paracrine manner with
those released by fetal membranes (Dudley, et al., 1992).
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Amniotic fluid
In early pregnancy, amniotic fluid is mainly a transudate of fetal serum via fetal skin and
the umbilical cord. At term, there are contributions from the amniotic membrane, fetal
urine and excretion of lung fluids. The primary function of amniotic fluid is to protect the
fetus from external trauma, however it also acts as a reservoir for waste products and
inflammatory mediators. Prior to and during labour, concentrations of cytokines (IL-1,
IL-8; Halgunset, et al., 1994; Laham, et al., 1993) and prostaglandins (Romero, et al.,
1994) increase significantly within amniotic fluid.
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SUMMARY
To summarise, the literature review has considered some of the cytokines, chemokines
and inflammatory mediators including prostaglandins, nitric oxide, MMPs and TIMPs
likely involved in the control and regulation of reproductive processes. Current
knowledge as to their roles in the specific processes of the initiation and maintenance of
pregnancy, parturition and control of cervical ripening and was then considered.
HYPOTHESIS
It is therefore hypothesised that inflammatory mediators play a vital role in the initiation
and maintenance of pregnancy, the control of cervical ripening and parturition.
AIMS
The specific aims of this thesis were therefore to :
1. Investigate the roles of inflammatory mediators in the initiation and maintenance of
pregnancy
2. Examine the roles of inflammatory mediators in cervical ripening and parturition
58
CHAPTER 2
GENERAL MATERIALS AND METHODS
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2.1 MATERIALS
The sources of all the reagents used for the experiments described in all the following
chapters are detailed below (Table 3). For ease of reference, they have been subdivided
into experimental categories.
Table 3




Li-Heparin blood collecting tubes Monovette, Sarstedt, Amsterdam, Holland
RPMI 1640 Culture Medium Sigma-Aldrich Company Ltd., Poole, UK
10 % Neutral Buffered Formalin (NBF) See Appendix 1 for recipe
Tissue-Tek O.C.T Compound (Tissue
Collecting Medium)
Tissue-Tek, Miles Inc., Slough, UK
Peel-A-Way Disposal Embedding Moulds Polysciences Inc., Warrington, USA
Nunc Cryotubes Gibco, Paisley, UK
Isopentane Merck Ltd. (BDH), Lutterworth, UK
TISSUE CULTURE MATERIALS -
GENERAL
SOURCE
24 well culture plates Costar Ltd., High Wycombe, UK
RPMI 1640 culture medium Sigma-Aldrich Company Ltd., Poole, UK
Fetal calf serum (FCS) Sigma-Aldrich Company Ltd., Poole, UK
Phosphate buffered saline (PBS) Gibco, Paisley, UK
Penicillin/Streptomycin Gibco, Paisley, UK
Gentamicin Sigma-Aldrich Company Ltd., Poole, UK
60
TISSUE CULTURE MATERIALS -
GENERAL cont.
SOURCE
Complete medium See Appendix 1 for recipe
Phorbol 12-Myristate 13-Acetate Sigma-Aldrich Company Ltd., Poole, UK
Prostaglandin E2 Sigma-Aldrich Company Ltd., Poole, UK
19-hydroxy PGE Cayman Chemicals, Ann Arbor,
Michigan, USA
Progesterone Sigma-Aldrich Company Ltd., Poole, UK
Dexamethasone Sigma-Aldrich Company Ltd., Poole, UK
Medroxy progesterone acetate Sigma-Aldrich Company Ltd., Poole, UK
Oestrogen Sigma-Aldrich Company Ltd., Poole, UK
Mifepristone Roussel-Uclaf, Paris, France
Lipopolysaccharide Sigma-Aldrich Company Ltd., Poole, UK
Spermine NONOate Sigma-Aldrich Company Ltd., Poole, UK
Interleukin-la R&D Systems, Oxford, UK
Interleukin-l|3 R&D Systems, Oxford, UK
Tumour necrosis factor-a Sigma-Aldrich Company Ltd., Poole, UK
Insulin/Transferrin/Selenium Gibco, Paisley, UK
Trypsin Sigma-AJdrich Company Ltd., Poole, UK
DNAse Sigma-Aldrich Company Ltd., Poole, UK
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PBMC/CD 14 CELL SEPARATION SOURCE
Lymphocyte separation medium Sigma, Density 1.077, Poole, UK
Cell separation buffer See Appendix 1 for details
30 mm filter Miltenyi Biotec, Bergisch Gladbach,
Germany
MACS anti-CD14+ Microbeads Miltenyi Biotec, Bergisch Gladbach,
Germany




Steeping buffer See appendix 1 for details
Dispase I (neutral protease; grade I) Boehringer Mannheim, Lewes, UK
Tissue culture flasks Corning, Costar, High Wycombe, UK
Amnion and chorio-decidua cell
preparation
Absorbent capillary matting The Fyba Pot Company Ltd, Khottingley,
UK
Transport solution See appendix 1 for details
Digestion medium See appendix 1 for details
0.171 mm nylon mesh Lockertex, Warrington, UK
Placental perfusion
Kreb's Solution Gibco, Paisley, UK
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Placental perfusion cont. SOURCE
Dextran Sigma-Aldrich Company Ltd., Poole, UK
Noradrenalin Sigma-Aldrich Company Ltd., Poole, UK
Seminal plasma fraction
Ethanol Hayman, Witham, UK
ENV+ extraction columns International Sorbent Technology Ltd.,
YstradMynach, Hengoed, UK
Hexafluoropropanol Sigma-Aldrich Company Ltd., Poole, UK
Chloroform Merk, Poole, UK
CELL LINES SOURCE






Plates (96 well) Nunc Maxi Sorp, Gibco, Paisley, UK
Coating solution See Appendix 1 for recipe
Wash buffer See Appendix 1 for recipe
ELISA assay buffer See Appendix 1 for recipe
Streptavidin peroxidase Boehringer Mannheim, Lewes, UK
Substrate See Appendix 1 for recipe




MCP-1 capture antibody Toray Industries Inc., Tokyo, Japan
MCP-1 standard Toray Industries Inc., Tokyo, Japan
Peroxidase labelled Fab fragment to
recombinant MCP-1
Fab fragment from Toray Industries Inc.,
Tokyo, Japan.
Peroxidation undertaken in house.
IL-8 ELISA
IL-8 capture antibody R&D Systems, Oxford, UK
IL-8 recombinant standard Toray Industries Inc., Tokyo, Japan
IL-8 detection antibody R&D Systems, Oxford, UK
Amplex red substrate See Appendix I for recipe
RANTES ELISA
RANTES coating antibody R&D Systems, Oxford, UK
RANTES recombinant standard R&D Systems, Oxford, UK
RANTES detection antibody R&D Systems, Oxford, UK
IL-10 ELISA
IL-10 coating antibody Pharmingen, San Diego, USA
IL-10 recombinant standard Pharmingen, San Diego, USA
IL-10 detection antibody Pharmingen, San Diego, USA





Recombinant secretory leukocyte protease
inhibitor
R&D Systems, Oxford, UK
Polyclonal anti-secretory leukocyte
protease inhibitor
R&D Systems, Oxford, UK
Anti-sheep/goat IgG-peroxidase Fab
fragments
Boehringer Mannheim, Lewes, UK
Commercial secretory leukocyte protease
inhibitor assay kit
R&D Systems, Oxford, UK
PROSTAGLANDIN ASSAYS SOURCE
PGE2 ELISA
Methyloximating solution See Appendix 1 for recipe
Plates (96 well) Costar amine-binding plates, Paisley, UK
Donkey anti-rabbit (DAR) serum Scottish Antibody Production Unit,
Carluke, UK
Blocking solution See Appendix 1 for recipe
Synthetic standards Applied Therapeutics, Paisley, UK
Dimethylformamide (DMF) Sigma-Aldrich Company Ltd., Poole, UK
Tributylamine Sigma-Aldrich Company Ltd., Poole, UK
Butylchloroformate Sigma-Aldrich Company Ltd., Poole, UK
Biocytin Sigma-Aldrich Company Ltd., Poole, UK
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19-hydroxy PGE ELISA SOURCE
Plates (96 well) Costar amine-binding plates, Paisley, UK
Standards Purified in house
Acetonitrile Merk, Poole, UK
Methanol Merk, Poole, UK
Methyl formate Merk, Poole, UK
Tributylamine Sigma-Aldrich Company Ltd., Poole, UK
Butylchloroformate Sigma-Aldrich Company Ltd., Poole, UK




Histoclear National Diagnostics, Atlanta, Georgia,
USA
Hydrogen peroxide (H202) Merck Ltd. (BDH), Lutterworth, UK
Methanol Merck Ltd. (BDH), Lutterworth, UK
ABC-HRP and Elite complexes Vectastain kits, Vector laboratories,
Peterborough, UK
3, 3'-diaminobenzidine (DAB) substrate Vector SK-4100, Vector Laboratories,
Peterborough, UK
Harris's haematoxylin Pioneer Research Chemicals Ltd.,
Colchester, UK
Microscope glass slides Merck Ltd. (BDH), Lutterworth, UK






Monoclonal human anti-mouse pan
cytokeratin antibody
Sigma-Aldrich Company Ltd., Poole,
UK
Vimentin
Monoclonal human anti-mouse vimentin
antibody
Sigma-Aldrich Company Ltd., Poole,
UK
MMP-1
Human anti-rabbit monoclonal antibody Triple Point Biologies, Insight
Biotechnology, Wembley, UK
MMP-2
Human anti-mouse monoclonal antibody Calbiochem, Nottingham, UK
MMP-8
Human anti-rabbit monoclonal antibody Triple Point Biologies, Insight
Biotechnology, Wembley, UK
MMP-9
Human anti-mouse monoclonal antibody Triple Point Biologies, Insight
Biotechnology, Wembley, UK
TIMP-1
Human anti-rabbit monoclonal antibody Triple Point Biologies, Insight
Biotechnology, Wembley, UK
TIMP-2







Human anti-rabbit monoclonal antibody Triple Point Biologies, Insight
Biotechnology, Wembley, UK
TIMP-4
Human anti-rabbit monoclonal antibody Chemicon, Harrow, UK
CD45 (leukocyte common antigen)
Human anti-mouse monoclonal antibody Dako, Cambridge, UK
CD68
Human anti-mouse monoclonal antibody Dako, Cambridge, UK
Neutrophil elastase
Human anti-mouse monoclonal antibody Dako, Cambridge, UK
Secretory leukocyte protease
inhibitor
Normal donkey serum Scottish Antibody Production Unit,
Carluke, UK
Polyclonal SLPI primary a/b (as for ELISA) R&D Systems, Oxford, UK
Anti-sheep/goat Fab secondary antibody (as
for ELISA)
R&D Systems, Oxford, UK
ZYMOGRAPHY SOURCE
Sample application buffer See Appendix 1 for recipe
Running tank buffer See Appendix 1 for recipe
Resolving gel buffer (Stock A) See Appendix 1 for recipe
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ZYMOGRAPHY SOURCE
Stacking gel buffer (Stock B) See Appendix 1 for recipe
Stock wash buffer X 10 See Appendix 1 for recipe
Resolving gel See Appendix 1 for recipe
Stacking gel See Appendix 1 for recipe
Triton-X-100 Wash See Appendix 1 for recipe
Digestion buffer See Appendix 1 for recipe
Destaining solution See Appendix 1 for recipe
Staining solution See Appendix 1 for recipe
Butanol Sigma-Aldrich Company Ltd., Poole, UK
REVERSE ZYMOGRAPHY SOURCE
Wash buffer/Rinse buffer See Appendix 1 for recipe
Incubation buffer/Digestion buffer See Appendix 1 for recipe
Resolving gel (Lower gel) See Appendix 1 for recipe
Stacking gel (Upper gel) See Appendix 1 for recipe
All other reagents/solutions as for
Zymography
WESTERN BLOT SOURCE
Dialysis cellulose membrane (D 9277, 10
mm)
Sigma-Aldrich Company Ltd., Poole, UK
Homogenisation/Extraction buffer See Appendix 1 for recipe
Sample application buffer See Appendix 1 for recipe
Stock wash buffer See Appendix 1 for recipe
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WESTERN BLOT cont. SOURCE
Membrane blocking buffer See Appendix 1 for recipe
Transfer/Blotting buffer See Appendix 1 for recipe
Resolving gel (Lower gel) See Appendix 1 for recipe
Stacking gel (Upper gel) See Appendix 1 for recipe





Peripheral blood was obtained by sterile venepuncture in Li-heparin tubes from:
Non-pregnant women
The women had regular menstrual cycles, were not using any hormonal form of
contraception and were at various stages of the menstrual cycle. Preliminary studies
demonstrated that results were not influenced by stage of the menstrual cycle.
Pregnant women
1. First trimester
Healthy pregnant women during the first trimester of pregnancy (8 - 12 weeks).
2. Term not in labour
Healthy women with uncomplicated pregnancies at term (>37 weeks) who were not in
labour.
Labour was defined as the onset of regular uterine activity leading to progressive cervical
effacement and dilatation of greater than 3 cm.
3. Term in labour
Healthy women with uncomplicated pregnancies at term (>37 weeks) who were in
spontaneous, active labour. Exclusion criteria included use of analgesia, oxytocics,
pyrexia (37.5°C) and prolonged rupture of membranes.
Prolonged rupture of membranes was defined as rupture of membranes more than 48
hours prior to the onset of labour.
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Peripheral blood was
1. Stored at 4°C until dilution 1 : 10 in Rosewell Park Memorial Institute Medium (RPMI
1640) within 20 minutes of collection.
2. Separated as described below (Section 2.221).
2.212 CERVICAL BIOPSIES
Cervical biopsies were obtained from:
Non-pregnant women
A longitudinal section of the anterior lip of the cervix was taken using a scalpel within 10
minutes of hysterectomy. Biopsies, approximately 20 - 35 mg in weight, 15 - 20 mm in
length and 2-3 mm in diameter, were obtained from healthy, non-pregnant women (n =
50, ages 29 - 45) with regular menstrual cycles undergoing a hysterectomy for a non-
malignant condition. Preliminary studies demonstrated that stage of the menstrual cycle
did not affect the results.
Biopsies were divided into two pieces on a sterile surgical swab and placed immediately
into:
1. RPMI 1640 culture medium at 4°C, for transport.
2. 10 % Neutral Buffered Formalin (NBF) to fix overnight at 4°C, then stored in 70
% ethanol prior to routine paraffin embedding.
Pregnant women
Mifepristone (RU486) treatmentprior to termination ofpregnancy
Thirty nulliparous women of less than 9 weeks amenorrhoea who were to have a
therapeutic suction termination of pregnancy under general anaesthesia were recruited.
Exclusion criteria included age less than 16, serious medical condition, previous cervical
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surgery and inability to give informed consent. Women were randomised into one of six
groups. The surgeons performing the terminations were blinded to the treatment
allocation of the women.
Study Groups
Group Interval between mifepristone
treatment and termination
Number
Group 1 No treatment 6
Group 2 6 hours 6
Group 3 12 hours 6
Group 4 24 hours 6
Group 5 36 hours 6
Table 4
Details of patient numbers and treatment protocols for mifepristone (RU486) treatment
prior to termination of pregnancy
Immediately prior to termination, a cervical biopsy was taken from the anterior lip of the
cervix using a Shumaker punch biopsy forceps. Biopsies were fixed overnight in 10 %
NBF at 4°C, then stored in 70 % ethanol prior to routine paraffin embedding.
Written, informed consent was obtained prior to tissue collection from Lothian Research
Ethics Committee.
2.213 AMNION, CHORIO-DECIDUA, DECIDUA AND PLACENTA
TISSUE
Amnion, chorio-decidua, decidua and placenta were collected from women at term with
uncomplicated pregnancies either at caesarean section (elective caesarean section, not in
labour; emergency caesarean section in spontaneous, active labour, not induced) or after
spontaneous vaginal delivery as detailed below:
1. Explant studies
Term elective caesarean section, n = 6
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2. Placental perfusion studies
After spontaneous vaginal delivery, n = 8.
3. Immunohistochemistry
Term elective caesarean section, n = 4.
Term emergency caesarean section in spontaneous, active labour, n = 4.
Tissue was transported to the laboratory in RPMI 1640 at 4°C and processed within 10
minutes of collection. Informed and written consent was obtained from women prior to
collection of all samples.
2.214 AMNIOTIC FLUID AND EXTRA-EMBRYONIC COELOMIC
FLUID
First trimester
Amniotic and extra-embryonic coelomic fluid were collected by transvaginal ultrasound-
guided needle aspiration between 8-11 weeks of gestation prior to the termination of
pregnancy under general anaesthesia, as described in detail previously (Wathen, et al.,
1991). Women with vaginal bleeding or uncertain menstrual dates were excluded from
the study. Fetal viability and gestational age were confirmed by identification of the fetal
heart and by measurement of crown-rump length, respectively by ultrasonic measurement.
Second trimester
Samples of amniotic fluid from the second trimester (n = 20; 15 - 18 weeks) were
obtained from women undergoing an amniocentesis as part of the karyotype screening
programme for Downs' Syndrome. All pregnancies were karyotypically normal.
Third trimester
Samples of amniotic fluid were obtained from women undergoing an elective caesarean
section (n = 15; >37 weeks) or after spontaneous vaginal delivery (n = 15; >37 weeks,
uncomplicated labour, not induced).
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All samples were centrifuged at 1000 g for 5 minutes and stored at -20°C prior to analysis.
Informed and written consent was obtained from women prior to collection of all samples.
2.215 FETAL URINE SAMPLES
Fetal urine samples, which were clear and not contaminated with blood, were collected at
first micturition immediately after delivery at term by elective caesarean section from
women with uncomplicated pregnancies (n = 12). Samples were centrifuged at 1000 g for
5 minutes and stored at -20°C prior to immunoassay. Informed and written consent was
obtained from women prior to collection of all samples.
2.216 FETAL SERUM SAMPLES
Fetal serum was collected at term from the placental venous cord vein after spontaneous
vaginal delivery (n = 5) and emergency caesarean section (spontaneous active labour, n =
5). Samples were centrifuged at 1000 g for 10 minutes. Informed and written consent
was obtained from women prior to collection of all samples.
2.217 SEMINAL PLASMA
Human seminal plasma was obtained from healthy young men (ages 18 - 45) involved in
the ongoing semen donor programme. Informed and written consent was obtained from




Peripheral whole blood, which had been diluted 1 : 10 in RPMI 1640, was plated out (1
ml/well) in 24 well culture plates and cultured for 24 hours at 37°C in 95 % air and 5 %
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C02 under humid conditions with treatments added at the time of subculturing. The
harvested media were frozen at -20°C until analysis.
Peripheral blood mononuclear cell preparations (PBMC)
A PBMC preparation separates out peripheral blood mononuclear cells (all leukocytes
apart from neutrophils) by centrifuging whole blood with lymphocyte separation medium
by density separation. Mononuclear cells form a layer at the interface between serum and
the separation medium after centrifugation.
Undiluted whole blood (10 mis) was layered on top of lymphocyte separation medium (5
mis; Figure 2A and 2B). Tubes were centrifuged at 2500 rpm for 25 minutes at 25°C
prior to removing the interface mononuclear cell (Figure 2C) and resuspending the cells in
PBS (15 mis). The pellet containing the neutrophils and red blood cells was saved for
subsequent neutrophil extraction. Mononuclear cells were then centrifuged at 1500 rpm
for 40 minutes at 25°C, the supernatant removed and the pellet washed twice in PBS
(centrifuged at 1500 rpm for 10 minutes at 25°C). Cells were resuspended in 10 mis
complete medium (Figure 2D), counted with a haemocytometer and plated out at 1 x 105
cells/ml prior to culturing as described previously. Cell viability by trypan blue exclusion
was >95 %. Media were stored at -20°C until analysis.
Neutrophil isolation
Sterile water (5 mis) was added (45 seconds) to the pelleted neutrophils and red blood
cells to lyse the red blood cells, prior to adding double strength PBS (5 mis) to quench the
reaction. Neutrophils were then pelleted by centrifugation (1000 rpm for 8 minutes),
resuspended in complete medium, counted and plated out as described above. Cell
viability by trypan blue exclusion was >95 %. Media were stored at -20°C until analysis.
Magnetic Cell Sorting of PBMC preparations into CD14+ and CD14" cell
fractions
Magnetic cell sorting (MACS) is a technique which enables a heterogeneous cell
population to be sorted into a distinct cell populations. Cells are labelled with colloidal
super-paramagnetic Microbeads (~ 100 nm diameter) conjugated to an antibody which
recognises an epitope of a specific cell surface marker. Labelled cells are then passed
through a high gradient magnetic column. Unlabelled cells pass through the column while














Peripheral blood mononuclear cell preparation. A) Lymphocyte separation medium,
B) Peripheral blood layered on medium, C) Mononuclear and red cell/lymphocyte
layer after centrifugation and D) Resuspended mononuclear cells.
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the magnetic field. More than 109 cells can be processed within 15 minutes and
enrichment and depletion rates of more than 100- and 1000-fold, respectively can be
achieved. The magnetic tagging does not appear to affect cell viability and proliferation.
CD 14 is a glycosylphosphatidylinositol (GPI) - anchored cell surface protein of myeloid
lineage cells which is expressed on the surface of peripheral monocytes. It acts as a LPS
receptor, binding LPS in conjunction with the soluble LPS binding protein (LBP). This
initiates cellular activation via kinase cascades (Ulevitch and Tobias, 1995). CD14 can be
used to isolate cells of myeloid lineage from peripheral blood.
Pelleted PBMC preparations were resuspended in separation buffer (2 mis), passed
through a 30 mm filter, centrifuged at 1500 rpm for 15 minutes at 20°C then resuspended
in separation buffer (100 (.d). MACS colloidal super-paramagnetic Microbeads,
conjugated with mouse anti-human CD14 antibodies (Mouse isotype IgG2a) were then
added (25 pi) and the sample incubated at 4°C for 15 - 20 minutes. The MACS separation
column was pre-washed with 500 fh separation buffer, placed within the magnetic field of
the MACS separator magnet, and separation buffer (700 nO added to elute the CD14
fraction. The column was washed with separation buffer (1.5 mis), removed from the
magnet and rewashed (1.2 mis) to elute the CD14+ fraction. Both fractions were
resuspended in 5 mis complete medium, counted and plated out at 1 x 10s cells/ml prior to
culturing for 24 hours as described above. Cell viability by trypan blue exclusion was
>95 %. Media were stored at -20°C until analysis.
2.222 CERVICAL BIOPSIES
Whole tissue explants
Cervical biopsies from non-pregnant and pregnant women were dissected into small
pieces (1-2 mm3, 2-4 mg) and cultured with treatments in quadruplicate as previously
described. Biopsies for cytokine analysis were cultured in complete media and those for
zymography and reverse zymography in RPMI 1640. Biopsies were weighed after 24
hours culture. Media were stored at -20°C until analysis.
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Cervical Fibroblast cell preparation
Non-pregnant cervical explants were washed twice in PBS and incubated in steeping
buffer for 60 minutes at 23°C. Biopsies were then incubated with Dispase I (1 U/ml in
PBS) for 2 - 3 hours at 37°C with gentle agitation. Dispase is a neutral protease derived
from Bacillus polymyxa which does not damage cell membranes and separates epithelial
cells from the underlying stroma by cleaving the basement membrane zone region (Stenn,
et al., 1989). Explants were washed twice in PBS, the ecto- and endo-cervical epithelium
sheared off in sheets using a scalpel and the underlying cervical stroma scraped and
dissected into small pieces 1 mm'. The resulting cellular and tissue debri was placed into
75 mm3 tissue culture flasks and cultured in complete medium as previously described.
Cervical fibroblasts grew to confluence within 28 days and were used up to passage 6.
Cells for cytokine ELISAs were subsequently grown in complete medium and those for
zymography in RPMI 1640. Viability was >95 % by trypan blue exclusion and cells were
>95 % vimentin positive.
2.223 AMNION, CHORION-DECIDUA, DECIDUA AND
PLACENTA EXPLANI CULTURE
Discs of amnion (12 mm diameter; wet weight 15 - 20 mg) and chorio-decidua (9 mm
diameter; wet weight 15 - 25 mg) were prepared using a cork borer. Decidua (wet weight
15 - 25 mg) was dissected off the myometrial aspect of the posterior uterine wall from a
site away from the placental bed and pieces of villous placental tissue dissected from the
middle of a central cotyledon (wet weight 15 - 30 mg). Explants were placed on
absorbent capillary matting in a 24-well plate and maintained in complete medium for 24
hours at 37°C in 95 % air and 5 % CO, under humid conditions. The harvested media
were then frozen at -20°C until analysis.
Preparation of amnion and chorion cells
Amnion and chorion were collected immediately after delivery from patients undergoing
elective caesarean section at term (not in labour), transported to the laboratory in transport
solution at 4°C then incubated in steeping buffer for 60 minutes at 23°C. Amnion and
chorion trophoblast cells were prepared for and maintained in culture using methods
adapted from Jones et al. (1989) (Jones, et al., 1989; See Appendix I for recipes and
Appendix II for detailed experimental protocols). Briefly, excess decidua was scraped
from the chorion laeve and amnion and chorion were minced, washed and incubated in
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digestion medium with mechanical agitation for 40 minutes at 37°C. Dispersed cells were
collected by passing through a 0.171 mm nylon mesh three times. Cells were washed in
complete medium and viability's for all preparations were assessed as >90 % by trypan
blue exclusion. Cells were cultured in 24 well plates (2 x 105/well; 1 ml medium/well) in
complete culture medium for 2 - 4 days. Chorion fibroblasts were obtained by dilution of
chorion trophoblast cells with subsequent overgrowth of fibroblasts to confluence within
28 days. Cells were used up to passage 5. Cells for cytokine ELISAs were subsequently
grown in complete medium. Amnion epithelial cells, chorion trophoblast and chorion
fibroblasts were characterised with the epithelial and fibroblast cell markers cytokeratin
and vimentin, respectively. Amnion cell preparations were 95 % cytokeratin positive and
5 % vimentin positive, chorion trophoblast cells preparations were 95 % cytokeratin
positive and 5 % vimentin positive and chorion fibroblasts were 95 % vimentin positive
and 5 % cytokeratin positive.
2.224 DUAL PERFUSION OF A PLACENTAL COTYLEDON
A peripheral cotyledon was selected which was macroscopically intact with parallel
chorionic artery and vein, cannulated and mounted in a perfusion chamber as described
previously (Schneider and Huch, 1985; Schneider, et al., 1972), with minor
modifications (Benediktsson, et al., 1997). The maternal and fetal compartments were
perfused with Kreb's solution at flow rates of 10 and 6 ml/minute, and gassed with 95 %
02/5 % C02 and 95 % N2/5 % C02, respectively. The perfusate on the fetal side was
supplemented with dextran (20 g/1; average molecular weight 74 kDa). Perfusions were
started within 10 minutes of delivery. After a 40 minute equilibration period, which
permitted the residual blood to be eluted and circulatory perfusion pressures to stabilise,
consecutive 10 minute samples were collected from both maternal and fetal circuits. A
pre-infusion sample was followed by three samples during the infusion of PGE2 (500
pg/ml for 30 minutes) into the maternal circuit, followed by two post-infusion samples.
Samples were stored at -20°C before being assayed.
2.225 PREPARATION OF SEMINAL PLASMA FRACTION
Lipid extraction of seminal plasma was performed to remove the majority of the cytotoxic
polyamines such as spermine and spermidine (Allen and Roberts, 1986). Human seminal
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plasma (700 mis) was treated with ethanol (1000 mis) and centrifuged at 4°C for 20
minutes at 1,500 g. The supernatant was evaporated at 23°C to a final volume of 450 mis
then passed through ENV+ extraction columns which had previously been washed with 1
: 1 ethanol/hexafluoropropanol (HFP). Lipid was eluted with 1 : 1 ethanol/HFP and the
liquid evaporated at 23°C to 10 mis. Chloroform (15 mis) was added to leach the residue
and the chloroform layer evaporated and redissolved in ethanol (4 mis) to give the seminal
plasma fraction.
2.226 U937 CELL LINE
U937 cells are a pro-monocytic cell line derived from a diffuse hystiocytic lymphoma,
which is committed to the macrophage branch of the myeloid lineage. Cells were used as
a model to further investigate cytokine release. Cells were maintained in complete medium
and plated out at 1x10s cells/ml for experiments. Studies were either performed on
undifferentiated cells or on those which had received phorbol 12-myristate 13-acetate
(PMA), coincident with treatments, for 24 hours to differentiate them into macrophages.
2.23 ENZYME LINKED IMMUNOSORBENT ASSAYS (ELISAs)
This technique is used to determine the concentration of a given substance in a solution by
comparison with a standard curve created from solutions of known concentrations. There
are two principal types of ELISA:
1. Two site ELISA
In this technique, plates are precoated with a coating antibody (Figure 3A and 3B). The
substance (X) to be measured is then added and is recognised and bound by the coating
antibody by a specific epitope (Figure 3C). Next, the detection antibody, labelled with
biotin, is added which binds to X by a different epitope (Figure 3D). Finally, streptavidin
peroxidase is added which binds to the biotin (Figure 3E) and this is detected by addition
of substrate (Figure 3F). For example: IL-8, RANTES, IL-10. Alternatively, the
detection antibody may be peroxidase linked thus omitting the streptavidin peroxidase
step. For example: MCP-1.
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2. Competition ELISA
Plates are coated with the recombinant protein to be measured (rY) and then blocked to
remove non-specific binding (Figures 4A and B). The media containing the substance Y
to be measured is then added with anti-sera (Figures 4C1 and C2). The anti-sera
recognises identical epitopes on the rY to that on Y and competes for binding. The plates
are then washed. If the media being measured contains a high concentration of Y, then the
majority of the anti-sera will have become conjugated to it and will be washed off (Figure
4D2). However, if the media contains low concentrations of Y, then anti-sera will have
become conjugated and bound to the rY on the plate (Figure 4D1). The secondary
antibody is then added which binds to an epitope on the anti-sera and this is then detected
by adding the detection system. Wells with a lots of anti-sera bound (low levels of Y in
original sample) will read high (Figure 4E1) and those with low amounts of anti-sera
bound will read low (high levels of Y in origin sample; Figure 4E2). The amount of Y in
the origin sample can be calculated by comparing values obtained by using a standard
curve.
Detailed protocols
Monocyte chemotactic protein-1 (MCP-1)
MCP-1 was measured by ELISA using a peroxidase labelled fragment antibody binding
(Fab) fragment of an antibody to recombinant MCP-1 as previously described (Ida, et al.,
1994; Kelly, et al., 1997). Briefly, plates were coated overnight at 4°C with MCP-1
capture antibody (4 ng/ml in PBS; 100 (xl/well) then washed once in tap water and coating
solution added (100 (xl/well) for 30 minutes. Plates were air dried and stored with a
desiccant at 4°C. Samples and standards were added (diluted in ELISA buffer; 100
nl/well) with the highest concentration of standard being 500 pg/ml. Plates were
incubated for 3 hours at 23°C on an orbital plate shaker prior to adding peroxidase-coupled
detection antibody (diluted 1 : 200 in ELISA Buffer; 100 ^1/well) and incubating for 45
minutes at 23°C on an orbital shaker. Finally, plates were washed and substrate added
(200 nl/well) prior to quenching with 2N H2S04. Absorption was read at 450 nm within
30 minutes of quenching. The intra-assay precision was 6.3 % relative standard deviation
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Two site ELISA. A) Uncoated ELISA plate, B) Plate coated with coating antibody,
C) Substance X binding to coating antibody, D) Detection antibody added,





















# * Detection system
Low [Y] in sample/
High reading
High [Y] in sample/
Low reading
Figure 4
Competition ELISA. A) Uncoated ELISA plate, B) Plate coated with recombinant
protein (rY), CI) Media (low concentration substance Y) and anti-sera added,
C2) Media (high concentration substance Y) and anti-sera added, Dl) High amounts
anti-sera conjugated to secondary antibody bound to plate after washing, D2) Low
amounts anti-sera conjugated to secondary antibody bound to plate after washing,
El) Detection system added, high reading, E2) Detection system added, low reading.
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Interleukin-8 (IL-8)
IL-8 was measured by ELISA utilising matched pairs of capture and biotinylated labelled
detection antibodies against IL-8. Briefly, plates were coated overnight at 4°C with
capture antibody (100 M-l/well), washed once in water, and coating solution (100 jd/well)
added for 30 minutes at 23°C. The coating solution was removed and the plates stored as
for MCP-1. Prior to use, the plates were washed once in water. Samples and standards
were added (100 nl/well) with the top standard being 500 pg/ml. Plates were incubated
for 3 hours at 23°C on an orbital shaker, washed as above then detection antibody (30
ng/ml in ELISA buffer) added and incubated on a shaker for 45 minutes at 23°C. After a
further wash, streptavidin peroxidase was added at (0.02 U; 100 ^l/well) and plates were
incubated for 20 minutes at 23°C on an orbital shaker. They were then washed, substrate
was added and were read as for MCP-1. The intra- and inter-assay precision's were 9.1
% r.s.d and 22.1 % r.s.d. respectively, and the detection limit of the assay was 7.5 pg/ml.
For the high sensitivity method, the following modifications were made. The top standard
was 2000 pg/ml (12 standards), streptavidin multi-peroxidase (100 ng/ml, 100 nl/well)
was utilised instead of streptavidin peroxidase and Amplex red substrate was added (200
!.d/well). Plated were read after 30 - 40 minutes using a fluorimeter in the Amplex red
setting (excitation 563, emission 587).
Assays for RANTES, IL-lp, IL-6 and TNF-a were performed as for IL-8 (normal
sensitivity) with the following modifications:
Assay for RANTES
RANTES was measured by ELISA utilising matched pairs of capture and biotinylated
labelled detection antibodies against RANTES. The capture antibody (coated at 2 ng/ml;
100 i^l/well), standards (recombinant, top standard 500 pg/ml, 100 |xl/well) and detection
antibody (added at 50 ng/ml) were all obtained from R&D Systems, Oxford, UK. The
intra- and inter-assay precisions for this assay were 10.4 % r.s.d and 11.2 % r.s.d
respectively, and the detection limit of the assay was 7.5 pg/ml.
Interleukin-10
All dilutions were in 10 % FCS in PBS unless otherwise stated. Plates were coated with
capture antibody (200 ng/ml in PBS; 100 pl/well) for 60 minutes at 23°C, then blocked
(10 % FCS in PBS; 300 ril/well) for a further 60 minutes at 23°C then washed. Samples
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and standards were added (100 pl/well) with the top standard being 500 pg/ml. Plates
were incubated on an orbital shaker for 60 minutes, washed and detection antibody (125
ng/ml; 100 pl/well) added and incubated for 60 minutes at 23°C. After a further wash,
polyperoxidase (1 ng/ml in ELISA buffer without Tween; 100 pl/well) was added for 30
minutes. Finally, plates were washed and read as for MCP-1. The intra- and inter-assay
variations were 6.4 % and 10.1 % respectively, and the detection limit of the assay was
7.5 pg/ml.
Secretory leukocyte protease inhibitor assay
Secretory leukocyte protease inhibitor was measured by a competitive ELISA. Plates
were coated with recombinant secretory leukocyte protease inhibitor raised against the
human peptide sequence (Thompson and Ohlsson, 1986); (0.025 pg/ml in PBS/1 %
carbonate buffer; 300 pl/well) for 60 minutes at 23°C, blocked with milk powder (0.1
mg/ml in distilled H20; 400 pl/well) for 30 minutes at 23°C then washed. ELISA assay
buffer was added (250 pl/well) for the non-specific binding (NSB). Recombinant
standards (highest concentration 50 ng/ml; 200 pl/well), samples (200 pl/well) and the
polyclonal antibody raised in goat against recombinant human secretory leukocyte protease
inhibitor (2 pg/ml in ELISA buffer; 50 (.d/well) were added. Plates were incubated for 120
minutes at 23°C, washed and anti-sheep/goat IgG Fab fragments raised in donkey
conjugated to peroxidase (diluted 1 : 500 in ELISA buffer; 100 pl/well) added. Finally,
plates were incubated for 120 minutes at 23°C, washed, substrate added and plates read as
for MCP-1. The intra- and inter- assay precisions were 9.2 % r.s.d and 10.1 % r.s.d
respectively, and the detection limit of the assay was 9.8 pg/ml.
PGE2 ELISA
Samples were treated 1 : 1 with methyloximating solution overnight at 4°C. Amine
binding plates were coated with donkey anti-rabbit (DAR serum). Briefly, they were
coated with rabbit IgG (1 mg/ml diluted in PBS/1 % carbonate buffer; 200 pl/well) for 16
hours at 4°C, the solution flicked out and blocking solution added (250 pl/well) for 120
minutes at 23°C. They were then washed, DAR serum added (150 pl/well), incubated for
16 hours at 4°C then washed, air dried and stored with a desiccant at 4°C. The assay used
a PGE-biotin link as a pro-label. To prepare the link, 0.06 M synthetic PGE2 was added
to 320 pi dry dimethylformamide (DMF), the solution cooled to 4°C and 6 pi tributylamine
and 3 pi butylchloroformate were added with stirring for 30 minutes at 4°C. Next 0.05 M
biocytin (diluted in 300 pi 1 : 1 DMF/distilled H90) was added and the vial left at 4°C for
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30 minutes then at 23°C for a further 30 minutes. Finally, the solution was ether extracted
and purified by reverse phase chromatography. Rabbit anti-sera were raised against PGE2
complexed to keyhole limpet haemocyanin and have been previously characterised (Kelly,
et al., 1989). Samples (100 pl/well) and synthetic standards (highest concentration 5120
pg/ml; 100 pl/well) were added in duplicate and link (l:1.5xl06; 50 pl/well) was added to
all wells. Anti-sera was added (1:50,000; 50 pl/well) to all wells except the NSB. The
final concentration of methyloximating solution in standards and samples was 12.5 %.
Plates were incubated at 4°C for 16 hours, washed and streptavidin peroxidase (0.2 U/ml;
100 pl/well) added. The plates were then incubated for 20 minutes at 23°C on an orbital
shaker, washed, substrate added and plates read as for MCP-1. The intra- and inter-
assay coefficients were 7.8 % and 15.0 % respectively and the ED50 was 195 pg/ml.
19-hydroxy PGE assay
The plates and anti-sera were prepared as described above. 19-hydroxy PGE standards
containing equal amounts of 19-hydroxy PGE, and 19-hydroxy PGE2 were prepared as
follows. Human seminal plasma (65 ml) was centrifuged at 4°C for 15 minutes at 1000 g,
mixed with acetonitrile (65 ml), centrifuged at 4°C for 15 minutes at 2000 g prior to
freeze-drying the supernatant overnight. The residue was leached with methanol,
evaporated, added to a silica column and the prostaglandins (PGE2 and 19-hydroxy PGE)
were eluted with increasing concentrations of methanol in methyl formate. The fractions
were analysed by thin layer chromatography and that corresponding to the 19-hydroxy
PGE fraction was quantitated, using crystalline synthetic PGE2 as a standard, by
treatment with 0.05 M NaOH and measurement of UV absorption at 280 nm in ethanol.
To prepare the link, approximately 1 mg 19-hydroxy PGE was added to 200 ul dry DMF,
the solution cooled to 4°C and 3 (.d tributylamine and 1.5 (.il butylchloroformate were
added with stirring for 30 minutes at 4°C. Finally, 12 mM Pro-Gly-Tyr-Biotin (dissolved
in 300 ^1 1 : 1 DMF/distilled H20) was added and the solution extracted as described
above. Standards (5120 pg/ml to 78 pg/ml), link (1 : 20,000) and anti-sera (1 : 20,000)
were diluted in ELISA buffer without Tween and the assay set up as for PGE2. The intra-
assay coefficient was 8.46 % and the ED50 was 196 pg/ml.
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2.24 ZYMOGRAPHY
The technique of zymography detects activity of the latent and active forms of matrix
metalloproteinases (MMPs). Samples are separated by electrophoresis on a sodium
dodecyl sulphate-polyacrylamide gel which has a substrate, in this case gelatin,
incorporated within it. The gels are then incubated overnight at 37°C and the latent form
of the enzyme, which is activated by the sodium dodecyl sulphate, and the active form of
the enzyme digest the substrate within the gel at the site corresponding to their molecular
weight. The gel is then stained with Coomassie Blue then destained. The sites of
enzymatic gelatinase activity are manifest as a clear area of digestion within the gel. The
zymograms may then be semi-quantitated by densitometry (See Appendix I for recipes and
Appendix II for detailed experimental protocols).
Briefly, freeze dried samples, which had been reconstituted in 0.1 % SDS, were loaded
(maximum loading 15 pi) into the prepared gelatin sodium dodecyl sulphate-
polyacrylamide gel (4 % stacking, 7.5 % resolving gel optimal for separating 50 - 120
kDa proteins) and run at 100 V for 90 minutes. Gels were washed twice in Triton X
Wash Buffer (15 minutes/wash) and twice in wash buffer (~ 2 minutes/wash). Digestion
buffer was then added and gels were incubated at 37°C overnight. The following day,
gels were transferred to staining solution for ~ 3 hours prior to destaining for ~ 90
minutes. The gels were then be stored in water until photographed or scanned.
2.25 REVERSE ZYMOGRAPHY
Reverse zymography detects activity of the TIMPs. In this technique, active MMP
incorporated into the gelatin sodium dodecyl sulphate polyacrylamide gel binds to TIMPs
within the samples. When the electrophoresed gels are incubated overnight, the MMPs
within the gel become activated and digest the gelatin throughout the gel apart from where
it is bound to TIMPs within the sample. After staining, the TIMPs are detected as a
stained band on an otherwise clear background (See Appendix I for recipes and Appendix
II for detailed experimental protocols).
Briefly, reconstituted samples (in 0.1 % SDS) were electrophoresed on a sodium dodecyl
sulphate-polyacrylamide gel (5 % stacking, 12 % resolving gel optimal for separation of
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10 - 40 kDa proteins) which contained gelatin and a MMP preparation from BHK-21 cells
at 100 V for 90 minutes. Gels were washed twice in rinse buffer (15 minutes/wash) with
gentle agitation and then for a further 150 minutes in fresh rinse buffer. The buffer was
then discarded, gels were washed twice in ElgaStat H20, transferred to digestion buffer
and incubated at 37°C for 17 hours. The following day, gels were rinsed twice in ElgaStat
H20 and stained and destained as for zymography.
2.2 6 WESTERN BLOT
Western blotting detects the presence of proteins, separated by electrophoresis by specific
antibodies after transfer to a nitro-cellulose membrane. When compared with zymography
and reverse zymography, it has the advantage that it can distinguish between proteins
which electrophorese to the same points on a gel, for example TIMP-1 and TIMP-4 (See
Appendix I for recipes and Appendix II for detailed experimental protocols).
Briefly, samples which had been dialysed then freeze dried were reconstituted in sample
buffer, boiled for 5 minutes, centrifuged at 13,000 rpm for 3 minutes at 4° C, added to the
prepared gel and electrophoresed at 100 V for 120 minutes. For optimal separation, 8 %
gels were used for 60 - 120 kDa proteins, 10 % gels for 40 - 70 kDa proteins and 12 %
gels for 10 - 40 kDa proteins. Gels and nitro-cellulose membranes, and fibre pads and
filter papers, were equilibrated in transfer buffer for 30 minutes and 10 minutes,
respectively. The gel sandwich was constructed and electrophoresed with a Bio-Rad Ice
Cooling Unit at 100 V for 60 minutes. Gels were then stained (60 - 120 minutes) and
destained as necessary to check protein transfer.
Membranes were blocked in 5 % BSA in TTBS overnight at 4°C prior to adding the
primary antibody for 3 to 4 hours (diluted in primary antibody solution). Next,
membranes were washed in TTBS (1 x wash for 30 seconds; 3x5 minute washes), the
secondary antibody was added (diluted in TTBS; 1 : 200 - 1 : 400) for 45 minutes at 23°C
and the membranes rewashed (3x5 minute washes). Finally, Avidin Biotinylated
enzyme Complex (ABC) peroxidase was added for 30 minutes at 23°C, the membranes
were washed (3x5 minutes in TTBS) and positive staining detected by addition of DAB.
Staining was quenched in distilled H20, and membranes dried and stored in the dark.
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2.27 IMMUNOHISTOCHEMISTRY
The technique of immunohistochemistry involves localisation of an antigen within a
section of tissue by a specific primary antibody. A variety of detection systems can then
be used to detect and visualise the specific staining.
Non-specific staining
Non-specific staining occurs when tissue other than at the site of the desired antigen stains
immunopositive and may be due to a variety of causes.
1. Non-specific primary antibody binding
Problem: The primary antibody may bind non-specifically to epitopes in the tissue.
Solution: Having a good antibody is essential. The immunohistochemistry results can be
compared with those obtained by Western Blotting to ensure that the results are valid.
2. Endogenous peroxidase
Problem: Tissues may contain endogenous peroxidase which may catalyse the enzymatic
detection thus producing 3, 3' -diaminobenzidine (DAB) staining at the site of the
endogenous enzyme.
Solution: Prior to addition of the primary antibody, tissues were exposed to dilute H202
to saturate any endogenous peroxidase thus rendering it inactive.
3. Non-specific secondary antibody binding
Problem: The secondary antibody may bind to epitopes in the original tissue mimicking
those from the species it was raised against as well as to the primary antibody.
Solution: Normal serum from the species from which the secondary antibody was raised
against was added prior to addition of the secondary antibody.
Controls
Positive Control: The relevant positive control included on each staining run contained the
desired antigen and was therefore expected to stain positively.
Negative Control: Cells or sections of tissue being stained were included which were
treated in an identical manner except the primary antibody was omitted or they received
non-immune serum or immunoglobulins from the species providing the primary antibody.
These sections should be expected to exhibit minimal staining.
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General protocol
Immunohistochemistry was performed on cultured cells and on tissue sections. Cultured
cells were fixed for 30 minutes in 10 % NBF at 23°C and then stored in 70 % ethanol.
Tissue was fixed in 10 % NBF for 24 hours at 4°C and stored in ethanol 70 % ethanol
prior to routine paraffin embedding.
Cultured Cell Immunohistochemistry
Cells were rehydrated through descending graded of ethanol to distilled water (2 minute
washes) then washed in PBS (2 minutes). Next, cells were permeabilised with 0.05 %
Triton (10 minutes), washed in PBS (3x2 minute washes) and microwaved in 0.01 M
sodium citrate on 10 % power (3 minutes/plate). After standing for 10 minutes, plates
were washed in PBS (5 minutes) and endogenous peroxide was blocked (3 % H202).
Plates were washed in distilled H20 (2x2 minute washes), PBS (2 minute wash) and
blocked (30 minutes) prior to adding the primary antibody (diluted in blocking serum) to
incubate overnight at 4°C. The following day, cells were washed in PBS (2x2 minute
washes) and the secondary antibody was added (30 minutes). Plates were then washed in
PBS (2 minutes), avidin-biotin complex added (30 minutes) and rewashed in PBS (2
minutes). The positive staining was then detected by application of the peroxidase
substrate DAB, which produces a brown stain. Cells were lightly counterstained with
Harris' haematoxylin, a purple non-specific nuclear stain. Following washing in distilled
H,0, cells were left in distilled H20.
Slide immunohistochemistry
Sections of tissue (5 j.im) were mounted on glass slides, then dewaxed in histoclear and
rehydrated as described above. Endogenous peroxidase was blocked by H2Oz (1 % - 3 %
solution in distilled H20), slides were washed, blocked and primary antibody added as
described above. The protocol for the following day was as for the cell
immunohistochemistry protocol. After detection and counterstaining, slides were
dehydrated in graded ethanol (2 minute/solution) and histoclear (5 minutes) and mounted
from Xylene (60 minutes) with Pertex mounting medium.
Haematoxylin and Eosin stain (H & E stain)
Tissue sections were dewaxed in histoclear (5 minutes), rehydrated in graded alcohols
(absolute ethanol 20 seconds, 95 % IMS 20 seconds and 70 % IMS 20 seconds) and
rinsed in tap water prior to staining in Haematoxylin (5 minutes). Next, slides were
rinsed in 1 % acid alcohol (5 - 20 seconds), Scotts tap water (5 - 20 seconds) then Eosin
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(5 - 20 seconds) being rinsed in tap water between each stage. Finally, slides were
dehydrated in graded alcohols (70 % IMS 20 seconds, 95 % IMS 20 seconds and absolute
ethanol 20 seconds) steeped in histoclear (5 minutes) and Pertex mounted. H and E
staining was utilised to check the morphology of the non-pregnant (data not shown) and
first trimester cervical biopsies (Figure 5).
Specific Protocols
Cytokeratin (epithelial marker)
Endogenous peroxide was blocked with 3 % H202 (30 minutes at 23°C). Non-specific
binding was eliminated by pre-blocking with normal goat serum (150 (xl normal goat
serum : 10 mis 0.01 M PBS, 60 minutes at 23°C). The human anti-rabbit polyclonal
primary antibody was added at 1 : 500 (in diluted in goat serum, overnight at 4°C) and
secondary goat anti-rabbit added at 1 : 200 (diluted in 0.01 M PBS, 45 minutes at 23°C).
Vimentin (fibroblast marker)
Endogenous peroxide was blocked with 3 % H202 (30 minutes at 23°C). Non-specific
binding was eliminated by pre-blocking with normal horse serum (150 |^1 normal horse
serum : 10 mis 0.01M PBS, 60 minutes at 23°C). The human anti-mouse polyclonal
primary antibody was added at 1 : 10 - 1 : 25 (in diluted horse serum, overnight at 4°C)
and secondary horse anti-mouse added at 1 : 200 (diluted in 0.01M PBS, 45 minutes at
23°C).
MMP-1
Endogenous peroxide was blocked with 2 % H202 (30 minutes at 23°C). Non-specific
binding was eliminated by pre-blocking with normal goat serum (150 jrl normal goat
serum : 10 mis 0.01 M PBS, 60 minutes at 23°C). The human anti-rabbit primary
antibody was added at 1 : 1000 (in diluted goat serum, overnight at 4°C) and secondary
goat anti-rabbit biotinylated IgG antibody added at 1 : 200 (diluted in 0.01 M PBS, 45
minutes at 23°C).
MMP-2
Endogenous peroxide was blocked with 1 % H202 (30 minutes at 23°C). Non-specific
binding was eliminated by pre-blocking with normal horse serum (150 pi normal horse
serum : 10 mis 0.01M PBS, 60 minutes at 23°C). The human anti-mouse primary






Haematoxylin and Eosin stained first trimester cervical biopsies after in vivo
administration of mifepristone. A) untreated, B) 24 hours post mifepristone treatment
demonstrating glandular cervical morphology and C) 36 hours post mifepristone. Scale
bars = 100 jim.
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horse anti-mouse biotinylated IgG antibody added at 1 : 200 (diluted in 0.01M PBS, 45
minutes at 23°C).
MMP-8
Endogenous peroxide was blocked with 2 % H202 (30 minutes at 23°C). Non-specific
binding was eliminated by pre-blocking with normal goat serum (150 j.d normal goat
serum : 10 mis 0.01M PBS, 60 minutes at 23°C). The human anti-rabbit primary
antibody was added at 1 : 2000 (in diluted horse serum, overnight at 4°C) and secondary
goat anti-rabbit biotinylated IgG antibody added at 1 : 200 (diluted in 0.01 M PBS, 45
minutes at 23°C).
MMP-9
Endogenous peroxide was blocked with 1 % H202 (30 minutes at 23°C). Non-specific
binding was eliminated by pre-blocking with normal horse serum (150 ^1 normal horse
serum : 10 mis 0.01M PBS, 60 minutes at 23°C). The human anti-mouse primary
antibody was added at 1 : 50 (in diluted horse serum, overnight at 4°C) and secondary
horse anti-mouse biotinylated IgG antibody added at 1 : 200 (diluted in 0.01 M PBS, 45
minutes at 23°C).
TIMP-1
Endogenous peroxide was blocked with 2 % H20, (30 minutes at 23°C). Non-specific
binding was eliminated by pre-blocking with normal goat serum (150 nl normal goat
serum : 10 mis 0.01 M PBS, 60 minutes at 23°C). The human anti-rabbit primary
antibody was added at 1 : 250 (in diluted goat serum, overnight at 4°C) and the secondary
goat anti-rabbit biotinylated antibody added at 1 : 200 (diluted in 0.01 M PBS, 45 minutes
at 23°C).
TIMP-2
Endogenous peroxide was blocked with 2 % H202 (30 minutes at 23°C). Non-specific
binding was eliminated by pre-blocking with normal goat serum (150 n-1 normal goat
serum : 10 mis 0.01M PBS, 60 minutes at 23°C). The human anti-rabbit primary
antibody was added at 1 : 500 (in diluted goat serum, overnight at 4°C) and the secondary




Endogenous peroxide was blocked with 2 % H202 (30 minutes at 23°C). Non-specific
binding was eliminated by pre-blocking with normal goat serum (150 jd normal goat
serum : 10 mis 0.01M PBS, 60 minutes at 23°C). The human anti-rabbit primary
antibody was added at 1 : 1000 and the secondary goat anti-rabbit biotinylated antibody
added at 1 : 200 (diluted in 0.01M PBS, 45 minutes at 23°C).
TIMP-4
Endogenous peroxide was blocked with 2 % H,02 (30 minutes at 23°C). Non-specific
binding was eliminated by pre-blocking with normal goat serum (150 |d normal goat
serum : 10 mis 0.01M PBS, 60 minutes at 23°C). The human anti-rabbit primary
antibody was added at 1 : 1000 (in diluted goat serum, overnight at 4°C) and the
secondary goat anti-rabbit biotinylated antibody added at 1 : 200 (diluted in 0.01M PBS,
45 minutes at 23°C).
Neutrophil elastase
Endogenous peroxide was blocked with 3 % H202 (5 minutes at 23°C). Non-specific
binding was eliminated by pre-blocking with normal horse serum (150 jd normal horse
serum : 10 mis 0.01M PBS, 20 minutes at 23°C). The human anti-mouse primary
antibody was added at 1 : 50 (diluted in 0.01 M PBS, overnight at 4°C), mouse IgG was
added at 1 : 800 (diluted in 0.01M PBS, overnight at 4°C) for the negative control and the
secondary horse anti-mouse biotinylated IgG antibody added at 1 : 200 (diluted in 0.01 M
PBS, 30 minutes at 23°C).
CD45 (leukocyte common antigen)
Endogenous peroxide was blocked with 3 % H202 (5 minutes at 23°C). Non-specific
binding was eliminated by pre-blocking with normal horse serum (150 nl normal horse
serum : 10 mis 0.01M PBS, 20 minutes at 23°C). The human anti-mouse primary
antibody was added at 1 : 50 (diluted in 0.01M PBS, 60 minutes at 23°C), mouse IgG
was added at 1 : 800 (diluted in 0.01M PBS, 60 minutes at 23°C) for the negative control
and the secondary horse anti-mouse biotinylated IgG antibody added at 1 : 200 (diluted in
0.01M PBS, 30 minutes at 23°C).
CD68 (monocyte/macrophage marker)
Slides were trypsin digested (0.1 % trypsin in 0.1 % CaCl2, 60 minutes at 23°C).
Endogenous peroxide was blocked with 3 % H202 (10 minutes at 23°C). Non-specific
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binding was eliminated by pre-blocking with normal horse serum (150 (d normal horse
serum : 10 mis 0.01 M PBS, 20 minutes at 23°C). The human anti-mouse primary
antibody was added at 1 : 50 (diluted in 0.01M PBS, 60 minutes at 23°C), mouse IgG
was added at 1 : 300 (diluted in 0.01M PBS, 60 minutes at 23°C) for the negative control
and the secondary horse anti-mouse biotinylated IgG antibody added at 1 : 200 (diluted in
0.01M PBS, 30 minutes at 23°C).
Secretory leukocyte protease inhibitor
Endogenous peroxide was blocked with 1 % H202 (30 minutes at 23°C). Non-specific
binding was eliminated by pre-blocking with 10 % normal donkey serum (30 minutes at
23°C) The polyclonal secretory leukocyte protease inhibitor primary antibody was applied
at 1 : 400 (25 ^g/ml in 10 % normal donkey serum, 60 minutes at 23°C) and the secondary
anti-sheep/goat Fab fragment raised in donkey conjugated to peroxidase applied at 1 : 100
(diluted in 0.01M PBS, 90 minutes at 23°C). Term fetal membranes were used as a
positive control. The primary antibody was omitted or normal donkey serum used as the
negative control.
Scoring of immunohistochemistry
All sections were assessed qualitatively by two independent observers who were blinded
to the identity of the slides. Slides were assessed as having -, -/+, +, ++ or +++ intensity
of stromal immunostaining and specific cellular staining. Positive immunostaining was
defined as +, ++ or +++ and negative immunostaining as -.
Stromal staining Cellular staining
- None None
-/+ Patchy staining in some fields Occasional cells in some fields
+ Weak diffuse staining in most fields Few cells staining in most fields
++ Moderate staining in all fields Many cells staining in all fields
+++ Strong staining in all fields Numerous cells staining in all fields
It has previously been demonstrated in endometrial sections that there is a high correlation
between objectively measured immunoreactivity (measured by computerised image




INFLAMMATORY MEDIATORS: INITIATION AND
MAINTENANCE OF PREGNANCY
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GENERAL INTRODUCTION - PART 1
The initiation and maintenance of pregnancy necessitates profound alterations in the
maternal immune response to prevent rejection of the fetus. In 1953, Sir Peter Medawar
observed that this posed the immunologist "some immunological and endocrinological
problems raised by the evolution of viviparity in vertebrates." He called the enigma the
"riddle of the success of the fetal allograft" and envisaged that the uterus was an
"immunologically privileged site", analogous to the anterior chamber of the eye
(Medawar, 1953). Medawar's initial concept of the immunoprotective uterus has
however, recently been challenged by the suggestion that maternal recognition of fetal
antigens by non-classical MHC-1 (E and G) expressed by trophoblast might be beneficial
or even necessary for the establishment of normal pregnancy (Loke and King, 1996). An
alternative hypothesis was proposed by Thomas Wegmann in 1993. He suggested that
successful pregnancy might depend on bi-directional cytokine interactions in the maternal-
fetal relationship resulting in a Th-1 to Th-2 shift in the maternal immune response
(Wegmann, et al., 1993).
However, the precise nature of these cytokine interactions during conception, initiation
and maintenance of the early pregnancy are not well understood. The aim of the first part
of this thesis was therefore to investigate the release and regulation of cytokines (MCP-1,
IL-8, RANTES and IL-10) during these processes. The specific questions which were
addressed were:
1. Initiation and maintenance
Does seminal plasma have a role in biasing the maternal immune response towards a
pro-pregnancy state? How does this equate with the observed post-coital pro¬
inflammatory cervical leukocytosis?
2. Adaptation of maternal immune system, specifically peripheral
leukocytes to pregnancy
Does the potential of peripheral blood to release cytokines (MCP-1, IL-8 and
RANTES) alter during pregnancy? If changes do occur, do they have implications
for the initiation and maintenance of pregnancy?
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3. Inflammatory mediators within the first trimester uterus and the
initiation and maintenance of pregnancy
Are cytokines (MCP-1, IL-8 and RANTES) present in the fluid compartments of the
first trimester? Does their distribution have implications for the initiation and
maintenance of the early conceptus and placentation?
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CHAPTER 3
SEMINAL PLASMA COMPONENTS STIMULATE
INTERLEUKIN-8 AND INHIBIT INTERLEUKIN-10
RELEASE FROM CERVIX, PERIPHERAL BLOOD AND U937
CELLS (MONOCYTE CELL LINE)
100
3.1 INTRODUCTION
Coitus and the deposition of semen into the female vagina precedes the inception of every
naturally conceived pregnancy. However, the nature of the initial interactions between
seminal plasma and spermatozoa, the principal constituents of semen, and the local
immune system of the female reproductive tract remain poorly understood.
There is clearly documented evidence that a significant leukocyte infiltration, comprising
predominately polymorphonuclear cells and macrophages, occurs within the cervix
(Hunter, et al., 1987; Mortimer, 1983; Moyer, et al., 1970; Sinosich and Saunders, 1987)
after insemination. This physiological post-coital leukocytic cell reaction develops very
rapidly with large numbers of leukocytes being detected 15 minutes post insemination
with cells (>10y) significantly outnumbering spermatozoa (<3 x 108) by 4 hours post-
coitus (Pandaya and Cohen, 1985). A similar phenomenon has also been reported in
other vaginal inseminators including rabbits (Tyler, 1977), goats (Mattner, 1968) and
cattle (Howe and Black, 1963) and in intra-uterine inseminators such as mice (De, et al.,
1991; Parr and Parr, 1991) and rats. The function of this leukocytic reaction is however
not certain, with phagocytosis of those sperm destined not to be involved in fertilisation
(Moyer, et al., 1970), prevention of infection and modulation of the local immune
response all being proposed (Barratt, et al., 1990) as putative functions. In addition, the
factor or factors which initiate the leukocytosis in humans are unknown and pure sperm,
seminal plasma stripped of spermatozoa and a combination have all been implicated
(Howe and Black, 1963; Mattner, 1968).
In contrast, it is vital that the maternal immune system does not mount a pro-inflammatory
rejection response to novel antigens expressed by sperm and the conceptus during the
critical processes of sperm transport, fertilisation and implantation. Clinically, there is
indirect evidence that the presence of seminal plasma during coitus may play a role in
preventing such adverse immune responses from developing. In women, who have
conceived with minimal exposure to seminal plasma, such as those with limited sexual
experience, using barrier contraceptives or undergoing in vitro fertilisation, there is an
increased risk of implantation failure, spontaneous abortion and pre-eclampsia (Bellinge,
et al., 1986; Klonoff-Cohen, et al., 1989). All of these conditions are thought to be
mediated, in part by underlying immunological abnormalities.
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Human seminal plasma is highly heterogeneous and contains many factors which could
affect the maternal immune response. These include soluble p55 TNF-a receptor
(Liabakk, et ah, 1993), receptors for the Fc portion of y-globulin, TGF-p (Nocera and
Chu, 1993), spermine (Evans, et al., 1995) and complement inhibitors (Kelly, 1995).
However, it is the prostaglandins PGE2 and 19-hydroxy PGE, present in mM
concentrations within semen (Kelly, et al., 1976; Templeton, et al., 1978), which are
thought to be the principal effectors of immunosuppression and immunomodulation
(Kelly, 1995). Seminal plasma prostaglandins are potent stimulators of cAMP and have
been shown to inhibit lymphocyte proliferation and NK cell activity. In addition, in vitro
studies in peripheral blood have demonstrated that PGE2 modifies cytokine release from
antigen presenting cells by stimulating release of the immunosuppressive, pregnancy
favourable, Th-2 type cytokine IL-10 and inhibiting release of the Th-1 type cytokine 1L-
12 (Kelly, et al., 1997; Wegmann, et al., 1993). However, whether seminal plasma,
PGE2 or 19-hydroxy PGE, effect a similar cytokine shift in the human cervix or female
reproductive immune system is not known.
This study therefore had two principal aims. First, to investigate whether any factors in
seminal plasma could be responsible for the observed pro-inflammatory post-coital
leukocytosis and second to assess if seminal plasma could effect development of a Th-2
cytokine profile in cervical explants. The cytokines studied were the pro-inflammatory IL-
8, the anti-inflammatory secretory leukocyte protease inhibitor and Th-2 type cytokine IL-
10. The initial findings with seminal plasma extracts on cervical explants were further
characterised by examining the effect of seminal plasma, a seminal plasma extract, PGE2
and 19-hydroxy PGE on mediator release by peripheral blood and the human pro¬
monocyte cell line U937.
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3.2 MATERIAL AND METHODS
Tissue Collection
Pooled human seminal plasma was obtained from healthy young men involved in the
ongoing semen donor programme (more than 20 men). Cervical biopsies, approximately
20 to 35 mg in weight, 15 - 20 mm in length and 2-3 mm in diameter, were obtained
from healthy, non-pregnant women (n = 15, ages 29 - 45) with regular menstrual cycles
undergoing a hysterectomy for a non-malignant condition. These were taken from the
anterior lip of the cervix immediately post-hysterectomy. Peripheral blood was taken
using a Li-heparin from healthy non-pregnant women (n = 6, ages 20 - 35) with normal
menstrual cycles not using any hormonal form of contraception. The women were at
various stages of the menstrual cycle.
Preparation of seminal plasma fraction
A seminal plasma fraction was prepared by lipid extraction as previously described
(Section 2.225) to remove the majority of the polyamines such as spermine and
spermidine, which may have cytotoxic effects (Allen and Roberts, 1986). PGE2 and 19-
hydroxy PGE concentrations were assayed as previously described (Section 2.23). The
seminal plasma fraction contained 165 gg/ml PGE7and 705 gg/ml 19-hydroxy PGE.
Tissue culture
Cervical biopsies
Explants were cultured in complete medium supplemented with seminal plasma fraction
diluted 1 : 2000 with treatments in quadruplicate. The harvested media were frozen at
-20°C until analysis.
Peripheral blood
Peripheral blood was cultured as previously described (Section 2.221) in RPMI 1640
supplemented with whole seminal plasma (1 % to 0.0001 %), seminal plasma fraction (1
% to 0.0001 %), PGE2 (10"fiM - 10"M) and 19-hydroxy PGE (106 M - 10"9 M).




U937 cells were plated out as previously described at 2 x 105 cells/ml in complete media
(section 2.226), supplemented with whole seminal plasma (1 % to 0.0001 %), seminal
plasma fraction (1 % to 0.0001 %), PGE2 (10"6 to 10"10 M) and 19-hydroxy PGE (10~6 to
10"10 M). In addition, cells were treated with 10~7M PMA for the IL-10 experiments
because no IL-10 was released from cells without PMA treatment. Treatments were
added in quadruplicate and media were removed and stored at -20°C until analysis.
Cytokine assays
IL-8, secretory leukocyte protease inhibitor, IL-10, PGE2 and 19-hydroxy PGE were
assayed by ELISA as previously described (Section 2.23).
Statistical analysis
Statistical analysis of the data was performed using StatView 4.1 (Abacus Inc., Berkley,
CA, USA). The data were normally distributed and are expressed as cytokine release as
% of control (mean ± s.e.m) with a statistically significant difference defined as p<0.05.
Ethical Approval
Ethical approval for the collection of all samples was obtained from the Lothian Trust




The lipid extracted seminal plasma fraction significantly stimulated (p<0.005) IL-8 and
inhibited (p<0.005) secretory leukocyte protease inhibitor release (Figure 6; n = 15
different women, treatments in quadruplicate). IL-10 release was below the detection limit
of the assay employed.
Peripheral blood data
Whole seminal plasma significantly (p<0.05) inhibited IL-8 release at concentrations of
greater than 0.1 %. Maximum inhibition of IL-8 release down to 8 % of control values
(p<0.005) was achieved when seminal plasma was added at 1 %. In contrast, seminal
plasma fraction significantly (p<0.05) stimulated IL-8 release when used at 0.001 % with
a 10-fold stimulation achieved when peripheral blood was cultured with 0.1 % seminal
plasma fraction (p<0.005; Figure 7; n = 6 separate experiments, treatments in
quadruplicate). Both PGE, and 19-hydroxy PGE significantly stimulated (p<0.05;
p<0.005 respectively) IL-8 release with maximal stimulation achieved at 10"fiM. 19-
hydroxy PGE was significantly (p<0.05) more effective in stimulating IL-8 release than
PGE2 at concentrations of greater than 10"8M (Figure 8; n = 6 separate experiments,
treatments in quadruplicate). Secretory leukocyte protease inhibitor release was below the
detection limit of the assay used.
U937 monocyte cell line
Seminal plasma and the seminal plasma fraction significantly (both p<0.005) stimulated
IL-8 release from U937 cells cultured without PMA by comparable amounts with
maximum stimulation at 0.1 % (Figure 9; n = 6 separate experiments, treatments in
quadruplicate). PGE2 significantly (p<0.05) stimulated IL-8 release from U937 cells with
maximum stimulation at 10"('M. 19-hydroxy PGE also stimulated (p<0.005) IL-8 release
and, as demonstrated in peripheral blood, it was significantly (p<0.05) more effective in
inducing IL-8 release than PGE2 (Figure 10; n = 6 separate experiments, treatments in
quadruplicate). Secretory leukocyte protease inhibitor release was not detectable from
U937 cells.
Seminal plasma and the seminal plasma fraction significantly stimulated (p<0.05) IL-10
release from U937 cells with maximum stimulation at 0.1 % and 0.01 % respectively, for
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seminal plasma and its fraction (Figure 11; n = 6 separate experiments, treatments in
quadruplicate). The seminal plasma fraction inhibited secretion of IL-10 back to control
values when added at 0.1 %. PGE2 significantly (p<0.05) stimulated IL-10 release from
U937 cells with maximum stimulation at 10"6M. Although 19-hydroxy PGE also
stimulated IL-10 release this failed to reach significance (Figure 12; n = 6 separate




















































Control Seminal plasma fraction
1: 2000
Figure 6
Effect of seminal plasma fraction on IL-8 and secretory leukocyte protease inhibitor
release from non-pregnant cervical explants. Release of IL-8 release was stimulated
and secretory leukocyte protease inhibitor inhibited by seminal plasma fraction at 1 :
2000. SLPI, secretory leukocyte protease inhibitor. Values are expressed as cytokine
release as % of control; mean ± s.e.m. n = 15 different women, treatments in
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Figure 7
The effect of seminal plasma and seminal plasma fraction on IL-8 release from
peripheral blood. IL-8 release was significantly stimulated by the seminal plasma
fraction whereas seminal plasma significantly inhibited EL-8 release. Values are
expressed as the log of IL-8 release as % of control; mean ± s.e.m. Typical of n = 6
separate experiments, treatments in quadruplicate. Significance of difference from
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Figure 8
The effect of PGE2 and 19-hydroxy PGE on EL-8 release from peripheral blood. EL-8
release was significantly stimulated by both PGE2 and 19-hydroxy PGE. At
concentrations of greater than 10'8M, 19-hydroxy PGE was significantly more
effective in stimulating EL-8 release than PGE2. Values are expressed as EL-8 release
as % of control; mean ± s.e.m. Typical of n = 6 separate experiments, treatments in
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The effect of seminal plasma and seminal plasma fraction on EL-8 release from U937
cells. IL-8 release was significantly stimulated by both seminal plasma and seminal
plasma fraction. Values are expressed as IL-8 release as % of control; mean ± s.e.m.
Typical of n = 6 separate experiments, treatments in quadruplicate. Significance of
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The effect of PGE2 and 19-hydroxy PGE on IL-8 release from U937 cells. EL-8
release was significantly stimulated by both PGE2 and 19-hydroxy PGE. 19-hydroxy
PGE was significantly more effective in stimulating IL-8 release than PGE2. Values
are expressed as IL-8 release as % of control; mean ± s.e.m. Typical of n = 6 separate
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The effect of seminal plasma and seminal plasma fraction on IL-10 release from U937
cells. Seminal plasma significantly stimulated IL-10 release from U937 cells. Seminal
plasma fraction significantly stimulated IL-10 release at 0.001 % and 0.01 % but
inhibited its release back to control values at 0.1 %. Values are expressed as IL-10
release as % of control; mean ± s.e.m. Typical of n = 6 separate experiments,
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Figure 12
The effect of PGE2 and 19-hydroxy PGE on IL-10 release from U937 cells. PGE2
significantly stimulated IL-10 release from U937 cells. 19-hydroxy PGE stimulated
IL-10 release but this failed to reach significance. Values are expressed as IL-10
release as % of control; mean ± s.e.m. Typical of n = 6 separate experiments,
treatments in quadruplicate. Significance of difference from control; *, p<0.05.
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3.4 DISCUSSION
Prostaglandin E2 (Samuelsson, 1963) and 19-hydroxy PGE (Taylor and Kelly, 1974) are
thought to be the principal immunosuppressive agents present in semen. In addition to
favouring development of a Th-2 type of cytokine release from CD4+ T cells (Kelly, et al.,
1997), PGE2 and IL-10, whose release it stimulates (Kelly, et al., 1997), inhibit the
expression of the T-cell co-stimulatory ligands B7-1 and B7-2 (Ding, et al., 1993;
Iglesias, et al., 1997). Antigens, which are presented to T-cells in the absence of such
molecules are rendered anergic or non-responsive to that specific antigen and do not
recognise it when it is represented in a subsequent occasion. IL-10 is also capable of
inducing anergy in CD4+ T-cells directly (Groux, et al., 1996).
Less is known about the function of 19-hydroxy PGE, which is synthesised in the
microsomal fraction of the seminal vesicles from prostaglandins by PGE 19-hydroxylase.
Like PGE2, it is thought to act principally as an immunosuppressive agent inhibiting NK
cell activity (Tarter, et al., 1986), elevating levels of cAMP (Kelly, et al., 1994) and
stimulating IL-10 release. Despite the fact that in vitro 19-hydroxy PGE is a less potent
immunosuppressive agent than PGE?, its three-fold higher levels within seminal plasma
may confer on it greater immunosuppressive activity in vivo. In addition, 19-hydroxy
PGE is a relatively selective EP-2 receptor agonist (Woodward, et al., 1993), unlike PGE2
which binds to all of the EP receptors. Given that the primate cervix contains mainly EP-2
receptors (Smith, et al., 1998) then the higher affinity of 19-hydroxy PGE for the EP-2
receptor may make it more active in vivo.
This study demonstrates that seminal plasma, a lipid extract, PGE2 and 19-hydroxy PGE
stimulate IL-10 release by U937 cells. IL-10 release by cervical explants was below the
detection limit of the assay employed. This data is supported by previous studies, in
peripheral blood and peripheral blood mononuclear cells in which semen and its
component prostaglandins stimulated expression and release of IL-10 (Jeremias, et al.,
1998; Kelly, et al., 1997).
It is hypothesised that stimulation of IL-10 release by seminal plasma prostaglandins
would favour development of a pregnancy favourable Th-2 response locally within the
upper vaginal tract. In other animals, seminal plasma, its component plasma proteins and
lymphocytes are transported from the vagina and uterus to draining lymph nodes
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(Carballada and Esponda, 1997; Ibata, et al., 1997). These nodes have been shown to
enlarge post-coitus (Alexander and Anderson, 1987) and in mice to alter their cytokine
receptor profile in direct response to the presence of seminal plasma within the uterus
(Bischof, et al., 1994). Given that some seminal plasma also enters the uterus (Egli and
Newton, 1961) after intercourse in women, then it is further suggested that transport of
seminal plasma prostaglandins to draining lymph nodes from either the upper vagina or
uterus may stimulate IL-10 release and a Th-2 type response in endometrium and the
draining lymph nodes. A shift to a pro-pregnancy Th-2 type immune response would
potentially favour implantation (Lim, et al., 1998) and the development of a successful
pregnancy.
PGE2 is an enigmatic mediator possessing both anti- and pro-inflammatory (Williams and
Peck, 1977) properties. However, recently several novel pro-inflammatory properties
have been described. Within human skin it synergises with the neutrophil chemotactic and
activating agent IL-8 to promote neutrophil chemotaxis and activation (Colditz, 1990).
Prostaglandin E2 also promotes release of IL-6 and IL-8 from IL-1(3 stimulated synovial
fibroblasts (Agro, et al., 1996), mediates bradykinin induced stimulation of IL-8 release
from cultured human airway epithelial cells (Pang and Knox, 1998) and stimulates IL-8
release from human colonic epithelial cells (Yu and Chadee, 1998). The mechanism by
which PGE2 stimulates IL-8 is not certain but may be via post-transcriptional stabilisation
of its mRNA. There is no direct evidence that seminal plasma PGE2 stimulates IL-8
release either within semen or the female genital tract. However, elevated levels of IL-8
within seminal plasma do correlate with leukocytospermia, a condition characterised by
abnormally high levels of pro-inflammatory leukocytes in seminal plasma (Shimoya, et
al., 1993). A pro-inflammatory action for 19-hydroxy PGE has not been previously
described.
This study demonstrates that seminal plasma and its component prostaglandins stimulate
IL-8 release. The only exception to this was in peripheral blood where whole semen
inhibited IL-8. However, seminal plasma is a potent stimulator of IL-10 release in
peripheral blood and given that there is mutual repression between release of IL-10 and
IL-8 (Kang, et al., 1998; Lu, et al., 1995) then the high levels of IL-10 generated may
have inhibited IL-8 release. In addition, other factors within seminal plasma may also
affect IL-8 release in peripheral blood preparations.
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It is therefore suggested that PGE2 and 19-hydroxy PGE, by stimulating release of the
neutrophil chemoattractant IL-8 from the female genital tract mucosa, may have a role in
inducing the post-coital leukocytic reaction in humans. Spermatozoa not involved in
fertilisation could then either be phagocytosed by the invading leukocytes (Moyer, et al.,
1970), or endocytosed by vaginal (Phillips and Mahler, 1975) or uterine epithelium
(Carballada and Esponda, 1997). The pro-inflammatory action of seminal plasma in
stimulating IL-8 release may seem to conflict with its anti-inflammatory effect in
stimulating IL-10 release. However, IL-8 is also a potent chemotactic factor for T-
lymphocytes (Taub, et al., 1996). It could therefore induce their entry into the upper
vaginal tract where they could be presented with spermatozoal antigen by the submucosal
dendritic antigen presenting cells. Presentation of antigen in the presence of high
concentrations of immunomodulatory agents such as PGE2, TGF-p and IL-10, either
found in or induced by seminal plasma would favour development of an anergic response
to spermatozoa. In addition, dendritic cells which mature in the presence of PGE2 show
impaired IL-12 production and thus their naive Th cell development is biased towards a
Th-2 type (Kalinski, et al., 1998). In combination, these immune responses would
facilitate survival of those sperm which were destined to be involved in fertilisation
(Groux, et al., 1996; Tremellen, et al., 1998) and prevent their destruction by a hostile
maternal immune response.
It has been suggested that pure seminal plasma stripped of sperm is not capable of
leukocytosis and therefore the hypothesis proposed would be invalid. The published data
are however conflicting and this may be due to different methods of collecting and
purifying the seminal plasma and the age of the semen used for the studies. In addition,
pure spermatozoa washed of seminal plasma have also been reported to induce
leukocytosis (Thompson, et al., 1992). However, washing spermatozoa may induce
alterations in membrane structure including lipid peroxidation generating oxygen free
radicles and leukotrienes both of which are chemotactic for neutrophils (Krauss, et al.,
1994; Wizemann and Laskin, 1994). This could account for the observed leukocytosis
post insemination of pure sperm. It is likely therefore that in vivo a combination of
seminal plasma constituents such as PGE2, 19-hydroxy PGE and spermatozoa would act
together to induce leukocytosis.
In conclusion, this study demonstrates that seminal plasma prostaglandins can induce
release of both pro-and anti-inflammatory cytokines and that PGE2 and 19-hydroxy PGE
differ in their capacity to induce cytokine secretion. The potential immunomodulatory
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properties of seminal plasma prostaglandins in women have many parallels with the
mouse model. In mice, seminal plasma TGF-(3 (analogous to PGE2) stimulates release of
GM-CSF (analogous to IL-8), which induces an inflammatory leukocytosis within the
uterus (Tremellen, et al., 1998). TGF-p also induces tolerance and a Th-2 type of immune
response within the uterus. It is suggested that the anti- and pro-inflammatory effects
elicited by seminal plasma prostaglandins in humans are not mutually exclusive. The
different cytokines released may act in combination to promote sperm survival, facilitate
removal of excess sperm from the female reproductive tract and also to favour
development of a pregnancy favourable Th-2 type of immune response within the genital
tract and local immune system.
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CHAPTER 4
DIFFERENTIAL SECRETION OF CHEMOKINES FROM




The initiation and maintenance of pregnancy may necessitate profound changes in the
immune system with the development of a Th-2 bias in immune responses (Wegmann, et
al., 1993). These immunological alterations have marked effects on the presentation and
course of diseases during pregnancy. For example, conditions such as rheumatoid
arthritis (Hensch, 1938; Nelson and Ostensen, 1997) and psoriasis (Boyd, et al., 1996),
which are mediated by a Th-1 type of immune response, often remit during pregnancy and
those associated with a Th-2 response such as systemic lupus erythematosis are frequently
exacerbated (Kitridou and Mintz, 1993). These clinical observations suggest that the
maternal adaptation of the immune response extends beyond the feto-placental unit to
circulating leukocytes and the peripheral immune system.
Early studies, which attempted to identify alterations in the immunological potential of
circulating leukocytes, frequently yielded conflicting results. The non-specific immunity
afforded by polymorphonuclear leukocytes was demonstrated to be both up- (Crouch, et
al., 1995) and down-regulated (Shibuya, et al., 1991) and the proliferative response of
leukocytes to noxious stimuli to be increased and decreased (Bermas and Hill, 1997)
during pregnancy. More recently, the potential of circulating cells to release cytokines
(Elsasser-Beile, et al., 1992), and their concentrations within peripheral plasma have been
used to assess the state of the peripheral immune response. The reported findings, again
frequently conflict, with results depending on the nature and timing of sampling during
pregnancy, assay technique employed and cytokines being investigated. For example,
studies have variously demonstrated that serum concentrations of IL-1 and IL-6 correlate
positively with gestation (Augustulen, et al., 1994), plasma levels of IL-8 to be unaffected
(Laham, et al., 1993) and plasma concentrations of TNF-a to either increase (Beckmann,
et al., 1997) or be unaffected by gestation (Laham, et al., 1994).
A further factor, which is frequently ignored in studies examining peripheral immune
responses, are the profound haemodynamic alterations that occur during pregnancy. By
15 weeks gestation (Clapp, et al., 1988), a 20 % increase in plasma volume has occurred.
Less than 20 weeks later, it has expanded a further 30 % giving a final plasma volume of
approximately 3800 ml (de Swiet and Chamberlain, 1997). The bone marrow responds
by hyperplasia and increased erythropoietin output, thus stimulating erythrocyte
production and effecting a gradual increase in red cell mass. This is accompanied by a
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gradual haemodilution, due to preferential expansion of plasma volume over red cell
volume, reducing the haemoglobin and haematocrit to about 11 g/dl and 37 %,
respectively (Whitfield, 1995). Of direct relevance to studies on immune potential of
circulating leukocytes, is the tendency towards leukocytosis during pregnancy. This
elevation, which occurs relatively early in gestation and is attributable principally to
doubling of polymorphonuclear leukocyte counts (Pitkin and Witte, 1979), is frequently
not corrected for in peripheral blood studies. Whether monocyte, basophil, eosinophil or
platelet counts increase, decrease or remain unaltered during pregnancy is less certain
(Damm, et al., 1991; Pitkin and Witte, 1979; Sejeny, et al., 1975; Tsakonas, et al.,
1995).
The aim of this study was therefore to examine plasma concentrations and potential release
of immunomodulatory chemotactic cytokines by peripheral blood during pregnancy. The
cytokines studied were MCP-1, IL-8 and RANTES, chosen as markers of monocyte,
neutrophil and T-cell function, respectively.
120
4.2 MATERIALS AND METHODS
Sample Collection
Peripheral blood was obtained in the morning by sterile venepuncture in Li-Heparin tubes
from pregnant (n = 18) and non-pregnant (n = 36) women (Section 2.211). The patient
characteristics are demonstrated in Table 5. Blood was analysed for haemoglobin,
leukocyte count, including differential count, and platelet count using an automated NE
Sysmex counter.
Patient Group
Characteristic Non-pregnant, n = 18 Pregnant, n = 36
Age 22 - 47 (n = 30) 16-37 (n = 26)
Parity
P0 12 24
P 1 2 9




Non Smoker 16 29
Table 5
Patient characteristics for peripheral blood samples
Tissue culture
Whole blood was centrifuged at 1500 rpm for 5 minutes at 4°C, the upper plasma layer
removed and stored at -20°C prior to immunoassay.
Whole blood was cultured and neutrophils, PBMC preparations and CD14+ and CD14"
cells were separated and cultured (Section 2.221). To assess the effect of steroid
antagonism, PBMC preparations were cultured at 1x10s cells/ml in complete media
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supplemented with 10"6M progesterone for 48 hours. The media were then removed and
replaced with media supplemented with 10"6M mifepristone for 24 hours prior to removing
and storing the media at -20°C until analysis.
Assays
Media and plasma were analysed for MCP-1, IL-8 and RANTES by ELISA (Section
2.23).
Statistics
Statistical analysis was performed using ANOVA multiple variate analysis in StatView.
Assignment of difference to individual groups was achieved using Fisher's probability of
least squared differences (PLSD) with significance taken to be p<0.05. Results are
expressed as mean +/- standard error of the mean (s.e.m).
Ethical Approval
Ethical approval for the collection of all samples was obtained from the Lothian Trust




The haemoglobin levels were significantly lower during labour (p<0.01) compared with
non-pregnant samples. There was a tendency towards leukocytosis during pregnancy but
this failed to reach significance. The neutrophil count was (p<0.01) significantly greater
at term than during the first trimester or in non-pregnant samples. There was no
difference in any of the other haematological parameters measured between the different
patient groups (Table 6).
Plasma chemokine levels
MCP-1 and RANTES were detectable in non-pregnant (187 ± 7 pg/ml; 23 ± 4 ng/ml) and
pregnant (155 ± 8 pg/ml; 20 ± 2 ng/ml) plasma, respectively. There was no significant
difference in plasma MCP-1 and RANTES concentrations between non-pregnant and
pregnant samples. IL-8 was not detectable in peripheral plasma.
Peripheral blood cultures
Significantly (pcO.OOl) higher concentrations of MCP-1 were secreted by peripheral
blood cultures from pregnant (term not in labour, TNIL; n = 10; 4325 ± 857 pg/ml)
compared with non-pregnant (n = 12; 1739 ± 391 pg/ml) women (Figure 13). In a
separate study, significantly (pcO.OOl) greater amounts of MCP-1 were released at term
compared with first trimester (3890 ± 481 pg/ml) or non-pregnant (2531 ± 319 pg/ml)
cultures. More MCP-1 was released by samples taken at term from women not in labour
(n = 14; 7635 ± 612 pg/ml) compared with those in labour (term in labour, TIL; n = 12;
6125 ± 521 pg/ml) although this was not statistically significant (Figure 14).
Both IL-8 and RANTES were detectable in non-pregnant (456 ± 96 pg/ml; 736 ±251
pg/ml) and pregnant (540 ± 182 pg/ml; 1222 ± 247 pg/ml) culture supernatants. There
were no significant differences in IL-8 and RANTES release by non-pregnant and
pregnant cultures (Figure 13).
Neutrophil separation
Given that observed differences in neutrophil count between patient groups, it was
possible that the increased release of MCP-1 from pregnant whole blood cultures was due
to its release by neutrophils present in the cultures. Neutrophils were therefore extracted
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from non-pregnant (n = 6) and pregnant (TNIL, n = 6) blood samples, counted and
cultured at lxlO5 cells/ml. There were no significant differences in release of MCP-1 or
IL-8 from non-pregnant (59.6 ± 12.3 pg/ml; 91.3 ± 14.5 pg/ml) or pregnant (81.9 ± 13.6
pg/ml; 94.1 ± 17.2 pg/ml) preparations. RANTES release was not detectable from
neutrophil preparations (Table 7).
PBMC preparations
PBMC preparations were prepared to investigate whether mononuclear cells in peripheral
blood could be responsible for the differences in MCP-1 release. Significantly (p<0.05)
more MCP-1 was secreted by pregnant (TNIL, n = 6) compared with non-pregnant (n =
6) preparations with this differential being maintained over 72 hours culture (Figure 15).
There was no difference in the capacity of non-pregnant and pregnant PBMC preparations
to release IL-8 and RANTES (data not shown).
Steroid antagonism studies were performed to assess the effect on chemokine release of
removing pregnant peripheral blood from the progesterone rich environment of
pregnancy. Progesterone antagonism had no effect on MCP-1, IL-8 or RANTES release.
CD147CD14 separated cells
To further characterise the cells responsible for MCP-1, IL-8 and RANTES release,
PBMC preparations were separated into CD14+ (monocyte enriched) and CD 14
(monocyte depleted) cell fractions. MCP-1 and IL-8 were secreted predominately by
CD14+ cells with there being a tendency towards more MCP-1 and IL-8 being released by
CD14+ cells isolated from pregnant (TNIL, n = 3; 726 ±219 pg/ml; 2573 ± 791 pg/ml)
compared with non-pregnant (n = 3; 210 ± 184 pg/ml; 1279 ± 942 pg/ml) women.
RANTES was released mainly by CD14 cells with more being released by CD14 from
non-pregnant (1378 ± 535 pg/ml) compared with pregnant (976 ± 230 pg/ml) women
(Table 8). There was no correlation in release of MCP-1, IL-8 or RANTES from
separated cells with gestation (data not shown).
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Parameter Non¬ First TNIL TIL
pregnant trimester
Haemoglobin 132.1 ± 3.4* 120.3 ± 3.2 114.9 ± 3.5 101.2 ± 2.8*
(g/D
Leukocyte count 6.73 ± 0.51 7.72 ± 1.10 8.75 ± 0.47 9.2 ± 0.91
(xl09/l)
Neutrophil 3.92 ± 0.32 5.45 ± 0.96 6.4 ± 0.45 * 6.9 ± 0.41*
(xl09/l)
Lymphocyte 1.77 ± 0.13 1.77 ± 0.15 1.75 ± 0.17 1.79 ± 0.20
(x 109/l)
Monocyte 0.30 ± 0.04 0.3 ± 0.03 0.32 ± 0.06 0.3 ± 0.04
(x 109/l)
Eosinophil 0.14 ± 0.02 0.16 ± 0.02 0.16 ± 0.02 0.15 ± 0.02
(xl09/l)
Basophil 0.08 ± 0.02 0.05 ± 0.01 0.06 ± 0.01 0.06 ± 0.01
(x 109/l)
Platelet count 250.6 ± 14.2 286.3 ± 19.9 311.6 ± 22.9 251 ± 21.7
(xl 09/l)
Table 6
Haematological parameters. The haemoglobin levels were significantly lower during
labour compared with non-pregnant samples. There was a tendency towards leukocytosis
during pregnancy but this failed to reach significance. The neutrophil count was
significantly greater at term than during the first trimester or in non-pregnant samples.








































The difference in release of the cheraokines IL-8, MCP-1 and RANTES from cultured
peripheral blood. Significantly more MCP-1 was released from pregnant (n = 10)
compared with non-pregnant samples (n = 12). There was no significant difference in
release of either IL-8 or RANTES between pregnant and non-pregnant samples.






























Differential release of MCP-1 through gestation from peripheral blood in a separate
study. Significantly higher levels of MCP-1 were released from peripheral blood
cultures taken at the end of pregnancy (TNIL, n = 14; TNIL, n = 12) compared with
those from first trimester (n = 10) or from women who were not pregnant (n = 13).
TNIL, term not in labour; TIL, term in labour. Values expressed as pg/ml; mean ±
s.e.m. Significance; *, p<0.05.
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Chemokine release, pg/ml (s.e.m)
Sample MCP-1 IL-8 RANTES
type
NP TNIL NP TNIL NP TNIL
(n = 6) (n = 6) (n = 6) (n = 6) (n = 6) (n = 6)
Peripheral 2652 8697 209 185 1472 1820
blood (278)** (896)** (32) (69) (121) (390)
Neutrophil 60 (12) 82 (14) 91 (14) 94 (17) n.d n.d
PBMC 1292 2665 2105 4319 3161 5048
(211)* (214)* (401) (362) (389) (1171)
Table 7
The release of MCP-1, IL-8 and RANTES from peripheral blood cultures compared with
that from peripheral blood mononuclear cell preparations prepared from the same blood
sample. Significantly more MCP-1 was produced by both the cultured (pcO.OOl) and the
PBMC preparations (p<0.005) from pregnant compared with non-pregnant women.
PBMC, peripheral blood mononuclear cells; NP, non-pregnant; TNIL, term not in labour;
















• Pregnant TNIL n = 6
O Non-pregnant n = 6
Day 1 Day 2 Day 3
Days of Culture
Figure 15
Release of MCP-1 from peripheral blood mononuclear cell preparations over three
days culture with media being replaced and assayed every 24 hours. Even after three
days culture, more MCP-1 was released from peripheral blood mononuclear cell
preparations from pregnant (n = 6) compared with non-pregnant women (n = 6).
PBMC, peripheral blood mononuclear cell; TNIL, term not in labour. Values are
expressed as pg/ml; mean ± s.e.m.
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Chemokine release, pg/ml/lO"' cells (s.e.m)
Cell MCP-1 IL-8 RANTES
population NP TNIL NP TNIL NP TNIL
(n = 3) (n = 3) (n = 3) (n = 3) con (n = 3)
CD14+ 210 726 1279 2573 225 293
(184) (219) (942) (791) (55) (86)
CD 14" 17 70 197 108 1378 976
(2) (26) (51) (20) (535) (230)
Table 8
The production of MCP-1, IL-8 and RANTES from CD14+ and CD 14" cells. MCP-1 and
IL-8 were released predominately by the CD14+ cells whereas RANTES was released
predominately by the CD 14" cells. There was no statistical difference in release of any of
the chemokines measured between pregnant and non-pregnant blood although this may be
due to the small sample size. NP, non-pregnant; TNIL, term not in labour.
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4.4 DISCUSSION
This study demonstrates that significantly more MCP-1 is released by peripheral blood
cultures from pregnant compared with non-pregnant women with secretion increasing
during gestation. The mononuclear cell fraction of peripheral blood, specifically the
CD14+ monocyte cells are the likely cellular source of MCP-1. There was no significant
difference in secretion of IL-8 or RANTES by peripheral blood preparations or separated
cells between pregnant and non-pregnant women.
High levels of circulating progesterone are essential for the initiation and maintenance of
pregnancy. In addition, progesterone is an important immunomodulator, inhibiting
release of many inflammatory mediators including MCP-1 (Kelly, et al., 1997) and IL-8
(Arici, et al., 1996; Ito, et al., 1994) possibly via the transcription factor NFkB. It could
therefore be argued that, on removing blood from the inhibitory, progesterone rich
environment of pregnancy, there would be a rebound stimulation of MCP-1 secretion.
The experimental data presented discounts this proposal on several counts. Increased
release of MCP-1 by pregnant compared with non-pregnant mononuclear cells was still
observed after 72 hours culture, long after any inhibitory effect of progesterone would be
expected to have dissipated. In addition, since IL-8 is also inhibited by progesterone and
if progesterone were an important regulatory factor, then one would also expect a rebound
stimulation of IL-8 release, analogous to that observed for MCP-1. This was not
observed and was further supported by the failure of steroid antagonism studies to
demonstrate any effect on MCP-1 or IL-8 release. Finally, whether pregnant leukocytes
do (Paldi, et al., 1994; Szekeres-Bartho, 1992) or do not (Mansour, et al., 1994; Schust,
et al., 1996) possess a functioning progesterone receptor, and could therefore respond to
progesterone, is controversial.
These studies demonstrated the development of a peripheral leukocytosis and an increase
in neutrophil count during pregnancy. Unlike other studies, the former failed to reach
significance (Pitkin and Witte, 1979). This may have been due to the relatively small
sample size in this study. One explanation, which could be proposed to account for the
increased release of MCP-1 by peripheral blood cultures, is that it was purely a function of
there being more cells, for example neutrophils, in the pregnant cultures. However, when
neutrophils were separated from peripheral blood, counted and cultured, there was no
difference in cytokine release between pregnant and non-pregnant cultures. In contrast,
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significantly more MCP-1 was released from mononuclear cells from pregnant compared
with non-pregnant women suggesting that there might be an intrinsic difference between
pregnant and non-pregnant monocytes.
Due to their capacity to present antigens and synthesise a wide range of different
cytokines, monocytes and their counterparts, the resident tissue macrophages, play pivotal
roles in the induction and regulation of local immune responses. At the feto-matemal
interface, resident macrophages are thought to preferentially secrete Th-2 type cytokines
(IL-4, IL-5 and IL-10), thus preparing the uterus for implantation and maintenance of the
early conceptus (Lin, et al., 1993). Similarly, peripheral blood mononuclear cells from
women with normal reproductive histories, which are exposed to trophoblast antigen
preferentially secrete Th-2 type cytokines (IL-4 and IL-10) (Marzi, et al., 1996). In
contrast, in women with endometrial dysfunction, which results in the inability to permit
implantation, endometrial leukocyte populations tend to express more Th-1 (IFN-y) than
Th-2 (IL-4 and IL-10) type cytokines (StewartAkers, et al., 1998). A similar pattern is
observed peripherally in women with a history of recurrent spontaneous miscarriage with
exposure of peripheral blood mononuclear cells to trophoblast antigen inducing a Th-1
(IL-2, TNF-a, IFN-y) or embryotoxic response (Hill, 1995). Similarly, mononuclear
cells from women who subsequently miscarry or who have small for gestational age
fetuses also preferentially secrete Th-1 type cytokines (IL-2 and IFN-y; Marzi, et al.,
1996).
The C-C chemokine MCP-1 was initially described as a monocyte chemoattractant and
activating agent. Recently, it has been suggested that it may act as an immunomodulator,
favouring development of a Th-2 type of immune response. Studies in mice have
demonstrated that MCP-1 expression was increased in the secondary, Th-2 granuloma
mediated response to schistosomal infection (Chensue, et al., 1995; Chensue, et al.,
1996). In addition, exposure of nai've, murine T-cells to MCP-1 induced them to
differentiate into the Th-2 phenotype, capable of releasing IL-4 (Karpus, et al., 1997). It
is hypothesised that the increased release of MCP-1 by pregnant compared with non¬
pregnant monocytes may therefore reflect the Th-2 bias that exists during pregnancy.
MCP-1 may act to direct monocyte cytokine synthesis away from a Th-1 type of response
and towards a Th-2 type or pregnancy favourable response.
In summary, this study demonstrates that peripheral blood, specifically the monocyte cell
fraction releases more MCP-1 than non-pregnant preparations. This suggests that
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pregnant monocytes are intrinsically different from non-pregnant monocytes in their
cytokine synthetic capacity. This is supported by previous data that demonstrated that
monocytes from pregnant women released more IL-1 and TNF-a (Fukuoka, et al., 1993)
and expressed higher concentrations of the surface (32-integrins CD18, CDlla and CDllc
(Thilaganathan, et al., 1995) than those from non-pregnant women. Finally, it is
proposed that the increased secretion of MCP-1 may bias the immune response towards a
pregnancy favourable Th-2 type of immune response and facilitate the initiation and
maintenance of a normal pregnancy.
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CHAPTER 5
DIFFERENTIAL CONCENTRATIONS OF MCP-1 AND IL-8
WITHIN THE FLUID COMPARTMENTS PRESENT DURING
THE FIRST TRIMESTER OF PREGNANCY
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5.1 INTRODUCTION
During the first trimester, the human embryo is surrounded by two fluid-filled
compartments, the amniotic fluid cavity and the extra-embryonic coelom fluid cavity,
which also contains the yolk sac (Figure 16).
The amniotic cavity first appears as a slit-like space between the cytotrophoblast and the
adjacent embryonic ectoderm. It enlarges to form a small cavity by the 12th post-ovulatory
day whose walls and roof are formed by cytotrophoblast and floor by embryonic
ectoderm. The amniotic cavity expands at the expense of the extra-embryonic coelom with
the developing embryo bulging into the expanded amniotic cavity. Further enlargement
results in complete obliteration of the extra-embryonic coelomic cavity with ultimate fusion
of the amnion with the chorion to form the amniochorionic membrane (Fox, 1989).
The extra-embryonic coelomic fluid cavity is formed during the 4lh week of gestation from
cavities within the extra-embryonic mesoderm, which is derived from the outer layer of
the trophoblast (Jones and Jauniaux, 1995). It is contiguous externally with the
mesenchyme of the placental plate and is bounded internally by the mesothelial layer of the
amnion membrane. With the expansion of the amniotic cavity, it becomes completely
obliterated at the end of the first trimester.
The human secondary yolk sac is an independent organ present within the extra¬
embryonic coelomic cavity. It develops during the 6lh week of gestation as cystic,
spherical structure enveloped by numerous small vessels, which merge to form the
vitelline duct. It is connected via this duct to the ventral surface of the embryo, its gut and
ultimately to the main embryonic blood circulation (Gonzales-Crussi and Roth, 1976;
Jones and Jauniaux, 1995). The yolk sac wall is formed by an external mesothelial layer
facing the coelomic cavity, a vascular mesenchyme and an internal endodermal layer. It
regresses during the 10th week of gestation, rapidly becomes non-functional (Jones and
Jauniaux, 1995) and is completely obliterated along with the extra-embryonic coelomic
cavity at the end of the first trimester.
The composition of amniotic fluid and extra-embryonic coelom differs considerably in
hormonal, biochemical and protein composition (Docherty, et al., 1996; Jauniaux, et al.,
1993). Amniotic fluid comprises mainly transcutaneous secretions from the
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Figure 16
Figure demonstrating the fluid compartments present in the uterus during the first
trimester.
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fetus and digestive and respiratory tract secretions, after the oropharyngeal membrane has
opened (McCarthy and Saunders, 1978). In contrast, extra-embryonic coelom is the site
of molecular exchanges between mother and fetus and its contents are the result of an
ultra-filtrate of maternal serum with additional contributions from the placenta and
secondary yolk sac. Generally, extra-embryonic coelom has higher concentrations of
proteins hormones such as hCG and steroids, enzymes and fetal waste products,
including urea, creatinine and bilirubin than amniotic fluid. Consequently, extra¬
embryonic coelom has been proposed as the "physiological liquid extension of the early
placenta which may act as a reservoir for nutrients needed by the developing embryo"
(Gulbis, et al., 1998). The mechanism for such segregation is not fully understood,
however the amnion is thought to play an important role by actively transporting
substances between compartments. This concept is supported by the presence of high
concentrations of bicarbonate in amniotic fluid and phosphate in extra-embryonic coelom,
suggesting the presence of ion anti-ports driving active transport channels (Docherty, et
al., 1996). In addition, amnion has rich stores of glycogen, which may represent an
energy source for active transport (Jones and Jauniaux, 1995).
The yolk sac has a role in haemopoiesis (Migliaccio, et al., 1986), is the source of
primordial germ cells and is involved in protein biosynthesis prior to maturation of the
embryonic liver (Gitlin and Perricelli, 1970; Shi, et al., 1985). It is also an important
zone of transfer between the extra-embryonic and embryonic compartments (Gulbis, et
al., 1998).
Despite this, the role of each compartment in early fetal development remains poorly
understood. Cytokines have an essential role in the initiation and maintenance of the early
pregnancy by preparing the uterus for implantation and subsequent fetal development.
However, whether cytokines are present in the first trimester fluid compartments, and
could thus act locally from within the uterus at the feto-maternal interface, is not known.
With the advent of modern ultra-sound scans, detailed study of these compartments is
now possible with selective aspiration of fluid. Given that studies presented in Chapter 4
had previously demonstrated significant differences in the secretion of MCP-1 but not IL-
8 and RANTES by pregnant compared with non-pregnant peripheral blood, then it was of
interest to establish whether these chemokines were also present within the first trimester
uterus. The aim of this study was therefore to determine the concentrations of MCP-1,
IL-8 and RANTES in extra-embryonic coelom, amniotic fluid and maternal serum.
Specifically, this study examined whether these cytokines could potentially play a role in
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initial development of the fetus and placenta and maintenance of the early pregnancy from
within the uterus.
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5.2 MATERIALS AND METHODS
Collection of samples
Amniotic and extra-embryonic coelomic fluid were collected by transvaginal ultrasound-
guided needle aspiration between 8-11 weeks of gestation prior to the termination of
pregnancy under general anaesthesia, as described in detail previously (Wathen, et al.,
1991). Briefly, women with vaginal bleeding or uncertain menstrual dates were excluded
from the study. Peripheral blood (10 mis) was collected prior to the induction of
anaesthesia. The perineum and vagina were prepared with Betadine solution.
Transvaginal ultrasound scanning was performed to assess fetal viability, gestational age
by measurement of the crown-rump length and uterine position. An 18-gauge needle
guide was fitted to the probe and a 22 cm 18-gauge needle with trocar was used for the
amniocentesis. The needle was advanced under ultrasound guidance through the vaginal
vault and myometrium into the fluid. The extra-embryonic coelomic fluid was usually
aspirated first due to anatomical reasons. The trocar was then reintroduced and amniotic
fluid was aspirated. The extra-embryonic coelomic fluid was always darker than the
amniotic fluid. All samples, which were a kind gift from Wathen and Chard and were
stored at -20°C prior to immunoassay.
Cytokine ELISAs
MCP-1, IL-8 and RANTES were analysed by ELISA (Section 2.23). Serial dilutions of
amniotic fluid, maternal serum and extra-embryonic coelomic fluid gave dose response
curves parallel to that of immunopurified standard for MCP-f and IL-8 (data not shown).
Statistical analysis
The data were normally distributed and statistical analyses of concentrations of MCP-1
and IL-8 between and within compartments with gestation were performed using ANOVA
(StatView 4.1, Abacus Inc., Berkeley, CA, USA). The data are expressed as pg/ml mean
± s.e.m with a statistical significant difference considered to be p<0.05.
Ethical Approval
These protocols were approved by the Ethics Committee, St Bartholomew's Hospital and
informed written consent was obtained from all patients.
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5.3 RESULTS
MCP-1 was present in matched samples of amniotic fluid, maternal serum and extra¬
embryonic coelomic fluid. High levels of MCP-1 were present in all compartments
measured with levels of MCP-1 being significantly higher in extra-embryonic coelomic
fluid (337.3 ± 40.2 pg/ml) compared with amniotic fluid (151.5 ± 31.5 pg/ml; p<0.0001)
and maternal serum (142.6 ± 15.9 pg/ml; p<0.0001; Figure 17). There was no difference
in levels of MCP-1 between amniotic fluid and maternal serum. There was no correlation
in levels of MCP-1 in any compartment with gestational age.
IL-8 was present in all compartments measured. The concentration of IL-8 in the extra¬
embryonic coelomic fluid (339.6 ± 53.8 pg/ml) was significantly higher than those in the
maternal serum (33.1 ± 8.2 pg/ml; p<0.0005) and amniotic fluid (9.72 ± 6.6 pg/ml;
p<0.0001). Moreover, significantly greater levels of IL-8 were present in maternal serum
compared with amniotic fluid (p<0.05; Figure 18). There was no correlation in levels of
IL-8 in any compartment with gestation.
The ratios of MCP-1 to IL-8 in amniotic fluid, maternal serum and extra-embryonic
coelomic fluid were 15 : 1, 4 : 1 and 1 : 1 respectively.
RANTES was not detectable in extra-embryonic coelomic or amniotic fluid but was
















Concentrations of MCP-1 in matched samples of amniotic fluid, maternal serum and
extra-embryonic coelom. Significantly higher levels of MCP-1 were present in extra¬
embryonic coelomic fluid compared with those in amniotic fluid and maternal serum.
AF, amniodc fluid; MS, maternal serum and EECF, extra-embryonic coelomic fluid.
Values are expressed as pg/ml; mean ± s.e.m. Samples collected from 27 women at 8






Concentrations of EL-8 in matched samples of amniotic fluid, maternal serum and
extra-embryonic coelomic fluid. Significantly higher levels of EL-8 were present in
extra-embryonic coelomic fluid compared with those in amniotic fluid and maternal
serum. The concentration of IL-8 was significantly higher in maternal serum
compared with amniotic fluid. AF, amniotic fluid; MS, maternal serum and EECF,
extra-embryonic coelomic fluid. Values are expressed as pg/ml; mean ± s.e.m.
Samples collected from 27 women at 8 - 11 weeks of pregnancy. Significance; *,
p<0.027; **, p<0.0001, ***, p<0.0005.
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5.4 DISCUSSION
This study demonstrates the presence of MCP-1 and IL-8 in amniotic fluid, maternal
serum and extra-embryonic coelom during the first trimester, with the highest
concentrations of both chemokines being in the latter compartment. RANTES was
detectable in peripheral serum but in neither amniotic fluid nor extra-embryonic coelom.
During normal pregnancy, it is postulated that a Th-1 to Th-2 shift occurs in the maternal
immune response (Wegmann, et al., 1993) with Th-2 type cytokines being preferentially
expressed and secreted at the materno-fetal interface (Lin, et al., 1993). In addition to
being a potent monocyte chemotactic and activating factor, MCP-1 facilitates development
of a Th-2 type of immune response (Chensue, et al., 1996). MCP-1 is secreted by and
has been immunolocalised to perivascular cells present in first trimester decidua (Jones, et
al., 1997) and chorio-decidual cells (Kelly, et al., 1997). Although extra-embryonic
coelomic fluid mainly comprises an ultra-filtrate of maternal serum, it receives additional
contributions from decidua, secondary yolk sac, chorion, chorionic plate and the
developing trophoblast. It is therefore hypothesised that the high levels of MCP-1 in the
extra-embryonic coelom, which may be due to contributions from maternal serum,
decidua and chorion, would facilitate the occurrence of a Th-2 response at the materno-
fetal interface.
Amniotic fluid also contains relatively high concentrations of MCP-1. This is unusual in
that amniotic fluid is devoid of most proteins during the first trimester (Docherty, et al.,
1996). If however, MCP-1 is promoting a pregnancy favourable Th-2 response, then
comparable levels would not be unexpected between compartments as demonstrated in this
study. MCP-1 could be actively transported from the extra-embryonic coelom across the
amnion to the amniotic cavity, gain access to amniotic fluid via yolk sac secretions and the
vitelline circulation or be secreted by the embryo as has been demonstrated for alpha feto¬
protein (Jauniaux, et al., 1993) and cancer antigen 125 (Campbell, et al., 1992),
respectively.
IL-8 was located predominately within extra-embryonic coelom with minimal levels in
either amniotic fluid or maternal serum. It has been proposed that extra-embryonic coelom
may segregate highly active molecules including differentiation factors (insulin-like
growth factor-1 and insulin-like growth factor binding protein-1 (Wathen, et al., 1992))
143
and hormones (progesterone, oestradiol (Jauniaux, et al., 1993)) thus protecting the
poorly keratinised fetus when crucial differentiation and organogenesis are occurring
(Docherty, et al., 1996). IL-8, due to its potent chemotactic and pro-inflammatory
properties (Barclay, et al., 1993; Cherouny, et al., 1992; Sennstrom, et al., 1997) could
therefore be confined to extra-embryonic coelom to minimise pro-inflammatory responses
within the developing fetus. In contrast, towards the end of the first trimester, the extra¬
embryonic coelom is obliterated by expansion of the amniotic cavity with subsequent
fusion of the amnion with the chorion to form the amniochorionic membrane. Little is
known about the mechanism of this fusion process or whether inflammatory cells are
recruited but the leucoattractant properties of IL-8 could be beneficial and play a role in
this process.
During the first trimester, there is extensive angiogenesis in the chorionic plate and
primary villi and haemopoiesis within the secondary yolk sac. The mechanisms and
mediators of angiogenesis in the first trimester are poorly understood, however factors
such as vascular endothelial growth factor have been implicated. In addition to being a
highly specific neutrophil chemoattractant, IL-8 is also angiogenic, haemopoietic (Hu, et
al., 1993; Yoshida, et al., 1997) and chemotactic for vascular smooth muscle (Yue, et al.,
1994), although the mechanism of the former is not fully understood (Petzelbauer, et al.,
1995). IL-8 and vascular endothelial growth factor are both released by and have been
immunolocalised to first trimester cytotrophoblast, syncytiotrophoblast and syncytial
sprouts, decidua and Hofbauer cells (Athanassiades, et al., 1998; Elliott, et al., 1998;
Kelly, et al., 1992; Saito, et al., 1994; Shiraishi, et al., 1996). In other sites, IL-8 and
vascular endothelial growth factor synergise to effect angiogenesis with the process being
induced by TNF-a (Yoshida, et al., 1997) and hypoxia induced NFkB activation and
inhibited to a similar extent by neutralising antibodies to IL-8 and vascular endothelial
growth factor (Yoshida, et al., 1998). It is therefore hypothesised that the high
concentrations of IL-8 within extra-embryonic coelom, which is adjacent to the actively
angiogenic chorionic plate and primary villi, makes IL-8 ideally located to act as a potent
mediator of angiogenesis and vascular smooth muscle migration. Even less is known
about the factors regulating yolk sac haemopoeisis. However, IL-8 could also play a role
in extra-embryonic haemopoiesis, in conjunction with erythropoietin, which has the same
distribution in the fluid compartments as IL-8 and has also been implicated in this process
(Campbell, et al., 1992).
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In summary, this study demonstrates the differential secretion of MCP-1 and IL-8 into the
various fluid compartments present during the first trimester. The role of these potent
chemokines is not established, however they may be involved in mediating a Th-1 to Th-2
cytokine shift in pregnancy and could play a role in early fetal and placental development.
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GENERAL CONCLUSION - PART 1
The first part of this thesis provides support for the hypothesis that cytokines are
important in the initiation and maintenance of pregnancy.
Adaptation of maternal immune response
The studies with seminal plasma (Chapter 3) demonstrated that adaptation of the maternal
immune system may begin at conception with the principal prostaglandins found in
semen, PGE2 and 19-hydroxy PGE, inducing release of IL-10. This supports
Wegmann's hypothesis that a Th-1 to Th-2 shift in immune response may occur during
pregnancy and provides a possible mechanism by which this could be induced even prior
to fertilisation. Further support for Wegmann's hypothesis was obtained from the
peripheral blood studies (Chapter 4), which demonstrated that peripheral blood cultures
and monocytes from pregnant women released more MCP-1, which induces Th-2 type
cytokine release, than those from non-pregnant women. Although this effect was
demonstrated only in circulating monocytes, it is likely that monocytes and macrophages,
which are resident within the uterus would also secrete a predominant Th-2 type of
cytokine profile. This is supported by previous data that demonstrated that resident
macrophages within the uterus preferentially secrete the Th-2 type cytokines IL-4, IL-5
and IL-10 (Lin, et al., 1993). Finally, it was shown that cytokines are present in the fluid
compartments of the first trimester of pregnancy with high levels of MCP-1 being present
in both amniotic and extra-embryonic coelom (Chapter 5). It was speculated that MCP-1
may be facilitating occurrence of a Th-2 response at the materno-fetal interface. Further
studies should be undertaken to examine the secretion and distribution of other Th-1 and
Th-2 type cytokines by monocytes and their distribution within the fluid compartments of
the first trimester uterus.
Chemokines, cellular recruitment and early fetal development
Seminal plasma prostaglandins stimulated IL-8 release and it was suggested that an
increase in the pro-inflammatory, neutrophil chemoattractant IL-8 may have a role in
mediating post-coital cervical leukocytosis. It was also hypothesised that IL-8, present in
high concentrations in extra-embryonic coelom, may be involved in cellular recruitment
during obliteration of the extra-embryonic cavity at the end of the first trimester. Although
its role in cellular recruitment within the cervix post-coitus and late first trimester uterus
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are novel hypotheses, they are consistent with the known roles of IL-8 in mediating
leukocyte infiltration in asthma, dermatitis and menstruation (Jones, et al., 1997; Park, et
al., 1998; Strickland, et al., 1997). In addition, it is suggested that IL-8 may play a role
in early placental and fetal development. Unfortunately, some of the studies which might
be undertaken to further investigate these hypotheses, such as taking post-coital cervical
biopsies and samples of the fetal membranes during the fusion process, would be difficult
due to ethical and practical reasons.
In summary, the first part of this thesis provides evidence that cytokines have an important
role in modulating the maternal immune response to accommodate pregnancy and support
Wegmann's hypothesis that a Th-1 to Th-2 shift in immune response may be central to
this process. In addition, preliminary data suggests that cytokines are likely involved in
cellular recruitment and early fetal and placental development.
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PART 2
INFLAMMATORY MEDIATORS: CERVICAL RIPENING
AND PARTURITION
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GENERAL INTRODUCTION - PART 2
The processes of cervical ripening and myometrial contractility resulting in the ultimate
expulsion of the fetus from the uterine cavity at parturition conclude every successful
pregnancy. At the local level within the uterus, these events have many analogies with an
acute inflammatory reaction, both being associated with cellular infiltration, a rise in
inflammatory mediators and tissue remodelling. However, the mediators and regulatory
factors involved in cervical ripening and parturition within the third trimester uterus are
poorly understood. In the first part of this thesis, the roles of inflammatory mediators in
the initiation and maintenance of pregnancy were considered. The second part of this
thesis will consider the roles that these factors may play in cervical ripening, parturition
and the conclusion of pregnancy. The specific questions which will be addressed are as
follows.
1. Cervical ripening
What inflammatory mediators, MMPs and TIMPs are released by the cervix and how
are they regulated in vitro? What effect does in vivo treatment with an
antigestogen have on MMP, TIMP and leukocyte immunolocalisation?
2. Inflammatory mediators and intra-uterine tissues
Are MCP-1, IL-8, RANTES and IL-10 released by third trimester amnion, chorion,
decidua and placenta and is their release affected by PGE2 in vitro? What are the
likely roles of these mediators in parturition?
3. Anti-inflammatory agents and parturition
Is the anti-inflammatory agent secretory leukocyte protease inhibitor released by
third trimester intra-uterine structures and present within amniotic fluid? What




INFLAMMATORY MEDIATOR RELEASE BY THE CERVIX
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6.1 INTRODUCTION
Cervical ripening, which has been compared to an inflammatory reaction, is an essential
pre-requisite to parturition. Cytokines, in particular the chemokines are thought to play a
pivotal role in co-ordinating cellular recruitment, degranulation and activation. However,
their paracrine interactions with other inflammatory mediators, metalloproteinases, and
hormones are not well understood. The aim of these studies was therefore to investigate
these interactions in non-pregnant and pregnant cervical explants using an in vitro culture
system and in vivo treatment, respectively.
Specifically, the following questions were addressed:
6.2 In vitro studies on cervix
6.21 Release and regulation of cytokines
The aim was to investigate the release and regulation of IL-8, secretory
leukocyte protease inhibitor and PGE2 by non-pregnant cervical explants and
to identify their cellular source of secretion. The regulatory factors studied
included progesterone, dexamethasone, PGE2 and nitric oxide.
6.22 Release and regulation of MMP-2, MMP-9 and their inhibitors
by non-pregnant cervical explants.
The aim was to examine whether the gelatinases MMP-2 and MMP-9 and their
endogenous inhibitors TIMPs-1, -2, -3 and -4 were released by the non¬
pregnant cervix, to identify their source of secretion and to study whether their
release was affected by administration of PGE2 and nitric oxide to explants in
vitro.
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6.3 In vivo studies on cervix
6.31 Effect of mifepristone administration on the
immunolocalisation of MMPs, TIMPs and leukocyte
populations during the first trimester
The aim was to investigate whether mifepristone given 6, 12, 24 or 36 hours
prior to first trimester termination of pregnancy altered expression of MMP-1,
-2, -8 and -9, TIMP-1, -2 and -4, CD45 (leukocyte common antigen),
neutrophil elastase and CD68 (monocyte/macrophage marker) as detected by
immunohistochemistry.
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6.2 IN VITRO STUDIES
6.21 RELEASE AND REGULATION OF INFLAMMATORY




A variety of mediators have been implicated in cervical remodelling including IL-8 and
PGE2. Interleukin-8 is released in vitro (Barclay, et al., 1993) and in vivo (Sennstrom, et
al., 1997) by the human cervix. In animal models, topical application of IL-8 has been
shown to effect cervical ripening, which is morphologically identical to the physiological
process (Chwalisz, et al., 1994; El Maradny, et al., 1994). In humans, the concentration
of IL-8 within the term cervix increases during ripening and is associated with the release
of MMP-8 and MMP-9 (Osmers, et al., 1995) and neutrophil invasion of the lower uterine
segment (Winkler, et al., 1997). IL-8 is thought to initiate cervical ripening by promoting
neutrophil chemotaxis and activation within cervical stroma.
Prostaglandin E2 is the most effective and widely utilised cervical ripening agent in clinical
practice (Calder, 1990) and has been shown to rise in amniotic fluid prior to the
establishment of labour (Challis and Lye, 1994; Gravett, et al., 1994). The mechanism of
action of PGE2 is not well understood although it may involve vasodilation and inducing
alterations in stromal and fibroblast proteoglycan metabolism and composition (Carbonne,
et al., 1996; Norman, et al., 1993). Whether PGE, affects release of other inflammatory
mediators, such as IL-8 is not known.
It is likely however, that the highly complex process of cervical ripening will involve a
wide range of inflammatory mediators in addition to PGE2 and IL-8. One such mediator
is secretory leukocyte protease inhibitor, which is present in cervical mucus (Helmig, et
al., 1995). Secretory leukocyte protease inhibitor is a potent inhibitor of neutrophil
function (Sallenave, et al., 1997) and thus might be expected to oppose the action of IL-8
during inflammatory responses such as cervical ripening.
In order to effect controlled, co-ordinated cervical ripening, the release of inflammatory
mediators must be tightly regulated. Two factors, which may be involved are nitric oxide
and progesterone. Nitric oxide has very recently been shown in humans (Thomson, et
al., 1997) and animal models (Chwalisz, et al., 1997) to effect cervical ripening. Its
mechanism of action is not fully defined but is thought to be complex involving
vasodilation, initiation of apoptosis and induction of synthesis of GAGs and collagen
degrading MMPs (Chwalisz and Garfield, 1998). Progesterone appears to exert some
control over cervical ripening since progesterone withdrawal initiates cervical softening in
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humans throughout gestation despite there being no fall in peripheral serum progesterone
prior to cervical remodelling (Chwalisz, 1994). However, the role of nitric oxide and
progesterone in regulating release of inflammatory mediators, such as IL-8, secretory
leukocyte protease inhibitor and PGE2, from the cervix has not been well characterised.
The purpose of this study was therefore to investigate the release and regulation of
inflammatory modulators within the cervix with the aim of better understanding their role
in cervical ripening.
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6.212 MATERIALS AND METHODS
Sample collection
Biopsies from the anterior lip of the cervix, approximately 20 - 35 mg in weight, 15 - 20
mm in length and 2-3 mm in diameter, were taken from healthy, non-pregnant women
(ages 29 - 45) with regular menstrual cycles undergoing a hysterectomy for a non-
malignant condition. All women were Caucasian, had no underlying hormonal
dysfunction and had not used hormonal contraception, hormone replacement therapy or
received GNRH antagonists in the 6 months prior to surgery. The women were at
various stages of the menstrual cycle. A different set of biopsies was used for each of the
studies.
Tissue culture
Biopsies (n = 39 different women) and cervical fibroblasts (n = 6 different women) were
collected, dissected and isolated (Section 2.222). Explants (1-2 mg) and fibroblasts (1 x
105 cells/ml) were cultured (treatments in quadruplicate) in complete media supplemented
with progesterone 10"7M, dexamethasone 10 7M, PGE2 10"7M and spermine NONOate 50
Hg/ml as a nitric oxide donor for 24 hours at 37°C in 95 % air and 5 % carbon dioxide
under humid conditions. Spermine NONOate releases nitric oxide at predictable rates and
in predictable amounts, with decomposition of the complex generating two molecules of
nitric oxide and one molecule of free spermine (Maragos, et al., 1991). To assess the
effect of steroid antagonism, explants were cultured in media supplemented with
progesterone 1()"7M or dexamethasone 10"7M for 24 hours prior to changing and
supplementing the media in addition with the anti-gestogen and anti-glucocorticoid
mifepristone 10"7M for a further 24 hours (n = 6 different women). The harvested media
were then split into two portions, one frozen at -20°C for subsequent ELISA and the other
treated 1 : 1 with methyloximating solution overnight at 4°C for prostaglandin assay.
Cervical epithelial cells (n = 6 different women) were isolated by incubating washed,
steeped cervical biopsies in Dispase I (1 U/ml in PBS) for 2 - 3 hours at 37°C with gentle
agitation. The ecto-cervical epithelium was then sheared off in sheets using a scalpel and
cultured to confluence in complete media as previously described. Media was removed
from epithelial cell cultures and stored at -20°C until analysis. Subculturing and treatment
of cervical epithelial cells was unfortunately not possible.
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ELISA assays
IL-8, secretory leukocyte protease inhibitor and PGE2 release into culture media were
analysed by ELISA (Section 2.23).
Statistical analysis
Statistical analysis of concentrations of IL-8, secretory leukocyte protease inhibitor and
PGE2 in culture media was performed using ANOVA StatView 4.1 (Abacus Inc.;
Berkley, CA, USA). Fisher's protected least significant difference was used as a post-
hoc test to determine significance. The data are expressed as pg/mg mean ± s.e.m with a
statistical significant difference being p<0.05.
Ethical Approval
Ethical approval for the collection of all samples was obtained from the Lothian Trust




Cervical explants released IL-8. IL-8 release was significantly stimulated by PGE2 in a
dose dependant manner with maximal stimulation at 10~6M (pcO.OOl; Figures 19 and 20a,
n = 15 and n = 3 different women with treatments in quadruplicate, respectively). IL-8
release correlated with PGE2 release by cervical explants (correlation coefficient = 0.82; n
= 19 different women, Figure 20b). Nitric oxide (p<0.05) stimulated IL-8 release. IL-8
release was inhibited by dexamethasone (p<0.005) and progesterone (p<0.05). In the
studies, which assessed the effect of steroid antagonism on IL-8 release, the inhibition of
IL-8 release from explants cultured with progesterone and dexamethasone was
antagonised by the addition of mifepristone. There was no significant change in IL-8
release from control biopsies or those cultured with mifepristone alone for 48 hours (Table
9).
IL-8 was released by cervical fibroblasts (n = 6 different women) and epithelial cells (n =
6 different women). Dexamethasone and progesterone significantly inhibited (both
p<0.05) IL-8 release by cervical fibroblasts (Figure 21).
Secretory leukocyte protease inhibitor release
Cervical explants release secretory leukocyte protease inhibitor (n = 15 different women
with treatments in quadruplicate). Secretory leukocyte protease inhibitor release was
stimulated by progesterone (p<0.005) and inhibited by PGE2 (p<0.05). Nitric oxide,
dexamethasone and IL-8 had no effect on secretory leukocyte protease inhibitor release
(Figure 22).
Secretory leukocyte protease inhibitor was released by cervical fibroblasts (n = 6 different
women) and epithelial cells (n = 6 different women). Release of secretory leukocyte
protease inhibitor by cervical fibroblasts was not affected by any of the culture conditions
employed (Figure 23).
PGE2 release
Cervical explants release PGE2 (n = 15 different women with treatments in quadruplicate).
PGE2 release was stimulated by nitric oxide (p<0.05). Progesterone, dexamethasone and
IL-8 had no effect on PGE2 release (Figure 24).
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PGE, was released by cervical fibroblasts (n = 6 different women) and epithelial cells (n =
6 different women). Release of PGE2 from cervical fibroblasts was significantly






































Control Dex Prog PGE2 NO
10"7M 10 "7M 10"7M50jj.g/ml
Culture conditions
Figure 19
Modulation of DL-8 release by cervical explants by different culture conditions. EL-8
was significantly inhibited by progesterone and dexamethasone and stimulated by
PGE2 and nitric oxide donor. Dex, dexamethasone; Prog, progesterone; NO, nitric
oxide donor. Values are expressed as pg/mg wet weight tissue; mean ± s.e.m. n = 15
different women, treatments in quadruplicate. Significance of treatment versus control;
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IL-8 release, pg/mg tissue
Figure 20
A) Dose response curve of PGE2 stimulation of IL-8 release with maximal stimulation
at 10"6M. Values are expressed as pg/mg wet weight tissue; mean ± s.e.m. Typical of
n = 3. Significance; *, p<0.05, **, p<0.005.
B) IL-8 release correlates positively with PGE2. Values are expressed as pg/mg wet
weight, n = 19 different women, r = 0.82.
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Figure 20
A) Dose response curve of PGE2 stimulation of IL-8 release with maximal stimulation at
10"6M. Values are expressed as pg/mg wet weight tissue; mean ± s.e.m. Typical of n =
3. Significance; *, p<0.05, **, p<0.005.
B) IL-8 release correlates positively with PGE2. Values are expressed as pg/mg wet























100 61 (9)* 53 (3)* 103 (8)
100 187(31)* 156(13)* 140(27)
Table 9
The effect of steroid antagonism on IL-8 release by cervical explants. Explants were
cultured with steroids for 24 hours prior to changing media and supplementing it with
mifepristone 10"7M for a further 24 hours. Treatment with progesterone 10"7M and
dexamethasone 10"7M for the first 24 hours inhibited IL-8 release. This inhibition was
antagonised by addition of mifepristone to cultures during the second 24 hours.
Treatment with mifepristone alone for 48 hours did not affect IL-8 release. Significance






Control Prog 10*7M PGE2 10'7M NO 50 ng/mlDex 10' 7M
Culture conditions
Figure 21
DL-8 release by cervical fibroblasts. Dexamethasone and progesterone significandy
inhibited IL-8 release by cervical fibroblasts. Dex, dexamethasone; Prog,
progesterone; NO, nitric oxide donor. Values are expressed as pg/105 cells; mean ±
s.e.m. n = 6 different women, treatments in quadruplicate. Significance of difference








































Control Dex Prog PGE2 NO
10-7M 10-7M 10-7M 50jLig/ml
Culture condition
Figure 22
Modulation of secretory leukocyte protease inhibitor release by cervical explants by
different culture conditions. Secretory leukocyte protease inhibitor was significantly
stimulated by progesterone and inhibited by PGE2. Dex, dexamethasone; Prog,
progesterone; NO, nitric oxide donor. Values are expressed as pg/mg wet weight;
mean ± s.e.m. n = 15 different women, treatments in quadruplicate. Significance of











Control Dex10'7M Prog10'7M PGE2 10"7M NO 50 ,ug/ml
Culture conditions
Figure 23
Secretory leukocyte protease release by cervical fibroblasts. Release of secretory
leukocyte protease inhibitor was unaffected by the culture conditions employed. Dex,
dexamethasone; Prog, progesterone; NO, nitric oxide donor, n = 6 different women;
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Modulation of PGE2 release by cervical explants by different culture conditions. PGE2
was significantly stimulated by nitric oxide (NO). Progesterone (Prog),
dexamethasone (Dex) and IL-8 had no effect. Values are expressed as pg/mg wet
weight tissue; mean ± s.e.m. n = 15 different women, treatments in quadruplicate.








































PGE2 release by cervical fibroblasts. Release of PGE2 from cervical fibroblasts was
significantly stimulated by nitric oxide and inhibited by dexamethasone. Dex,
dexamethasone; Prog, progesterone; NO, nitric oxide donor. Values are expressed as
pg/105 cells; mean ± s.e.m. n = 6 different women, treatments in quadruplicate.
Significance of treatment versus control; *, p<0.05.
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6.214 DISCUSSION
These results further our understanding of the mechanism of cervical ripening by
demonstrating that complex interactions occur between inflammatory mediators within the
cervix. Release of IL-8 by cervical explants was significantly stimulated by nitric oxide
and PGE2 in a dose dependant manner and inhibited by progesterone and dexamethasone.
IL-8 was secreted by cervical epithelium and fibroblasts, with release from the latter cell
type being stimulated by nitric oxide and inhibited by progesterone and dexamethasone.
Inhibition of IL-8 release from cervical fibroblasts by progesterone has been previously
demonstrated in the rabbit (Ito, et al., 1994). In contrast to previous studies (Agro, et al.,
1996), IL-8 release by cervical fibroblasts was not affected by PGE2. In the latter studies,
PGE2 mediated stimulation of IL-8 was observed in stimulated human fibroblasts,
whereas the cultures employed in these studies were unstimulated. However, during an
inflammatory process such as cervical ripening, cervical fibroblasts may be stimulated by
a rise in pro-inflammatory cytokines, such as IL-1, and may therefore be primed to
increase their secretion of IL-8 in response to PGE2. Alternatively, PGE2 may stimulate
IL-8 release from cervical epithelial cells, as has been demonstrated in human colonic
epithelium (Yu and Chadee, 1998).
Secretory leukocyte protease inhibitor was released by cervical explants, fibroblasts and
epithelial cells. Although secretory leukocyte protease inhibitor release was significantly
stimulated by progesterone and inhibited by PGE2 in cervical explants, culture condition
had no effect on its release by cervical fibroblasts. It could be therefore that cervical
epithelial cells might be responsible for the effect of culture condition on secretory
leukocyte protease inhibitor release from cervical explants.
Finally, PGE2 was released by cervical explants, fibroblasts and epithelial cells with its
secretion being stimulated by nitric oxide in explants and fibroblasts and inhibited by
dexamethasone in fibroblast preparations. Nitric oxide has previously been shown to
stimulate PGE2 release, via induction of COX-2 in both fibroblasts (Salvemini, et al.,
1993) and epithelial cells (Watkins, et al., 1997). It may be that therefore that cervical
epithelial cells might also be partially responsible for the nitric oxide mediated stimulation
of PGE2 observed in the tissue explants.
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These studies demonstrate that progesterone and dexamethasone inhibit IL-8 and stimulate
secretory leukocyte protease inhibitor release from cervical explants. Progesterone plays a
vital role in the maintenance of pregnancy and uterine quiescence. In animals such as
sheep, a profound reduction in progesterone at term is thought to trigger parturition
(Challis and Lye, 1994). In humans, despite there being no peripheral fall in progesterone
during the third trimester, indirect evidence suggests that a local reduction within the feto¬
placental unit may herald the onset of labour (Baird, 1993). Cervical ripening and labour
are thought to be co-ordinated at a local level by inflammatory mediators such as the
neutrophil chemoattractant IL-8. Progesterone (Kalkhoven, et al., 1996) and
glucocorticoids (Mukaida, et al., 1994) inhibit transcription of these mediators, including
IL-8 via mutual repression between the steroid receptors and the RelA (p65) subunit of
NFkB. This factor is involved in transcriptional regulation of many inflammatory
mediators. Glucocorticoids are also known to stimulate secretory leukocyte protease
inhibitor synthesis (Abbinantenissen, et al., 1995), although the mechanism is not fully
understood. In addition, secretory leukocyte protease inhibitor inhibits cytokine activation
by NFkB probably by interfering with the NFi<B/rel binding site (Jin, et al., 1997).
It is hypothesised that a local fall in progesterone or interference with its action would
stimulate IL-8 and inhibit secretory leukocyte protease inhibitor release from cervical
tissue, possibly via NFkB. A rise in IL-8, which has been shown to occur during cervical
ripening (Sennstrom, et al., 1997), would initiate neutrophil chemotaxis, emigration and
activation within the cervical stroma. Secretory leukocyte protease inhibitor is a potent
inhibitor of neutrophil function and elastase release; thus, a fall in its levels would facilitate
neutrophil recruitment and activation within the cervical stroma. The overall result would
be to favour inflammation and cervical ripening (Figure 26).
It is widely believed that PGE2 plays an important role in initiating cervical ripening and
labour but its mechanisms are not fully understood. In other inflammatory processes,
PGE2 is thought to act principally as a vasoactive agent thus facilitating inflammatory cell
infiltration. However, in extra-uterine sites it also upregulates release of many
inflammatory cytokines such as IL-8 (Agro, et al., 1996), synergises with IL-8 to
augment neutrophil chemotaxis (Colditz, 1990) and stimulates MMP release by
monocytes. This latter effect can be inhibited by secretory leukocyte protease inhibitor via
inhibition of COX-2, the inducible form of the enzyme, and is independent of secretory
leukocyte protease inhibitor's antiprotease activity and regulatory effects on other
169
cytokines (Zhang, et al., 1997). Finally, PGE2 is potentially inhibited by progesterone
that acts via NFkB to inhibit COX-2 expression.
The data presented demonstrates that in vitro treatment of cervical explants with PGE2 has
the dual effect of stimulating IL-8 and inhibiting secretory leukocyte protease inhibitor
release. At term, progesterone withdrawal and possible upregulation of NFkB would
simulate PGE2, which would act with IL-8 to promote neutrophil emigration and
activation within cervical stroma. In addition to facilitating neutrophil and monocyte
chemotaxis and activation, a reduction in secretory leukocyte protease inhibitor would
further increase PGE2 synthesis via upregulation of NFkB mediated COX-2 transcription
(Figure 26).
Nitric oxide is a pleiotrophic short-lived free radical gas which mediates a wide range of
physiological processes including inhibition of platelet aggregation, smooth muscle
relaxation, host immunity and inflammation (Kroncke, et al., 1995). Experimental and
clinical evidence also suggests that that nitric oxide plays an important role during
pregnancy by maintaining uterine quiescence and placental perfusion. In addition, it may
be involved in initiating parturition (Chwalisz and Garfield, 1998). In the rat uterus and
placenta, nitric oxide is up-regulated in a gestationally dependant manner during
pregnancy and is significantly downregulated prior to parturition (Buhimschi, et al., 1996;
Purcell, et al., 1997). Paradoxically, in the rat cervix nitric oxide is regulated in the
opposite direction with levels being low during pregnancy but increasing significantly
prior to both preterm and term parturition. This may be explained by nitric oxide being
synthesised by invading neutrophils (Takeichi, et al., 1998) and monocytes. It is not
known if a similar pattern of nitric oxide release exists in humans but recent data suggest
that uterine and placental nitric oxide levels do not fall prior to parturition (Thomson, et
al., 1997). However, in that study nitric oxide was measured in uteri after 37 weeks by
which time any reduction in nitric oxide may have already occurred. Regulation of nitric
oxide synthesis is controversial but iNOS appears to be inhibited by progesterone (Miller,
et al., 1996) and glucocorticoids possibly via NFkB (De Vera, et al., 1997) and to be
stimulated by a variety of inflammatory mediators including IL-1 and TNF-a. Moreover,
nitric oxide, like PGE2 plays a complex immunomodulatory role and can induce both anti-
and pro-inflammatory immune responses with high levels, such as might be expected
during cervical ripening, favouring inflammation. Nitric oxide induces COX-2 synthesis
(Swaisgood, et al., 1997), stimulates MMP-2 secretion by rat mesangial cells (Trachtman,
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et al., 1996) and elastase and IL-8 release from peripheral blood (Cuthbertson, et al.,
1998), the latter by a cGMP-independent pathway (Corriveau, et al., 1998).
The data presented here demonstrate that nitric oxide stimulates both IL-8 and PGE2
release from cervical explants. Thus, any fall in progesterone at term and subsequent
neutrophil and monocyte invasion of the cervical stroma may produce a rise in nitric oxide
via activation of NFkB and local synthesis by invading cells. Nitric oxide would stimulate
IL-8 and elastase release and promote PGE2 synthesis via COX-2 induction leading to a
pro-inflammatory state and cervical remodelling (Figure 26).
In summary, the data presented demonstrate that complex interactions occur between
inflammatory mediators treated in vitro. It is suggested that cervical ripening is not due to
a single inflammatory mediator but is the consequence of a cascade of several such agents
that interact with each other (Figure 26). Whilst a change in progesterone or its cognate
receptor may be the initiating event, studies on progesterone receptor subtype status, local
levels and bioavailability of progesterone at term within the cervix need to be performed to
confirm this. In addition, these studies have been performed on non-pregnant cervical
explants, which have obvious limitations as a model for term cervical ripening, and should
be repeated on pregnant tissues to assess whether prior steroid exposure during pregnancy
affects interactions between mediators.
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Figure 26
Hypothesis of cervical ripening at term. PGE2 stimulates the pro-inflammatory IL-8 and
inhibits the anti-inflammatory secretory leukocyte protease inhibitor. The pro¬
inflammatory cascade may be further enhanced by stimulation of PGE2 and IL-8 by rising
nitric oxide levels and the effect of falling progesterone on inflammatory mediators.
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6.22 RELEASE AND REGULATION OF MATRIX
METALLOPROTEINASES -2 AND -9 AND TISSUE
INHIBITORS OF METALLOPROTEINASES -1, -2




During the process of cervical ripening, the cervix undergoes profound tissue remodelling
resulting in disorganisation and dissolution of the collagen fibrils, which comprise the
bulk of the ECM. Release and activation of MMPs, which include gelatinases (MMP-2
and MMP-9) and collagenases (MMP-1 and MMP-8), are thought to be pivotal in
effecting these alterations in animal and human cervices at term (Osmers, et al., 1991;
Rajabi, et al., 1991; Uldbjerg, et al., 1983). In rabbits, increased levels of proMMP-2
and pro-MMP-9 are released by term cervical fibroblasts and are associated with cervical
remodelling (Imada, et al., 1997). In women, collagenolytic activity increases within the
cervix during remodelling (Uldbjerg, et al., 1983) and concentrations of MMP-8 and
MMP-9 increase within the lower uterine segment at parturition, correlating with the
degree of cervical ripening and dilatation (Osmers, et al., 1995). However, the exact
MMPs and their endogenous TIMPs, which are present in the human cervix, their cellular
site of secretion and the mechanisms by which their activities are controlled during cervical
ripening are not fully understood.
Topical administration of prostaglandins (Calder and Embrey, 1973; Calder, 1990) and
more recently nitric oxide (Thomson, et al., 1997) have been used to soften the cervix in
vivo. However, the mechanisms by which they effect this and how they interact with
other mediators of cervical ripening remains unclear, although both have been
demonstrated to increase the activity of gelatinases (MMP-2 and MMP-9) in other tissues
(Murrell, et al., 1995; Zahner, et al., 1997; Zeng, et al., 1996). It is hypothesised that
PGE2 and nitric oxide may mediate cervical ripening by activating MMP-2 and MMP-9
thus degrading type IV collagen within the basement membrane and endothelium. This
would facilitate emigration of neutrophils and macrophages into the cervical stroma, which
by degranulation and release of collagenolytic enzymes, could effect remodelling of
cervical ECM.
The aims of this study were therefore to examine whether MMPs -2 and -9 and TIMPs -1,
-2 and -4 were released by the cervix, to identify their cellular sources and to investigate
whether administration of PGE2 and nitric oxide to explants in vitro affected their release.
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6.222 MATERIALS AND METHODS
Sample Collection
Cervical biopsies were obtained from healthy, non-pregnant, premenopausal women (n =
15) with regular menstrual cycles undergoing a hysterectomy for non-malignant
conditions (Table 10). Tissue was either transported to the laboratory in RPMI 1640 at
4°C or placed immediately in 10 % NBF and fixed overnight at 4°C and stored in 70 %
ethanol prior to routine paraffin embedding.
Characteristic Number patients
Total number 15












Patient details for cervical biopsies.
Tissue Culture
Cervical biopsies were dissected and cultured in RPMI 1640 supplemented with
antibiotics (Section 2.222). Explants were either treated with media alone or media
supplemented with PGE2 (10"6M - 10"9M) and the nitric oxide donor spermine NONOate
(50 |a.g/ml) with treatments in quadruplicate. Cervical fibroblasts were isolated and
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cultured in complete media (Section 2.222). Viability was > 95 % by trypan blue
exclusion and > 95 % of cells were positive for vimentin immunoreactivity. Prior to
experimentation, fibroblasts were cultured in RPMI 1640 supplemented with antibiotics
for 24 hours. Media were removed and stored at -20°C prior to freeze drying and
reconstituting in 0.1 % SDS for zymography and reverse zymography or sample buffer
for western blotting.
Zymography, reverse zymography and western blotting
Gelatinase zymography, reverse zymography and western blotting were performed for
MMP-2, MMP-9, TIMP-1 and TIMP-4 (Sections 2.24, 2.25 and 2.26).
Immunohistochemistry
Paraffin embedded cervical sections were immunostained for MMP-2, MMP-9, TIMP-1
and TIMP-4 (Section 2.27).
Ethical Approval
Ethical approval for the collection of all samples was obtained from the Lothian Trust
Ethical Committee with the informed and written consent of patients.
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6.223 RESULTS
Production of MMP-2 and -9 by cervix
Zymography showed gelatinase activities corresponding to MMP-2 and MMP-9 at 72 and
92 kDa molecular weight, respectively (Figures 27 and 28). Cervical tissue explants
released predominantly MMP-2 (72 kDa latent pro-form, 66 kDa active form) with lesser
amounts of MMP-9 activity (92 kDa latent pro-form, 86 kDa active form; Figures 27a and
28). Cervical fibroblasts released only MMP-2 (Figure 27b). Western blotting confirmed
the presence of MMP-2 protein in non-pregnant cervical explants and in cervical
fibroblasts (Figure 29a). MMP-9 protein was not detected in either tissue by western
blotting (Figure 29b). Localisation using immunohistochemistry showed that MMP-2
was mainly present in the stromal connective tissue with minimal staining in blood vessels
or cervical smooth muscle (Figure 30a). MMP-9 was localised weakly in some
perivascular cells and connective tissue stroma (Figure 30b).
Effect of PGE2 or nitric oxide donor treatment on release of MMP-2 and
MMP-9
Treatment with PGE2 or spermine NONOate in vitro had no effect on release of MMP-2
and MMP-9 by explants or cervical fibroblasts, as characterised by zymography (Figure
28 and data not shown; Figures 27a and 27b, respectively), western blot (data not shown;
Figures 29a and 29b, respectively) or immunohistochemistry (data not shown for either
PGE2 or spermine NONOate).
Production of TIMPs by cervix
Reverse zymography detected TIMP secretion by non-pregnant cervical tissue and
fibroblasts (Figure 31). A band representing the 27 - 30 kDa TIMPs (which may include
TIMP-1, -4 and the glycosylated form of TIMP-3) was demonstrated in both explant and
fibroblast groups. Western blotting was performed to further delineate the components of
the 27 - 30 kDa band obtained by reverse zymography (Figures 29c and 29d). This was
unlikely to consist of TIMP-3 since no discrete banding pattern had been obtained on
zymography for the unglycosylated 28 kDa form. Analysis for TIMPs -1 and -4 was
therefore performed by western blotting and confirmed the presence of both proteins in the
cervical tissue explants of cervical biopsies from non-pregnant women (Figures 29c and
29d). Cervical fibroblasts produced TIMP-1 but not TIMP-4 (Figures 29c and 29d).
TIMP-1 was localised to blood vessels and connective tissue stroma (Figure 30c). TIMP-
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4 was present predominately in the cervical connective tissue stromal cells (Figure 30d).
Effect of PGE2and nitric oxide donor treatment on release of TIMPs
In vitro treatment with PGE2 or spermine NONOate of biopsies from non-pregnant
women had no effect on TIMP activity as confirmed by reverse zymography (data not
shown; Figures 31a and b, respectively), western blot (data not shown; Figures 29c and




Zymography showing gelatinase activity in culture media of (a) non-pregnant cervical
tissue explants and (b) fibroblasts. Matrix metalloproteinase (MMP)-2 activity is
observed predominantly at 72 kDa (latent pro-form) and 66 kDa (active form). MMP-9
activity is shown at 92 kDa (latent pro-form) and 86 kDa (active form). Both explants and
fibroblasts were untreated (control) or treated with the NO donor spermine NONOate (+
NO donor). NO, nitric oxide, mw - molecular weight markers as marked kDa. af -
amniotic fluid used as positive control.
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Figure 28
Zymography showing gelatinase activity (visualised as light bands) in culture media of
non-pregnant cervical tissue explants. Matrix metalloproteinase (MMP)-2 activity is
observed predominantly at 72 kDa (latent pro-form) and 66 kDa (active form). MMP-9
activity is shown at 92 kDa (latent pro-form) and 86 kDa (active form). Explants were
untreated (C) or were treated with dexamethasone (D) or PGE2 (PGE2; 10"6 - 10 s M). mw
- molecular weight markers as marked kDa. af - amniotic fluid used as positive control. 1
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Western blot analysis using antibodies to (a) MMP-2, (b) MMP-9, (c) TIMP-1 and (d)
TIMP-4. MMP-2 is shown at 72 kDa (latent pro-form) and 66 kDa (active form). MMP-
9 is shown at 92 kDa (latent pro-form) and 86 kDa (active form). TIMP-l and -4 are
shown at 27 - 30 kDa. Samples of culture supernatant from explants and fibroblasts from
non-pregnant women include controls (C) and those treated in vitro with spermine




Immunohistochemical localisation in non-pregnant cervical tissue of A) MMP-2, B)
MMP-9, C) negative control, D) TIMP-1 and E) TIMP-4.
Key: a = artery, v = vein, s = stroma, m = muscle. Scale bars = 100 (xm.
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Figure 31
Reverse zymography to detect TIMPs (visualised as dark bands) in culture supernatant
from (a) cervical explants and (b) cervical fibroblasts either untreated (control) or treated
with spermine NONOate 50 ng/ml (+NO). Standards of TIMPs 1 and 2 (1+2, separately
identified on the gel by arrows) and of TIMP 3 (3; identified on the gel in the 27 - 30 kDa
glycosylated form {g3} and 24 kDa unglycosylated form {ung3}). NO, nitric oxide, af -
amniotic fluid used as a positive control.
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6.224 DISCUSSION
This study demonstrates that MMPs -2 and -9 and TIMPs -1 and -4 are released by and
immunolocalised to the non-pregnant human uterine cervix. These results are supported
by that of previous studies, which have previously demonstrated the presence of MMPs -2
and -9 in cultured non-pregnant endocervical cells by zymography and western blotting
(Agarwal, et al., 1994). These MMPs and their endogenous inhibitors may play a role in
the normal turnover of the ECM type IV collagen, elastin and fibronectin in the cervix.
MMP-2 was released by cervical explants and fibroblasts whereas MMP-9 was only
released by explants. This was confirmed by detection of MMP-2 but not MMP-9 protein
in cervical fibroblast culture supernatants by western blot. These data suggest that cervical
fibroblasts may not be the source of MMP-9 in the non-pregnant human cervix. This is
supported by previous studies in which MMP-9 was neither released by nor expressed in
unstimulated cultured rabbit cervical (Imada, et al., 1997) and human thyroid fibroblast
cultures (Hofmann, et al., 1998), respectively. MMP-9 has however been
immunolocalised to epithelium, neutrophils, monocyte-macrophages and eosinophils in
normal cycling human endometrium (Jeziorska, et al., 1996). It is likely therefore that the
source of MMP-9 in non-pregnant explants is either the surface epithelium or bone-
marrow derived cells. An alternative explanation for the lack of MMP-9 secretion by
cervical fibroblasts is that the amount of protein present in the fibroblast cultures was
considerably less than that in the equivalent whole tissue sample and therefore failed to
reach the detection limit of either zymography or western blot. In contrast, release of
MMP-2 by fibroblasts is supported by studies, which have previously demonstrated its
release by such cell types (Hofmann, et al., 1998; Imada, et al., 1997).
Reverse zymography demonstrated that 27 - 30 kDa TIMPs were released by cervical
explants. By western blotting it was confirmed that TIMP-1 was released by cervical
explants and fibroblasts whereas TIMP-4 was only released by explants. Release of
TIMPs have not been previously demonstrated by cervical explants. However, the release
and immunolocalisation of TIMP-1 are consistent with studies showing its presence in
human epithelium (Mackay, et al., 1992), basement membrane and connective tissue
stroma (Ye and Azar, 1998). TIMP-4 has only been identified and cloned recently
(Greene, et al., 1996) and little is known about its secretion and localisation in human
tissues.
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The vasodilators PGE2 and nitric oxide have been demonstrated to modulate MMP-2 and
MMP-9 release in other sites (Murrell, et al., 1995; Zahner, et al., 1997; Zeng, et al.,
1996). The mechanisms by which they effect cervical ripening in vivo and whether
remodelling enzymes are involved are however poorly understood. In this study, in vitro
administration of PGE2 and nitric oxide had no effect on release of MMP-2, MMP-9,
TIMP-1 or TIMP-4 by cervical explants. A variety of explanations could be proposed to
explain these results. During physiological cervical ripening, neutrophils and
macrophages invade the cervical stroma and degranulate, releasing their inflammatory
mediators. By using an in vitro model there is no cellular infiltrate and therefore, if PGE2
and nitric oxide were to affect MMP release by infiltrating cells, then this could not be
examined in the in vitro system utilised in these studies. Alternatively, PGE2 and nitric
oxide may affect release of other MMPs such as MMP-1 and MMP-8 (Murrell, et al.,
1995), which have also been implicated in cervical ripening (Osmers, et al., 1995).
MMP-1 and MMP-8 were not examined in these studies. Finally, these experiments were
undertaken on non-pregnant cervical explants which are morphologically different to
pregnant cervices and have not been exposed to the high concentrations of circulating
progesterone found in pregnancy. Consequently, their response to PGE2 and nitric oxide
may be different from pregnant cervical explants.
In summary, these studies have demonstrated the release and localisation of MMP-2,
MMP-9, TIMP-1 and TIMP-4 by non-pregnant cervical explants. Administration of
PGE2 and nitric oxide in vitro had no effect on the secretion and immunolocalisation of the
MMPs and the endogenous inhibitors studied.
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6.3 IN VIVO STUDIES ON CERVIX
6.31 EFFECT OF MIFEPRISTONE ON
IMMUNOLOCALISATION OF MATRIX
METALLOPROTEINASES, TISSUE INHIBITORS OF
METALLOPROTEINASES AND LEUKOCYTE
POPULATIONS IN THE FIRST TRIMESTER CERVIX
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6.311 INTRODUCTION
Progesterone is essential for the initiation and maintenance of pregnancy with its
withdrawal initiating cervical ripening and parturition throughout gestation. The anti-
gestogen, anti-glucocorticoid mifepristone (RU486), which was first described in 1981
(Philibert, et al., 1981), is highly effective in inducing cervical ripening in women
(Bugalho, et al., 1996; Carbonne, et al., 1995; Elliott, et al., 1998). Mifepristone acts as
a progesterone antagonist or a partial agonist, depending on whether progesterone is
present or absent, respectively (Spitz and Bardin, 1993). Its mechanism of action at the
cellular level is highly complex and a variety of hypotheses have been proposed. These
include interfering with the dissociation of receptor and heat shock proteins, which is an
essential pre-requisite for receptor dimerisation and gene association and inducing a
conformational change in the receptor rendering it able to bind to but unable to activate the
progesterone response element of responsive genes (Elashry, et al., 1989).
However, the exact mechanisms by which mifepristone increases cervical compliance,
reduces cervical resistance and effects cervical ripening in vivo are not well understood.
Studies have failed to demonstrate any alterations in cervical morphology, collagenolytic
activity, collagen content, plasminogen activator levels, muscle contractility, 12-
hydroxyeicosatetraenoic acid production or subsequent in vitro bioconversion of
radiolabeled arachidonic acid to thromboxane, PGE2 or PGF2„ after in vivo administration
of mifepristone (Bokstrom, et al., 1998; Bokstrom and Norstrom, 1995; Bokstrom, et al.,
1994; Heidvall, et al., 1992; Radestad, et al., 1990). A decrease in the ratio of a-2 to |3-
adrenoceptors (Falkay, 1990), an increase in mast cells and signs of new capillary
formation in cervical stroma (Radestad, et al., 1993) have however been found after
mifepristone administration. Whether mifepristone affects release of MMPs, their
inhibitors or favours cellular infiltration into the cervix, as has been demonstrated in
animal models and in human endometrium (Jones, et al., 1997; Marbaix, et al., 1992) is
not known.
There is increasing evidence that MMPs and their endogenous inhibitors, which play a
pivotal role in effecting cervical remodelling, are differentially regulated by progesterone.
However, whether such regulatory mechanisms exist within the cervix and could therefore
be implicated in mifepristone induced cervical ripening are not known.
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The aims of this study were therefore to investigate the effect of in vivo administration of
mifepristone on the immunolocalisation of the basement membrane digesting gelatinases
MMP-2 and -9, fibrillar collagenases MMP-1 and -8, and their endogenous inhibitors
T1MP-1, -2 and -4 within the first trimester human cervix. In addition, given that cervical
ripening has been compared to an inflammatory reaction characterised by leukocyte
invasion, the effect of mifepristone on leukocyte, neutrophil and monocyte invasion of
cervical stroma was also studied.
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6.312 MATERIALS AND METHODS
Sample Collection
Cervical biopsies were obtained from women who had received mifepristone at 6, 12, 24
and 36 hours prior to first trimester termination of pregnancy. In addition, there was a
control group (untreated) who had not received mifepristone prior to termination (Section
2.211, Table 1). Biopsies were fixed in NBF prior to routine paraffin embedding.
Immunohistochemistry
Immunohistochemistry was performed for MMP-1, -2, -8 and -9, TIMP-1, -2 and -4,
CD45 (leukocyte common antigen), neutrophil elastase and CD68 (monocyte marker;
Section 2.27). TIMP-3 was not examined because preliminary studies failed to
demonstrate its immunolocalisation within cervical stroma.
Ethical Approval
Ethical approval for the collection of all samples was obtained from the Lothian Trust





All negative controls were immunonegative for the respective antigen. Representative
negative control sections for CD45, CD68, neutrophil elastase and TIMP-2 are
demonstrated in Figure 32.
MMP-2
In the untreated biopsies, diffuse positive immunoreactivity for MMP-2 was visualised as
dark brown staining in the epithelium, stromal cells and ECM connective tissue with
minimal staining in cervical smooth muscle (Figure 33A). In vivo treatment with
mifepristone had no effect on MMP-2 immunolocalisation (Figure 33B).
MMP-9
In untreated women, MMP-9 was immunolocalised weakly to some cervical epithelial
cells (Figure 33C). In biopsies taken more than 24 hours after mifepristone
administration, there was a marked increase in positive immunoreactivity for MMP-9
throughout the cervical epithelium, basement membrane and stromal cells and ECM
connective tissue (Figure 33D).
MMP-1 (interstitial collagenase)
In women who had not received mifepristone, there was weak, patchy positive
immunoreactivity for MMP-1 in cervical epithelium and stromal connective tissue. In
addition, there were a few scattered cells of fibroblast morphology, which stained
specifically for MMP-1 in cervical stromal (Figure 34A). In biopsies taken more than 6
hours post-mifepristone administration, there was a marked increase in stromal cells
staining specifically for MMP-1. The patchy positive immunostaining in the epithelium
and stroma was comparable with untreated women (Figure 34B and 34C).
MMP-8 (neutrophil collagenase)
Patchy positive immunostaining was observed for MMP-8 in cervical epithelium and
stromal ECM in untreated women (Figure 34D). In addition, there were a few isolated
stromal cells which stained specifically for MMP-8. After 24 hours treatment with
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mifepristone, there was a marked increase in the population of stromal cells, which stained
specifically for MMP-8. The patchy positive immunostaining of epithelium and stromal
ECM was comparable with control sections (Figure 34E and 34F).
TIMPs-1, -2 and -4
In untreated women, TIMPs-1, -2 and -4 were immunolocalised to cervical epithelium and
connective tissue stroma ECM with relative sparing of blood vessel endothelium and
smooth muscle (Figure 35A, 35C and 36A). Mifepristone administration had no effect on
the pattern of immunostaining for TIMP-1, -2 or -4 at any timepoint (Figures 35B, 35D
and 36B).
Leukocyte markers
CD45 (leukocyte common antigen)
A few isolated cells, which were mainly sub-epithelial, stained immunopositive for CD45
in biopsies from untreated women (Figure 37A). There was a marked increase in the
number of discrete, immunopositive cells in biopsies taken more than 12 to 24 hours after
mifepristone administration (Figure 37B and 37C). These cells were located
predominately in the sup-epithelial layer and diffusely scattered within the cervical stromal
ECM.
Neutrophil elastase
A few sub-epithelial cells stained immunopositive for neutrophil elastase in biopsies from
untreated women (Figure 38A). There was a marked increase in the number of
immunopositive cells in biopsies taken more than 12 hours after mifepristone
administration. These cells were located mainly within cervical stroma ECM and within
the lumen of stromal blood vessels (Figure 38B and 38C).
CD68 (monocyte/macrophage cell marker)
Biopsies taken from women who had not received mifepristone were immunonegative for
CD68 (Figure 39A). After 12 hours treatment with mifepristone, there was an increase in
numbers of cells within cervical stromal ECM and in the sub-epithelial layer stained
immunopositive for CD68 (Figure 39B and 39C, cells highlighted by arrows).
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Figure 32
Representative negative control sections of first trimester cervical biopsies stained for A)
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MMP-2 and -9 immunolocalisation in human cervix after mifepristone administration. A)
and C) untreated; B) and D) 24 hours after treatment. MMP-2 immunolocalisation was
unaffected by mifepristone administration. MMP-9 staining increased in epithelial, stromal
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matrix metalloproteinase-8
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Figure 34
MMP-1 and -8 immunolocalisation in human cervix after administration of mifepristone in
vivo. A) untreated, B) 6 hours, C) 24 hours, D) untreated, E) and F) 24 hours after
treatment. There was increased number of stromal cells staining specifically for MMP-1
and -8 in biopsies taken more than 6 hours and 24 hours, respectively after mifepristone
administration. Epithelial staining for MMP-1 and -8 was unaffected by mifepristone
treatment. Scale bars = 100 ^m.
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Figure 35
TIMP-1 and -2 immunolocalisation in human cervix after mifepristone treatment. A) and
C) untreated, B) 12 hours and D) 24 hours post treatment. Mifepristone had no effect on
TIMP-1 and -2 immunolocalisation. Scale bars = 100 nm.
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tissue inhibitor of matrix metalloproteinases-4
untreated 24 hours
Figure 36
TIMP-4 immunolocalisation in human cervix after administration of mifepristone in vivo.
A) untreated and B) 24 hours post treatment. Immunolocalisation of TIMP-4 was
unaffected by mifepristone administration. Scale bars = 100 H-m.
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Figure 37
CD45 (leukocyte common antigen) immunolocalisation in human cervix after
administration of mifepristone in vivo. A) untreated, B) 12 hours and C) 24 hours post
treatment. There was an increased number of cells staining specifically for CD45 in the
sub-epithelial layer and in cervical stroma in biopsies taken more than 12 hours post





Neutrophil elastase immunolocalisation in human cervix after administration of
mifepristone. A) untreated, B) 6 hours and C) 24 hours after mifepristone treatment.
There was an increased number of stromal cells staining specifically for neutrophil elastase
12 hours after mifepristone administration. Scale bars = 100 nm.
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Figure 39
CD68 (monocyte marker) immunolocalisation in human cervix after administration of
mifepristone in vivo. A) untreated, B) 12 hours and C) 24 hours after mifepristone
treatment. Untreated biopsies were immunonegative for CD68. There was an increased
number of cells staining specifically for CD68 in epithelium, sup-epithelium and cervical




This study demonstrates that administration of mifepristone increased immunostaining for
MMP-1, -8 and -9, CD45, neutrophil elastase and CD68 within cervical biopsies but had
no effect on immunostaining of MMP-2, TIMP-1, -2 and -4.
Minimal immunostaining for the gelatinase MMP-9 was observed in control biopsies with
a marked increase in immunoreactivity in biopsies taken more than 24 hours after
mifepristone administration. Physiological concentrations of progesterone have
previously been demonstrated to suppress MMP-9 release by rabbit cervical fibroblasts
(Imada, et al., 1997) and human trophoblast cells (Shimonovitz, et al., 1998) with MMP-
9 inhibition being antagonised by progesterone withdrawal (Shimonovitz, et al., 1998).
The high levels of progesterone in the circulation and within the cervix during normal
pregnancy may be a protective mechanism to prevent premature cervical ripening. Up-
regulation of MMP-9 post mifepristone administration suggests that MMP-9 may play a
role in mifepristone induced cervical ripening.
In contrast, immunolocalisation of the gelatinase MMP-2 was unaffected by mifepristone
administration. Whether MMP-2 is under progesterone regulation is controversial with
studies variously demonstrating inhibition of release by progesterone (Irwin, et al., 1996;
Marbaix, et al., 1992) and no effect (Lockwood, et al., 1998). It may be therefore that
cervical MMP-2 is not progesterone regulated or that inhibition of its release was not
detectable by immunohistochemistry.
Specific stromal cellular immunostaining for both interstitial (MMP-1) and neutrophil
collagenase (MMP-8) was increased in biopsies taken more than 24 hours after
mifepristone administration. Upregulation of MMP-1 release by mifepristone has been
previously demonstrated in human endometrial stroma and fibroblasts (Lockwood, et al.,
1998; Singer, et al., 1997), however stimulation of MMP-8 by progesterone antagonism
is a novel finding. MMP-8 is unique in that it is expressed exclusively in inflammatory
conditions (Balbin, et al., 1998). Although originally described as being released
specifically by neutrophils, it is has recently been shown to be secreted by cytokine
activated fibroblasts (Halinen, et al., 1996). The majority of immunopositive stromal cells
were of fibroblast morphology. This is therefore consistent with MMP-1 being a
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fibroblast product and release of MMP-8 by cytokine activated fibroblasts, such as would
be found during the inflammatory process of cervical ripening.
The immunolocalisation of TIMPs -1, -2 and -4 was not affected by mifepristone
administration. This conflicts with studies in rabbit cervical fibroblasts in which
progesterone stimulated release of TIMP-1 and -2 (Imada, et al., 1994) but is consistent
with those in human endometrial stromal cells where progesterone had no effect on TIMP-
1 release (Lockwood, et al., 1998).
Progesterone and other steroid hormones, acting via nuclear receptors, such as
glucocorticoids and androgens are thought to modulate MMP and TIMP release by a
variety of diverse mechanisms (Schroen and Brinckerhoff, 1996). First, steroid receptors
and their ligands can act on the promoters of MMP genes to enhance or suppress trans-
activation by binding to hormone responsive elements, forming complexes on the DNA
with AP-1 proteins and or decreasing mRNA transcription factor expression. Second,
nuclear receptors and their ligands can indirectly reduce MMP activity. For example,
progesterone both upregulates expression of TIMPs, which complex with MMPs and
inhibit enzymatic activity, and stimulate production of TGF-p, which in turn suppresses
expression of certain MMPs. Finally, nuclear receptors and their ligands can bind to co-
activators, co-repressors and components of the general transcription apparatus, thereby
affecting MMP expression and release. Mifepristone, by acting as a progesterone receptor
antagonist or partial agonist, could potentially act at any of these regulatory points to
modulate MMP or TIMP release.
Mifepristone administration also increased leukocyte invasion into cervical stroma.
Further characterisation demonstrated that some of these cells were neutrophils and
monocytes, as demonstrated by increased numbers of cells staining immunopositive for
neutrophil elastase and CD68 within cervical stroma and blood. It has been previously
demonstrated that 24 hours post-mifepristone administration there is a significant increase
in mast cells within cervical stroma (Radestad, et al., 1993). Mast cells may therefore
account for some of the leukocytes, which did not stain with the neutrophil elastase or
monocyte marker. Leukocyte invasion of the connective tissue stroma and their
subsequent degranulation releasing collagenolytic enzymes could be a further mechanism
by which mifepristone induces cervical softening.
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In summary therefore, the following hypothesis can be proposed to explain the
mechanisms by which mifepristone could induce cervical ripening. A fall in local
progesterone levels, effected by mifepristone administration, would induce new blood
capillary formation (Radestad, et al., 1993) and upregulate MMP-9 release, which would
degrade vascular basement membrane. Together, these would favour accumulation of
leukocytes, specifically neutrophils, monocytes and mast cells, in cervical vasculature and
their subsequent emigration and degranulation within the connective tissue stroma. In
addition, increased release of the collagenases MMP-1 and MMP-8 by stromal cells would
further promote remodelling and loosening of the connective tissue stroma. Finally, the
failure of mifepristone to effect changes in TIMP expression would alter homeostatic
balance between MMPs and TIMPs towards increased ECM and tissue breakdown
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6.4 CONCLUSION
In summary, these studies (Sections 6.21, 6.22 and 6.31) have demonstrated that the non¬
pregnant and pregnant cervix are capable of releasing a wide range of inflammatory
mediators, MMPs and TIMPs. At term, it is likely that these mediators are tightly
regulated and act in a co-ordinated manner to effect cervical ripening and tissue
remodelling.
Before attempting to propose a unifying hypothesis to explain cervical ripening, the
following caveats are acknowledged. First, it is appreciated that non-pregnant and first
trimester cervical tissue are not directly comparable. However, due to difficulty in
obtaining cervical biopsies and the small size, particularly of the first trimester samples, it
was not possible to perform all the studies on a single sample set. Second, neither sample
set are directly comparable to the term pregnant cervix. Ideally, these experiments should
be repeated on term samples, however ethically and practically these proved very difficult
to collect but should be considered for study in the future. With the preceding caveats, the
following hypothesis, illustrated in Figure 40, is therefore proposed to explain cervical
ripening at term.
A fall in progesterone or interference with its action at term would stimulate release of the
vasodilators PGE2and nitric oxide, MMP-9 and promote new capillary growth (Radestad,
et al., 1993). The vasodilation would be enhanced by nitric oxide mediated stimulation of
PGE2. Progesterone antagonism would also stimulate release of the neutrophil
chemoattractant IL-8 (Kelly, et al., 1994) and inhibit secretion of secretory leukocyte
protease inhibitor. The fall in secretory leukocyte protease inhibitor would stimulate PGE2
release, which could then further up-regulate IL-8 secretion. A rise in the IL-8 and other
chemokines, in combination with PGE2/nitric oxide mediated vasodilation, MMP-9
induced degradation of vascular basement membrane and up-regulation of leukocyte
adhesion molecules (Winkler, et al., 1998) would promote cellular infiltration into cervical
stroma. The leukocytes, specifically neutrophils (Winkler, et al., 1997), monocytes and
mast cells (Radestad, et al., 1993), could then be induced to degranulate by the presence
of high concentrations of pro-inflammatory cytokines such as IL-8 and IL-1 (Winkler, et
al., 1998) within cervical stroma. Furthermore, cytokines are released by leukocyte
degranulation, thus generating a positive feedback by inducing further cellular infiltration,
cytokine and MMP release. Digestion of cervical stroma and tissue remodelling would
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then ensue mediated by MMPs such as MMP-1, MMP-8 and MMP-9 released by
leukocyte degranulation and cytokine activated fibroblasts. This tissue re-organisation
would be further promoted by a reduction in secretory leukocyte protease inhibitor, which
would normally inhibit neutrophil activation and MMP release. In addition, since
progesterone antagonism had no effect on TIMP release, then the balance between MMPs
and TIMPs would shift to favour tissue remodelling (Figure 40).
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Figure 40
Hypothesis of cervical ripening. It is hypothesised that an increase in pro-inflammatory
mediators, inflammatory cell infiltrate and metalloproteinase release, a decrease in anti¬
inflammatory mediators and no change in levels of tissue inhibitors of metalloproteinases,







CHEMOKINE SECRETION BY HUMAN FETAL
MEMBRANES, DECIDUA AND PLACENTA AT TERM
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7.1 INTRODUCTION
Parturition is analogous to an inflammatory reaction. Chemokines, by acting as local
effectors and mediators of cell trafficking, are thought to play an important regulatory role
at the materno-fetal interface during this process. However, their sites of secretion and
regulation within the term uterus have not been fully characterised.
The neutrophil chemoattractant IL-8 has been implicated in the initiation of infection
mediated pre-term labour (Cherouny, et al., 1993), cervical ripening (Sennstrom, et al.,
1997) and parturition at term. It is found in high concentrations within term amniotic fluid
(Laham, et al., 1993) and is released by cervix (Barclay, et al., 1993; Sennstrom, et al.,
1997), amnion, chorion, decidua and placenta (Elliott, et al., 1998; Laham, et al., 1997).
The monocyte chemotactic factor MCP-1, is released by many reproductive tissues
including the ovarian follicles (Arici, et al., 1997), endometrium (Arici, et al., 1995), third
trimester chorio-decidua (Kelly, et al., 1997) and is expressed in term placental
trophoblasts (Shimoya, et al., 1998). RANTES, which is chemotactic for T-cells, is
released by endometrium (Hornung, et al., 1997) and a first trimester trophoblast cell line
(Svinarich, et al., 1996). However, whether MCP-1 is released by amnion or placenta or
RANTES by amnion, chorion, decidua or placenta during the third trimester is not
known.
1L-10 is a potent immunomodulatory cytokine that promotes development of a humoral or
Th-2 type of immune response, which is associated with a successful outcome to
pregnancy (Wegmann, et al., 1993). In addition, it inhibits release of many pro¬
inflammatory cytokines including IL-8 (Chen and Manning, 1996), MCP-1 (Kucharzik, et
al., 1998) and RANTES (MarfaingKoka, et al., 1996). IL-10 is present in amniotic fluid
throughout pregnancy (Dudley, et al., 1997) and is released by most of the intra-uterine
structures present during the third trimester (Trautman, et al., 1997). The factors which
regulate IL-10 release from these tissues and its function within the uterus at term are
however less well defined.
It is now recognised that PGE2, although initially described as a potent vasodilator, is an
important immunomodulator and mediator of inflammation within the uterus (Kelly, et al.,
1995). During the third trimester, it is released by amnion (Edwin, et al., 1996), chorion
(Dudley, et al., 1996), decidua (Ishihara, et al., 1991) and placenta (Wetzka, et al., 1997)
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and a rise in its levels within the uterus is associated with the onset of parturition. The
effects of PGE2 on the release of other cytokines such as IL-8, which may be involved in
parturition, is not well understood.
The aim of this study was to investigate the release of MCP-1, IL-8, RANTES and IL-10
from third trimester amnion, chorion, decidua and placenta and to evaluate the possible
contribution of these chemokines to parturition. A dynamic dual placental cotyledon
perfusion model was then used to study the influence of PGE2 infusion on placental
chemokine release and to assess whether any regulation of chemokine secretion could
have implications for the immunological mechanisms involved in the maintenance of
pregnancy and parturition.
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7.2 MATERIALS AND METHODS
Tissue Collection
Tissue samples for explant cultures were obtained from normal healthy women (n = 7
different women) with uncomplicated pregnancies undergoing elective caesarean section at
term as follows:
a cork borer.
Chorion laeve Discs (9 mm diameter; wet weight 15 - 25 mg) were prepared using a
cork borer.
For placental perfusion studies, placentae (n = 8 different women) were collected from
normal healthy women with uncomplicated pregnancies at term immediately after
spontaneous delivery or elective caesarean section and transported to the laboratory at 4°C.
Explant Culture
Tissue explants (four explants of each tissue from each woman) were placed on absorbent
capillary matting and maintained in culture (Section 2.223; (Brennand, et al., 1995)).
Media were collected after 24 hours and stored at -20°C until analysis.
Dual perfusion of a placental cotyledon
Term placentae (n = 8), collected after elective caesarean section were perfused with
Kreb's solution followed by PGE2 (Section 2.224). Consecutive 10 minute samples from
both the maternal and fetal circulations were collected and stored at -20°C until analysis.
The integrity and viability of each preparation was established throughout the experimental
period by ensuring that:
1. The rate of perfusate input in both the fetal and maternal circuits equalled the rate of
output.
Amnion Discs (12 mm diameter; wet weight 10 - 20 mg) were prepared using
Placenta
Decidua Decidual pieces (wet weight 20 - 30 mg) were obtained by curettage
off the myometrium.
Villous placenta (wet weight 20 - 30 mg) by dissection of placental
tissue.
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2. There was adequate exchange of 02 from the maternal to fetal circuits (step up
pressures of <40 to 70 mm Hg in fetal perfusate).
3. Lactate concentrations remained within the normal low range (<2 mM; (Benediktsson,
et al., 1997).
4. At the end of the experiment the fetal vasculature responded to a bolus infusion of
noradrenaline (20 mg) by a vasoconstriction of > 2 mmHg.
5. Subsequent microscopic histological investigations revealed no significant
morphological changes.
Cytokine assays
MCP-1, IL-8, RANTES and IL-10 were analysed by ELISA (Section 2.23).
Statistical analysis
Statistical analysis of the tissue explant data was performed using ANOVA and a
Student's paired 't'-test was used for the placental perfusion model (StatView 4.1, Abacus
Inc., Berkley, CA, USA). The data were normally distributed and are expressed as
pg/mg or pg/min/cotyledon (mean ± s.e.m) with a statistically significant difference
defined as p<0.05.
Ethical Approval
Ethical approval for the collection of all samples was obtained from the Lothian Trust




Explants of amnion, chorion, decidua and placenta exhibit distinct profiles of cytokine
release (Figure 41). Significantly higher levels of MCP-1 were released by chorion (78.2
± pg/mg; p<0.001), decidua (112.4 ± 5.2 pg/mg; pcO.OOl) and placenta (101.8 ± 5.0
pg/mg; p<0.001) than from amnion (1.3 ± 0.4 pg/mg). IL-8 was secreted in large
amounts by all tissues studied with release from chorion, decidua, placenta and amnion
being 52.8 ±1.9 pg/mg, 42.2 ±1.5 pg/mg, 45 ± 1.3 pg/mg and 39.9 ± 5 pg/mg,
respectively. The placenta (26.9 ± 1.6 pg/mg) and decidua (15.2 ± 1.4 pg/mg) were the
principal sources of RANTES with significantly more being released than by chorion (6.0
± 1.2 pg/mg; p<0.01). IL-10 was released mainly by chorion (6.8 ± 0.8 pg/mg) and
decidua (9.0 ± 0.9 pg/mg) with levels which were lower, but which failed to reach
significance, from placenta (3.3 ± 0.3 pg/mg). Neither RANTES nor IL-10 were released
in detectable concentrations by amnion. The ratio of MCP-1 : IL-8 release by amnion was
1 : 31 and the ratios of MCP-1 : IL-8 : RANTES : IL-10 release by chorion, placenta and
decidua were 13 : 9 : 1 : 1, 31 : 14 : 8 : 1 and 12:5:2:1, respectively.
Placental perfusion
The basal cytokine output from the perfused placental cotyledon (maternal and fetal
combined) prior to commencing the PGE2 infusion was less than that by placental explants
for MCP-1, IL-8 and IL-10 (relative ratios 1 : 4, 1 : 13, 1 : 2) but not for RANTES
(relative ratio 1 : 1). The basal output of all cytokines measured was greater from the
maternal than the fetal circulation in the perfusion system with the ratios of basal output of
MCP-1, IL-8, RANTES and IL-10 between maternal and fetal circuits being 145 : 1, 79 :
1, 7 : 1 and 2:1, respectively. The differential release of cytokines between the two
circulations was maintained for the duration of the perfusion and study period.
Perfusion of placentae with PGE2 significantly (p<0.01) stimulated release of IL-8, MCP-
1 and IL-10 from the maternal and IL-8 and MCP-1 from the fetal circulation. The
stimulation became significant approximately 20 minutes after commencing the PGE2
infusion and was maintained for the duration of the perfusion and study period (Figures
42a, 42b and 43).
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RANTES was released into both the maternal and fetal circulation, but secretion was not






—— r-» — V V 11 ——S
Amnion Chorion Decidua Placenta
Figure 41
Release of MCP-1, IL-8, RANTES and IL-10 from amnion, chorion, placenta and
decidua. Significantly higher levels of MCP-1 were released by chorion, placenta and
decidua than from amnion, respectively. RANTES was secreted in significantly
greater amounts from decidua and placenta than from chorion. The majority of EL-10
was released by chorion and decidua with lower levels from placenta. Neither
RANTES nor IL-IO were released by amnion. Values are expressed as pg/mg; mean ±
s.e.m. n = 7 different women. Statistical analysis for treatment versus control;
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Figure 42
Effect of PGE2 infusion on the release of MCP-1, IL-8 and RANTES into (a) the
maternal and (b) the fetal circulation in a dynamic dually perfused placental cotyledon.
The release of MCP-1 and IL-8 release was significantly stimulated into both maternal
and fetal circulations approximately 20 minutes after commencing the PGE2 infusion
and levels continued to be elevated until the end of the study period. The PGE2
infusion had no effect on RANTES release. Values are expressed as




























Effect of PGE2 infusion on the release of EL-10 into the maternal and fetal circulation ii
dually perfused placental cotyledon. The release of EL-10 was significantly stimulatec
into the maternal circulation approximately 20 minutes after commencing the PGE
infusion and levels continued to be elevated until the end of the study period. There
was no rise in levels of EL-10 in the fetal circulation post-infusion. Values are




The heterogeneous intra-uterine structures present during the third trimester originate from
both maternal and fetal tissue and have widely differing functions. This study
demonstrates that third trimester amnion, chorion, decidua and placenta explants secrete
quite distinct cytokine profiles. MCP-1 was released predominately by chorion, decidua
and placenta with low amounts from amnion (relative ratios 62 : 94 : 85 : 1, respectively).
High levels of IL-8 were released by amnion, chorion, decidua and placenta (relative
ratios 1:1:1:1, respectively). Release of RANTES was not detectable from amnion but
was in moderate amounts from chorion, decidua and placenta (relative ratios 1 : 3 : 4).
Low levels of IL-10 were secreted by chorion, decidua and placenta with none detectable
from amnion (relative ratios 2:3:1).
The fetal membranes comprise of amnion and chorion. Amnion, which is composed of an
epithelial and fibroblast layer, released both IL-8 and MCP-1. Local release of IL-8 from
unstimulated (Laham, et al., 1997) and cytokine stimulated amnion explants (Trautman, et
ah, 1992) has been previously demonstrated and has been postulated to have a role in
parturition. The demonstration of MCP-1 release is however novel. IL-8 and MCP-1
could be released from either epithelium or fibroblasts, both of which are capable of their
synthesis in extra-uterine sites (Agro, et ah, 1996; Arici, et ah, 1998; Elner, et ah, 1997).
Chorion, whose principal constituent is trophoblast (Chard and Lilford, 1997), released
all cytokines measured. MCP-1 and IL-8 release have been previously demonstrated in
unstimulated and cytokine stimulated chorion and immunolocalised to chorion trophoblast,
stromal fibroblasts and macrophage like cells (Ito, et ah, 1994; Kelly, et ah, 1997;
Laham, et ah, 1997). The release of IL-10 by unstimulated chorion explants contrasts
with the findings of others. Previous studies have shown IL-10 to be released by
stimulated chorion (Dudley, et ah, 1997) but have not demonstrated its secretion and only
rarely its immunolocalisation in unstimulated explants (Trautman, et ah, 1997). In the
latter study however, IL-10 release was readily detected from decidua. Decidua, adherent
to chorion trophoblast, could therefore be responsible for IL-10 release in both this study
and the latter study of Trautman et ah, 1997. RANTES could be released from either the
chorion trophoblast (Svinarich, et ah, 1996), fibroblasts or adherent decidua.
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Decidua released high levels of MCP-1 and IL-8 and moderate levels of RANTES and IL-
10. The release and immunolocalisation of IL-8 and IL-10 has been previously
demonstrated within decidua (Saito, et al., 1994; Trautman, et al., 1997). Although
decidua is comprised of a wide range of different cell types, it is likely that decidual
macrophages and T-cells would be the principal source of MCP-1 and RANTES,
respectively.
Placenta released high levels of MCP-1, IL-8 and RANTES and low levels of IL-10.
Secretion of IL-8 and IL-10 by placenta supports previous data demonstrating release and
localisation of IL-8 to cytotrophoblast, syncytiotrophoblast, perivascular cells and
placental Hofbauer cells (Elliott, et al., 1998; Saito, et al., 1994; Shimoya, et al., 1992)
and IL-10 to cytotrophoblast (Roth, et al., 1996). MCP-1 has recently been found to be
expressed in increasing amounts by placental trophoblast during pregnancy but its release
by placental explants has not previously been demonstrated. Although release of
RANTES protein by placenta has not been reported before, a novel chemokine receptor C-
C RIO has been described which binds MCP-1 with high and RANTES with much lower
affinity. This receptor is uniquely expressed within placenta and fetal liver (Bonini, et al.,
1997) and its expression pattern is therefore consistent with placental secretion of both
MCP-1 and RANTES. A variety of cells within placenta would be capable of secreting
MCP-1 and RANTES including trophoblast, placental macrophages and T-cells.
However, some placental explants were contaminated with blood and therefore peripheral
leukocytes, in particular monocytes and T-cells could be an additional source of MCP-1
and RANTES, respectively.
Parturition has been likened to an inflammatory reaction with cytokines such as IL-8
playing a key role in cellular recruitment and activation within the utero-placental unit at
term (Sennstrom, et al., 1997). Prostaglandin E2 is also thought to be an important
mediator and possible initiator of parturition with concentrations increasing peripartum
within amniotic fluid, placenta and cervix. In extra-uterine inflammatory responses,
synergy exists between PGE2 and IL-8 to facilitate neutrophil recruitment (Colditz, 1990).
Furthermore, IL-8 release can be upregulated by PGE2 (Agro, et al., 1996). Whether
PGE2 regulates release of other inflammatory mediators such as MCP-1 and RANTES,
which may also be involved in parturition is not known.
This study investigated whether PGE2 regulated release of MCP-1, IL-8, RANTES and
IL-10 within the placenta and studied its effect on cytokine release from a dually infused
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placental cotyledon. This demonstrated that PGE2 stimulated release of MCP-1 and IL-8
into the maternal and fetal circuits of the perfusion system but had no effect on RANTES
release. It is hypothesised that a rise in PGE2 at term would stimulate MCP-1 and IL-8
release thus promoting a local inflammatory reaction, cellular infiltration and favouring
parturition. The principal source of cytokines in such a system would be trophoblast
although there may be a slight contribution from decidua of the basal plate. Release of
cytokines by decidua (Dudley, et al., 1992) and trophoblast (Steinborn, et ah, 1995) have
previously been implicated in the initiation and propagation of parturition. In addition,
cytokines have been shown to stimulate synthesis of PGE2 in decidua and trophoblast via
upregulation of COX-2 (Pollard, et ah, 1994). Thus, there is the potential for a positive
feedback loop to be initiated between PGE2 and cytokines to generate pro-inflammatory
mediators and therefore propagate the pro-inflammatory parturient response.
The effect of PGE9 stimulation of cytokine release into the fetal circulation was less than
into the maternal circulation and this could be due to inefficient transport of PGE2 across
the trophoblast (Glance, et ah, 1986), inability of cells adjacent to the fetal circulation,
such as the Hofbauer cells, to respond by stimulation to PGE2 or metabolism of PGE2 by
the trophoblast (Cheung, et ah, 1990). RANTES secretion was not stimulated by PGE2.
This further supports the hypothesis that stimulation of IL-8 and MCP-1 was secondary to
PGE2, was not an artefact of perfusion and is consistent with the literature in which PGE2
has not been demonstrated to stimulate RANTES release.
Prostaglandin E2 also stimulated release of IL-10 into the maternal but not the fetal
circulation. The maternal immune system maintains tolerance to the fetus throughout
pregnancy although the mechanism is poorly understood. Interleukin-10 is present in
amniotic fluid in increasing quantities during pregnancy (Greig, et ah, 1995), and due to
its immunosuppressive properties (Mosmann and Moore, 1991) has been proposed as a
factor which may be involved in preventing fetal rejection by promoting a Th-2 type of
immune response (Rivera, et ah, 1998). It is proposed that at term, stimulation of IL-10
release from the maternal side of the placenta by PGE2 would enhance local
immunosuppression and tolerance towards fetal antigen. The fetus would then be
protected from maternal recognition and rejection during the "high risk" inflammatory
process of parturition. In addition, IL-10 could inhibit release of IL-8 (Chen and
Manning, 1996), MCP-1 (Kucharzik, et ah, 1998) and RANTES (MarfaingKoka, et ah,
1996) thereby acting as a negative feedback control on the pro-inflammatory parturient
response.
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In summary, this study demonstrates that amnion, chorion, placenta and decidua release
distinct profiles of both pro- and anti-inflammatory cytokines. Furthermore, in vitro
perfusion of a placental cotyledon by PGE2 stimulates release of IL-8, MCP-1 and IL-10
but not RANTES. It is speculated that the pro-inflammatory cytokines MCP-1 and IL-8
may play a role in the inflammatory process of parturition and that the anti-inflammatory
IL-10 may be involved in protecting the fetal allograft at parturition and regulating
generation of pro-inflammatory cytokines. Moreover, it is suggested that PGE2 may play
an important immunomodulatory role within the placenta at term.
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CHAPTER 8
SECRETORY LEUKOCYTE PROTEASE INHIBITOR
CONCENTRATION INCREASES IN AMNIOTIC FLUID WITH
THE ONSET OF LABOUR: CHARACTERISATION OF ITS
SITES OF RELEASE WITHIN THE UTERUS
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8.1 INTRODUCTION
Many pro-inflammatory cytokines and chemokines, such as IL-1 (Augustulen, et al.,
1994), IL-8 (Laham, et al., 1993), MlP-la, GRO-a (Cohen, et al., 1996), IL-6 (Arntzen,
et al., 1997) and TNF-a (Laham, et al., 1994), have been implicated in the initiation of
parturition with levels increasing within peripheral serum and amniotic during gestation
fluid with a further increase at the onset of labour. The roles of anti-inflammatory
cytokines and cytokine antagonists in the initiation and regulation of labour are however
less well defined. It has been proposed that increased production of anti-inflammatory
factors, such as IL-10 and TNF receptor antagonist, might prevent premature parturition
and their subsequent fall or failure to increase within the utero-placental unit at term, co¬
incident with increases in pro-inflammatory cytokines, might permit parturition to occur
(Arntzen, et al., 1998; Dudley, et al., 1997).
Secretory leukocyte protease inhibitor is a potent anti-inflammatory and
immunomodulatory agent. Little is known about its role within the human uterus during
pregnancy. In animal uteri, secretory leukocyte protease inhibitor has been found in the
endometrium and myometrium of pigs (Reed, et al., 1998), cows and horses (Badinga, et
al., 1994) with concentrations of the protein and mRNA tending to increase during
pregnancy. In women, secretory leukocyte protease inhibitor protein has not been
demonstrated within non-pregnant endometrium or fetal membranes but has been
immunolocalised to the crypts of endocervical glands in both the non-pregnant and
pregnant cervix (Helmig, et al., 1995). In addition, its concentration increases
significantly within amniotic fluid during pregnancy to term (Helmig, et al., 1995).
However, any change in concentration with the onset of labour, its site of secretion from
uterine tissues and the potential roles of secretory leukocyte protease inhibitor during
parturition have not been examined.
The aims of this study were to measure the levels of secretory leukocyte protease inhibitor
in amniotic fluid during pregnancy and labour. In addition, the sites of production within
the uterus at term have been characterised to determine the putative roles that secretory
leukocyte protease inhibitor might play in the paracrine interactions within the uterus for
the maintenance of pregnancy and the control of parturition.
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8.2 MATERIALS AND METHODS
Tissue Collection
Samples of amniotic fluid (15 - 18 weeks, n = 20; term not in labour, n = 15; term in
labour, n = 15), fetal urine (n = 12 neonates; > 37 weeks) and fetal serum (>37 weeks
either after spontaneous vaginal delivery, n = 5 or after emergency caesarean section, n =
5) were collected (Sections 2.214, 2.215 and 2.216). All samples were centrifuged at
1000 g for 5 minutes and stored at -20°C prior to immunoassay.
Tissues used for explants were obtained from women undergoing an elective caesarean
section at term (n = 6 women; > 37 weeks; not associated with labour; Section 2.213).
For placental perfusion, placentae were collected after spontaneous vaginal delivery at
term (n = 6; >37 weeks, active labour, not induced). For immunohistochemistry, tissues
(n = 4, > 37 weeks, elective caesarean; n = 4, >37 weeks, emergency caesarean section,
active labour, not induced) were fixed in 10 % NBF for 24 hours before washing twice in
70 % ethanol prior to mounting in paraffin wax. Ethical approval for the collection of all
samples was obtained from the Lothian Trust Ethical Committee with the informed and
written consent of patients.
Culture of explants of amnion, chorio-decidua, decidua and placenta
Discs of amnion (12 mm diameter; wet weight 15 - 20 mg), chorio-decidua (9 mm
diameter; wet weight 15-25 mg), decidua (wet weight 15 - 25 mg) and villous placenta
were prepared for and cultured as previously described (Section 2.223; (Brennand, et al.,
1995)). The harvested media was then frozen at -20°C until analysis.
Preparation and culture of amnion and chorion cells
Amnion and chorion were collected immediately after delivery from patients undergoing
elective caesarean section at term (> 37 weeks, not in labour, Section 2.213). Amnion
and chorion cells and chorion fibroblasts were prepared for and maintained in culture
(Section 2.223). Media were frozen and stored at -20°C until analysis.
Dual perfusion of placental cotyledons
Term placentae (n = 6) were perfused as previously described (Sections 2.224 and 7.2;
(Schneider and Huch, 1985; Schneider, et al., 1972). After a 40 minute equilibration
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period, consecutive 10 minute samples were collected from both maternal and fetal
circuits. Samples were stored at -20°C until being assayed.
Secretory leukocyte protease inhibitor assay
Secretory leukocyte protease inhibitor was measured by a ELISA (Section 2.23). To
validate the assay in amniotic fluid, serial dilutions of amniotic fluids were compared with
that of the recombinant standard and assay results were compared with those obtained
using a commercial kit which uses the same antibodies (R&D Systems).
Localisation of secretory leukocyte protease inhibitor in tissues by
immunohistochemistry
Secretory leukocyte protease inhibitor was immunolocalised by immunohistochemistry
(Section 2.27). Sections were counterstained with Harris' haematoxylin, dehydrated,
mounted and visualised by light microscopy.
Statistical analysis
Statistical analysis of the data was performed using ANOVA (StatView 4.1, Abacus Inc.,
Berkley, CA, USA). The data were normally distributed and are expressed as pg/ml,




Validation of secretory leukocyte protease inhibitor assay
Serial dilutions of amniotic fluids gave dose response curves parallel to that of the
recombinant standard (Figure 44). The results from this assay and those obtained by a
commercial assay (R&D Systems), which uses the same antibodies, were very highly
correlated (r = 0.99, total degrees of freedom, n = 5).
Presence of secretory leukocyte protease inhibitor in amniotic fluid
Secretory leukocyte protease inhibitor was present within amniotic fluid in increasing
concentrations from second trimester (24 ± 3 ng/ml; mean ± s.e.m) to term not in labour
(751 ± 53 ng/ml) to term in labour (3929 ± 1076 ng/ml) with this rise being significant
from second trimester to term (p<0.05) to term in labour (p<0.005; Figure 45).
Secretory leukocyte protease inhibitor release from amnion, chorion-
decidua, decidua and placenta and its concentration in cord serum and fetal
urine
Amnion, chorio-decidua, decidua and placenta explants demonstrated a distinct pattern of
secretory leukocyte protease inhibitor release with low levels being secreted by placenta
(9.2 ±1.9 pg/mg), more by amnion (55.6 ± 6.0 pg/mg; p<0.05) and significantly higher
levels from decidua (135.2 ± 12.4 pg/mg; p<0.01) and chorio-decidua (325.1 ± 26.4
pg/mg; p<0.005; Figure 46). Amnion epithelial cells, chorion trophoblast cells and
chorion fibroblasts released 613 ± 88 pg/ml/105 cells, 389 ± 62 pg/ml/105 cells and 1658
± 250 pg/ml/105 cells secretory leukocyte protease inhibitor, respectively.
Secretory leukocyte protease inhibitor was secreted into both the maternal (7080 ± 840
pg/ml/cotyledon) and fetal (1790 ± 230 pg/ml/cotyledon) circulations in the perfused
placental cotyledon system (Figure 47) with significantly higher (p<0.005) amounts being
released into the maternal than fetal circulation. However, it was undetectable in all cord
serum samples (n = 10) and below the detection limit of the assay in nine out of the twelve
fetal urine samples assayed with levels being 358 pg/ml, 320 pg/ml and 188 pg/ml,
respectively in the remaining three samples. There was no evidence of infection or
neonatal sepsis in the three neonates in which secretory leukocyte protease inhibitor was
detectable.
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Immunolocalisation of secretory leukocyte protease inhibitor within fetal
membranes, decidua and placenta
Intense specific immunoreactivity for secretory leukocyte protease inhibitor was localised
to the layer of decidua parietalis adherent to chorion trophoblast (Figure 48A). Similarly,
intense immunostaining was present in decidua parietalis collected from the myometrial
aspect (Figure 48B). Only a few isolated cells, which may be fibroblasts, stained
immunopositive within the amnion and chorion trophoblast with the majority of the cells
constituting these layers being immunonegative (Figure 48A). In placenta, the decidua
basalis which underlies the placenta also demonstrated intense specific immunoreactivity
(Figure 48C). The extra-villous trophoblast was immunonegative as was the majority of
the placenta apart from a small amount of staining around the margins and within fetal
blood vessels of the villi. Substitution of the primary antibody with normal donkey
(Figure 48D) and normal goat serum (data not shown) resulted in absence of staining in
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Figure 44
Dose response relationships (B/BO) for recombinant secretory leukocyte protease
inhibitor standards and two serially diluted amniotic fluid samples. Serial dilutions of


















































Increase in concentration of secretory leukocyte protease inhibitor in amniotic fluid
during pregnancy. The concentration increased significantly during pregnancy from
the second trimester (n = 20) to term (n = 15) to term in labour (n = 15). Values are
expressed as ng/ml; mean ± s.e.m. Significance; *, p<0.05, term not in labour to
second trimester; **, p<0.005, term not in labour to term in labour.
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Release of secretory leukocyte protease inhibitor by explants of third trimester amnion,
chorio-decidua, decidua and placenta maintained in culture for 24 hours. Significantly
more secretory leukocyte protease inhibitor was released by chorio-decidua and
decidua than by placenta and amnion. Values are expressed as pg/mg/wet weight; mean
± s.e.m. n = 6 different women. Significance; *, p<0.05, amnion compared to
placenta; **, p<0.01, decidua compared to amnion and placenta; ***, p<0.005,





































Release of secretory leukocyte protease inhibitor from the dually perfused placental
cotyledon. Significantly more secretory leukocyte protease inhibitor was released into
the maternal than the fetal circulation. Values are expressed as pg/ml; mean ± s.e.m. n
= 6 placentae. Significance; *, p<0.005, maternal compared to fetal effluent.
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Figure 48
Localisation of secretory leukocyte protease inhibitor by immunohistochemistry in:
A Fetal membranes and adherent decidua. Intense positive immunostaining is
localised predominantly in decidual cells and in some cells of fibroblast
morphology in chorion and amnion.
B Decidua parietalis with specific positive immunoreactivity in decidual stromal
cells.
C Placenta with little or no immunostaining in syncytiotrophoblast cells or
extravillous trophoblast in the placental bed. Some positive immunostaining
is present in cells of the villous core in the stroma and associated with the
vasculature. There is intense immunostaining in cells of the decidua basalis.
D Parallel negative control section of fetal membranes and adherent decidua with
no non-specific staining.
Key: a = amnion; c = chorion laeve; d = decidua parietalis adherent to the chorion; t
= trophoblast cell layer of chorion; s = syncytiotrophoblast cells; ev =
extravillous trophoblast; db = decidua basalis. Scale bars: A & D = 200 ^m;
B & C 100 um.
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8.4 DISCUSSION
This study demonstrates that secretory leukocyte protease inhibitor is present in increasing
concentrations within amniotic fluid during pregnancy and further increases with the onset
of labour. Secretory leukocyte protease inhibitor was secreted predominately by explants
of decidua and chorio-decidua with lower levels released by amnion and placenta.
Immunohistochemistry demonstrated cell-specific localisation of secretory leukocyte
protease inhibitor to both decidua parietalis and basalis.
The profound increase in the concentration of secretory leukocyte protease inhibitor within
amniotic fluid after the onset of labour is a novel finding. The presence of secretory
leukocyte protease inhibitor within amniotic fluid during the second trimester and at term
has been previously demonstrated (Helmig, et al., 1995) with the reported values being
comparable with our data. Term amniotic fluid comprises mainly of secretions from the
surrounding fetal membranes, decidua, fetal lung and from fetal urine (Gilbert and Brace,
1993). Release of secretory leukocyte protease inhibitor from amnion explants in vitro
was comparatively low. However, the potential release of secretory leukocyte protease
inhibitor by amnion in vivo may be considerable due to the large surface area of the
amniotic membrane. In addition, it has been previously demonstrated that secretory
leukocyte protease inhibitor is present in high concentrations within tracheal aspirates from
neonates (Ohlsson, et al., 1992) with levels correlating positively with gestational age
(Sluis, et al., 1994). Although this study demonstrates that fetal urine contains secretory
leukocyte protease inhibitor, it was only detectable in one quarter of all samples tested and
therefore unlikely to account for the consistently high levels of secretory leukocyte
protease inhibitor demonstrated in all labouring amniotic fluid samples. It is likely
therefore that release and transfer of secretory leukocyte protease inhibitor from decidua,
as has been suggested for prolactin (Rosenberg, et al., 1980), amnion epithelial and fetal
lung secretions may all contribute to secretory leukocyte protease inhibitor in amniotic
fluid.
The predominant source of secretory leukocyte protease inhibitor secretion in the uterus is
likely to be the decidua, with explants of decidua parietalis and chorio-decidua secreting
high levels. In decidua parietalis, intense immunoreactivity for secretory leukocyte
protease inhibitor was localised in the maternal aspect of the decidua and in that adjacent to
chorion. This adherent decidua is likely to be the principal site of production in chorio-
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decidual explants. Decidua collected from the myometrial aspect by curettage is usually
contaminated with some myometrium, which is immunonegative for the protein. This
may explain why decidual explants secrete slightly less secretory leukocyte protease
inhibitor compared to chorio-decidua, unless there is a gradient of secretion with highest
outputs from decidua adjacent to the chorion. Term decidua is heterogeneous, consisting
of stromal cells (53 %), macrophages (19 %), granulocytes (16 %) and T-cells (8 %)
(Adeleye, et al., 1996). Hence the stromal cells, macrophages and granulocytes, which
are capable of secretory leukocyte protease inhibitor secretion in other sites (Ohlsson, et
al., 1996) are potential sources. In the fetal membranes, amnion explants, which consist
of an epithelium and sub-epithelial layers containing fibroblasts, secrete secretory
leukocyte protease inhibitor. The potential paracrine interactions between the different cell
types present in the term amnion, chorion, composed of reticular fibroblast and the
trophoblast cell layers and decidua, to regulate the release of secretory leukocyte protease
inhibitor at the materno-fetal interface require further investigation.
Placental explants of villous core tissue released low levels of secretory leukocyte protease
inhibitor which is in agreement with only slight immunostaining within the fetal
vasculature. This immunostaining could represent either secretory leukocyte protease
inhibitor bound to elastin (Rudolphus, et al., 1994) within the syncytiotrophoblast blood
vessel wall or specific staining of residual fetal blood cells in the villi. Within the isolated
perfused placental cotyledon, secretory leukocyte protease inhibitor was released mainly
into the maternal and not the fetal circuit and was undetectable in cord serum. Decidua
basalis adherent to the perfused placental cotyledon stains intensely for secretory leukocyte
protease inhibitor reactivity and may be the principal source of the secretory leukocyte
protease inhibitor secretion into the maternal circulation effluent.
Parturition has been likened to an inflammatory reaction (Liggins, et al., 1977). Secretory
leukocyte protease inhibitor may be involved in the regulation of this response at the
materno-fetal interface. At the onset of labour, there is increased expression and release of
pro-inflammatory cytokines such as IL-1 and IL-6 within amniotic fluid (Cox, et al.,
1997) and decidua (Dudley, et al., 1992) which stimulate pro-inflammatory cascades
involved in the initiation and maintenance of parturition. However, IL-1 and IL-6 can also
stimulate release of secretory leukocyte protease inhibitor (Jin, et al., 1998; Sallenave, et
al., 1994). The significant rise in IL-1 and IL-6 within amniotic fluid and decidua at
parturition could therefore enhance release of secretory leukocyte protease inhibitor (Jin, et
al., 1998; Sallenave, et al., 1994) from amnion epithelium, fetal respiratory tract mucosa
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and decidua. Secretory leukocyte protease inhibitor could then exert a negative feedback
on release of inflammatory cytokines via inhibition of NFkB (Jin, et al., 1997) and
neutrophil function by inhibition of neutrophil elastase. Secretory leukocyte protease
inhibitor could also inhibit release of PGE2 and matrix metalloproteinases, which are also
involved in membrane remodelling and rupture, by inhibiting COX-2 (Zhang, et al.,
1997). During parturition, the uterine cavity is at high risk of invasion and infection by
microbial organisms. Secretory leukocyte protease inhibitor, by virtue of its anti-bacterial,
anti-fungal and anti-viral properties could therefore in addition, act as an endogenous
block to infection within the decidua and the amniotic cavity.
In summary, it has been demonstrated that secretory leukocyte protease inhibitor is present
in increasing concentrations within amniotic fluid during pregnancy and labour. Secretory
leukocyte protease inhibitor is also released by and immunolocalised to term decidua. This
tissue, together with fetal membranes and possibly the fetal lung, are the likely sources of
secretory leukocyte protease inhibitor within the uterus. It is suggested that secretory
leukocyte protease inhibitor might act both to limit the pro-inflammatory cascades ongoing
during parturition and to protect against microbial invasion and the response to infection.
Further studies are required to investigate the regulation of secretory leukocyte protease
inhibitor release by intra-uterine tissues and to examine its potential roles in the
maintenance of pregnancy and the initiation and progression of parturition, both preterm
and at term.
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GENERAL CONCLUSION - PART 2
The second part of this thesis provides support for the hypothesis that inflammatory
mediators are important in the initiation and regulation of cervical ripening and parturition
with complex interactions occurring within the cervix and at the feto-maternal interface.
Cervical ripening
The cervical studies in Chapter 6 demonstrated that the non-pregnant and pregnant cervix
release a wide range of inflammatory mediators and it was postulated that these mediators
may be involved in maintaining cervical competence and mediating cervical ripening at
term. In addition, a fall in progesterone or interference with its action at the local level
was proposed as a possible mechanism for initiating these processes. To investigate this,
cervical biopsies should also be taken from women at term after caesarean section or
spontaneous vaginal delivery post-administration of mifepristone. Furthermore, it is
speculated that inflammatory mediators, such as IL-8 and nitric oxide, may have a clinical
application as novel cervical ripening agents at term. Alternatively, antagonism of their
action may prevent premature cervical ripening and preterm delivery.
Inflammatory mediators and parturition
Chapters 7 and 8 investigated the sites of production of inflammatory mediators within the
uterus at term. Chorio-decidua was the principal source of release of the pro¬
inflammatory mediators MCP-1, IL-8 and RANTES. Anatomically, this tissue comprises
the feto-maternal interface and has been proposed as playing a pivotal role in the initiation
of a pro-inflammatory parturient response (Dudley, et al., 1992). The findings from the
above studies are consistent with this hypothesis and support the concept that paracrine
interactions within chorio-decidua may be involved in the initiation of parturition. Future
studies should investigate how release of these mediators is affected by the onset of labour
and study the secretion of these and other pro-inflammatory cytokines from intra-uterine
tissues peri- and intra-partum.
In addition, chorio-decidua was the principal site of secretion of the anti-inflammatory
mediators IL-10 and secretory leukocyte protease inhibitor. Together they could, via
different mechanisms (Chen and Manning, 1996; Jin, et al., 1997; Kucharzik, et al.,
1998; MarfaingKoka, et al., 1996), inhibit release of pro-inflammatory cytokines. Thus
they could act both as general inhibitors of an inflammatory response and specifically as a
negative feedback control on the pro-inflammatory parturient response. In addition, IL-10
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and secretory leukocyte protease inhibitor could protect the fetus during parturition by
generating a local Th-2 type immune response, thereby preventing fetal rejection, and by
acting as an endogenous block to infection within the decidua and the amniotic cavity,
respectively. Future studies could investigate the release of IL-10 and secretory leukocyte
protease inhibitor by intra-uterine tissues in pregnancies complicated by adverse
outcomes, such as intra-uterine growth retardation, infection, premature rupture of
membranes and preterm labour. In addition, release of other anti-inflammatory mediators
such as TGF-p, which has many parallels with IL-10 in its action, or other natural anti¬
microbial agents, such as defensins, at the materno-fetal interface could be investigated.
From the clinical perspective, IL-10 and secretory leukocyte protease inhibitor could have
a potential therapeutic application in antagonising unwanted inflammatory responses, such
as occur during many preterm labours. This therapeutic potential is already being
exploited in the field of respiratory medicine, where recombinant secretory leukocyte
protease inhibitor protein has been found to boost mucosal immunity (Stolk, et al., 1995)
and reduce lung damage mediated by inflammatory processes such as lipopolysaccharide
induced emphysema (Rudolphus, et al., 1993).
Finally, preliminary studies were undertaken into the regulation of inflammatory mediator
release by PGE2. Future studies could investigate the molecular mechanisms behind the
PGE2 mediated stimulation of inflammatory mediator release and assess whether
transcription factors such as NFkB are involved. In addition, the roles of other factors
such as nitric oxide in modulating inflammatory mediator release at the feto-maternal
interface could be investigated.
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All chemicals were from Sigma-Aldrich Co. Ltd., Poole, UK unless otherwise stated.
TISSUE COLLECTION










50 pg/ml streptomycin Gibco, Paisley, UK
2 mM L-glutamine









5 pg/ml amphotericin B










500 mis RPMI 1640
ELISA SOLUTIONS
Coating Solution pH 9.6
400 mM NaHCO,
40 mM Na2C03
Wash Buffer pH 7 - 7.5
150 mM NaCl
100 mMTris-HCl
0.05 % Tween - 20
ELISA Assay Buffer pH 7.2
150 mM NaCl
100 mMTris-HCl
50 mM phenol red solution
2 mM EDTA
1 mM 2-methylisothiazolone Boehringer Mannheim, Lewes, UK
1 mM bromonitrodioxane Boehringer Mannheim, Lewes, UK
2 mg/ml BSA
0.05 % Tween - 20
Substrate pH 6.0
10 mis 100 mM sodium acetate
1 ml 0.1 g/1 tetramethyl benzidine in DMF




9 mis 100 mM sodium acetate
1 ml 0.3 g/1 urea-hydrogen peroxide in 50 mM
sodium acetate
pH 6.0
100 nl 20 rig/ml Amplex Red in DMF
Methyloximating solution pH 5.6





10 mg/ml BSA (Grade A7888)
ZYMOGRAPHY
Sample application buffer
10 mis 20 % v/v glycerol
1 g 2 % w/v SDS BioRad, Hemelhempstead, UK
20 mg 0.04 % w/v bromophenol blue BioRad, Hemelhempstead, UK
Dissolve in 50 mis ElgaStat xl purified H20
Store in 1 ml aliquots at 5°C.
Running tank buffer xlO pH 8.3
1.9 M glycine




Dissolve in 1 litre ElgaStat xl purified H20.
Dilute 1 : 10 with ElgaStat xl purified H20 for
use.
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Resolving gel buffer: Stock A
1.5 M Tris
pH 8.8
Merck Ltd. (BDH), Lutterworth,
UK
Dissolve in 50 mis ElgaStat xl purified
H20. pH with 5 N HC1.
Make up volume to 100 mis with ElgaStat xl
purified H20.
Stacking gel buffer: Stock B
0.5 M Tris
pH 6.8
Merck Ltd. (BDH), Lutterworth,
UK
Dissolve in -50 mis ElgaStat xl purified H20.
Adjust pH with 5 N HC1.
Make up volume to 100 mis with ElgaStat xl
purified H20.
Stock Wash Buffer x 10 (TBS x 10) pH 8.0
0.5 M Tris Merck Ltd. (BDH), Lutterworth,
Dissolve in -750 mis ElgaStat xl purified H,0,
adjust pH with 5 N HC1.
Make up volume to 1 litre with ElgaStat xl
purified H20.




Merck Ltd. (BDH), Lutterworth,
UK
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Resolving gel (Lower gel)
2.35 mis ElgaStat xl purified H20
1.0 ml gelatin 10 mg/ml ElgaStat xl purified H20
2.5 mis Stock A Buffer
100 pi 10 % SDS
50 pi 10 % ammonium persulphate
4.0 mis acrylamide/bis
Mix by gentle swirling. Degas via water
pressure for 5 - 10 minutes.
5 pi ITEMED
Add TEMED, swirl to mix gently.
7.5 % Acrylamide/Bis
Bovine Skin Type III Bloom 225,
Sigma, Poole, UK
BioRad, Hemelhempstead, UK
acrylamide/bis-acrylamide 37.5 : 1
bought in as a 30 % solution from
BioRad, Hemelhempstead, UK
Stacking Gel (Upper gel)
3.05 mis ElgaStat xl purified H,0
1.25 mis stock B. buffer
50 pi 10 % SDS
50 pi 10 % ammonium persulphate
0.65 mis acrylamide/bis
Mix by gentle swirling. Degas by vacuum for 5
-10 minutes.
5 pi TEMED














Dissolve in -750 mis ElgaStat xl purified H20,
adjust pH with 5N HC1.
Make up volume to 1 litre with ElgaStat xl
purified H20. Store at 5°C.
Destaining solution
30 % methanol
10 % glacial acetic acid
600 mis ElgaStat xl purified H20
pH 7.6
Merck Ltd. (BDH), Lutterworth,
UK
Merck Ltd. (BDH), Lutterworth,
UK
Merck Ltd. (BDH), Lutterworth,
UK
Merck Ltd. (BDH), Lutterworth,
UK
Merck Ltd. (BDH), Lutterworth,
UK
Staining Solution








Dissolve in -750 mis ElgaStat xl purified H20,
adjust pH with 5N HC1.
Add 25 mis Triton-X-100, allow to dissolve
completely - 1 - 1.5 hours on magnetic stirrer.
Make up to 1 litre with ElgaStat xl purified H20.
pH 7.5
Merck Ltd. (BDH), Lutterworth, UK
Merck Ltd. (BDH), Lutterworth, UK
Merck Ltd. (BDH), Lutterworth, UK
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Incubation buffer/Digestion buffer
As rinse buffer but without the Triton-X-100.
Resolving gel (Lower gel) 12 % Acrylamide/Bis
1.69 mis ElgaStat xl purified H20
1.0 ml gelatin 10 mg/ml ElgaStat xl purified H20 Bovine Skin Type III Bloom 225
2.5 mis stock A buffer
0.66 mis solution A
Mix by gentle swirling. Degas via water
pressure/desiccator vacuum for 10 minutes.
5 pi TEMED
Swirl gently to mix.
Stacking gel (Upper gel) 5 % Acrylamide/Bis
2.89 mis ElgaStat xl purified H20
1.25 mis stock B buffer
50 pi 10 % SDS BioRad, Hemelhempstead, UK
50 pi 10 % ammonium persulphate
0.812 mis acrylamide/bis BioRad, Hemelhempstead, UK
Mix by gentle swirling. Degas via water pressure/'
vacuum for 5 minutes.
5 pi TEMED. Swirl gently to mix.
100 pi 10 % SDS
50 pi 10 % ammonium persulphate
4.0 mis acrylamide/bis BioRad, Hemelhempstead, UK
BioRad, Hemelhempstead, UK
WESTERN BLOT METHOD
Homogenisation/Extraction buffer pH 7.4
Merck Ltd. (BDH), Lutterworth, UK20 mM TrisHCl
150 mM NaCl
1 tablet protease inhibitor
Dissolve in 40 mis ElgaStat xl purified H,0,
adjust pH with 5 N HC1.
Make up volume to 50 mis with ElgaStat H20
Use straight away or store at -20°C.
Boehringer Mannheim, Lewes, UK
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Sample application buffer
1.5 % w/v Tris
pH 6.75
Merck Ltd. (BDH), Lutterworth, UK
BioRad, Hemelhempstead, UK4.0 % w/v SDS
2.0 % w/v dithiothreitol (DTT)
0.05 % w/v bromophenol blue BioRad, Hemelhempstead, UK
Dissolve Tris in ~ 20 mis ElgaStat xl purified
H20, adjust pH with 5 N HC1.
Add in other chemicals, dissolve, make volume
up to 25 mis.
Store in 0.5 ml aliquots at -20°C.
Stock wash buffer xlO (TBS xlO) pH 7.4
0.5 M Tris Merck Ltd. (BDH), Lutterworth,
1.5 M NaCl
Dissolve in -750 mis ElgaStat xl purified H20,
adjust pH with 5 N HC1.
Make up volume to 1 litre with ElgaStat xl
purified H20.
Dilute 1:10 with ElgaStat xl purified H20 for
use and add:-
0.05 % v/v Tween 20
Membrane Blocking Buffer
5 w/v BSA Sigma A3294
Dissolve in 100 mis TTBS
Make up freshly, do not store. Prepare ~ 30







20 % v/v methanol
Dissolve salts in 800 mis ElgaStat xl purified
H20, check pH, add methanol.
Store at 5°C.
Resolving gel (Lower gel)
% Acrylamide/Bis
7.5 % 12 %
ElgaStat xl purified H20 9.7 mis 6.7 mis
Stock A buffer 5.0 mis 5.0 mis
10% SDS 200 pi 200 pi
10 % ammonium 100 pi 100 pi
persulphate
acrylamide/bis 5.0 mis 8.0 mis
Mix by gentle swirling. Degas via vacuum for 5
-10 minutes.
TEMED 10 pi 10 pi
pH 8.1 - 8.4
Merck Ltd. (BDH), Lutterworth,
UK




Add TEMED, swirl gently to mix.
Stacking gel (Upper gel) 4 % Acrylamide/Bis
6.1 mis ElgaStat xl purified H,0
2.5 mis Stock B Buffer
100 pi 10 % SDS BioRad, Hemelhempstead, UK
100 pi 10 % ammonium persulphate
1.3 mis acrylamide/bis BioRad, Hemelhempstead, UK
Mix by gentle swirling. Degas via vacuum for 5
minutes.
10 pi TEMED
Add TEMED, swirl gently to mix.
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Blocking solution
5 % BSA or 5 % normal serum
TTBS
Primary antibody solution
Blocking solution or TTBS
0.025 % sodium azide
TTBS
APPENDIX II
AMNION/CHORION DISPERSED CELL METHOD
Method
• Collect membranes directly into PBS containing heparin 10 U/ml.
• Separate amnion and chorion then wash three times with PBS and discard any
meconium stained, abnormal tissue and blood clots. Weigh tissue.
• Steep tissue in PBS containing 40 mg gentamicin and 2.5 mg amphotericin B/500
mis (30 - 60 minutes, 4°C) then wash four times with PBS.
• Shred tissue into 3-4 mm pieces.
• Incubate chorion in digestion medium (10 minutes, 37°C) to remove red blood
cells then wash and retrieve tissue.
• Digest amnion and partially digested chorion in digestion medium with gentle
agitation (40 minutes, 37°C).
• Mechanically disperse digested cells then harvest with filter (0.171 mm nylon
mesh).
• Centrifuge (1500 rpm/~500 g, 10 minutes, 23°C), decant supernatant, combine
pelleted cells and resuspend in a lesser volume (-30 mis) of complete medium.
• Repeat 8 twice then resuspend amnion (10 mis) and chorion (20 mis) in complete
medium. Count cells to assess number and viability using trypan blue exclusion.
Viability for both amnion and chorion usually greater than 90 %.
ZYMOGRAPHY
Sample preparation
Cell/tissue culture incubation medium
• Remove supernatant and freeze to -70°C prior to lyophilising samples by freeze
drying.
• Either reconstitute samples with known volume of 0.1 % SDS or store lyophilised
at -20°C until use.
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Plate preparation
• Clean (70 % IMS) and assemble plates (8 x 10 cm) with spacers (0.75 mm)
between them.
• Prepare the resolving gel according to the recipe and pour immediately to 1.2 cm
below top of plate (fill line), avoiding bubbles and leaks if possible.
• Overlay gel with water saturated sec-Butanol to burst any bubbles and give an
even level to top of gel.
• Leave to set (45 minutes, 23°C) and pour off the butanol. Wash with water
followed by several washes with Tris Buffer (Solution B 1 : 4) and leave with Tris
buffer overlay to allow polymerisation to occur (minimum of 2 hours, 23°C).
• Pour off buffer, rinse overlay with water and dry with paper. Clean (70 % IMS)
combs (0.75 mm, 15 well) and position between the plates.
• Prepare the stacking gel according to the recipe, apply to the resolving gel as
before, removing any bubbles and leave to set (at least 90 minutes, 23°C).
Gel electrophoresis (Discontinuous system)
• Remove the combs from the gels, take gels off the holder and attach to
electrophoresis apparatus.
• Place the assembled core in the tank and fill chamber with running buffer (500
mis) to dislodge any trapped air bubbles.
• Load the samples (15 |d - 20 [xl; 50 % v/v sample buffer) into the wells, remove
any air bubbles and top up the core chamber to about 3 mm below the top edges of
the two plates.
• Run at Constant Voltage, 100 V for 90 minutes at 23°C.
• After electrophoresis measure molecular weight markers and dye front.
• Remove gel from plate and immerse in Triton X 100 Wash Buffer.
Wash, digestion and stain
• Wash the gels twice (15 minutes/wash, 23°C) in Triton wash buffer then twice (~
2 minutes/wash, 23°C) in wash buffer.
• Add digestion buffer and incubate at 37°C overnight. After incubation, decant
buffer, wash twice in wash buffer (~2 minutes/wash, 23°C) and add staining
solution (~3 hours, 23°C).
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• Decant staining solution and replace with destaining solution (-30 minutes then 60
minutes, 23°C). Store destained gels in air tight water-filled container until ready to
be photographed (Kodak Ratten Filter No. 21 orange) or scanned.
WESTERN BLOT METHOD
Tissue preparation and cell/tissue culture incubation medium
As for zymography.
Dialysis
Some samples from tissue/cell culture may require a dialysis step to 'clean' them up
prior to electrophoresis and blotting. This tubing retains proteins of MW 12000 or
greater.
• If samples have been freeze dried reconstitute with extraction buffer (no protease
inhibitor added) to original volume, otherwise dialyse culture medium directly.
• Dialyse samples with gentle agitation against distilled water overnight at 4°C.
• Store dialysed samples at -70° C prior to lyophilising.
Gel electrophoresis (Discontinuous system)
• Clean and assemble plates (plate size - 8 x 10 cm, spacers 1.5 mm, combs 1.5
mm, 10 well). Prepare gels according to recipe and assemble as described for
Zymography.
• Remove combs from the gels and attach plates to cooling core (frozen and stored at
-20°C) on electrophoresis apparatus.
• Fill up chamber with running buffer (500 mis xl running buffer) to dislodge air
bubbles trapped in the wells and place the assembled core in the tank.
• Sample preparation.
- Mix samples (maximum volume 20 jxl) with an equal volume of sample
application buffer.
- "Boil" samples for 5 minutes.
- Centrifuge at 13,000 rpm for 3 minutes at 4° C.
• Load the samples (maximum 40 jrl) into the wells (keep samples on ice while
loading gel).
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• Remove trapped air bubbles and top up core chamber to about 3 mm below the top
edges of the two plates.
• Run at constant 100 V for ~2 hours.
• After electrophoresis, remove gels from apparatus, measure molecular weight
markers and dye front and immerse in transfer buffer.
Mini trans-blot assembly and transfer
• Equilibrate gels in transfer buffer (~ 30 minutes).
• Soak nitro-cellulose membrane (30 minutes), fibre pads (10 minutes) and filter
paper (10 minutes) in transfer buffer.
• Assemble the gel sandwich in gel cassette holder as follows (bottom to top):
- Pre-soaked fibre pad.
- Saturated filter paper.
- Equilibrated gel, face down, on top of the paper. Flood gel surface with a few
mis of transfer buffer.
- Pre-wetted membrane on top of the gel. Mark the position of the MW markers
and flood membrane with transfer buffer.
- Saturated filter paper.
- Pre-soaked fibre pad.
• Place the assembled gel holder cassette into tank electrode panel and slot cooling
unit behind electrode. Add transfer buffer (-400 mis, 5°C) to the tank.
• Electrophorese at constant voltage 100 V for 1 hour (temperature at end of transfer
should be no higher than 30°C).
• Dismantle the gel sandwich and transfer membrane to blocking solution for
immunoblot (overnight, 4°C).
• Stain gels (~1 - 2 hours) with 0.5 % Coomassie Blue to check the protein transfer,
pour off stain, add destaining solution, destain as necessary. After destaining is
completed, transfer to water.
314
Immunoblot-blot
• Drain membrane, incubate with primary antibody (diluted in blocking solution or
TTBS plus 0.025 %, 3 - 4 hours, 23°C) then wash three times (TTBS, 10
minutes/wash).
• Incubate membrane with secondary antibody (1 : 200 in TTBS, 45 minutes, 23°C)
and prepare ABC (2 drops solution A : 10 mis TTBS : 2 drops solution B). After
incubation, wash membrane three times (TTBS, 10 minutes/wash) as before.
• Prepare substrate solution (6 drops buffer solution : 12 drops DAB solution : 6
drops H202 : 6 drops nickel solution, mixed in glass dish) and add membrane to
solution to develop.
• When desired staining intensity achieved, wash membrane in water, dry and scan
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The maintenance of a normal pregnancy is dependent on the delicate interaction between
the endocrine and the immune systems. Cytokines are thought to play a key role in
pregnancy by way of local modulation of the immune system at the level of peripheral
leukocytes. This study examined the potential of peripheral venous blood cultures from
pregnant women throughout gestation and from non-pregnant women to produce the
chemokines monocyte chemotactic protein-1 (MCP-1), interleukin-8 (IL-8) and RANTES.
Significantly (P = <0.001), higher levels of MCP-1 were released from peripheral blood
cultures from pregnant women at term than during the first trimester or from women who
were not pregnant. This could not be accounted for by differences in differential blood
counts. Significantly higher levels (P = <0.05) of MCP-1 were released from PBMC
preparations from pregnant compared with non-pregnant women. No 'rebound' increase in
MCP-1 was observed on withdrawing progesterone support to the PBMC preparations.
MCP-1 was secreted predominately from CD14+ cells with those from pregnant women
producing more than those from non-pregnant women. There was no statistical difference in
release of IL-8 or RANTES from either peripheral blood or PBMC preparations from
pregnant or non-pregnant women. IL-8 and RANTES were secreted from CD 14 ' and
CD14" cells, respectively. The hypothesis proposed is that the monocytes are fundamentally
* Corresponding author.
Abstract
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different in pregnancy and that measurement of MCP-1 has the potential to act as a marker
of pregnancy status. Published by Elsevier Science Ireland Ltd.
Keywords: Monocyte chemotactic protein-1; Pregnancy; Peripheral marker
1. Introduction
Evidence is accumulating that maintenance of a normal pregnancy is
dependent on a delicate interaction between the endocrine and immune
systems. Disturbance of this balance can result in a wide range of abnormal¬
ities including intra-uterine growth retardation (Stallmach et al., 1995),
pre-eclampsia (Vinatier and Monnier, 1995), pre-term labour (Romero et
al., 1991b) and in the mouse, implantation failure (Krishnan et al., 1996).
Cytokines, the local effectors of the immune system, are increasingly
thought to play a key role during pregnancy. Chemokines, a subset of
cytokines, specific in their ability to attract and activate immune cells, may
be particularly important mediators of pregnancy. For example, interleukin-
8, a neutrophil chemoattractant and activator, is produced by many tissues,
including the amnion (Trautman et al., 1992), placenta (Shimoya et al.,
1992), myometrium (Osmers et al., 1995) and cervix (Barclay et al., 1993)
and has been implicated in the processes of cervical ripening (El Maradny
et al., 1994), pre-term labour (Romero et al., 1991a) and term labour
(Osmers et al., 1995). The roles of other chemokines such as monocyte
chemotactic protein-1 (MCP-1) and the T-cell chemokine RANTES (regu¬
lated upon activation and normally T-cell expressed and presumably
secreted) are not known in pregnancy.
From clinical studies it has been shown that pregnancy also affects the
presentation of many clinical diseases either aggravating them, for example
in carcinoma of the cervix and melanoma (Gustaffson and Kottymeier,
1962; Shiu et al., 1976) or having the opposite effect by ameliorating them,
for example in psoriasis or rheumatoid arthritis (Boyd et al., 1996; Nelson
and Ostensen, 1997). However, the immunological basis for these differ¬
ences is often poorly understood and objective evidence regarding func¬
tional changes in leucocyte populations is conflicting. For example, Shibuya
et al. (1991) demonstrated that phagocyte mediated non-specific immunity
was up-regulated in pregnancy with there being an increased oxidative
responsiveness, whereas Crouch et al. (1995) demonstrated a significant
reduction in respiratory burst in polymorphonuclear leukocytes during
pregnancy. Evidence regarding differences in levels of cytokines in periph¬
eral venous plasma are also conflicting and dependent on the cytokine being
measured and possibly assay procedures. Laham et al. (1993, 1994) found
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no difference in levels of either TNFa or IL-8 in peripheral plasma between
pregnant and non- pregnant samples whereas Austgulen et al. (1994)
demonstrated a significant increase in levels of IL-6 and IL-1 in pregnant
compared with non-pregnant samples. Another approach, which has been
used by Elsasser-Beile et al. (1992), is to measure the production of
cytokines in mitogen-stimulated peripheral blood cultures as a measure of
lymphocyte function.
Two factors might influence circulating leukocytes during pregnancy.
First, they may respond to the prolonged exposure of high levels of
circulating hormones and second, given the rapid trafficking of leukocytes
through the uteroplacental unit, the potential of such cells to release
chemokines could reflect events occurring locally within the uterus. A
change in chemokine levels could potentially act as a marker of parturition.
We have therefore examined the potential production of IL-8 (an oc
chemokine), monocyte chemotactic peptide (MCP-1, a /? chemokine) and
RANTES by peripheral blood cells in culture to examine changes during
pregnancy.
2. Materials and methods
2.1. Peripheral blood collection
Ethical approval was obtained from the Local Ethical Committee. Pe¬
ripheral blood (10 ml) was obtained by venepuncture in sterile Li-heparin
blood collecting tubes (Monovette, Sarstedt) from non-pregnant (NP)
women (ages 22-47) with regular menstrual cycles who were not using any
hormonal forms of contraception and from pregnant women (ages 16-37)
experiencing a normal pregnancy either during first trimester (FT), at term
in labour (TIL) or at term not in labour (TNIL). Exclusion criteria included
clinical evidence of infection. Patient characteristics are shown in Table 1.
2.2. Plasma preparations
The peripheral blood with Li-FIeparin anticoagulant was centrifuged at
1500 rpm for 5 min at 4°C and the upper plasma layer removed. The
cytokine content was measured by ELISA.
2.3. Whole blood cultures
The blood was stored on ice at 4°C until processing within 20 min of
collection. Samples were diluted 1:10 in medium RPMI/1640 (Sigma, Poole)
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and cultured overnight at 37°C with 5% C02. The culture medium was
subsequently analysed for levels of IL-8, MCP-1 and RANTES by ELISA
as described below.
2.4. Peripheral blood mononuclear cell preparations
Undiluted whole blood (10 ml) was layered on top of 5 ml of lymphocyte
separation medium (Sigma, density 1.077). The tubes were then centrifuged
at 2500 rpm for 25 min at 25°C. The lymphocyte layer at the interface was
removed and the cells were resuspended in 15 ml PBS. They were then
centrifuged at 1500 rpm for 40 min at 25°C. Next, the supernatant was
removed and the cells were washed twice in PBS (centrifuged at 1500 rpm
for 10 min at 25°C). They were then suspended in 10 ml RPMI/1640 and
counted with a haemocytometer. Finally the cell suspension was aliquoted
at 104 cells per well into culture plates and treated as for the whole blood
preparations described above.
2.5. Cellular separation
A PBMC preparation was prepared. The supernatant was removed
completely and the pellet resuspended in 2 ml separation buffer (PBS + 5
mM EDTA + 0.5% BSA). The solution was passed through a 30-/tm filter
then centrifuged at 1500 rpm for 15 min at 20°C. The pellet was resus¬
pended in 100 p\ of separation buffer. 25 p\ of magnetic activated cell sorter
(MACS) anti-CD 14 Microbeads were added to the sample which was then
Table 1
Age, parity and smoking status of all the patients studied
Characteristic Patient group
Non-pregnant in = 18) Pregnant (n = 6)
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incubated at 4°C for 15-20 min. The MACS column was pre-washed with
500 //I separation buffer. The cell preparation was then added to the column
and washed through with 700 /d buffer (CD14~ fraction). The column was
then washed with 1.5 ml of buffer prior to being removed from the magnet.
A further 1.2 ml of buffer was added to the column to elute the CD14 +
fraction. Both CD14+ and CD14" fractions were resuspended in 5 ml
RPMI/1640 and counted with a haemocytometer. The cells were aliquoted
at 104 cells per well, cultured and the supernatant analysed for chemokine
release.
2.6. ELISA assays for cytokines
The culture supernatant was analysed for levels of IL-8, RANTES and
MCP-1 using enzyme-linked immunosorbent assays (ELISA) utilising
matched pairs of capture and biotinylated labelled detection antibodies for
IL-8 and RANTES (R and D detection system) and a peroxidase labelled
Fab fragment of antibody for MCP-1 by the method of Ida et al. (1994) as
previously described.
2.7. RANTES ELISA
ELISA plates were passively coated overnight at 4°C with 2 yMg/ml of
capture antibody (R and D, Oxford diluted in PBS pH 7.2) added at 100 /d
per well. After incubation, the plates were washed once in water and coating
solution was added (Polyvinyl pyrollidone 2%, BSA 5 mg/ml, EDTA 5 mM,
Tris 50 mM) at 100 n 1 per well. The plates were left for 30 min at room
temperature then the coating solution was flicked out. The plates were air
dried and stored at 4°C. Prior to use, the plates were washed once in water.
The culture supernatant was diluted 1:10 in ELISA buffer (10 mM Tris pH
7.2, preservatives, BSA 2 mg/ml (Sigma A3803), 300 ^1 0.5% Phenol Red
solution per 1, NaCl 9 g/1, EDTA 2 mM, Tween-20 0.05% to final pH of
7.2). Standards (R and D, Oxford) were diluted in ELISA buffer with 500
pg/ml used as the top standard. Then 100 /d of sample and standard were
added per well. The plates were then sealed and incubated at 4°C overnight
or for at least 3 h at room temperature on an orbital shaker. They were then
washed 4 times in washing buffer (0.05% Tween-20, 9 g/1 NaCl, 100 mM
Tris, pH 7-7.5) and the detection antibody (50 //g/ml) was added at 100
/d/well. The plates were then incubated on a shaker at room temperature
for 45 min and washed as above. Following this, 100 /d of diluted (1:100)
streptavidin peroxidase (Boerhringer) was added per well at 0.2 U/ml and
the plates were incubated for 20 min at room temperature on an orbital
shaker. Plates were washed as above and 200 /d of substrate added per well
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(1:1:10 of urea-hydrogen peroxide 0.3 g/50 ml of 50 mM sodium acetate
buffer pH 6.0: tetramethyl benzidine 2 mg/ml in DMF: 100 mM sodium
acetate, pH 6.0). The plates were left for 20 min to develop before
quenching with 50 /d 2 NH2S04. Absorption was read at 450 nm within 30
min of quenching. The intra- and inter-assay precisions were both 11%
R.S.D. and the limit of detection was 15 pg/ml.
2.8. IL-8 ELISA
The methodology was as for the RANTES ELISA above, with the
following modifications. The capture antibody was diluted to 4 yUg/ml (R
and D, Oxford diluted in PBS 7.2) with 100 /d added per well. The standard
used was supplied by Toray Industries with the top standard being 500
pg/ml. The intra- and inter-assay precisions were 9.1% and 22% R.S.D.,
respectively, and the detection limit of the assay was 15 pg/ml.
2.9. MCP-1 ELISA
MCP-1 was measured using a previously described method (Ida et al.,
1994). Briefly, plates were coated overnight at 4°C with 100 /ul of MCP-1
capture antibody (Toray, a generous gift, diluted to 4 mg/ml in PBS). They
were then washed once in tap water and 100 ^1 coating solution as above
was added for 20 min. Plates were completely air dried and stored with a
desiccant at 4°C. The samples were diluted 1:20 in ELISA buffer and added
at 100 // 1/well. The standards (Toray) were diluted in ELISA buffer and
added at 100 /d/well with the top standard being 500 pg/ml. The plates were
incubated at 4°C overnight or for a minimum of 3 h at room temperature
on an orbital plate shaker. Plates were then washed and 100 //I per well of
peroxidase-coupled detection antibody (diluted 1:200 in ELISA buffer) was
added. Plates were incubated for 45 min at room temperature on an orbital
shaker before washing as above. Substrate was added as above and left for
20 min prior to quenching with 50 ju\ 2 NH2S04. The plates were analysed
as described earlier. The intra-assay precision was 6.3% R.S.D. and inter-as¬
say precision was 8.6% R.S.D. and the detection limit of the assay was 15
pg/ml.
2.10. Cell cultures under different conditions
PBMC were diluted and cultured for 24 h in RPMI/1640 supplemented
with 10"6 M of progesterone. The medium was then removed and replaced
with identical medium for a further 24 h. After this period the medium was
removed and replaced with RPMI/1640 supplemented with 10~6 M RU486
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(Roussel-Uclaf) for a final 24 h. The culture supernatants from each 24-h
period were then analysed for chemokine release by ELISA.
2.11. Statistics
Statistical analysis was performed using ANOVA multiple variate anal¬
ysis in StatView. Assignment of difference to individual groups was
achieved using Fischers PLSD. Results are expressed as mean ± S.E.M.
3. Results
3.1. Plasma chemokine levels
IL-8 was not detectable in peripheral plasma. MCP-1 was detectable in
pregnant (155 + 6.7 pg/ml) and non-pregnant samples (187 + 7.17 pg/ml).
RANTES was present at high levels in both pregnant (20.1 ±2.2 ng/ml)
and non-pregnant samples (23 ± 4 ng/ml). There was no statistical differ¬
ence in levels between pregnant and non-pregnant plasma levels of any of
the chemokines measured.
3.2. Peripheral blood cultured samples
IL-8 was present in culture supernatants from non-pregnant and preg¬
nant samples at levels of 356 + 96 and 490+ 182 pg/ml, respectively.
RANTES was detectable in culture supernatants from samples taken from
non-pregnant and pregnant women at levels of 736 + 251 and 1222 + 247
pg/ml, respectively. There was no statistically significant difference in lev¬
els of IL-8 or RANTES released by culture supernatants from pregnant
and non-pregnant samples.
Significantly (P < 0.001) higher levels of MCP-1 were released from the
culture supernatants of peripheral blood samples taken from pregnant
(4325 + 857 pg/ml) compared with non-pregnant (1739 + 391 pg/ml)
women. Moreover, there was statistically more MCP-1 released from
women during the third trimester compared with those during first
trimester or who were not pregnant (P < 0.001). There was more MCP-1
produced in samples taken from women at term not in labour compared
with those in labour although this was not statistically significant (Figs. 1
and 2).

























Fig. 1. The difference in release of the chemokines IL-8, MCP-1 and RANTES from cultured
peripheral blood. Significantly more MCP-1 (P < 0.001) is released from pregnant compared
(TNIL, n= 17) with non-pregnant samples (n = 12). There was no significant difference in
release of either IL-8 or RANTES between pregnant and non-pregnant samples.
3.3. PBMC preparations
PBMC preparations released IL-8, MCP-1 and RANTES. In the case of
RANTES and IL-8 more chemokine was released from the PBMC prepara¬
tion than from the whole blood cultures, however, in the case of MCP-1,
the converse was true (Table 2). There was no significant difference between
pregnant and non-pregnant PBMC preparations in their capacity to release
either IL-8 or RANTES. However, PBMC preparations from pregnant
compared with non-pregnant released significantly more MCP-1 (P < 0.05)
and this difference was maintained over 3 days in culture (Fig. 3).
3.4. Separated cells
IL-8 and MCP-1 were released predominantly by the CD14+ cells,
whereas RANTES was secreted mainly by the CD14- cells. There was no
statistical difference in production of any of these chemokines between
pregnant and non-pregnant samples although there was a tendency towards
Table2 ReleaseofMCP-1,IL-8andANTESfr mp ripheralbl ocultur som ar dwithth tmon nucl are l preparations(PBMC)prep redfromthesabl odple Sampletype(24hChe okine,pg/mlS.E.M.) culture) MCP-1IL-8RANTES PregnantNon-pregnantro - rn pregna t (n=6) PBMC2665(214)*1292( 14319 )0150481713 8 Peripheralblood8697(89 )**2 522781 59)0320471 1 SignificantlymoreMCP-1wasproduc dbyoththecul e(P<0.001)andPBMCreparatio s( 5fr megn nte comparedwithth snotpregnant. *P<0.05. **PcO.OOl.
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more IL-8 and MCP-1 being secreted by separated cells from pregnant blood
with the converse being the case with RANTES production (Table 3).
3.5. Influence of culture conditions on chemokine release
Culture of PBMC preparations under conditions of progesterone and
medroxyprogesterone acetate (MPA) supplementation (10 ~6 M) followed by
progesterone withdrawal by addition of the antigestogen RU486 (10 ~6 M)
did not affect the release of any of the chemokines being measured.
4. Discussion
This study demonstrates that significantly more MCP-1 is released from
peripheral blood cultures from pregnant compared with non-pregnant
10000i
Non- 1st Term in Term not
pregnant trimester labour in labour
n = 13 n = 10 n = 12 n = 14
Patient Group
Fig. 2. Differential release of MCP-1 through gestation from peripheral blood in a separate
study. Significantly higher (P < 0.001) levels of MCP-1 were released from peripheral blood
cultures taken at the end of pregnancy (TNIL, n= 14; TIL n= 12) compared with those
from first trimester (n = 10) or from women who were not pregnant (n = 13).
Table3 TheproductionfMCP-1,IL-8andRANTESfr mCD14+C 14~ c lls CellPopulationhemoki e,pg/ml/104ce ls(S.E.M.) MCP-1IL-8RANTES PregnantNon-pregnantron-pr tPregnaNon-preg ant (n=3)«n= CD14+726(219)21084573791)1(942825 CD14-70(26)7080)97(519 630)378( 5 MCP-1/andIL-8rereleasedpredominantlybythCD14+c llswher asRANTESisr l asedpredominantlyt D14'c l .Th r wasnostatisticaldifferen ei releaofythech mokinesmeasur dbe weenpr gn tdnon-pregnantalthoughisydu
tohesmallamp eize.
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Fig. 3. Release of MCP-1 from PBMC preparations over 3 days culture with media being
replaced and assayed every 24 h. Even after three days culture, more MCP-1 is released from
PBMC preparations from pregnant (TNIL, n = 6) compared with non-pregnant women
(n = 6).
women and that release of MCP-1 from such cultures is significantly higher
at the end of pregnancy compared with first trimester. The differential
release of MCP-1 is maintained in the PBMC preparations and from the
separated cells it is evident that the majority of the MCP-1 is produced by
the CD14+ cells. There was no significant difference in either IL-8 or
RANTES production from peripheral blood preparations or from the
separated cells between pregnant and non-pregnant samples.
In other tissues, such as the breast cancer cell line T47D and chorio-de-
cidua (Kelly et ah, 1997, unpublished results), MCP-1 release is inhibited by
progesterone. Given that pregnancy is a progesterone rich environment it
could be argued that by removing peripheral blood from this hormonal
milieu there could be a rebound secretion of MCP-1. However, the experi¬
mental data presented discounts this proposition on several counts. Firstly,
if the above hypothesis were valid, one would expect that on culturing the
PBMC preparations over 3 days any progesterone withdrawal effect would
disappear and the production of MCP-1 from cultures between pregnant
and non-pregnant women would become the same. This did not occur and
the differential secretion was maintained for the duration of culture. Sec¬
ondly, the progesterone withdrawal experiments did not stimulate a rise in
MCP-1 secretion. Thirdly, IL-8 production is also inhibited by progesterone
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(Kelly et al., 1994) and as such were this a factor in secretion, one would
expect there to be a rise in IL-8 production analogous to that observed with
MCP-1. This was not observed. Fourthly, tissues such as the endometrium
and chorio-decidua have definite evidence of a progesterone receptor,
whereas there is no conclusive evidence as to whether peripheral
lymphocytes do (Szekeres-Bartho, 1995) or do not (Mansour et al., 1994;
Schust et al., 1996) possess such a receptor.
The maternal adaptation to pregnancy involves wide ranging changes in
peripheral blood. An increase in leucocyte count occurs which is due mainly
to an increase in neutrophil count (Pitkin and Witte, 1979). There is
conflicting evidence whether normal pregnancy influences the distribution of
mononuclear cells with Damm et al. (1991) finding no difference and
Tsakonas et al. (1995) finding that there was a significant increase in
circulating monocytes with gestation. A second argument which could
therefore be used to explain the above findings is that, owing to the
leukocytosis of pregnancy, the increased production of MCP-1 is simply a
function of there being more cells in the pregnant blood cultures. However,
when the peripheral blood was separated into either the PBMC prepara¬
tions or the CD14+ (a monocyte specific cell surface marker) or CD 14"
cells, the number of cells was counted prior to being aliquoted and cultured
overnight. When chemokine production was subsequently measured, the
level could be corrected for cell number. Under these circumstances, consis¬
tently more MCP-1 was produced by pregnant compared with non-pregnant
samples.
MCP-1 is a 76 amino acid ft chemokine which is secreted by a wide range
of cell types, including monocytes (Yoshimura et al., 1989a), macrophages
(Brieland et al., 1993), lymphocytes (Yoshimura et al., 1989b) and endothe¬
lial cells (Sica et al., 1990). It was initially so named due to its function as
a monocyte chemoattractant and activator. Recently, a number of other
functions have been ascribed to this chemokine including that of an
angiogenic factor and it is increasingly viewed as a key chemokine in
orchestrating inflammatory responses. A role has been proposed for MCP-1
in ovulation (Arici et al., 1997) but whether it has a function in pregnancy
is not known.
This study demonstrates that there is an increased production of MCP-1
from pregnant monocytes compared with non-pregnant monocytes. This
suggests that the monocytes in pregnancy are intrinsically different from
those in non-pregnant women. That the higher levels of MCP-1 are a
consequence of de novo synthesis is corroborated by there being only low
levels of MCP-1 present in peripheral plasma and no difference between
pregnant and non-pregnant samples. Moreover RT-PCR data (unpublished
results) show MCP-1 message rising only after 3-4 h culture. The statisti-
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cally significant rise in MCP-1 production during pregnancy and the further
increase in production during labour are intriguing findings suggesting that
MCP-1 may play a role which is more important as pregnancy advances.
Given the rapid trafficking of leukocytes through the uteroplacental unit,
particularly during the third trimester, it is tempting to speculate that the
potential of peripheral blood leukocytes to release chemokines could reflect
events occurring locally within the uterus with a change in chemokine levels
potentially acting as a marker of uterine function.
In conclusion, this study demonstrates that significantly higher levels of
MCP-1 are released from peripheral blood cultures from pregnant com¬
pared with non-pregnant women. Separation of the peripheral blood
demonstrates that the MCP-1 is secreted predominantly by the monocytes.
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Seminal plasma components stimulate interleukin-8 and
interleukin-10 release
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Human seminal plasma has potent anti-inflammatory properties which are thought to confer a survival
advantage to the spermatozoa within the hostile female genital tract. In contrast, a profound pro-inflammatory
leukocytosis has been observed post-coitus in animals and humans. Whether components of seminal plasma
are involved in initiating this leukocytic reaction is not known. This study investigated the effect of human
seminal plasma, a seminal plasma fraction and its principal constituent prostaglandins, prostaglandin E2
(PGE2) and 19-hydroxy PGE, on the release of the pro-inflammatory neutrophil chemotactic factor interleukin-
8 (IL-8) and the anti-inflammatory cytokines interleukin-10 (IL-10) and secretory leukocyte protease inhibitor
(SLPI). The tissues studied were non-pregnant cervical explants, peripheral blood and the monocyte cell line
U937. Seminal plasma fraction (SPF) significantly (P < 0.05) stimulated release of IL-8 and inhibited release
of SLPI from non-pregnant cervical explants. SPF, PGE2 and 19-hydroxy PGE significantly (P< 0.005) stimulated
IL-8 release from peripheral blood and U937 cells. 19-hydroxy PGE was significantly (P < 0.005) more effective
than PGE2 in stimulating IL-8 release. Seminal plasma, SPF and PGE2 significantly (P< 0.05) stimulated IL-10
release from U937 cells. 19-hydroxy PGE stimulated IL-10 release from U937 cells but this failed to reach
significance. Release of IL-10 by cervical explants and SLPI by peripheral blood and U937 cells were below
the detection limit of the assays employed. We suggest that the anti- and pro-inflammatory immune responses
which seminal plasma induces might act in combination initially to promote sperm survival and then to
facilitate their removal from the female genital tract.
Key words: human seminal plasma/19-hydroxprostaglandin/interleukins/prostaglandin E2/secretory leukocyte
protease inhibitor
Introduction
Human seminal plasma has powerful immunosuppressive
properties containing high concentrations of the soluble p55
tumour necrosis factor-a (TNF-a) receptor (Liabakk et al.,
1993), receptors for the Fc portion of y-globulin, transforming
growth factor(3 (TGF(3) (Nocera and Chu, 1993), spermine
(Evans et al., 1995) and complement inhibitors (Kelly, 1995).
However, it is the prostaglandins prostaglandin E2 (PGE2) and
19-hydroxyprostaglandin E (19-hydroxy PGE), present in mM
concentrations within semen (Taylor and Kelly, 1974;
Templeton et al., 1978) which are thought to be the principal
effectors of the immunosuppression. They are potent stimula¬
tors of cAMP, thus inhibiting lymphocyte proliferation and
natural killer cell activity, and are likely to modify cytokine
release from antigen presenting cells (Kelly, 1995). In addition,
human seminal plasma and its component prostaglandins
stimulate release of the immunosuppressive T-helper-2 (Th-2)
cytokine interleukin-10 (IL-10) and inhibit the release of the
Th-1 cytokine interleukin-12 (IL-12) from lipopolysaccharide-
stimulated whole blood (Kelly et al., 1997). The effect of
PGE2 and the subsequent cytokine shift would be to induce
an anergic response in T-cells (Mannie et al., 1995; Groux
et al., 1996) and may therefore have implications for non-
recognition of both sperm antigen and viral pathogen.
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In contrast, coitus and ejaculation of semen deposits millions
of potentially pro-inflammatory immunogenic spermatozoa
into the vagina in vaginal inseminators, such as humans and
into the uterus in intra-uterine inseminators, such as the horse.
Since in most animals only a handful of spermatozoa are
required for fertilization, then the majority of spermatozoa
are rendered redundant and need to be removed from the
reproductive tract. How this is achieved is not well understood
but there is good evidence in horses (Kotilainen et al., 1994),
rabbits (Tyler, 1977), goats (Mattner, 1968), cattle (Howe and
Black, 1963) and mouse (De et al., 1991; Parr and Parr, 1991)
that a profound pro-inflammatory leukocytosis develops within
the uterus and cervix post-coitus. The invading cells, which
are predominately neutrophils, are then thought to phagocytose
those spermatozoa not destined to be involved in fertilization.
A similar leukocytic reaction is thought to occur post-coitally
in humans (Thompson et al., 1992) but whether this performs
the same physiological function remains to be established. In
addition, the factor or factors which initiate the leukocytosis
are unknown and pure spermatozoa, seminal plasma stripped
of spermatozoa and a combination of both have all been
implicated (Howe and Black, 1963; Mattner, 1968). Finally,
heat stable enhancers of neutrophil chemotaxis identified in
human semen have not been fully characterized and their role,
© European Society of Human Reproduction and Embryology
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if any, in initiating leukocytosis remains uncertain (Clarke and
Klebanoff, 1976).
The host responses elicited by seminal plasma are therefore
highly complex and potentially conflicting. This study initially
investigated the effect of seminal plasma extracts on cytokine
release by human cervical explants. The pro-inflammatory
cytokine studied was the neutrophil chemotactic factor inter-
leukin-8 (IL-8) and the anti-inflammatory cytokines were
secretory leukocyte protease inhibitor (SLPI), an inhibitor of
neutrophil function and IL-10. These responses were further
characterized by examining the effect of whole seminal plasma,
a seminal plasma extract, PGE2 and 19-hydroxy PGE on




Pooled human seminal plasma was obtained from healthy young men
involved in the ongoing semen donor programme (more than 20
men). Cervical biopsies, ~20-35 mg in weight, 15-20 mm in length
and 2-3 mm in diameter, were obtained from healthy, non-pregnant
women (n =15, ages 29-45) with regular menstrual cycles undergoing
a hysterectomy for a non-malignant condition. These were taken
from the anterior lip of the cervix immediately post-hysterectomy.
Peripheral blood was taken using a Li-heparin tube (Monovette,
Sarstedt, Amsterdam, Holland) from healthy non-pregnant women
(n = 6, aged 20-35 years) with normal menstrual cycles not using
any hormonal form of contraception. The women were at various
stages of the menstrual cycle. Ethical approval was obtained for these
studies from the Local Ethics Committee.
Preparation of seminal plasma fraction (SPF)
All reagents were from Sigma (Poole, UK), unless otherwise stated.
Human seminal plasma (700 ml) was treated with ethanol (1000 ml)
and centrifuged at 4°C for 20 min at 1500 g. The supernatant was
evaporated at 23°C to a final volume of 450 ml then passed through
ENV + extraction columns (International Sorbent Technology Ltd.,
YstradMynach, Hengoed, UK) which had previously been washed
with 1:1 ethanol/hexfluoropropanol (HFP; Aldrich. Poole, UK). Lipid
was eluted with 1:1 ethanol/HFP and the liquid evaporated at 23°C
to 10 ml. Chloroform (15 ml; Merck, Poole, UK) was added to leach
the residue and the chloroform layer evaporated and redissolved in
ethanol (4 ml) to give the seminal plasma fraction. PGE2 and
19-hydroxy PGE were assayed as described below. The seminal
plasma fraction contained 165 pg/ml PGE2 and 705 |ig/ml 19-hydroxy
PGE. The lipid extraction of the seminal plasma removes the majority
of the polyamines such as spermine and spermidine which may have
cytotoxic effects (Allen and Roberts, 1986).
Tissue culture
Cervical biopsies
Cervical biopsies were placed immediately in Roswell Park Memorial
Institute (RPMI) 1640 medium at 4°C for transport. Explants were
washed in phosphate-buffered saline (PBS), dissected into small
pieces 1-2 mm3 then placed in 1 ml complete medium (RPMI 1640
supplemented with 10% fetal calf serum (FCS); 2 mM L-glutamine;
50 pg/ml streptomycin, Gibco, Paisley, UK; 20 pg/ml gentamicin
and 50 IU/ml penicillin) in a 24-well plate (Costar, High Wycombe,
UK). Explants were treated in quadruplicate with seminal plasma
fraction diluted 1:2000 then cultured for 24 h at 37°C in 95% air and
5% carbon dioxide under humid conditions. The harvested media
were frozen at -20°C until analysed.
Peripheral blood
Peripheral blood was diluted immediately 1:10 in RPMI 1640 prior
to plating out at 1 ml/well and culturing for 24 h at 37°C in 5% C02.
Media were stored at -20°C until analysis.
U937 cells
U937 cells, a human pro-monocytic cell line, were plated out at
2X105 cells/ml in complete media, treated with whole seminal plasma
(1-0.0001%), seminal plasma fraction (1-0.0001%), PGE2 (10"6 to
10~10 M) and 19-hydroxy PGE (Cayman Chemicals, Ann. Arbor,
Michigan, USA; 10"6 to 10"'° M) at the time of addition. In addition,
cells were treated with 10~7 M phorbol ester (PMA) for the IL-10
experiments because no IL-10 was released from cells without PMA
treatment. U937 cells were cultured for 24 h at 37°C in 5%




IL-8 was measured by enzyme-linked immunosorbent assay (ELISA)
using matched pairs of capture and biotinylated-labelled detection
antibodies for IL-8 (R&D Detection Systems, Oxford, UK) as
described in detail previously (Denison et al., 1997). The highest
concentration of standard was 500 pg/ml, the intra- and inter-assay
precision was 9.1% relative standard deviations (r.s.d) and 11% r.s.d.
respectively; the detection limit of the assay was 15 pg/ml.
Secretory leukocyte protease inhibitor (SLPI) assay
SLPI was measured by a competitive ELISA. Plates (96-well; Nunc
Maxi Sorp; Gibco) were coated with recombinant SLPI (R&D
Detection Systems; 0.025 pg/ml in PBS/1% carbonate buffer; 400 ntM
NaHC03, 40 mM Na2C03 in 500 ml distilled H20, pH 9.6) at 300
pl/well for 60 min at 23°C, blocked with milk powder (0.1 mg/ml in
distilled water) at 400 pl/well for 30 min at 23°C then washed (150
mM NaCl, 100 mM Tris, 0.05% Tween-20 to final pH of 7-7.5).
ELISA assay buffer (150 mM NaCl; 100 mM Tris; 50 mM Phenol
Red solution; 2 mM EDTA; 1 mM 2-methylisothiazolone, Boehringer
Mannheim, Lewes, UK; 1 mM bromonitrodioxane, Boehringer
Mannheim; 2 mg/ml bovine serum albumin; 0.05% Tween-20 to
final pH of 7.2) was added for the non-specific binding (NSB) in
singleton at 250 pl/well. Recombinant standards (R&D Detection
Systems; highest concentration 50 ng/ml) and samples were added at
200 pl/well and anti-SLPl (polyclonal anti-SLPI. R&D Detection
Systems; 2 pg/ml in ELISA buffer) added at 50 pl/well to all wells
except the NSB. Plates were incubated for 120 min at 23°C on an
orbital shaker then washed and anti-sheep/goat immunoglobulin
(Ig)G-peroxidase Fab fragments (Boehringer Mannheim; diluted
1:500 in ELISA buffer) added at 100 pl/well. Finally, plates were
incubated for 120 min at 23°C on an orbital shaker, washed and
substrate (0.3 g/1 urea-hydrogen peroxide; 0.1 g/1 tetramethyl benzidine
in 100 mM sodium acetate, pH 6.0) added at 200 pl/well for 10 min
prior to quenching with 2 N H2S04 at 50 pl/well. Absorption was
read at 450 nm within 30 min of quenching. The correlation between
the results from this assay and those obtained by a commercial assay
(,n = 10; R&D Detection Systems) was 0.85. The intra- and inter-
assay precision was 9.2% r.s.d and 10.1% r.s.d respectively, and the
detection limit of the assay was 9.8 pg/ml.
IL-10 assay
All dilutions were in 10% FCS in PBS unless otherwise stated. Plates
were coated with capture antibody (Pharmingen, San Diego, USA;
200 ng/ml in PBS) added at 100 pl/well for 60 min at 23°C then
blocked (10% FCS in PBS) at 300 pl/well for a further 60 min at
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23°C. The plates were then washed and both samples and recombinant
standards (Pharmingen) added at 100 pl/well with the top standard
being 500 pg/ml. Plates were then incubated on an orbital shaker for
60 min, washed, detection antibody (Pharmingen; 125 ng/ml) added
at 100 pl/well and incubated for 60 min at 23°C. After a further
wash, polyperoxidase (CLB laboratories, Amsterdam, Holland; 1 ng/
ml in ELISA buffer without Tween) was added at 100 pl/well for 30
min. Finally, plates were washed and read as for SLPI. The intra-
and inter-assay precision was 6.4% r.s.d and 10.1% r.s.d respectively,
and the detection limit of the assay was 15 pg/ml.
PGE2 ELISA
Samples were treated 1:1 with methyloximating solution (0.1 M
methoxyamine hydrochloride in 10% ethanol diluted in 1 M sodium
acetate, pH 5.6) overnight at 4°C. Plates (Costar Amine-binding
plates, Paisley, UK) were coated with donkey anti-rabbit (DAR serum;
Scottish Antibody Production Unit, Carluke, UK) using the direct y-
globulin binding procedure. Briefly, they were coated with rabbit IgG
(1 mg/ml diluted in PBS/1% carbonate buffer, pH 9.6) at 200 pl/well
for 16 h at 4°C, the solution flicked out and blocking solution (50
mM glycine; bovine serum albumin 10 mg/ml Sigma-A7888 in
distilled H20) added at 250 pl/well for 120 min at 23°C. They were
then washed, DAR serum added at 150 pl/well, incubated for 16 h
at 4°C then washed, air-dried and stored with a desiccant at 4°C.
The assay used a PGE-biotin link as a pro-label. To prepare the
link, 0.06 M synthetic PGE2 (kind gift of Applied Therapeutics,
Paisley, UK) was added to 320 pi dry dimethylformamide (DMF;
Aldrich, Poole, UK), the solution cooled to 4°C and 6 pi tributylamine
(Aldrich) and 3 pi butylchloroformate (Aldrich) were added with
stirring for 30 min at 4°C. Next 0.05 M biocytin, in 300 pi 1:1 DMF/
distilled H20 was added and the vial left at 4°C for 30 min then at
23°C for 30 min. Finally, the solution was ether extracted and purified
by reverse phase chromatography. Rabbit anti-sera were raised against
PGE2 complexed to keyhole limpet haeinocyanin and have been
previously characterized (Kelly et al., 1989). Samples and synthetic
standards (Applied Therapeutics, Paisley, UK; highest concentration
5120 pg/ml) were added in duplicate at 100 pl/well, link (1 in
1.5X106) at 50 pl/well and anti-sera (1 in 50 000) at 50 pl/well to
all wells except the NSB. The final concentration of methyloximating
solution in standards and samples was 12.5%. Plates were incubated
at 4°C for 16 h. washed and 100 pl/well of 0.2 IU/ml streptavidin
peroxidase (Boerhringer Mannheim) added. The plates were then
incubated for 20 min at 23°C on an orbital shaker, washed, substrate
added and plates read as for SLPI. The intra- and inter-assay
coefficients of variation were 7.8% and 15.0% respectively and the
ED50 was 195 pg/ml.
19-hydroxy PGE assay
The plates and anti-sera were prepared as described above. 19-
hydroxy PGE standards containing equal amounts of 19-hydroxy
PGE, and 19-hydroxy PGE2 were prepared as follows. Human
seminal plasma (65 ml) was centrifuged at 4°C for 15 min at 1000
g, mixed with acetonitrile (Merck; 65 ml), centrifuged at 4°C for 15
min at 2000 g prior to freeze-drying the supernatant overnight. The
residue was leached with methanol, evaporated, added to a silica
column and the prostaglandins (PGE2 and 19-hydroxy PGE) were
eluted with increasing concentrations of methanol (Merck) in methyl
formate (Merck). The fractions were analysed by thin layer chromato¬
graphy and that corresponding to the 19-hydroxy PGE fraction was
quantified, using crystalline synthetic PGE2 as a standard, by treatment
with 0.05 M NaOH and measurement of UV absorption at 280 nm
in ethanol. To prepare the link, ~1 mg 19-hydroxy PGE was added
to 200 pi dry DMF, the solution cooled to 4°C and 3 pi tributylamine
and 1.5 pi butylchloroformate were added with stirring for 30 min
at 4°C. Finally, 12 mM Pro-Gly-Tyr-Biotin (synthesized in house) in
300 pi 1:1 DMF/distilled H20 was added and the solution extracted
as described above. Standards (5120-78 pg/ml), link (1:20 000) and
anti-sera (1:20 000) were diluted in EUISA buffer without Tween
and the assay set up as for PGE2. The intra-assay coefficient of
variation was 8.46% and the ED50 was 196 pg/ml.
Statistical analysis
Statistical analysis of the data was performed using Statview 4.1
(Abacus Inc, Berkeley, CA, USA). The data were normally distributed
and are expressed as pg/ml (mean ± SEM) with a statistically
significant difference defined as P < 0.05.
Results
Cervical explants
Seminal plasma fraction significantly stimulated (P < 0.005)
IL-8 and inhibited (P < 0.005) SLPI release (Figure 1; n =
15 different women, treatments in quadruplicate). IL-10 release
was below the detection limit of the assay employed. Pure
seminal plasma was not used to treat cervical explants due
to possible immunological interactions between tissues and
cytotoxic effects. Cervical biopsies are scarce and difficult to
obtain. Hence the experiments performed were limited and
insufficient explants were obtained to treat with PGE2 and 19-
hydroxy PGE.
Peripheral blood data
Whole seminal plasma significantly (P < 0.05) inhibited IL-
8 release at concentrations of >0.1%. Maximum inhibition of
IL-8 release down to 8% of control values (P < 0.005) was



















Control Seminal plasma fraction
1: 2000
Figure 1. Effect of seminal plasma fraction on interleukin (IL)-8
and secretory leukocyte protease inhibitor (SLPI) release from
non-pregnant cervical explants (n = 15 different women, treatments
in quadruplicate). IL-8 release was significantly stimulated and
SLPI release significantly inhibited by seminal plasma fraction at
1:2000. Values are expressed as cytokine release as percentage of
control ± SEM. **Results are significantly different (P < 0.005).
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Figure 2. The effect of seminal plasma and seminal plasma
fraction on interleukin (IL)-8 release from peripheral blood (typical
of six separate experiments, treatments in quadruplicate). IL-8
release was significantly stimulated by the seminal plasma fraction
whereas seminal plasma significantly inhibited IL-8 release. Values
are expressed as the log of IL-8 release as percentage of control ±
SEM. Significantly different from control; *P < 0.05; **P <
0.005.
seminal plasma fraction significantly (P < 0.05) stimulated
IL-8 release when used at 0.001% with a 10-fold stimulation
achieved when peripheral blood was cultured with 0.1 %
seminal plasma fraction A (P < 0.005; Figure 2; n = 6
separate experiments, treatments in quadruplicate). Both PGE2
and 19-hydroxy PGE significantly stimulated (P < 0.05; P <
0.005 respectively) IL-8 release with maximal stimulation
achieved at 10"6 M. 19-hydroxy PGE was significantly (P <
0.05) more effective in stimulating IL-8 release than PGE2 at
concentrations of >10~8 M (Figure 3; n = 6 separate experi¬
ments, treatments in quadruplicate). SLPI release was below
the detection limit of the assay used.
U937 monocyte cell line
Seminal plasma and seminal plasma fraction significantly (both
P < 0.005) stimulated IL-8 release from U937 cells cultured
without PMA by comparable amounts with maximum stimula¬
tion at 0.1% (Figure 4; n = 6 separate experiments, treatments
in quadruplicate). PGE2 significantly (P < 0.05) stimulated
IL-8 release from U937 cells with maximum stimulation at
10-6 M. 19-hydroxy PGE also stimulated (P < 0.005) IL-8
release and as demonstrated in peripheral blood it was signific¬
antly (P < 0.05) more effective in inducing IL-8 release than
PGE2 (Figure 5; n = 6 separate experiments, treatments in
quadruplicate). SLPI release was not detectable from U937
cells.
Seminal plasma and seminal plasma fraction significantly
stimulated (P < 0.05) IL-10 release from U937 cells with
maximum stimulation at 0.1 and 0.01% respectively, for
seminal plasma and fraction (Figure 6; n = 6 separate
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Figure 3. The effect of prostaglandin E2 (PGE2) and 19-hydroxy
PGE on interleukin (IL)-8 release from peripheral blood (typical of
six separate experiments, treatments in quadruplicate). IL-8 release
was significantly stimulated by both PGE2 and 19-hydroxy PGE. At
concentrations of >10~8 M, 19-hydroxy PGE was significantly (P
< 0.005) more effective in stimulating IL-8 release than PGE2.
Values are expressed as IL-8 release as percentage of control ±
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Figure 4. The effect of seminal plasma and seminal plasma
fraction on interleukin (IL)-8 release from U937 cells (typical of
six separate experiments, treatments in quadruplicate). IL-8 release
was significantly stimulated by both seminal plasma and seminal
plasma fraction. Values are expressed as IL-8 release as a
percentage of control ± SEM. Significance of difference from
control; **P < 0.005.
fraction inhibited secretion of IL-10 back to control values
when added at 0.1%. PGE2 significantly (P < 0.05) stimulated







Figure 5. The effect of prostaglandin E2 (PGE2) and 19-hydroxy
PGE on interleukin (ILl-8 release from U937 cells (typical of six
separate experiments, treatments in quadruplicate). IL-8 release was
significantly stimulated by both PGE2 and 19-hydroxy PGE. 19-
hydroxy PGE was significantly (P < 0.005) more effective in
stimulating IL-8 release than PGE2. Values are expressed as IL-8
release as a percentage of control ± SEM. Significance of
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Figure 7. The effect of prostaglandin E2 (PGE2) and 19-hydroxy
PGE on interleukin (IL)-10 release from U937 cells (typical of six
separate experiments, treatments in quadruplicate). PGE2
significantly stimulated 1L-10 release from U937 cells. 19-hydroxy
PGE stimulated IL-10 release but this failed to reach significance.
Values are expressed as IL-10 release as a percentage of control ±




Figure 6. The effect of seminal plasma and seminal plasma
fraction on interleukin (IL)-10 release from U937 cells (typical of
n = 6 separate experiments, treatments in quadruplicate). Seminal
plasma significantly (P < 0.05) stimulated IL-10 release from
U937 cells. Seminal plasma fraction significantly (P < 0.05)
stimulated IL-10 release at 0.001 and 0.01%, but inhibited its
release back to control values at 0.1%. Values are expressed as
IL-10 release as a percentage of control ± SEM. Significance of
difference from control; *P < 0.05.
I0"6 M. Although 19-hydroxy PGE also stimulated IL-10
release this failed to reach significance (Figure 7; n = 6
separate experiments, treatments in quadruplicate).
Discussion
In this study, it is reported for the first time that seminal
plasma and its principal constituent prostaglandins, PGE2 and
19-hydroxy PGE stimulated IL-8 release from peripheral blood
and the monocyte cell line U937. Moreover, 19-hydroxy PGE
was significantly more potent than PGE2 in inducing IL-8
release. In addition, seminal plasma extracts were effective in
stimulating IL-8 release from cultured cervical explants. It
was also demonstrated that IL-10 release was stimulated in
U937 cells by seminal plasma, seminal plasma fractions, PGE
and 19-hydroxy PGE, although the latter was not significant.
This confirms previous data (Kelly et al., 1997) which showed
stimulation of IL-10 release from lipopolysaccharide-stimu-
lated whole blood under similar conditions.
Human seminal plasma contains very high concentrations
of PGE2 (Samuelsson, 1963) and 19-hydroxy PGE (Taylor and
Kelly, 1974) which are mainly synthesized de novo within the
seminal vesicles (Pourian et al., 1995). Seminal plasma PGE2
acts primarily to suppress the female genital tract immune
system thus conferring a survival advantage to spermatozoa
within the hostile female reproductive tract (Kelly and
Critchley, 1997). In addition to altering the ratio of IL-10 to
IL-12 release, it also reduces expression of the T-cell co-
stimulator ligands B7-1 and B7-2 required for normal T-cells
activation and antigen recognition (Iglesias et al., 1997). In
contrast, in other situations, PGE2 can act as a potent pro¬
inflammatory agent by virtue of its vasodilatory properties.
Within human skin it synergizes with the neutrophil chemotac-
tic and activating agent IL-8 to promote neutrophil chemotaxis
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fibroblasts PGE2 stimulates IL-8 release (Agro et al., 1996).
Whether seminal plasma PGE2 is capable of inducing a pro¬
inflammatory response either within semen or the female
genital tract is not known. Elevated concentrations of IL-8
within seminal plasma are, however, associated with leukocyto-
spermia, a condition characterized by abnormally high concen¬
trations of pro-inflammatory leukocytes in seminal plasma
(Shimoya et al., 1993).
Less is known about the function of 19-hydroxy PGE2
within seminal plasma although, like PGE2 it is thought to act
principally as an immunosuppressive agent inhibiting natural
killer cell activity (Tarter et al., 1986) and elevating concentra¬
tions of cAMP (Kelly et al., 1994). Despite the fact that 19-
hydroxy PGE is a less potent immunosuppressive agent than
PGE2 in vitro, its three-fold higher concentrations within
seminal plasma may confer on it greater immunosuppressive
activity in vivo. In addition, 19-hydroxy PGE is a relatively
selective cAMP prostaglandine (EP)-2 receptor agonist (Wood¬
ward et al., 1993) unlike PGE2 which binds to all of the EP
receptors. Given that the primate cervix contains mainly EP-
2 receptors (Smith et al., 1998) then the higher affinity of 19-
hydroxy PGE for the EP-2 receptor may make it even more
active in vivo. A pro-inflammatory effect for 19-hydroxy PGE
has not been demonstrated previously.
These results demonstrate that seminal plasma and its
component prostaglandins stimulate IL-8 release. The only
exception to this was in peripheral blood where whole semen
inhibited IL-8. However, seminal plasma is a potent stimulator
of IL-10 release in peripheral blood and given that there is
mutual repression between release of IL-10 and IL-8 (Lu et al.,
1995; Kang et al., 1998) then the high concentrations of IL-10
generated may have inhibited IL-8 release. In addition, other
factors within seminal plasma may also affect IL-8 release in
peripheral blood preparations. We therefore suggest that PGE2
and 19-hydroxy PGE, by stimulating IL-8 release from the
female genital tract mucosa, may act as potent neutrophil
leukoattractants within seminal plasma. Neutrophils invading
into the upper vaginal tract, cervical mucus and stroma would
then be ideally placed to phagocytose any spermatozoon not
involved in fertilization. In addition, 19-hydroxy PGE may be
useful in inducing cervical ripening at term, given that IL-8
induces tissue remodelling (Chwalisz et al., 1994).
It has been suggested that pure seminal plasma stripped of
spermatozoa is not capable of leukocytosis and therefore the
hypothesis proposed would be invalid. The published data are
however conflicting and this may be due to different methods
of collecting and purifying the seminal plasma and the age of
the semen used for the studies. In addition, pure spermatozoa
washed of seminal plasma have also been reported to induce
leukocytosis (Thompson et al., 1992). However, washing
spermatazoa may induce alterations in membrane structure
including lipid peroxidation generating oxygen free radicles
and leukotrienes both of which are chemotactic for neutrophils
(Krauss et al., 1994; Wizemann and Laskin, 1994). This could
account for the observed leukocytosis post insemination of pure
spermatozoa. It is likely therefore that in vivo a combination of
seminal plasma constituents such as PGE2, 19-hydroxy PGE
and spermatozoa would act together to induce leukocytosis.
In this study, we have also demonstrated that seminal plasma
and its constituent prostaglandins stimulate release of IL-10
from U937 cells, thus supporting earlier data (Kelly et al.,
1997) with PGE2 being more effective than 19-hydroxy PGE
in stimulating IL-10 release. This immunosuppressive action of
seminal plasma may seem to conflict with the pro-inflammatory
effect of stimulating IL-8 release. However, IL-8 is also a
potent chemotactic factor for T-lymphocytes (Taub et al.,
1996). It could therefore induce their entry into the upper
vaginal tract where they could be presented with antigen in
the presence of high concentrations of immunomodulatory
agents such as IL-10, PGE2 and TGF-J3 which would all favour
development of anergy (Groux et al., 1996; Tremellen et al.,
1998). In addition, seminal plasma prostaglandins could be
transported to draining lymph nodes together with foreign cells
(Ibata et al.. 1997). These nodes enlarge post-coitus (Alexander
and Anderson, 1987) and could be a further site of IL-10
mediated immunosuppression.
In conclusion, it has been demonstrated that seminal plasma
prostaglandins can induce release of both pro-and anti¬
inflammatory cytokines. Moreover, PGE2 and 19-hydroxy PGE
have differing capacities to induce anti- and pro-inflammatory
cytokine release respectively. We suggest that these observa¬
tions are not mutually exclusive and that the different cytokines
released may act in combination initially to promote sperm
survival, and then to facilitate their removal from the female
reproductive tract.
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Monocyte chemotactic protein-1 (MCP-1) and interleukin-8
(IL-8) are important chemokines which effect the chemo-
taxis of monocytes and neutrophils, respectively. There is
increasing evidence that such chemokines play an integral
role in the control and maintenance of a normal pregnancy
from implantation to parturition. However, little is known
about the sites of secretion and function of MCP-1 and
IL-8 in particular with respect to establishment of the
placenta and membranes during first trimester. The aim
of this study was therefore to investigate the concentrations
and localization of MCP-1 and IL-8 in amniotic fluid
and extra-embryonic coelomic fluid (EECF) collected by
ultrasound-guided needle aspiration and maternal serum
during the first trimester of pregnancy. Using specific
enzyme-linked immunosorbent assays, MCP-1 was present
at high concentrations in the EECF, significantly higher
than those in amniotic fluid and maternal serum. IL-8 was
also present predominantly in the EECF with concentra¬
tions being significantly higher than the low values detected
in maternal serum and the very low amounts found in
amniotic fluid. This strict compartmentalization of these
cytokines in the fluid compartments of early pregnancy
may be important for establishment and development of a
viable pregnancy.
Key words: amniotic fluid/extra-embryonic coelom/first tri-
mester/interleukin-8/monocyte chemotactic peptide-1
Introduction
Monocyte chemotactic protein-1 (MCP-1) and interleukin-8
(IL-8) are chemokines whose principal role is in effecting
leukocyte chemotaxis. MCP-1, a 76-amino acid protein, is a
member of the CC class of chemokines which are monocyte
chemoattractants in which the first two conserved cysteine (C)
residues in the molecule are adjacent. IL-8 is a 72-amino acid
molecule and a member of the CXC class of chemokines
which attract neutrophils and in which the first two cysteines
are separated by an intervening amino acid residue.
The control and regulation of many reproductive processes
is dependent on a delicate balance between immune and
endocrine systems. Cytokines, acting as local effectors are
thought to play pivotal roles in this regulation. MCP-1 is
released by many reproductive tissues including the endo¬
metrium (Arici et al., 1995) and ovarian follicles (Arici et al.,
1997). Although its presence and role in early fetal development
and pregnancy has not been defined, significantly higher levels
of MCP-1 are released from peripheral blood monocytes from
pregnant compared with non-pregnant women (Denison et al.,
1997). During pregnancy, IL-8 is produced by tissues including
the placenta (Shimoya et al., 1992), cervix (Barclay et al.,
1993) and myometrium (Osmers et al., 1995). In amniotic
fluid, IL-8 is not detectable during the second trimester or at
term not in labour but is present in significant amounts at
preterm and term labour (Romero et al., 1991).
During the first trimester, the human embryo is surrounded
by two fluid-filled compartments, the amniotic fluid cavity and
the extra-embryonic coelomic fluid (EECF) cavity which also
contains the yolk sac. The composition of amniotic fluid and
EECF differs considerably in hormonal, biochemical, protein
and enzymic composition (Jauniaux et al., 1993; Docherty
etal., 1996; Miell etal., 1997), although the specific role of each
compartment in early fetal development remains uncertain. In
addition, the potential for transfer between maternal serum
and fetal compartments is site- and gestational age-dependent
(Jauniaux et al., 1996). The yolk sac, which is connected with
the midgut of the developing fetus via the vitelline duct, is
obliterated along with the extra-embryonic coelom by the
expansion of the amniotic cavity at the end of the first trimester.
Little is known about the function of the yolk sac.
The purpose of this study was to determine the pattern of
secretion and possible sources of MCP-1 and IL-8 during the
first trimester. With the advent of modern ultrasound scans,
study of these compartments is now possible by selective
aspiration of fluid (Wathen et al., 1991). Specifically we
wanted to establish whether these chemokines could have
potential roles in the establishment and maintenance of preg¬
nancy and in the early development of the fetus and placenta.
Materials and methods
Collection of samples
Amniotic and EECF were collected by transvaginal ultrasound-guided
needle aspiration between 8-11 weeks of gestation prior to the elective
termination of a normal pregnancy under general anaesthesia, as
described in detail previously (Wathen et al., 1991). Women with
2292 © European Society for Human Reproduction and Embryology
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vaginal bleeding or uncertain menstrual dates, were excluded from
the study. Fetal viability and gestational age were confirmed by
ultrasonic identification of the fetal heart and by measurement of
crown-rump length. Maternal serum was collected before anaesthesia
and all samples were stored at -20°C prior to immunoassay. These
protocols were approved by the Ethics Committee, St Bartholomew's
Hospital and informed written consent was obtained from patients.
Assay for MCP-1
MCP-1 was measured by enzyme-linked immunosorbent assays
(ELISA) using a peroxidase-labelled Fab fragment of an antibody to
MCP-1 as previously described (Ida et al., 1994). All reagents were
from Sigma, Poole, UK, unless otherwise stated. Briefly, plates were
coated overnight at 4°C with 100 pl/well of MCP-1 capture antibody
(4 mg/ml in phosphate-buffered saline; Toray Industries, Inc., Tokyo,
Japan). Next, they were washed once in tap water and coating solution
added (2% polyvinyl pyrrollidone, 5 mg/ml BSA, 5 mM EDTA,
50 mM Tris) at 100 pl/well for 30 min. Plates were air-dried and
stored with a desiccant at 4°C. Samples were diluted 1:1 in ELISA
buffer [100 mM Tris, 100 mM 2-methylisothizolone (Boehringer
Mannheim, Germany), 100 mM bromonitrodioxane (Boehringer
Mannheim), 2 mg/ml BSA, 50 mM phenol red solution, 150 mM
NaCl, 2 mM EDTA, 0.05% Tween 20, to final pH of 7.2] and added
at 100 |il/weU. Recombinant standards (Toray Industries, Inc.) were
diluted in ELISA buffer and added at 100 pl/well with the top
standard being 500 pg/ml. The plates were incubated for a minimum
of 3 h at 23°C on an orbital plate shaker. Plates were washed (0.05%
Tween-20, 150 mM NaCl, 100 mM Tris to final pH of 7-7.5)
and peroxidase-coupled detection antibody (diluted 1:200 in ELISA
buffer) was added at 100 pl/well. Plates were incubated for 45 min
at 23 °C on an orbital shaker, washed and substrate added at
200 pl/well [0.3 g/1 urea-hydrogen peroxide, 0.1 g/1 tetramethyl
benzidine (Aldrich, Gillingham, UK) in 100 mM sodium acetate, pH
6.0] for 20 min prior to quenching with 1 M H2SO4 at 50 pl/well.
Absorption was read at 450 nm within 30 min of quenching. Serial
dilutions of amniotic fluid, maternal serum and EECF gave a dose-
response curve parallel to that of immunopurified standard (data not
shown). The intra- and interassay precisions were 6.3% and 8.6%
respectively and the detection limit of the assay was 15 pg/ml.
Assay for IL-8
IL-8 was measured by ELISA utilizing matched pairs of capture and
biotinylated labelled detection antibodies for IL-8 (R&D detection
system, Oxford, UK). Briefly, plates were coated overnight at 4°C
with capture antibody added at 100 pl/well, washed once in water,
and coating solution added at 100 pl/well for 30 min at 23°C. The
coating solution was removed and the plates stored as for MCP-1.
Before use, the plates were washed once in water. All samples were
diluted 1:1 in ELISA buffer. Recombinant standards (Toray Industries,
Inc.) were diluted in ELISA buffer (500 pg/ml highest standard) and
100 pi of sample and standard were added per well. Plates were
incubated for at least 3 h at 23°C on an orbital shaker, washed as
above, detection antibody (30 ng/ml in ELISA buffer) added at
100 pl/well and incubated on a shaker for 45 min at 23°C. After a
further wash, streptavidin-peroxidase (Boehringer Mannheim) was
added at 0.02 U in 100 pl/well and plates were incubated for 20 min
at 23°C on an orbital shaker. They were then washed, substrate was
added and were read as for MCP-1. Serial dilution of EECF gave a
dose-response curve parallel to that of immunopurified standard (data
not shown). The intra- and interassay precisions were 9.1% and 22%
respectively and the detection limit of the assay was 15 pg/ml.
Table I. Concentrations of monocyte chemotactic protein-1 (MCP-1) and
interleukin-8 (IL-8) in 27 matched samples of amniotic fluid, maternal
serum and extra-embryonic coelomic fluid (EECF) collected at 8-11 weeks
of pregnancy. Values are expressed as pg/ml ± SEM
Chemokine Source sample
Amniotic fluid Maternal serum EECF
(n = 27) (n = 27) (n = 27)
MCP-1 151.5 ± 31.5a 142.6 ± 15.9a 337.3 ± 40.2
IL-8 9.72 ± 6.6a,c 33.1 ± 8.2b 339.6 ± 53.8
aP < 0.0001 compared with EECF.
b.P < 0.0005 compared with EECF.
CP < 0.05 compared with maternal serum.
Statistical analysis
The data were normally distributed and statistical analyses of concen¬
trations of MCP-1 and IL-8 between and within compartments with
gestation were performed using ANOVA (Statview 4.1, Abacus Inc.,
Berkeley, CA, USA). The data are expressed as mean ± SEM; a P
value < 0.05 was considered to be statistically significant.
Results
MCP-1 was present in 27 matched samples of amniotic fluid,
maternal serum and EECF (Table I). High concentrations of
MCP-1 were present in all compartments measured, and were
significantly higher in EECF than in either amniotic fluid
(P < 0.0001) or maternal serum (P< 0.0001). There was no
correlation in concentrations of MCP-1 in any compartment
with gestational age (data not shown), though this may be due
either to the low number of samples collected in each week,
or to the short period of gestation (8-11 weeks) studied.
IL-8 was present in all compartments measured (Table I),
with concentrations in the EECF significantly higher than
those in the maternal serum (P < 0.0005) and amniotic fluid
(P < 0.0001). Moreover, significantly greater concentrations
of IL-8 were present in maternal serum compared with amniotic
fluid (P < 0.05). There was no correlation in concentrations
of IL-8 in any compartment with gestational age, as was
demonstrated with MCP-1.
Discussion
This is the first report to demonstrate the presence of MCP-1
and IL-8 in the various fluid compartments present during the
first trimester of pregnancy. The highest concentrations of both
chemokines was found in the EECF, while ratios of MCP-1
to IL-8 in amniotic fluid, maternal serum and EECF were
15:1, 4:1 and 1:1, respectively.
MCP-1 was found predominantly in the EECF which,
anatomically, is directly adjacent to the chorion, chorionic
plate, developing trophoblast and decidua. During pregnancy
it is postulated that a T-helper 1 (TH1) to TH2 shift occurs in
the maternal immune response with a TH2 or humoral response
favouring a successful outcome to pregnancy and a TH1 or
cytotoxic response an adverse outcome (Wegmann et al.,
1993). The principal function of MCP-1 is in inducing the
chemotaxis and activation of monocytes (Wuyts et al., 1994),
although recently several novel properties have been ascribed
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to it, including that of an immunological modulator, promoting
development of a TH2 type of immune response (Chensue
et al., 1995). We hypothesize that the high levels of MCP-1
in the EECF may facilitate either the occurrence of a TH2
immune response at the materno-fetal interface, or mediate
chemotaxis of macrophages in decidua or trophoblast. Both
amniotic fluid and maternal serum also contain relatively high
levels of MCP-1, suggesting that MCP-1 may be playing the
same role in these two compartments.
IL-8 was found in this study to be mainly located within
the EECF with minimal concentrations in both amniotic fluid
or maternal serum. Initially discovered as a highly specific
neutrophil chemoattractant and activator (Mukaida et al.,
1992), IL-8 is now known to have a number of other functions
including that of a T-cell chemotaxin (Baldwin et al., 1990),
mediator of vascular smooth muscle migration (Yue et al.,
1994) and an angiogenic factor (Hu et al., 1993; Yoshida
et al., 1997). How it affects angiogenesis is unknown, but IL-8
receptors were not detected on endothelial cells, suggesting an
indirect mechanism (Petzelbauer et al., 1995). Only those CXC
chemokines, such as IL-8, which have an ELR (Glu-Leu-Arg)
N-terminal motif preceding the first cysteine amino acid are
angiogenic (Strieter etal., 1995). The mechanism and mediators
of angiogenesis in the first trimester placenta are poorly
understood, although factors such as vascular endothelial
growth factor (Charnock-Jones et al., 1994) and epidermal
growth factor (John et al., 1997) have been implicated. IL-8
is released by chorion trophoblast (Kelly et al., 1992), decidua
(Saito et al., 1994) and amnion (Trautman et al., 1992) and is
localized to the perivascular cells of the placental villi during
the first trimester and at term (Elliott et al., 1998). In this
study, IL-8 was found predominantly within the EECF which
is adjacent to the chorionic plate and primary villi, both of
which are sites undergoing extensive angiogenesis. Thus, IL-8
is ideally located to act as a potent angiogenic factor and
mediator of vascular smooth muscle migration. Moreover,
hypoxia stimulates release of IL-8 (Karakurum et al., 1994)
and the hypoxic environment that exists in utero during the
first trimester (Genbacev et al., 1996), may therefore stimulate
IL-8 production.
As a coordinator of phagocytic cells, IL-8 has a role in
many inflammatory processes including infection-mediated
preterm labour (Cherouny et al., 1992), menstruation (Kelly
et al., 1994) and cervical ripening (Barclay et al., 1993;
Sennstrom et al., 1997). The mechanisms by which IL-8
mediates inflammation and cellular infiltration are not fully
understood, but recent evidence suggests that polarization of
chemokine receptors to the leading edge of migrating leuko¬
cytes may be a pivotal event (Nieto et al., 1997). Towards the
end of the first trimester the EECF is obliterated by the
expansion of the amnion which subsequently fuses with the
chorion. Little is known about the mechanism of this resorptive
process or whether inflammatory cells are recruited, but the
leukoattractant properties of IL-8 could play a role.
It has been suggested that the EECF may sequester some
biologically active substances, thus protecting the poorly
keratinized fetus when crucial organogenesis and differenti¬
ation are occurring (Docherty et al., 1996). This could explain
why the concentrations of IL-8, which mediates chemotaxis
of phagocytic cells, are negligible in amniotic fluid adjacent
to the embryo compared with those in the EECF. In addition,
given that fibroblasts secrete IL-8 and that the EECF is
surrounded by fibromesenchyme, IL-8 could be released
directly into the EECF. If MCP-1 is promoting a pregnancy-
favourable cytokine environment via a TH2 response, then
higher levels would be expected in all fluid compartments, as
was found in this study.
In summary, this study demonstrates differential concentra¬
tions of MCP-1 and IL-8 within the various fluid compartments
present during the first trimester. The role of these potent
cytokines is not established, but they may be involved in the
TH1 to TH2 shift in pregnancy and could play a role in early
fetal and placental development and cellular trafficking.
Acknowledgements
Dr F.C.Denison is supported by a Research Training Fellowship from
Action Research.
References
Arid, A., MacDonald, P.C. and Casey, M.L. (1995) Regulation of monocyte
chemotactic protein-1 gene expression in human endometrial cells in culture.
Mol. Cell. Endocrinol., 107, 189-197.
Arici, A., Oral, E„ Bukulmez, O. et al. (1997) Monocyte chemotactic protein-
1 expression in human preovulatory follicles and ovarian cells. J. Reprod.
Immunol., 32, 201-219.
Baldwin, E.T., Franklin, K.A., Appella, E. et al. (1990) Crystallization of
human interleukin-8 - a protein chemotactic for neutrophils and
lymphocytes-t. J. Biol. Chem., 265. 6851-6853.
Barclay, C.G., Brennand, J.E., Kelly, R.W. and Calder. A.A. (1993) Interleukin-
8 production by the human cervix. Am. J. Obstet. Gynecol., 169. 625-632.
Charnock-Jones, D.S., Sharkey. A.M., Boocock, C.A. et al. (1994) Vascular
endothelial growth-factor receptor localization and activation in human
trophoblast and choriocarcinoma cells. Biol. Reprod., 51, 524-530.
Chensue, S.W., Warmington, K.S., Ruth, J.H. et at. (1995) Monocyte
chemotactic protein-1 expression during schistosome egg granuloma
formation. Am. J. Pathol., 146, 130-138.
Cherouny, PH., Pankuch, G.A., Botti, J. et al. (1992) The presence of amniotic
fluid leukoattractants accurately identifies histologic chorioamnionitis and
predicts tocolytic efficacy in patients with idiopathic preterm labor. Am. J.
Obstet. Gynecol., 167. 683-688.
Denison, F.C., Kelly, R.W and Calder, A.A. (1997) Differential secretion of
chemokines from peripheral blood in pregnant compared with non-pregnant
women. J. Reprod. Immunol., 34, 225-240.
Docherty, S.M.. lies, R.K., Wathen, N. and Chard, T. (1996) The temporary
anatomical structures prominent in the first trimester may be fulfilling
exchange functions assigned to the placenta in the 2nd and 3rd trimester.
Hum. Reprod., 11. 1157-1161.
Elliot, C.L., Kelly, R.W., Critchley, H.O.D. et al. (1998) Regulation of
interleukin-8 production in the term human placenta during labour and by
anti-gestogens. Am. J. Obstet. Gynecol., in press.
Genbacev, O., Joslin, R., Damsky, C.H. et al. (1996) Hypoxia alters early
gestation human cytotrophoblast differentiation invasion in-vitro and models
the placental defects that occur in preeclampsia. J. Clin. Invest., 97, 540-550.
Hu, D.E., Hori, Y. and Fan. T.P.D. (1993) Interleukin-8 stimulates angiogenesis
in rats. Inflammation, 17. 135-143.
Ida, N., Sakurai, S. and Kawano, G. (1994) Detection of monocyte chemotactic
and activating factor (MCAF) in normal blood and urine using sensitive
ELISA. Cytokine, 6, 32-39.
Jauniaux. E., Gulbis, B.. Jurkovic, D. el al. (1993) Protein and steroid-levels
in embryonic cavities in early human pregnancy. Hum. Reprod., 8, 782-787.
Jauniaux, E., Jurkovic, D„ Lees, C. et al. (1996) In-vivo study of diazepam
transfer across the first trimester human placenta. Hum. Reprod., 11,
889-892.
2294
John, M., Rajalekshmy, T.N., Nair, B. et al. (1997) Expression of epidermal
growth factor and its receptor in gestational trophoblastic diseases. Oncology
Reports, 4, 177-182.
Karakurum, M., Shreeniwas, R., Chen, J. et al. (1994) Hypoxic induction of
interleukin-8 gene expression in human endothelial cells. J. Clin. Invest.,
93, 1564-1570.
Kelly, R.W., Leask, R. and Calder, A.A. (1992) Choriodecidual production of
interleukin-8 and mechanism of parturition. Lancet, 339, 776-777.
Kelly, R.W., lllingworth, P., Baldie, G. et al. (1994) Progesterone control of
interleukin-8 production in endometrium and chorio-decidual cells
underlines the role of the neutrophil in menstruation and parturition. Hum.
Reprod., 9, 253-258.
Miell, J.P., Jauniaux, E., Langford, K.S. et al. (1997) Insulin-like growth
factor binding protein concentration and posttranslational modification in
embryonic fluid. Mol. Hum. Reprod., 3, 343-349.
Mukaida, N., Harada, A., Yasumoto, K. and Matsushima, K. (1992) Properties
of pro-inflammatory cell type-specific leukocyte chemotactic cytokines,
interleukin 8 (11-8) and monocyte chemotactic and activating factor (mcaf).
Microbiol. Immunol., 36, 773-789.
Nieto, M., Frade, J.M.R., Sancho, D. et al. (1997) Polarization of chemokine
receptors to the leading edge during lymphocyte chemotaxis. J. Exp. Med.,
186, 153-158.
Osmers, R.G.W., Blaser, J., Kuhn, W. and Tschesche, H. (1995) Interleukin-
8 synthesis and the onset of labor. Obstet. Gynecol., 86, 223-229.
Petzelbauer, P., Watson, C.A., Pfau, S.E. and Pober, J.S. (1995) 11-8 and
angiogenesis - evidence that human endothelial cells lack receptors and do
not respond to 11-8 in-vitro. Cytokine, 7, 267-272.
Romero, R., Ceska, M., Avila, C. et al. (1991) Neutrophil attractant/activating
peptide-l/interleukin-8 in term and preterm parturition. Am. J. Obstet.
Gynecol., 165, 813-820.
Saito, S., Kasahara, T., Sakakura, S. et al. (1994) Detection and localization
of interleukin-8 mRNA and protein in human placenta and decidual tissues.
J. Reprod. Immunol., 27, 161—172.
Sennstrom, M.K.B., Brauner, A., Lu, Y. et al. (1997) Interleukin-8 is a
mediator of the final cervical ripening in humans. Eur. J. Obstet. Gynecol.
Reprod. Biol., 74, 89-92.
Shimoya, K., Matsuzaki, N., Taniguchi, T. et al. (1992) Human placenta
constitutively produces interleukin-8 during pregnancy and enhances its
production in intrauterine infection. Biol. Reprod., 47, 220-226.
Strieter, R.M., Polverini, P.J., Kunkel, S.L. et al. (1995) The functional role
of the elr motif in cxc chemokine-mediated angiogenesis. J. Biol. Chem.,
270, 27348-27357.
Trautman, M.S., Dudley, D.J., Edwin, S.S. et al. (1992) Amnion cell
biosynthesis of interleukin-8: regulation by inflammatory cytokines. J. Cell.
Physiol., 153, 38-43.
Wathen, N.C., Cass, PL., Kitau, M.J. and Chard, T. (1991) Human chorionic-
gonadotropin and alpha-fetoprotein levels in matched samples of amniotic-
fluid, extraembryonic celomic fluid, and maternal serum in the 1st trimester
of pregnancy. Prenat. Diagn., 11, 145-151.
Wegmann, T.G., Lin, H., Guilbert, L. and Mosmann, T.R. (1993) Bidirectional
cytokine interactions in the maternal-fetal relationship: is successful
pregnancy a TH2 phenomenon? Immunology Today, 14, 353-356.
Wuyts, A., Proost, P., Put, W. et al. (1994) Leukocyte recruitment by monocyte
chemotactic proteins (mcps) secreted by human phagocytes. J. Immunol.
Methods, 174, 237-247.
Yoshida, S., Ono, M., Shono, T. et al. (1997) Involvement of interleukin-8,
vascular endothelial growth factor, and basic fibroblast growth factor in
tumor necrosis factor alpha-dependent angiogenesis. Mol. Cell. Biol., 17,
4015-4023.
Yue, T.L., Wang, X., Sung, C.P et al. (1994) Interleukin-8, a mitogen and
chemoattractant for vascular smooth muscle cells. Circ. Res.. 75, 1-7.
Received on November 4, 1997; accepted on May 26, 1998
The action of prostaglandin E2 on the human cervix: Stimulation
of interleukin 8 and inhibition of secretory leukocyte protease
inhibitor
Fiona C. Denison, MD,a Andrew A. Calder, MD,a and Rodney W. Kelly, PhDb
Edinburgh, United Kingdom
OBJECTIVE: The objective of this study was to investigate regulation of inflammatory mediators implicated
in cervical ripening and to explore the mechanisms by which the clinically effective agent prostaglandin E2
may mediate cervical ripening.
STUDY DESIGN: Cervical biopsy specimens were taken from healthy, nonpregnant women undergoing a
hysterectomy for a benign nonmalignant condition and were cultured, with treatments in quadruplicate, for 24
hours in media supplemented with progesterone, dexamethasone, nitric oxide, interleukin 8, and
prostaglandin E2. Media were collected and assayed by enzyme-linked immunosorbent assay for interleukin
8, secretory leukocyte protease inhibitor, and prostaglandin E2. Ethical approval was obtained for this study
from the local ethics committee.
RESULTS: Interleukin 8 release from cervical explants was stimulated by prostaglandin E2 and nitric oxide
and inhibited by progesterone and dexamethasone. Secretory leukocyte protease inhibitor release from cer¬
vical explants was stimulated by progesterone and inhibited by prostaglandin E2. Prostaglandin E2 release
from cervical explants was stimulated by nitric oxide.
CONCLUSION: Complex interactions occur between inflammatory cytokines within the cervix; these results
further our understanding of the mechanism of cervical ripening. (Am J Obstet Gynecol 1999;180:614-20.)
Key words: Cervical ripening, interleukin 8, nitric oxide, prostaglandin E2, secretory leukocyte
protease inhibitor
Cervical ripening is the process by which the cervix
changes from a tightly closed structure designed to main¬
tain an intrauterine pregnancy to a soft, compliant organ
capable of dilating to accommodate passage of the fetus.
This process necessitates profound tissue remodeling
and is accompanied by disruption of collagen fibrils, al¬
teration in glycosaminoglycans, and edema of the cervi¬
cal stroma. Such changes within the cervix have been
likened to an inflammatory reaction1 and are accompa¬
nied by extensive neutrophil invasion of the underlying
cervical tissue.2
Progesterone appears to exert some control on cervi¬
cal ripening; progesterone withdrawal initiates cervical
softening in women throughout gestation, even though
there is no fall in peripheral serum progesterone before
cervical remodeling. The roles of local inflammatory me-
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diators in leukocyte migration and connective tissue re¬
arrangement during cervical ripening, however, are less
well defined.
A variety of mediators have been implicated in cervical
remodeling, including prostaglandin (PG) E2, inter¬
leukin (IL) 8, and more recently nitric oxide. The level
of PGE2, the most effective and widely used cervical
ripening agent in clinical practice,3 has been shown to
rise in amniotic fluid before the establishment of labor.
The mechanism of action of PGE2 is not known, al¬
though it may involve vasodilation. IL-8, a potent neu¬
trophil chemotactic and activating agent,4 is released in
vitro5 and in vivo6 by the human cervix. In animal mod¬
els progesterone inhibits IL-8 release7 and topical appli¬
cation of IL-8 has been shown to effect cervical ripening
that is morphologically identical to the physiologic
process.8 IL-8 is thought to initiate cervical ripening by
promoting neutrophil chemotaxis to and activation
within cervical stroma. Nitric oxide has quite recently
been shown to effect cervical ripening in women9 and in
animal models.10 Its mechanism of action is not fully de¬
fined but is thought to be complex, involving vasodila¬
tion, initiation of apoptosis, and induction of synthesis of
glycosaminoglycans and collagen degrading matrix met-
alloproteinases.
It is likely, however, that the highly complex process of
614
Volume 180, Number 3, Part 1
Am J Obstet Gynecol
Denison, Calder, and Kelly 615
cervical ripening will prove to involve orchestration of a
wide range of inflammatory mediators in addition to
PGE2, IL-8, and nitric oxide. One such mediator is secre¬
tory leukocyte protease inhibitor (SLPI), which is pre¬
sent in cervical mucus.11 SLPI is a potent inhibitor of
neutrophil function12 and thus might be expected to op¬
pose the action of IL-8 during inflammatory responses,
such as cervical ripening. The purpose of this study was
therefore to investigate the release and regulation of in¬
flammatory modulators (particularly by PGE2) within the
cervix, with the aim of better understanding their roles
in cervical ripening.
Material and methods
Tissue. Biopsy specimens from the anterior lip of the
cervix (approximately 20-35 mg in weight, 15-20 mm in
length, and 2-3 mm in diameter) were taken from
healthy, nonpregnant women (aged 29-45 years, n = 39
different women) with regular menstrual cycles under¬
going hysterectomy for a nonmalignant condition. All
women were white, had no underlying hormonal dys¬
function, and had not used hormonal contraception, re¬
ceived hormone replacement therapy, or received go-
nadotropin-releasing hormone antagonists in the 6
months before the operation. The women were at vari¬
ous stages of the menstrual cycle. A different set of
biopsy specimens was used for each of the studies. The
study had the approval of the local research ethics com¬
mittee.
Tissue culture. Biopsy specimens were placed immedi¬
ately in Roswell Park Memorial Institute medium 1640 at
4°C for transport. Reagents were from Sigma (Poole,
United Kingdom) unless otherwise stated. Explants were
washed in phosphate-buffered saline solution, dissected
into small pieces (1-2 mm3), and then placed in 1 ml
Roswell Park Memorial Institute medium 1640 supple¬
mented with 10% fetal calf serum, 20 pg/mL gentamicin,
50 IU/mL penicillin, 50 pg/mL streptomycin (Gibco,
Paisley, United Kingdom), and 2 mmol/L L-glutamine in
a 24-well plate (Costar, High Wycombe, United
Kingdom). Explants were treated in quadruplicate with
10-7 mol/L progesterone, 10~7 mol/L dexamethasone,
10~7 mol/L PGE2, and 50 pg/mL spermine NONOate
(Alexis Corp, Birmingham, United Kingdom) as a nitric
oxide donor before culture for 24 hours at 37°C in 95%
air and 5% carbon dioxide under humid conditions.
Medium from each explant was analyzed by enzyme-
linked immunosorbent assay (ELISA). Steroid antago¬
nism studies were performed with mifepristone. Each
harvested medium sample was then split into 2 portions,
1 ofwhich was frozen at -20°C for subsequent ELISA and
1 of which was treated 1:1 with methyloximating solution
(1 mol/L sodium acetate, pH 5.6, containing 0.1 mol/L
methoxyamine hydrochloride in 10% ethanol) overnight
at 4°C for prostaglandin assay.
ELISA
IL-8 assay. IL-8 was measured by ELISA with matched
pairs of capture and biotinylated labeled detection anti¬
bodies for IL-8, as described in detail previously.13 The
capture antibody (4 pg/mL) and detection antibody (50
pg/mL) were obtained from R&D Systems, (Oxford,
United Kingdom) and the standards (recombinant, top
standard 500 pg/ml) were a gift from Toray Industries,
Inc (Tokyo, Japan). The intra-assay and interassay preci¬
sion levels were 9.1% relative SDs and 22% relative SDs,
respectively, and the detection limit of the assay was 15
pg/mL.
SLPI assay. SLPI was measured by a competitive ELISA.
Plates (96-well Nunc Maxi Sorp Plates; Gibco) were coated
with recombinant SLPI (R&D Systems) as a solution of
0.025 pg/mL in phosphate-buffered saline solution with
1% carbonate buffer, 400 mmol/L monosodium carbon¬
ate, 40 mmol/L disodium carbonate in 500 mL distilled
water, pH 9.6) at 300 pL/well for 60 minutes at 23°C,
blocked with milk powder (diluted 1:10 in distilled water)
at 400 pL/well for 30 minutes at 23°C, then washed with
150 mmol/L sodium chloride, 100 mmol/L tris(hydroxy-
methyl)aminomethane, and 0.05% polysorbate 20 to final
pH of 7 to 7.5. ELISA assay buffer (150 mmol/L sodium
chloride, 100 mmol/L tris[hydroxymethyl]aminomethane,
50 mmol/L phenol red solution, 1 mmol/L 2-methyliso-
thiazolone [Boehringer Mannheim, Lewes, United
Kingdom], 1 mmol/L bromonitrodioxane [Boehringer
Mannheim], 2 mmol/L ethylenediaminetetraacetic acid,
2 mg/mL bovine serum albumin, and 0.05% polysorbate
20 to final pH of 7.2) was added for the nonspecific bind¬
ing in singleton at 250 pL/well. Recombinant standards
were diluted in ELISA buffer and added in triplicate at 200
pL/well from 50 ng/mL to 0.078 ng/mL and samples
were added at 200 pL/well. Anti-SLPI (recombinant, 2
pg/mL in ELISA buffer) was added at 50 pL/well to all
wells except that used for nonspecific binding. Plates were
incubated for 120 minutes at 23°C on an orbital shaker,
then washed, and antisheep goat immunoglobulin G-per-
oxidase (Boehringer Mannheim) diluted 1:500 in ELISA
buffer was added at 100 pL/well. Finally, plates were incu¬
bated for 120 minutes at 23°C on an orbital shaker and
then washed, and substrate (0.3 g/L urea-hydrogen per¬
oxide and 0.1 g/L tetramethyl benzidine in 100 mmol/L
sodium acetate, pH 6.0) was added at 200 pL/well for 10
minutes before quenching with 50 pL/well 2N sulfuric
acid. Absorption was read at 450 nm within 30 minutes of
quenching. Serial dilution of culture medium gave a dose-
response curve parallel to that of immunopurified stan¬
dard (data not shown). The correlation between the re¬
sults from this assay and those obtained by a commercial
assay (n = 10; R&D Systems) was 0.85. The intra-assay and
interassay precision levels were 9.2% relative SDs and
10.1% relative SDs, respectively, and the detection limit of
the assay was 9.8 pg/mL.
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Fig 1. A, Modulation of IL-8 release by cervical explants under different culture conditions, IL-8 was significantly in¬
hibited by 10mol/L progesterone (Prog) and 10~7 mol/L dexamethasone (Dex) and was stimulated by 10-7 mol/L
PGE2 and 10~7 mol/L nitric oxide (NO), n = 15. Statistical analyses were performed for treatment versus control; aster¬
isk, P< .05; two asterisks, P< .005; three asterisks, P< .001. Values are expressed as picograms per milligram wet weight of
tissue; error bars, SEM. B, Dose-response curve for PGE2 stimulation of IL-8 release. IL-8 is stimulated by PGE2, with
maximal stimulation at 10"6 mol/L. Typical of 3 samples. Statistical analyses were performed for treatment versus con¬
trol; asterisk, P< .05; two asterisks, P < .005. Values are expressed as picograms per milligram wet weight of tissue; error
bars, SEM. C, IL-8 release correlated positively with PGE2 concentration (r= 0.82, n = 19). Values are expressed as
picograms per milligram wet weight of tissue.
Table I. Effects of steroid antagonism on IL-8 release by cervical explants
Progesterone Dexamethasone Mifepristone
Control (10-7 mol/L) (10-7 mol/L) (10-7 mol/L)
No. 6 6 6 6
First 24 h 100 61 ±9* 53 ±3* 103 ±8
Second 24 h (10-7 mol/L mifepristone added) 100 187 ±31* 156± 13* 140 ± 27
Explants were cultured with corticosteroids for 24 hours before changing media and supplementing with 10-7 mol/L mifepristone for
a further 24 hours. Treatment with 10"7 mol/L progesterone and 10~7 mol/L dexamethasone for the first 24 hours inhibited IL-8 re¬
lease. This inhibition was antagonized by addition of mifepristone to cultures during the second 24 hours. Treatment with mifepristone
alone for 48 hours did not affect IL- 8 release. IL-8 release is expressed as a percentage of the control value and SEM.
*P< .05.
PGE2 ELISA. Plates (Amine-binding plates, Costar)
were coated with donkey antirabbit antibody by means of
the direct y-globulin binding procedure. Plates were
coated with rabbit immunoglobulin G (1 mg/mL diluted
in phosphate-buffered saline solution with 1% carbonate
buffer, pH 9.6) at 200 pL/well for 16 hours at 4°C, the so¬
lution was flicked out, and blocking solution (50
mmol/L glycine, 10 mg/ml bovine serum albumin
Sigma-A7888 in distilled water) was added at 250 pL/well
for 120 minutes at 23°C. Plates were then washed, don¬
key antirabbit serum (Scottish Antibody Production
Unit, Carluke, United Kingdom) was added at 150
pL/well, and plates were incubated for 16 hours at 4°C
before washing, air drying, and storage with a desiccant
at 4°C. To prepare the link 20 mg synthetic PGE2 (a gift
from Applied Therapeutics, Paisley, United Kingdom)
was added to 320 pL dry dimethylformamide (Aldrich,
Poole, United Kingdom), the solution was cooled to 4°C,
and 6 pL tributylamine (Aldrich) and 3 pL butylchloro-
formate (Aldrich) were added with stirring for 30 min¬
utes at 4°C. Finally, 0.05 mol/L biocytin (diluted in 300
pL 1:1 dimethylformamide/distilled water) was added
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10-7M 10-7M 1Q-7M 50gg/ml
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Fig 2. Modulation of SI.PI release by cervical explants under dif¬
ferent culture conditions. SLPI was significantly stimulated by
10-7 mol/L progesterone (Prog) and inhibited by 10-7 mol/L
PGE2. Nitric oxide (NO) at 50 gg/mL and dexamethasone at
10-7 mol/L had no effect, n = 15. Statistical analyses were per¬
formed for treatment versus control; asterisk, P< .05; two asterisks,
P < .005. Values are expressed as picograms per milligram wet
weight of tissue; error bars, SEM.
and the solution ether extracted and purified by reverse
chromatography. The rabbit antisera that were raised
against PGE2-complexed keyhole limpet hemocyanin
have been previously characterized.14 Samples and syn¬
thetic standards (Applied Therapeutics), diluted in
ELISA buffer from 5120 to 78 pg/mL, were added in du¬
plicate at 100 p.L/well. Link (diluted 1:1.5 x 10fi in ELISA
buffer) was added at 50 pi.,/well to all wells, and anti¬
serum (diluted 1:50,000 in ELISA buffer) was added at 50
pL/well to all wells except that used for nonspecific bind¬
ing. The final concentration of methyloximating solution
in standards and samples was 12.5%. Plates were incu¬
bated at 4°C for 16 hours, plates were washed and 100
pL/well of 0.2 unit/mL streptavidin peroxidase
(Boehringer Mannheim) was added. The plates were
then incubated for 20 minutes at 23°C on an orbital
shaker, plates were washed, substrate was added, and
plates were read as for SLPI. The intra-assay and interas-
say coefficients were 7.8% and 15.0%, respectively. The
median effective dose was 195 pg/mL.
Statistical analysis. Statistical analysis of concentra¬
tions of IL-8, SLPI, and PGE2 in culture media were per¬
formed with analysis of variance (Statview 4.1; Abacus
Inc, Berkeley, Calif). The Fisher protected least signifi¬
cant difference was used as a post hoc test to determine
significance. The data are expressed as mean and SEM in
picograms per milligram. P< .05 was considered to rep¬
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Fig 3. Modulation of PGE2 release by cervical explants under dif¬
ferent culture conditions. PGE2 was significantly stimulated by
50 pg/mL nitric oxide (NO). Progesterone (Prog) at 10-7 mol/L,
dexamethasone (Dex) at 10-7 mol/L, and IL-8 at 50 mg/mL had
no effect, n = 15. Statistical analyses were performed for treat¬
ment versus control; asterisk, P < .05. Values are expressed as
picograms per milligram wet weight of tissue; error bars, SEM.
Results
IL-8 release. Cervical explants released IL-8. IL-8 re¬
lease was significandy stimulated by PGE2 in a dose-de-
pendent manner, with maximal stimulation at 10-6
mol/L (P< .001; Fig 1, A and B, n = 15 and n = 3 different
women, respectively, with treatments in quadruplicate).
IL-8 release correlated with PGE2 release by cervical ex-
plants (correlation coefficient 0.82, n = 19 different
women; Fig 1,6). Nitric oxide stimulated IL-8 release (P
< .05). IL-8 release was inhibited by dexamethasone (P <
.005) and progesterone (P< .05). To assess the effect of
steroid antagonism, explants were cultured in media sup¬
plemented with 10-7 mol/L progesterone or 10-7 mol/L
dexamethasone for 24 hours before the media were
changed and supplemented with the antigestogen and
antiglucocorticoid mifepristone at 10-7 mol/L for a fur¬
ther 24 hours (n = 6 different women). IL-8 inhibition in
biopsy specimens cultured with progesterone or dexam¬
ethasone was antagonized by mifepristone. There was no
significant difference in IL-8 release between control
biopsy samples and those cultured with mifepristone for
48 hours (Table I).
SLPI release. Cervical explants release SLPI (n = 15
different women with treatments in quadruplicate). SLPI
release was stimulated by progesterone (P< .005) and in¬
hibited by PGE2 (P< .05). Nitric oxide, dexamethasone,
and IL-8 had no effect on SLPI release (Fig 2).
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Tissue remodelling
Fig 4. Hypothesis for cervical ripening at term. PGE2 stimulates
proinflammatory IL-8 and inhibits anti-inflammatory SLP1. The
proinflammatory cascade may be further enhanced by stimula¬
tion of PGE2 and IL-8 by rising nitric oxide (NO) levels and the
effect of falling progesterone on inflammatory mediators. MMP,
Matrix metalloproteinase.
PGE2 release. Cervical explants released PGE2 (n = 15
different women with treatments in quadruplicate).
PGE2 release was stimulated by nitric oxide (P < .05).
Progesterone, dexamethasone, and IL-8 had no effect on
PGE2 release (Fig 3).
Comment
These results further our understanding of the mecha¬
nism of cervical ripening by demonstrating that complex
interactions occur between inflammatory mediators
within the cervix. We demonstrated that release of IL-8
by cervical explants was significantly stimulated by nitric
oxide and PGE2 in a dose-dependent manner and was in¬
hibited by progesterone and dexamethasone. Moreover,
SLPI was released by cervical explants and this secretion
was significantly stimulated by progesterone and inhib¬
ited by PGE2. Finally, release of PGE2, the currently pre¬
ferred clinical cervical ripening agent, was stimulated by
nitric oxide, a potential new mediator of cervical ripen¬
ing.
We demonstrated that progesterone and dexametha¬
sone inhibit IL-8 and stimulate SLPI release from cervical
explants. Progesterone plays a vital role in the mainte¬
nance of pregnancy and uterine quiescence. In animals
such as sheep, a profound reduction in progesterone at
term is thought to trigger parturition. In women, al¬
though there is no peripheral fall in progesterone during
the third trimester, indirect evidence suggests that a local
reduction within the fetoplacental unit may herald the
onset of labor. Cervical ripening and labor are thought to
be coordinated at a local level by inflammatory media¬
tors, such as the neutrophil chemoattractant IL-8.
Progesterone15 and glucocorticoids inhibit transcription
of these mediators, including IL-8, through mutual re¬
pression between the steroid receptors and the relA
(p65) subunit of nuclear factor k-p (NFkB) . This factor is
involved in transcriptional regulation of many inflamma¬
tory mediators. Glucocorticoids are also known to stimu¬
late SLPI synthesis,16 although the mechanism is not fully
understood and no such effect was demonstrated in this
study. In addition, SLPI inhibits cytokine activation by
NFkB, probably by interfering with the NFtcB-relA bind¬
ing site.17
We hypothesize that a local fall in progesterone or in¬
terference with its action would stimulate IL-8 and in¬
hibit SLPI release from cervical tissue, possibly by means
of NFkB. A rise in IL-8, which has been shown to occur
during cervical ripening,6 would initiate neutrophil
chemotaxis, emigration, and activation within the cervi¬
cal stroma. SLPI is a potent inhibitor of neutrophil func¬
tion and elastase release; a fall in its levels thus would fa¬
cilitate neutrophil recruitment and activation within the
cervical stroma. The overall result would be to favor in¬
flammation and cervical ripening (Fig 4).
It is widely believed that PGE2 plays an important role
in initiating cervical ripening and labor, but its mecha¬
nisms are not fully understood. In other inflammatory
processes PGE2 is thought to act principally as a vasoac¬
tive agent, thus facilitating inflammatory cell infiltration.
In extrauterine sites, however, it also upwardly regulates
release of many inflammatory cytokines such as IL-8,18
acts synergistically with IL-8 to augment neutrophil
chemotaxis,19 and stimulates matrix metalloproteinase
release by monocytes. This last effect can be inhibited by
SLPI through inhibition of cyclooxygenase 2, the in¬
ducible form of the enzyme, and is independent of
SLPI's antiprotease activity and regulatory effects on
other cytokines. Finally, PGE2 is potentially inhibited by
progesterone, which acts through NFkB to inhibit cyclo¬
oxygenase 2 expression.
The data presented here demonstrate that in vitro
treatment of cervical explants with PGE2 has the dual ef¬
fect of stimulating IL-8 and inhibiting SLPI release. At
term, progesterone withdrawal and possible upward reg¬
ulation of NFkB would simulate PGE2, which would act
with IL-8 to promote neutrophil emigration and activa¬
tion within cervical stroma. In addition to facilitating
neutrophil and monocyte chemotaxis and activation, a
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reduction in SLPI would further increase PGE2 synthesis
through upward regulation of NFtcB-mediateu yclo-
oxygenase 2 transcription (Fig 4).
Nitric oxide is a pleiotropic, short-lived free radical gas
that mediates a wide range of physiologic processes, in¬
cluding inhibition of platelet aggregation, smooth mus¬
cle relaxation, host immunity, and inflammation.
Experimental and clinical evidence also suggests that ni¬
tric oxide plays an important role during pregnancy by
maintaining uterine quiescence and placental perfusion.
In addition, it may be involved in initiating parturition.
In the rat uterus and placenta, nitric oxide is upwardly
regulated in a gestationally dependent manner during
pregnancy and is significantly downwardly regulated be¬
fore parturition.20 Paradoxically, in the rat cervix nitric
oxide is regulated in the opposite direction, with levels
being low during pregnancy but increasing significantly
before both preterm and term parturition. This may be
explained by nitric oxide being synthesized by invading
neutrophils and monocytes. It is not known whether a
similar pattern of nitric oxide release exists in women,
but recent data suggest that uterine and placental nitric
oxide levels do not fall before parturition.21 In that study,
however, nitric oxide was measured in uteri after 37
weeks' gestation, by which time any reduction in nitric
oxide could already have occurred. Regulation of nitric
oxide synthesis is controversial, but inducible nitric oxide
synthase appears to be inhibited by progesterone22 and
glucocorticoids, possibly through NFkB. and to be stimu¬
lated by a variety of inflammatory mediators, including
IL-1 and tumor necrosis factor a. Moreover, nitric oxide,
like PGE2, plays a complex immunomodulatory role and
can induce both anti-inflammatory and proinflammatory
immune responses, with high levels such as might be ex¬
pected during cervical ripening favoring inflammation.
Nitric oxide induces cyclooxygenase 2 synthesis,23 stimu¬
lates gelatinase secretion by rat mesangial cells,24 and
stimulates elastase and IL-8 release from peripheral
blood,25 the last by a cyclic guanosine monophosphate-in-
dependent pathway.
The data presented here demonstrate that nitric oxide
stimulates both IL-8 and PGE2 release from cervical ex-
plants. Thus any fall in progesterone at term and subse¬
quent neutrophil and monocyte invasion of the cervical
stroma could produce a rise in nitric oxide through acti¬
vation of NFkB and local synthesis by invading cells.
Nitric oxide would stimulate IL-8 and elastase release
and would promote PGE2 synthesis through cyclooxyge¬
nase 2 induction, leading to a proinflammatory state and
cervical remodeling (Fig 4).
Complex interactions occur between inflammatory
mediators in vitro. We suggest that cervical ripening is
not due to a single inflammatory mediator but is the con¬
sequence of a cascade of several such agents that interact
with each other (Fig 4). Although a change in proges¬
terone or its cognate receptor may be the initiating
event, studies on progesterone receptor subtype status
and on local levels and bioavailability of progesterone at
term within the cervix need to be performed to confirm
this hypothesis. In addition, these studies were per¬
formed on nonpregnant cervical explants, which have
obvious limitations as a model for term cervical ripening,
and should be repeated with pregnant tissues to assess
whether previous steroid exposure during pregnancy af¬
fects interactions between mediators.
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Abstract
Secretory leukocyte protease inhibitor is a potent inhibitor
of neutrophil function, a mediator of mucosal immunity
and an inhibitor of NFkB regulated inflammatory
responses. However, its source, function and regulation
within the uterus during pregnancy and at parturition are
not well defined. In amniotic fluid, the concentration of
secretory leukocyte protease inhibitor increased signifi¬
cantly from 2nd trimester (24 ± 3 ng/nil; mean ± s.e.m.;
n=20) to term (751 ±53 ng/nil; P<0-05; n=15) with a
further profound increase (P<0-005) with the onset of
labour (3929 ± 1076 ng/ml; «=15). To establish the intra¬
uterine sites of secretion, explants (n=6 different patients
per tissue) were collected at term after elective caesarean
section. High levels of secretory leukocyte protease in¬
hibitor were released by decidua (135-2 ± 12-4 pg/mg;
mean ± s.e.m.) and chorio-decidua (325-1 ± 26-4 pg/mg)
with less by amnion (55-6 ± 6-0 pg/mg) and placenta
(9-2 ±1-9 pg/mg). Intense immunoreactivity for secretory
leukocyte protease inhibitor was detected predominantly
in decidua parietalis cells adherent to the chorion laeve and
myometrium, and also in decidua basalis. We propose that,
within the pregnant uterus, secretory leukocyte protease
inhibitor is released by decidua, fetal membranes and
potentially the fetal lung. The increase in secretory
leukocyte protease inhibitor may act to modulate pro¬
inflammatory paracrine interactions for the maintenance of
pregnancy and limit those occurring at parturition within
the uterus.
Journal of Endocrinology (1999) 161, 299-306
Introduction
Secretory leukocyte protease inhibitor, also known as
anti-leukoprotease inhibitor and human mucus proteinase
inhibitor, is a 12 kDa member of the chelonianin class of
serine protease inhibitors (Francart et al. 1997). The
protease inhibitory sequence has been identified in the
carboxy domain (Meckelein et al. 1991). Although initially
described as a potent inhibitor of neutrophil elastase
and cathepsin-G (Thompson & Ohlsson 1986), secretory
leukocyte protease inhibitor has many other functions,
including inhibition of mast cell kinases (Pemberton et al.
1998), as an anti-bacterial (Hiemstra et al. 1996), anti-viral
(Shine et al. 1997) and anti-fungal (Tomee et al. 1997)
agent and anti-coagulant (Masuda et al. 1995). In addition,
it has recently been shown to inhibit the release of
matrix metalloproteinases by monocytes via inhibition
of cyclo-oxygenase-2 (Zhang et al. 1997) and the
lipopolysaccharide-induced activation of the pro¬
inflammatory transcription factor, NFkB (Jin et al. 1997).
Secretory leukocyte protease inhibitor is found in mono¬
cytes and polymorphonuclear leukocytes (Ohlsson et al.
1996) and is secreted in large amounts from bronchial
epithelium (Marchand et al. 1995) and mucus-secreting
glands (Bergenfeldt et al. 1996) where it acts as an
important mediator of innate mucosal immunity.
In the uterus, secretory leukocyte protease inhibitor has
been found in the endometrium and myometrium of pigs
(Reed et al. 1998), cows and horses (Badinga et al. 1994),
with concentrations of the protein and mRNA tending to
increase during pregnancy. In women, secretory leukocyte
protease inhibitor protein has not been demonstrated
within non-pregnant endometrium or fetal membranes
but has been immunolocalised to the crypts of endo-
cervical glands in both the non-pregnant and pregnant
cervix (Helmig et al. 1995). In addition, its concentration
increases significantly within amniotic fluid during preg¬
nancy to term (Helmig et al. 1995). However, any change
in concentration with the onset of labour, its site of
secretion from uterine tissues and the potential roles of
secretory leukocyte protease inhibitor during parturition
have not been examined.
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The aims of this study were to measure the levels of
secretory leukocyte protease inhibitor in amniotic fluid
during pregnancy and labour. In addition, the sites of
production within the uterus at term have been charac¬
terised to determine the putative roles that secretory
leukocyte protease inhibitor might play in the paracrine
interactions within the uterus for the maintenance of
pregnancy and the control of parturition.
Materials and Methods
Tissue collection
Samples of amniotic fluid from the second trimester (n—20
women; 15—18 weeks) were obtained from women un¬
dergoing an amniocentesis as part of the karyotype screen¬
ing programme for Downs' Syndrome. All pregnancies
were karyotypically normal. At term, samples of amniotic
fluid were obtained from women undergoing elective
caesarean section («=15 women; >37 weeks) and after
spontaneous vaginal delivery («=15 women; >37 weeks,
uncomplicated labour, not induced). Fetal urine samples,
which were clear and not contaminated with blood, were
collected at first micturition immediately after delivery by
elective caesarean section from uncomplicated pregnancies
(«=12 neonates; >37 weeks). Fetal serum samples were
collected at term (>37 weeks) from the placental venous
^ord vein after spontaneous vaginal delivery (n=5
neonates) and emergency caesarean section (spontaneous
active labour, n—5 neonates). All samples were centrifuged
at 1000^ for 5 min and stored at — 20 °C prior to
immunoassay. Tissues used for explants were obtained
from women undergoing an elective caesarean section
at term (n=6 women; >37 weeks; not associated with
labour). For placental perfusion, placentae were collected
after spontaneous vaginal delivery at term (n—6; >37
weeks, active labour, not induced). For immunohisto-
chemistry, tissues (n=4; >37 weeks, elective caesarean;
n=4; >37 weeks, emergency caesarean section, active
labour, not induced) were fixed in 10% neutral buffered
formalin for 24 h before washing twice in 70% ethanol
prior to mounting in paraffin wax. Ethical approval for the
collection of all samples was obtained from the Lothian
Trust Ethical Committee with the informed and written
consent of patients.
Culture of explants of amnion, chorio-decidua, decidua
and placenta
Discs of amnion (12 mm diameter; wet weight 15—20 mg)
and chorio-decidua (9 mm diameter; wet weight 15—
25 mg) were prepared using a cork borer. Decidua (wet
weight 15-25 mg) was dissected off the myometrial
aspect of the posterior uterine wall from a site away from
the placental bed and pieces of villous placental tissue
dissected from the middle of a central cotyledon (wet
weight 15-30 mg). Tissues explants (four explants of each
tissue from each woman) were maintained in culture, as
described previously by this laboratory (Brennand et al.,
1995). All reagents were obtained from Sigma, Poole,
UK unless otherwise stated. Explants were placed on
absorbent capillary matting (The Fyba Pot Company
Ltd, Knottingley, UK) in a 24-well plate (Costar, High
Wycombe, UK) and maintained in complete culture
medium (RPM1 1640 with 2 mM L-glutamine, Gibco,
Paisley, UK supplemented with 10% fetal calf serum,
Gibco; 50 IU/ml penicillin, Gibco; 50pg/ml strepto¬
mycin, and insulin/transferrin/selenium, Gibco) for 24 h
at 37 °C in 95% air and 5% C02 under humid conditions
in 24 well culture plates (Costar). The harvested media
was then .frozen at — 20 °C until analysis.
Preparation and culture of amnion and chorion cells
Amnion and chorion were collected immediately after
delivery from patients undergoing elective caesarean
section at term (>37 weeks, not in labour), transported to
the laboratory in Dulbecco's phosphate buffered saline
(DPBS; Gibco) containing heparin (10 U/ml; LeoLabs
Ltd, Risborough, UK), then incubated in DPBS contain¬
ing gentamicin (80 pg/ml) and amphotericin B (5 pg/ml)
for 60 min at 23 °C. Amnion and chorion cells were
prepared for and maintained in culture adapting methods
described previously (Jones et al. 1989). Excess decidua
was scraped from the chorion laeve, and amnion and
chorion were minced, washed and incubated in digestion
medium (RPMI 1640 containing 5 mg/ml trypsin and
20 pg/ml DNAse) with mechanical agitation for 40 min at
37 °C. Dispersed cells were collected by passing through a
0T6 mm nylon mesh (Lockertex, Warrington, UK) three
times. Cells were washed in complete culture medium and
viabilities for all preparations were assessed as >90% by
trypan blue exclusion. Cells were cultured in complete
culture medium for 2—4 days. Chorion fibroblasts were
obtained by dilution of chorion trophoblast cell prep¬
arations with subsequent overgrowth of fibroblasts to
confluence within 28 days. Chorion fibroblasts were used
up to passage five. Amnion cell preparations were >95%
positive for the epithelial cell marker cytokeratin and <5%
positive to the fibroblast/mesenchyme marker vimentin;
chorion trophoblast cells preparations were >90% cyto¬
keratin positive and <5% vimentin positive and chorion
fibroblasts were >95% vimentin positive.
Dual pefusion ofplacental cotyledons
A peripheral cotyledon was selected which was macro-
scopically intact with parallel chorionic artery and vein,
cannulated and mounted in a perfusion chamber as
described previously (Schneider et al. 1972, Schneider &
Huch 1985), with minor modifications (Benediktsson et al.
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Figure 1 Dose-response relationships (B/BO) for recombinant
secretory leukocyte protease inhibitor standards and two serially
diluted amniotic fluid samples. Serial dilutions of amniotic fluid
gave dose responses parallel to that of recombinant standard.
trimester (24 ± 3 ng/ml; mean ± s.e.m.) to term not
in labour (751 ± 53 ng/ml) to term in labour (3929 ±
1076 ng/ml), with this rise being significant from second
trimester to term (P<0-05) to term in labour (P<0-005;
Fig. 2).
Secretory leukocyte protease inhibitor release from amnion,
chorion-decidua, decidua and placenta and its concentration in
cord serum and fetal urine
Amnion, chorio-decidua, decidua and placenta explants
demonstrated a distinct pattern of secretory leukocyte
protease inhibitor release with low levels being secreted
by placenta (9-2 ±1-9 pg/mg), more by amnion
(55-6 ± 6-0 pg/mg; P<0-05) and significantly higher
levels from decidua (135-2 ± 12-4 pg/mg; P<0-01) and
chorio-decidua (325-1 ± 26-4 pg/mg; P<0-005; Fig. 3).
Amnion epithelial cells, chorion trophoblast cells and
chorion fibroblasts released 613 ± 88 pg/ml/1 CP cells,
389 ± 62 pg/ml/l(P cells and 1658 ± 250 pg/ml/105
cells secretory leukocyte protease inhibitor, respectively.
Secretory leukocyte protease inhibitor was secreted into
both the maternal (7080 ± 840 pg/min) and fetal (1790 ±
230 pg/min) circulations in the perfused placental coty¬




































Figure 2 Increase in concentration of secretory leukocyte protease
inhibitor in amniotic fluid during pregnancy. The concentration
increased significantly during pregnancy from the second trimester
(n=20) to term (n=15) to term in labour (n=15). Values are
expressed as ng/ml ± s.e.m. Significance: *P<0-05, term not in
labour to second trimester; **P<0-005, term not in labour to term
in labour.
amounts being released into the maternal than fetal circu¬
lation. However, it was undetectable in all cord serum
samples (n=10) and below the detection limit of the assay in
nine out of the twelve fetal urine samples assayed, with levels
being 358 pg/ml, 320 pg/ml and 188 pg/ml, respectively in
the remaining three samples. There was no evidence of
infection or neonatal sepsis in the three neonates in which
secretory leukocyte protease inhibitor was detectable.
Immunolocalisation of secretory leukocyte protease inhibitor
within fetal membranes, decidua and placenta
Intense specific immunoreactivity for secretory leukocyte
protease inhibitor was localised to the layer of decidua
parietalis adherent to chorion trophoblast (Fig. 5A).
Similarly, intense immunostaining was present in decidua
parietalis collected from the myometrial aspect (Fig. 5B).
Only a few isolated cells, which may be fibroblasts, stained
immunopositive within the amnion and chorion tropho¬
blast, with the majority of the cells constituting these layers
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1997). The maternal and fetal compartments were per¬
fused with Kreb's solution at flow rates of 10 and 6 ml/
min, and gassed with 95% 02/5% CO, and 95% N2/5%
C02, respectively. The perfusate on the fetal side was
supplemented with dextran (20 g/1; average molecular
weight 74 kDa; Sigma Chemical Co., Poole, UK). Per¬
fusions were started within 10 min of delivery. After a
40 min equilibration period, which permitted the residual
blood to be eluted and circulatory perfusion pressures to
stabilise, consecutive 10 min samples were collected from
both maternal and fetal circuits. Samples were stored at
— 20 °C before being assayed. The integrity and viability
of each preparation were established throughout the ex¬
perimental period by ensuring that (a) the rate of perfusate
input in both the fetal and maternal circuits equalled the
rate of output, (b) there was adequate exchange of 02 from
the maternal to fetal circuits (step up pressures of >40 mm
Hg in fetal perfusate), (c) lactate concentrations remained
within the normal low range (<2 mM; Benediktsson et al.
1997), (d) at the end of the experiment a bolus of
noradrenaline induced an increase in fetal vascular resist¬
ance of >2 mm Hg and (e) subsequent microscopic
histological investigations revealed no significant morpho¬
logical changes.
Secretory leukocyte protease inhibitor assay
Secretory leukocyte protease inhibitor was measured by a
competitive enzyme linked immunosorbent assay. Plates
(96 well; Nunc Maxi-Sorp, Gibco) were coated with
recombinant human secretory leukocyte protease inhibitor
(R&D Systems, Oxford, UK; 0-025 pg/ml in PBS/1%
carbonate buffer; 400 mM NaHC03; 40 ntM Na2C03;
pH 9-6; 300 pl/well) for 60 min at 23 °C then blocked
with milk powder (0T mg/ml in H20; 400 pl/well)
for 30 min at 23 °C. Plates were then washed (150 mM
NaCl; 100 mM Tris; 0-05% Tween-20; pH 7-7-5) and
ELISA assay buffer (150 mM NaCl; 100 mM Tris;
50 mM Phenol Red solution; 2 mM EDTA; 1 mM 2-
ethylisothiazolone, Boehringer Mannheim, Lewes, UK;
1 mM bromonitrodioxane, Boehringer Mannheim; 2 mg/
ml BSA; 0-05% Tween-20 to final pH of 7-2; 250 pl/well)
added for determination of non-specific binding (NSB).
Recombinant standards (R&D Systems; highest concen¬
tration 50 ng/rnl; 200 pl/well) and samples (200 pl/well)
were added, followed by the polyclonal antibody raised in
goat against recombinant human secretory leukocyte pro¬
tease inhibitor (R&D Systems; 2 pg/nrl in ELISA buffer;
50 pl/well) and incubated for 120 min at 23 °C. Plates
were washed and anti sheep/goat IgG Fab fragments
raised in donkey conjugated to peroxidase (Boehringer
Mannheim; diluted 1:500 in ELISA buffer; 100 pi/well)
added and incubated for 120 min at 23 °C. Finally, plates
were washed again and substrate (0'3 g/1 urea-hydrogen
peroxide; 0-1 g/1 tetramethyl benzidine in 100 mM so¬
dium acetate, pH 6-0; 200 pl/well) was added prior to
quenching with 2N H2S04 (50 pl/well). Absorption was
read at 450 nm within 30 min of quenching. The mtra-
and inter-assay precisions were 9-2% relative standard
deviations (r.s.d.) and 10-1% r.s.d., respectively and the
detection limit of the assay was 9-8 pg/ml. To validate the
assay, serial dilutions of amniotic fluids were compared
with that of the recombinant standard and assay results
were compared with those obtained using a commercial
kit which uses the same antibodies (R&D Systems).
Localisation of secretory leukocyte protease inhibitor in tissues
by immunohistochemistry
Sections (5 pm) were dewaxed, rehydrated and endogenous
peroxidase quenched with H202 (1% v/v in methanol) for
30 min at 23 °C. Non-specific binding was eliminated by
pre-blocking with 10% normal donkey serum (Scottish
Antibody Production Unit, Carluke, UK) for 30 min at
37 °C. The polyclonal secretory leukocyte protease inhibi¬
tor primary antibody, previously described (R&D Sys¬
tems), was then applied (25 pg/ml in 10% normal donkey
serum) for 17 h at 4 °C. Sections were washed and specific
binding detected using an anti-sheep/goat Fab fragment
raised in donkey conjugated to peroxidase (R&D Systems)
applied for 90 min at 23 °C. This peroxidase activity was
localised using 3,3'-diaminobenzidine (Vector Labs Ltd,
Peterborough, UK) as chromagen. Sections were counter-
stained with Harris' haematoxylin, dehydrated, mounted
and visualised by light microscopy.
Statistical analysis
Statistical analysis of the data was performed using
ANOVA (Statview 4-1, Abacus Inc., Berkeley, CA,
USA). The data were normally distributed and are
expressed as pg/ml, ng/nil or pg/mg/wet weight tissue
(mean ± s.e.m.) with a statistically significant difference
defined as P<0-05.
Results
Validation of secretory leukocyte protease inhibitor assay
Serial dilutions of amniotic fluids gave dose—response
curves parallel to that of the recombinant standard (Fig. 1).
The results from this assay and those obtained by a
commercial assay (R&D Systems), which uses the same
antibodies, were very highly correlated (r=0-99, total
degrees of freedom, n=5).
Presence of secretory leukocyte protease inhibitor in
amniotic fluid
Secretory leukocyte protease inhibitor was present within
amniotic fluid in increasing concentrations from second
journal of Endocrinology (1999) 161, 299-306




























Figure 3 Release of secretory leukocyte protease inhibitor by
explants of third trimester amnion, chorio-decidua, decidua and
placenta maintained in culture for 24 h. Significantly more
secretory leukocyte protease inhibitor was released by chorio-
decidua and decidua than by placenta and amnion. Values are
expressed as pg/mg/wet weight tissue ± s.e.m.; tissues collected
from n=6 different women. Significance: *P<0 05, amnion
compared with placenta; **P<001, decidua compared with
amnion and placenta; ***P<0 005, chorio-decidua compared with
decidua, amnion and placenta.
being immunonegative (Fig. 5A). In placenta, the
decidua basalis which underlies the placenta also demon¬
strated intense specific immunoreactivity (Fig. 5C). The
extra-villous trophoblast was immunonegative, as was the
majority of the placenta apart from a small amount of
staining around the margins and within fetal blood vessels
of the villi. Substitution of the primary antibody with
normal donkey (Fig. 5D) and normal goat serum (data not
shown) resulted in absence of staining in decidua, fetal
membranes and placenta.
Discussion
We demonstrate that secretory leukocyte protease inhibi¬
tor is present in increasing concentrations within amniotic
fluid during pregnancy and further increases with the
onset of labour. Secretory leukocyte protease inhibitor































Figure 4 Release of secretory leukocyte protease inhibitor from
the dually perfused placental cotyledon. Significantly more
secretory leukocyte protease inhibitor was released into the
maternal than the fetal circulation. Values are expressed as
pg/min ± s.e.m.; n=6 placentae. Significance: *P<0-005, maternal
compared with fetal effluent.
chorio-decidua, with lower levels released by amnion
and placenta. Immunohistochemistry demonstrated cell-
specific localisation of secretory leukocyte protease
inhibitor to both decidua parietalis and basalis.
The profound increase in the concentration of secretory
leukocyte protease inhibitor within amniotic fluid after
the onset of labour is a novel finding. The presence of
secretory leukocyte protease inhibitor within amniotic
fluid during the second trimester and at term has been
previously demonstrated (Helmig et al. 1995) with the
reported values being comparable to our data. Term
amniotic fluid comprises mainly of secretions from the
surrounding fetal membranes, decidua, fetal lung and from
fetal urine (Gilbert & Brace 1993). Release of secretory
leukocyte protease inhibitor from amnion explants in vitro
was comparatively low. However, the potential release of
secretory leukocyte protease inhibitor by amnion in vivo
may be considerable, due to the large surface area of the
amniotic membrane. In addition, it has been previously
demonstrated that secretory leukocyte protease inhibitor is
present in high concentrations within tracheal aspirates
from neonates (Ohlsson et al. 1992) with levels correlating
positively with gestational age (Sluis et al. 1994). Although
we have demonstrated that fetal urine contains secretory
leukocyte protease inhibitor, it was only detectable in
one quarter of all samples tested and therefore unlikely
to account for the consistently high levels of secretory
Journal of Endocrinology (1999) 161, 299-306
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Figure 5 Localisation of secretory leukocyte protease inhibitor by immunohistochemistry in: A, Fetal membranes and adherent decidua
collected at emergency caesarean section in active labour. Intense immunostaining for secretory leukocyte protease inhibitor is localised
predominantly in decidual cells and in some cells of fibroblast morphology in chorion and amnion. Key: a=amnion; c=chorion laeve;
d=decidua parietalis adherent to the chorion; t=trophoblast cell layer of chorion. B, Decidua parietalis collected from the myometrial
aspect after emergency caesarean section in active labour with specific positive immunoreactivity in decidual stromal cells. C, Placenta
collected at emergency caesarean section in active labour with little or no immunostaining in syncytiotrophoblast cells or extravillous
trophoblast in the placental bed. Some positive immunostaining is present in cells of the villous core in the stroma and associated with
the vasculature. There is intense immunostaining in cells of the decidua basalis. Key: s=syncytiotrophoblast cells; ev=extravillous
trophoblast; db=decidua basalis. D, Parallel negative control section of fetal membranes and adherent decidua with no non-specific
staining. Scale bars: A and D, 200 ;im; B and C, 100 pm.
leukocyte protease inhibitor demonstrated in all labouring
amniotic fluid samples. It is likely therefore that release and
transfer of secretory leukocyte protease inhibitor from
decidua, as has been suggested for prolactin (Rosenberg
et al. 1980), amnion epithelial and fetal lung secretions
may all contribute to secretory leukocyte protease inhibitor
in amniotic fluid.
The predominant source of secretory leukocyte protease
inhibitor secretion in the uterus is likely to be the decidua,
with explains of decidua parietalis and chorio-decidua
secreting high levels. In decidua parietalis, intense
immunoreactivity tor secretory leukocyte protease
inhibitor was localised in the maternal aspect of the
decidua and in that adjacent to chorion. This adherent
decidua is likely to be the principal site of production
in chorio-decidual explains. Decidua collected from the
myometrial aspect by curettage is usually contaminated
with some myometrium, which is immunonegative for the
protein. This may explain why decidua explains secrete
slightly less secretory leukocyte protease inhibitor com¬
pared with chorio-decidua, unless there is a gradient of
secretion with highest outputs from decidua adjacent to
the chorion. Term decidua is heterogeneous, consisting of
stromal cells (53%), macrophages (19%), granulocytes
(16%>) and T-cells (8%>) (Adeleye ct al. 1996). Hence the
stromal cells, macrophages and granulocytes, which are
capable of secretory leukocyte protease inhibitor secretion
in other sites (Ohlsson ct al. 1996), are potential sources. In
the fetal membranes, amnion explants, which consist of
an epithelium and sub-epithelial layers containing fibro¬
blasts, secrete secretory leukocyte protease inhibitor. The
potential for paracrine interactions between the different
cell types present in the term amnion, chorion, composed
of reticular fibroblast and the trophoblast cell layers and
Journal of Endocrinology (1999) 161, 299 -306
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decidua, to regulate the release of secretory leukocyte
protease inhibitor at the materno—fetal interface requires
further investigation.
Placental explants of villous core tissue released low
levels of secretory leukocyte protease inhibitor, which is in
agreement with only slight immunostaining within the
fetal vasculature. This immunostaining could represent
either secretory leukocyte protease inhibitor bound to
elastin (Rudolphus et al. 1994) within the blood vessel wall
or specific staining of residual fetal blood cells in the villi.
Within the isolated perfused placental cotyledon, secretory
leukocyte protease inhibitor was released mainly into the
maternal and not the fetal circuit and was undetectable in
cord serum. Decidua basalis adherent to the perfused
placental cotyledon stains intensely for secretory leukocyte
protease inhibitor reactivity and may be the principal
source of the secretory leukocyte protease inhibitor
secretion into the maternal circulation effluent.
Parturition has been likened to an inflammatory
reaction (Liggins et al. 1977). Secretory leukocyte protease
inhibitor may be involved in the regulation of this response
at the materno-fetal interface. At the onset of labour, there
is increased expression and release of pro-inflammatory
cytokines such as IL-1 and IL-6 within amniotic fluid
(Cox et al. 1997) and decidua (Dudley et al. 1992), which
stimulate pro-inflammatory cascades involved in the
initiation and maintenance of parturition. However, IL-1
and IL-6 can also stimulate release of secretory leukocyte
protease inhibitor (Sallenave et al. 1994, Jin et al. 1998).
The significant rise in IL-1 and IL-6 within amniotic fluid
and decidua at parturition could therefore enhance release
of secretory leukocyte protease inhibitor (Sallenave et al.
1994, Jin et al. 1998) from amnion epithelium, fetal
respiratory tract mucosa and decidua. Secretory leukocyte
protease inhibitor could then exert a negative feedback on
release of inflammatory cytokines via inhibition of NFkB
(Jin et al. 1997) and neutrophil function by inhibition of
neutrophil elastase. Secretory leukocyte protease inhibitor
could also inhibit release of PGE2 and matrix metallo-
proteinases, which are also involved in membrane
remodelling and rupture, by inhibiting cyclo-oxygenase-2
(Zhang et al. 1997). During parturition, the uterine cavity
is at high risk of invasion and infection by microbial
organisms. Secretory leukocyte protease inhibitor, by
virtue of its anti-bacterial, anti-furjgal and anti-viral
properties, could therefore in addition act as an endogen¬
ous block to infection within the decidua and the amniotic
cavity.
In summary, we demonstrate that secretory leukocyte
protease inhibitor is present in increasing concentrations
within amniotic fluid during pregnancy and labour.
Secretory leukocyte protease inhibitor is also released by
and immunolocalised to term decidua. This tissue,
together with fetal membranes and possibly the fetal lung,
are the likely sources of secretory leukocyte protease
inhibitor within the uterus. We suggest that secretory
leukocyte protease inhibitor might act both to limit the
pro-inflammatory cascades ongoing during parturition and
to protect against microbial invasion and the response to
infection. Further studies are required to investigate the
regulation of secretory leukocyte protease inhibitor release
by intra-uterine tissues and to examine its potential roles in
the maintenance of pregnancy and the initiation and
progression of parturition, both preterm and at term.
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Cytokines such as monocyte chemotactic peptide-1 (MCP-
1), interleukin-8 (IL-8), RANTES (Regulated on Activation
and Normally T-cells Expressed and presumably Secreted)
and interleukin-10 (IL-10) are thought to play pivotal roles
in immune recognition, acceptance of the fetal allograft,
maintenance of pregnancy and parturition. Their secretion
and regulation within the third trimester uterus is, however,
less well defined. We therefore investigated the release of
these cytokines by third trimester amnion, chorion, pla¬
centa and decidua, and studied the influence of prosta¬
glandin E2 (PGE2) infusion on their release in a dynamic
placental cotyledon perfusion system. MCP-1 was released
predominately by the chorion (78.2 ± 7.3 pg/mg wet tissue
weight; mean ± SEM), decidua (112.4 ± 5.2 pg/mg) and
placenta (101.8 ± 5.0 pg/mg) with low amounts from the
amnion (1.3 ± 0.4 pg/mg). High concentrations of IL-8
were released by the amnion (39.9 ± 5.3 pg/mg), chorion
(52.8 ± 1.9 pg/mg), decidua (42.2 ± 1.5 pg/mg) and
placenta (45 ± 1.3 pg/mg). Release of RANTES was not
detectable from the amnion but was detected in moderate
amounts from the chorion (6.0 ± 1.2 pg/mg), decidua (15.2
± 1.4 pg/mg) and placenta (26.9 ± 1.6 pg/mg). Low
concentrations of IL-10 were secreted by the chorion (6.8
± 0.8 pg/mg), decidua (9.0 ± 0.9 pg/mg) and placenta (3.3
± 0.3 pg/mg) with none detectable from the amnion. MCP-
1, IL-8, RANTES and IL-10 were all released by perfused
placental cotyledons. PGE2 stimulated release of MCP-1,
IL-8 and IL-10 into the maternal and of MCP-1 and IL-8
into the fetal circulation of the placenta but had no effect
on RANTES release. It is suggested that MCP-1 and IL-8
may be involved in the inflammatory process of parturition
and IL-10 in the protection of the fetal allograft. In addition,
PGE2 may have an important immunomodulatory role
within the uterus at term.
Key words: cytokines/placenta/pregnancy/prostaglandin E2/
uterus
Introduction
The control and regulation of intrauterine function during
pregnancy and parturition is dependent on a delicate balance
between immune and endocrine systems. Chemokines, acting
as local effectors and mediators of cell trafficking, are thought
to play pivotal roles in the immune recognition and maintenance
of pregnancy, acceptance of the fetal allograft and parturition.
Monocyte chemotactic peptide-1 (MCP-1), interleukin-8 (IL-8)
and RANTES (Regulated on Activation and Normally T-cell
Expressed and presumably Secreted) are chemokines whose
principal role is in effecting chemotaxis of monocytes, neutro¬
phils and T-cells respectively. IL-8, an a-chemokine, is released
by many of the intrauterine tissues present during the third
trimester (Elliott et al., 1998), is found in high concentrations
within amniotic fluid, and has been implicated in the initiation
of infection-mediated pre-term labour (Cherouny et al., 1993)
and cervical ripening (Sennstrom et al., 1997). MCP-1, a (3-
chemokine, is released by many reproductive tissues, including
the ovarian follicles (Arici et al., 1997), endometrium (Arici
et al., 1995) and third trimester chorio-decidua (Kelly et al.,
1997), and RANTES is released by the endometrium (Hornung
et al., 1997) and a first trimester trophoblast cell line (Svinarich
et al., 1996). However, whether MCP-1 is released by amnion
or placenta or RANTES by amnion, chorion, decidua or
placenta during the third trimester is not known.
Interleukin-10 (IL-10) is a potent immunomodulatory cyto¬
kine that promotes development of a humoral or T-helper 2
(TH-2) type of immune response, which is associated with a
successful outcome to pregnancy (Wegmann et al., 1993).
IL-10 is present in amniotic fluid throughout pregnancy and
is released by most of the intrauterine structures present during
the third trimester. The factors which regulate IL-10 release
from these tissues and its function within the uterus at term
are, however, less well defined.
It is now recognized that prostaglandin E2 (PGE2), although
initially described as a potent vasodilator, is an important
immunomodulator and mediator of inflammation within the
uterus (Kelly et al., 1995). During the third trimester, it is
released by the amnion (Edwin et al., 1996), chorion (Dudley
et al., 1996), decidua (Ishihara et al., 1991) and placenta
(Wetzka et al., 1997), and a rise in its concentrations within
the uterus is associated with the onset of parturition. The
effects of PGE2 on the release of other cytokines such as
IL-8, which may be involved in parturition, are not well
understood.
The aim of this study was to investigate the release of MCP-
1, IL-8, RANTES and IL-10 from third-trimester amnion,
chorion, decidua and placenta and to evaluate the possible
contribution of these chemokines to parturition. A dynamic
dual placental cotyledon perfusion model was then used to
study the influence of PGE2 infusion on placental chemokine
release and to assess whether any regulation of chemokine
3560 © European Society of Human Reproduction and Embryology
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secretion could have implications for the immunological mech¬




Tissue samples for explant cultures were obtained from normal
healthy women with uncomplicated pregnancies undergoing elective
Caesarean section at term. Discs of amnion (12-mm diameter; wet
weight 10-20 mg; n = 7 different women) and chorion laeve (9-mm
diameter; 15-25 mg; n = 7 different women) were prepared using a
cork borer, pieces of decidua (20-30 mg; n = 7 different women)
by curettage off the myometrium and villous placenta (20-30 mg;
n = l different women) by dissection of placental tissue. For placental
perfusion studies, placentae (/; = 8 different placentae) were collected
from normal healthy women with uncomplicated pregnancies immedi¬
ately after elective Caesarean section or spontaneous delivery and
were transported to the laboratory on ice. Ethical approval was
obtained for this study from the local Ethics Committee.
Explant culture
Discs of amnion, chorion laeve, pieces of decidua and villous placental
tissue were placed on absorbent capillary matting and maintained in
culture as described previously (Brennand et al., 1995). Four explants
of each tissue were cultured from each woman. Culture medium was
collected after 24 h and stored at -20°C before being assayed.
Dual perfusion of a placental cotyledon
A peripheral cotyledon was selected which was macroscopically
intact with parallel chorionic artery and vein, cannulated and mounted
in a perfusion chamber as described previously (Schneider et al.,
1972; Schneider and Huch, 1985), with minor modifications
(Benediktsson et al., 1997). The maternal and fetal compartments
were perfused with Kreb's'solution at flow rates of 10 and 6 ml/min,
and gassed with 95%-02n% C02 and 95% N2/5% C02 respectively.
The perfusate on the fetal side was supplemented with dextran (20
g/1; average molecular weight 74 kDa; Sigma Chemical Co., Poole,
Dorset, UK). Perfusions were started within 10 min of delivery. After
a 40-min equilibration period, which permitted the residual blood to
be eluted and circulatory perfusion pressures to stabilize, consecutive
10-min samples were collected from both maternal and fetal circuits.
A pre-infusion sample was followed by three samples during the
infusion of PGE2 (500 pg/ml for 30 min; Upjohn Co., Kalamazoo,
MI, USA) into the maternal circuit, followed by two post-infusion
samples. Samples were stored at -20°C before being assayed.
The integrity and viability of each preparation was established
throughout the experimental period by ensuring that: (i) the rate of
perfusate input in both the fetal and maternal circuits equalled the
rate of output; (ii) there was adequate exchange of 02 from the
maternal to fetal circuits (step-up pressures of <40 to 70 mm Hg in
fetal perfusate); (iii) lactate concentrations remained within the normal
low range (<2 mM; Benediktsson et al., 1997); (iv) at the end of
the experiment the fetal vasculature responded to a bolus infusion of
noradrenaline (20 mg; Sigma); and (v) subsequent microscopic




MCP-1 was measured by an enzyme-linked immunosorbent assay
(ELISA) using a peroxidase labelled Fab fragment of an antibody to
MCP-1 as described previously (Ida et al., 1994; Kelly et al., 1997).
Briefly, plates were coated overnight at 4°C with MCP-1 capture
antibody [4 pg/ml in phosphate-buffered saline (PBS); Toray Indus¬
tries Inc., Tokyo, Japan], then washed once in tap water and coating
solution added [50 mM Tris, 5 mg/ml bovine serum albumin (BSA),
5 mM EDTA, 2% polyvinyl pyrrolidone; all reagents were from
Sigma, unless otherwise stated] for 30 min. Plates were air dried and
stored with a desiccant at 4°C. Samples and standards (Toray
Industries, Inc., diluted in ELISA buffer; 150 mM NaCl; 100 mM
Tris; 100 mM 2-methylisothizolone, Boehringer Mannheim, Lewes,
Sussex, UK; 100 mM bromonitrodioxane, Boehringer Mannheim;
50 mM Phenol Red solution; 2 mM EDTA; 2 mg/ml BSA; 0.05%
Tween 20 to final pH of 7.2) were added with the highest concentration
of standard being 500 pg/ml. Plates were then incubated for 3 h at
23°C on an orbital plate shaker, washed (150 mM NaCl; 100 mM
Tris; 0.05% Tween 20 to final pH of 7-7.5), then peroxidase-coupled
detection antibody (diluted 1:200 in ELISA Buffer) was added and
incubated for 45 min at 23 °C on an orbital shaker. Plates were then
washed and substrate (0.3 g/1 urea-hydrogen peroxide; 0.1 g/1
tetramethyl benzidine in 100 mM sodium acetate, pH 6.0) added
prior to quenching with 2 N H2S04. Absorption was read at 450 nm
within 30 min of quenching. The intra-assay precision was 6.3%
relative standard deviation, inter-assay precision was 8.6% relative
standard deviation and the detection limit of the assay was 7:5 pg/ml.
Assay for 1L-8
IL-8 was measured by ELISA, utilizing matched pairs of capture and
biotinylated-labelled detection antibodies against IL-8 (R&D Systems,
Oxford, UK) (Denison et al., 1997). Briefly, plates were coated
overnight at 4°C with capture antibody, washed once in water, and
coating solution added for 30 min at 23°C. The coating solution was
removed and the plates stored as for MCP-1. Prior to use, the plates
were washed once in water. Samples and standards (recombinant
standards; Toray Industries Inc.; diluted in ELISA buffer) were added,
with the top standard being 500 pg/ml. Plates were incubated for 3
h at 23°C on an orbital shaker, washed as above, then detection
antibody (30 ng/ml in ELISA buffer) was added and plates were
incubated on a shaker for 45 min at 23°C. After a further wash,
streptavidin peroxidase (Boehringer Mannheim) was added at 0.02
U/well and plates were incubated for 20 min at 23°C on an orbital
shaker. They were then washed, substrate was added and were read
as for MCP-1. The intra- and inter-assay precisions were 9.1% relative
standard deviation and 22.1% relative standard deviation respectively,
and the detection limit of the assay was 7.5 pg/ml.
Assay for RANTES
This assay has been performed previously in this laboratory and has
been described in detail (Denison et al., 1997). The capture antibody
(coated at 2 pg/ml), standards (recombinant, top standard 500 pg/ml)
and detection antibody (added at 50 pg/ml) were all obtained from
R&D Systems. The intra- and inter-assay precisions for this assay
were 10.4% relative standard deviation and 11.2% relative standard
deviation respectively, and the detection limit of the assay was 7.5
pg/ml.
Assay for IL-10
All dilutions were in 10% fetal calf serum in PBS unless otherwise
stated. Plates were coated with capture antibody (Pharmingen, San
Diego, USA; 200 ng/ml in PBS) added at 100 pl/well for 60 min at
23°C, then blocked (10% fetal calf serum in PBS) at 300 pl/well for
a further 60 min at 23°C. The plates were then washed and both
samples and standards (recombinant; Pharmingen) added with the top
standard being 500 pg/ml. Plates were then incubated on an orbital
shaker for 60 min, washed, detection antibody (Pharmingen, San
















Amnion Chorion Decidua Placenta
rigure 1. Release of monocyte chemotactic peptide-1 (MCP-1),
nterleukin-8 (IL-8), RANTES (Regulated on Activation and
formally T-cells Expressed and presumably Secreted) and
nterleukin-10 (IL-10) from the amnion, chorion, placenta and
lecidua. Significantly higher concentrations of MCP-1 were
eleased by the chorion {P < 0.001), placenta (P < 0.001) and
!ecidua (P < 0.001) than from the amnion respectively. RANTES
/as secreted in significantly greater amounts from the decidua
P < 0.01) and placenta (P < 0.01) than from the chorion. The
aajority of IL-10 was released by the chorion and decidua with
Dwer but non-significant concentrations from the placenta. Neither
LANTES nor IL-10 were released by the amnion. Significance: a,
' < 0.001; b, P < 0.01; n = 7 different women. Values are
xpressed as pg/mg wet weight ± SEM.
lin at 23°C. After a further wash, polyperoxidase (CLB laboratories,
Amsterdam, The Netherlands; 100 pi; 1 ng/ml in ELISA buffer
/ithout Tween) was added for 30 min. Finally, plates were washed
nd read as for MCP-1. The intra- and inter-assay variations were
.4% and 10.1% respectively, and the detection limit of the assay
/as 7.5 pg/ml.
tatistical analysis
tatistical analysis of the tissue explant data was performed using
nalysis of variance and a Student's paired t-test was used for the
lacental perfusion model (Statview 4.1, Abacus Inc., Berkeley, CA,
ISA). The data were normally distributed and are expressed as
g/mg wet weight (mean ± SEM) with a statistically significant
ifference defined as P < 0.05.
lesults
issue explants
ixplants of amnion, chorion, decidua and placenta exhibit
istinct profiles of cytokine release (see Figure 1). Significantly
igher concentrations of MCP-1 were released by the chorion
78.2 ± pg/mg wet weight; P < 0.001), decidua (112.4 ± 5.2
g/mg; P < 0.001) and placenta (101.8 ± 5.0 pg/mg; P <
.001) than from the amnion (1.3 ± 0.4 pg/mg). IL-8 was
;creted in large amounts by all tissues studied with release
om the chorion, decidua, placenta and amnion being 52.8 ±
.9 pg/mg, 42.2 ± 1.5 pg/mg, 45 ± 1.3 pg/mg and 39.9 ± 5
;spectively. The placenta (26.9 ± 1.6 pg/mg) and decidua
15.2 ± 1.4 pg/mg) were the principal sources of RANTES,
with significantly more being released than by the chorion
(6.0 ± 1.2 pg/mg; P < 0.01). IL-10 was released mainly by
the chorion (6.8 ± 0.8 pg/mg) and decidua (9.0 ± 0.9 pg/mg)
with concentrations which were lower, but which failed to
reach significance, from the placenta (3.3 ± 0.3 pg/mg).
Neither RANTES nor IL-10 were released in detectable concen¬
trations by the amnion. The ratio of MCP-1 :IL-8 release by
the amnion was 1:31 and the ratios of MCP-1 :IL-8: RANTES:
IL-10 release by the chorion, placenta and decidua were
13:9:1:1, 31:14:8:1 and 12:5:2:1 respectively.
Placental perfusion
The basal cytokine output from the perfused placental coty¬
ledon (maternal and fetal combined) prior to commencing the
PGE2 infusion was less than that by placental explants for
MCP-1, IL-8 and IL-10 (relative ratios 1:4; 1:13; 1:2) but not
for RANTES (relative ratio 1:1). The basal output of all
cytokines measured was greater from the maternal than the
fetal circulation in the perfusion system, with the ratios of
basal output of MCP-1, IL-8, RANTES and IL-10 between
maternal and fetal circuits being 145:1, 79:1, 7:1 and 2:1
respectively. The differential release of cytokines between the
two circulations was maintained for the duration of the
perfusion and study period.
Perfusion of placentae with PGE2 significantly (P < 0.01)
stimulated release of IL-8, MCP-1 and IL-10 from the maternal
and IL-8 and MCP-1 from the fetal circulation. The stimulation
became significant ~20 min after commencing the PGE2
infusion and was maintained for the duration of the perfusion
and study period (Figures 2a, b and 3).
RANTES was released into both the maternal and fetal
circulation, but secretion was not affected by infusion of PGE2,
unlike the other cytokines measured (Figures 2a, b).
Discussion
The heterogeneous intrauterine structures present during the
third trimester originate from both maternal and fetal tissue
and have widely differing functions. In this study it has been
demonstrated that third trimester amnion, chorion, decidua and
placenta explants secrete quite distinct cytokine profiles. MCP-
1 was released predominately by the chorion, decidua and
placenta with low amounts from the amnion (relative ratios
62:94:85:1 respectively). High concentrations of IL-8 were
released by the amnion, chorion, decidua and placenta (relative
ratios 1:1:1:1 respectively). Release of RANTES was not
detectable from the amnion but was detected in moderate
amounts from the chorion, decidua and placenta (relative ratios
1:3:4). Low concentrations of IL-10 were secreted by the
chorion, decidua and placenta with none detectable from the
amnion (relative ratios 2:3:1).
The fetal membranes comprise the amnion and chorion. The
amnion, which is composed of an epithelial and fibroblast
layer, released both IL-8 and MCP-1. Local release of IL-8
from unstimulated (Laham etal., 1997) and cytokine-stimulated
amnion explants (Trautman et al., 1992) has been demonstrated
previously and has been postulated to have a role in parturition.
The demonstration of MCP-1 release is, however, novel and







Figure 2. Effect of prostaglandin E2 (PGE2) infusion on the release
of monocyte chemotactic peptide-1 (MCP-1), interleukin-8 (IL-8),
RANTES (Regulated on Activation and Normally T-cells Expressed
and presumably Secreted) into (a) the maternal and (b) the fetal
circulation in a dynamic dually perfused placental cotyledon. The
release of MCP-1 and IL-8 release was significantly {P < 0.01)
stimulated into both maternal and fetal circulations ~20 min after
commencing the PGE2 infusion and concentrations continued to be
elevated until the end of the study period. The PGE2 infusion had
no effect on RANTES release. Significance: a, P < 0.01; n = 8
different placentae. Values are expressed as pg/min/cotyledon ±
SEM.
could be from either epithelium or fibroblasts, both of which are
capable of its synthesis in extra-uterine sites (Elner et al., 1997).
The chorion, whose principal constituent is the trophoblast,
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Figure 3. Effect of prostaglandin E2 (PGE2) infusion on the release
of interleukin-10 (IL-10) into the maternal and fetal circulation in
dually perfused placental cotyledon. The release of IL-10 was
significantly (P < 0.01) stimulated into the maternal circulation
~20 min after commencing the PGE2 infusion and concentrations
continued to be elevated until the end of the study period. There
was no rise in concentrations of IL-10 in the fetal circulation post-
infusion. Significance: a, P < 0.01; n — 8 different placentae.
Values are expressed as pg/min/cotyledon ± SEM.
strated previously and has been immunolocalized in cytokine-
stimulated chorion to the trophoblast, stromal fibroblasts and
macrophage-like cells (Ito et al., 1994). The release of IL-10
by the chorion contrasts with the findings of others (Trautman
et al., 1997) who were not able to demonstrate its release
and only rarely its immunolocalization within the chorion.
However, they readily detected IL-10 in the decidua, and it
may be that the decidua adherent to the chorionic trophoblast
is responsible for IL-10 release in these explant preparations.
The decidua released high concentrations of MCP-1 and
IL-8 and moderate concentrations of RANTES and IL-10. The
release and immunolocalization of IL-8 and IL-10 has been
demonstrated previously within the decidua (Saito et al., 1994;
Trautman et al., 1997). Although the decidua comprises a
wide range of different cell types, it is likely that decidual
macrophages and T-cells would be the principal source of
MCP-1 and RANTES respectively.
The placenta released high concentrations of MCP-1, IL-8
and RANTES and low concentrations of IL-10. Secretion
of IL-8 and IL-10 by the placenta supports previous data
demonstrating release and localization of IL-8 to the cyto-
trophoblast, the syncytiotrophoblast, perivascular cells and
placental Hofbauer cells (Saito et al., 1994; Elliott et al., 1998)
and of IL-10 to the cytotrophoblast (Roth et al., 1996).












placenta has not been reported before, a novel chemokine
receptor CCR10 has been detected recently, which binds
MCP-1 with high affinity and RANTES with much lower
affinity. This receptor is uniquely expressed within placenta
and fetal liver (Bonini et al., 1997). A variety of cells
within the placenta would be capable of secreting MCP-1 and
RANTES, including the trophoblast, placental macrophages
and T-cells. However, some placental explants were contamin¬
ated with blood, and therefore peripheral leukocytes, in particu¬
lar monocytes and T-cells, could be an additional source of
MCP-1 and RANTES respectively.
Parturition has been likened to an inflammatory reaction,
with cytokines such as IL-8 playing a key role in cellular
recruitment and activation within the utero-placental unit at
term (Sennstrom et al., 1997). Prostaglandin E2 is also thought
to be an important mediator and possible initiator of parturition,
with concentrations increasing peripartum within amniotic
fluid, placenta and cervix. In extra-uterine inflammatory
responses, synergy exists between PGE2 and IL-8 to facilitate
neutrophil recruitment (Colditz, 1990). Furthermore, IL-8
release can be up-regulated by PGE2 (Agro et al., 1996) and,
although the mechanism is not well defined, it may be via
PGE2 stimulation of cAMP (Brar et al., 1997; Kaveleers et al.,
1997). Whether PGE2 regulates release of other inflammatory
mediators, such as MCP-1 and RANTES, which may also be
involved in parturition is not known.
In this study it was investigated whether PGE2 regulated
release of MCP-1, IL-8, RANTES and IL-10 within the
placenta and also its effect on cytokine release from a dually
infused placental cotyledon. This demonstrated that PGE2
stimulated release of MCP-1 and IL-8 into the maternal and
fetal circuits of the perfusion system but had no effect on
RANTES release. It can be postulated that a rise in PGE2 at
term would stimulate MCP-1 and IL-8 release, thus promoting
a local inflammatory reaction and favouring parturition. The
principal source of cytokines in such a system would be the
trophoblast, although there may be a slight contribution from
the decidua of the basal plate. The effect of PGE2 stimulation
of cytokine release into the fetal circulation was less than into
the maternal circulation, and this could be due to inefficient
transport of PGE2 across the trophoblast, inability of cells
adjacent to the fetal circulation, such as the Hofbauer cells, to
respond by stimulation to PGE2, or metabolism of PGE2 by
the trophoblast (Cheung et al., 1990). RANTES secretion was
not stimulated by PGE2. This further supports the hypothesis
that stimulation of IL-8 and MCP-1 was secondary to PGE2
and not an artefact of perfusion.
In addition, PGE2 stimulated release of IL-10 into the
maternal but not the fetal circulation. The maternal immune
system maintains tolerance to the fetus throughout pregnancy,
although the mechanism is poorly understood. IL-10 is present
in amniotic fluid in increasing quantities during pregnancy
(Greig et al., 1995) and, because of its immunosuppressive
properties (Mosmann and Moore, 1991), has been proposed
as a factor which may be involved in preventing fetal rejection
(Rivera et al., 1998). In other systems, PGE2 is a potent
stimulator of IL-10 and inhibitor of IL-12, a pro-inflammatory
cytokine (Kelly et al., 1997) which favours a TH-1 or cell-
mediated immune response (Trinchieri, 1993). A rise in IL-10
and fall in IL-12 concentrations favour immunosuppression
and can induce anergy or non-recognition of antigen by T-
cells (Groux et al., 1996). We propose that, at term, stimulation
of IL-10 release from the maternal side of the placenta by
PGE2 would enhance local immunosuppression and tolerance
towards fetal antigen. The fetus would then be protected from
maternal recognition and rejection during the 'high risk'
inflammatory process of parturition.
In summary, it has been demonstrated that the amnion,
chorion, placenta and decidua release distinct profiles of both
pro- and anti-inflammatory cytokines. Furthermore, in-vitro
perfusion of a placental cotyledon by PGE2 stimulates release
of IL-8, MCP-1 and IL-10, but not RANTES. We speculate
that the pro-inflammatory cytokines MCP-1 and IL-8 may play
a role in the inflammatory process of parturition and that the
anti-inflammatory IL-10 may be involved in protecting the
fetal allograft at parturition. Moreover, we suggest that PGE2
may play an important immunomodulatory role within the
placenta at term. Further studies are now underway to assess
the effect of PGE2 and other immunomodulators on cytokine
release by the amnion, chorion, decidua and placenta.
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